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Abstract 
Vaccination  of older adults is a key component of public health policy, but 
further evidence is required to understand its effectiveness in practice. 
Electronic health records (EHRs) present a potential alternative to the gold-
standard evidence of clinical trials, particularly for populations, such as older 
adults, who may be under-represented in trials due to ethical and practical 
constraints in recruitment. Importantly, EHRs also allow the real-world study of 
an intervention as it is delivered in practice, and its effect in clinically important 
sub-groups. However, EHRs are not purposed to collect informaton on 
confounders, which may bias results from the analyisis of routinely-collected 
data. This motivated my review of quasi-experimental (QE) methods as a 
means of indirectly adjusting for confounding. My published methodological 
review found that the longitudinal information available in EHRs offer many 
opportunities for mitigating against confounding bias, but many methods may be 
under-utilised. The  prior event rate ratio (PERR) and its alternative formulation, 
described under the Pairwise framework, is a recently developed method that 
utilises longitudinal information. This before-and-after approach can be applied 
to rate and survival data, allowing an easy comparison to many trial results. The 
data on vaccination in UK older adults was also the basis for further study of the 
performance and limitations of the method beyond exisiting simulation studies. 
Through comparison to weighted regression, I demonstrated how the source of 
confounding and robustness of the results could be explored. In a novel 
application of the PERR and Pairwise methods to interactions, I investigated the 
effectiveness of the pneumococcal vaccine in older patients, and found 
evidence for an increase in effectiveness with age across the years of policy 
implementation, 2003-2005. In my investigation of the influenza vaccine in 
annual cohorts from 1997 to 2011, I found consistent evidence of a moderately 
protective effect against myocardial infarction, but that this may decrease with 
age. The evidence also indicated a protective effect against influenza itself, but 
no age trend in its effectiveness was detected.  
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Chapter 1  -  Introduction 
1.1 Introduction 
It is the digital storage of routinely-collected health data that underpins this PhD 
as well as many other current, observational investigations into human health. 
Many casual observers will be aware of the rise of the “big data” phenomenon - 
an inevitable consequence of improvements in not only computer hardware, 
processor speeds and data storage, but also in the connectivity of distributed 
computing. This has greatly influenced the direction of health research, with 
benefits to the relatively new science of bioinformatics through increases in the 
capacity to store and analyse ever larger data from genetic studies and 
molecular biology. Simultaneously, the growth of “big data” has led to a greater 
investment in other observational studies, and the development of “real-world 
evidence”: Large, observational data on a population from routinely-collected 
electronic health records (EHR) may allow investigators to observe the effect of 
an intervention, away from the constraints of a clinical trial and according to how 
it might be delivered in practice, under real-world conditions. Extra information 
is likely to be available from longer follow-up times, enabling the monitoring of 
long term adverse events, or the discovery of unexpected, secondary benefits 
of a treatment. Furthermore, larger data captures more information across a 
wider mix of patients, and hence results can be compared across a variety of 
key sub-groups. EHR data tend to be more representative of the population 
from which they have been sampled, than trial data, and so results from 
analysis are more easily generalisable to that same population. In particular, 
some risk groups, such as older patients, may be under-represented in trials 
due to ethical and practical issues in recruiting to clinical randomised trials. 
However, in the absence of experimental rigor designed into clinical trials, this 
improvement in the representativeness of the sample (and thus, the 
generalisability of the results to the population of interest) may come at the 
expense of the accuracy of the results i.e: internal validity. The doubt over 
internal validity implies that results may not be reliable estimates of the true 
effect being investigated. 
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An oft cited example in relation to the problem of misusing “big data” for health 
is that of Google Flu Trends. Briefly, this approach used an unsupervised (i.e: 
theory free), algorithmic machine-learning to estimate the arrival of the annual 
influenza season based on the top 50 million search terms. The findings were 
published in Nature and the system proved to be much quicker than the usual 
surveillance through the sentinel laboratories of the Centre for Disease Control 
and Prevention. Unfortunately, the system also proved to be error-prone when 
the spread of influenza-like illness was overestimated by nearly a factor of two 
for the 2012/2013 influenza season. This was a problem of prediction modelling 
however, rather than one of inference, but the anecdote serves to illustrate the 
need for a robust model-based approach to investigating clinical questions. 
The threat to internal validity may arise through more than one mechanism, but 
all variously lead to biased estimates of the treatment or exposure under 
investigation. The focus of this PhD was to seek causal inference from 
observational data, mitigating for the bias arising from an absence of 
information about important prognostic factors related to the outcome of 
interest. Given the prognostic factors are often likely to be imbalanced between 
exposure groups, confounding the effect of treatment, the resulting bias is 
referred to as confounding bias. Confounding and how it biases causal 
inference will be given a fuller discourse in a subsequent section in this chapter. 
Methods are available for correcting for confounding bias, and many of these 
were presented in a comprehensive systematic review, which was performed as 
part of this PhD project and published in the Journal of Clinical Epidemiology. 
This is included as the second chapter of this thesis, and is supplemented with 
a subsequent chapter comprising a review of sensitivity-analysis methods, 
presenting a complementary approach to the problem of confounding. 
As will become apparent in the method review, many methods were developed 
for economic data, and many are only applicable to continuous outcomes. 
Health research is often concerned with the epidemiological study of outcomes 
presented as binary clinical events, such disease states or death. The 
complement to the study of the rate at which clinical events occur is a 
prognostic investigation of the time until such an event occurs. In health 
research, survival until an event such as a disease or death or recovery from 
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disease is of intrinsic, prognostic clinical interest, and so survival analysis is 
often the method used for evaluating the effect of intervention in many trials. 
Therefore, this PhD sought to focus on extending the application of particular 
quasi-experimental (QE) methods that can be used to adjust for bias arising 
from unmeasured confounding in survival data. These methods were the prior 
event rate ratio (PERR) method, and its alternative formulation, described as 
under the Pairwise framework. Although these particular methods were covered 
in the method review of chapter two, a literature review of the PERR and 
Pairwise methods is presented and discussed in chapter four. 
Following chapter four are two chapters, which use QE methods applied to EHR 
data, to investigate the real-world effectiveness of vaccination in older adults. 
Observational studies such as these have an important role in the study of older 
adults, and other populations that may be under-represented in clinical trials 
due to ethical and practical barriers to recruitment. The data used for the 
studies are introduced in a section below (section 1.6), and in another (1.7), 
details of the clinical question and the population are presented. Both chapters 
five and six have been written with intention of soon being submitted for 
publication in a clinical journal and will likely be submitted between the 
submission of this thesis and the viva voce. In the final chapter, the findings are 
summarised and the implications presented. The challenges in applying the 
PERR and Pairwise methods to this particular population and their performance 
are also discussed, along with any further methodological constraints and 
opportunities for development that were identified. 
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1.2 History of causal Inference 
A definition of causal inference, seemingly so fundamental to empirical scientific 
discovery, has its roots in philosophy, and a history of development that dates 
back to work by John Stuart Mill (A System of Logic, Ratiocinative and 
Inductive, 1843), David Hume (A Treatise of Human Nature, 1739) and Sir 
Francis Bacon (Novum Organum, 1620), with influences from the classical 
Greek world in figures like Aristotle 1,2. 
The concept of causal inference may at first seem intuitive to lay-people and 
scientists alike, as it asks the question: 
 
What causes an observed event? 
 
It is this experimental approach to resolving the problem of causal inference that 
is found in Jerzy Neyman’s work on experimental design in agronomy for his 
Master’s thesis 3. This was considered by many to be a landmark development 
in a statistical framework for causal inference, although many leading statistical 
figures such as Ronald Fisher, Sir Austin Bradford Hill, William Cochran, David 
Cox and others have been acknowledged as contributing to the development of 
what came to be known as the potential outcomes framework 4–6. The 
understanding of causal inference in the context of this PhD project was based 
on the potential outcomes framework, also referred to as the counterfactual 
model. However, it is accepted that this may oversimplify and reduce real-world 
mechanisms to an untestable theory 7. 
The potential outcomes model is sometimes attributed to Donald Rubin 8 as 
Rubin’s causal model 9, although Rubin, himself, modestly acknowledged that 
his efforts extended much work that had preceded his. While the model 
provided a framework for understanding the mechanism of inference from 
experimental data, this was also extended to observational data 10. Donald 
Rubin with Paul Rosenbaum would later seek a solution to the problem of bias 
in observational data arising through from the imbalance in prognostic variables 
between treatment groups – the confounders of the effect of treatment. They 
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proposed that the unbiased average treatment effect could be estimated 
through either matching on, or adjusting for, a propensity score – the predicted 
membership of one of two treatment groups from a logistic model of the 
measured confounding variables 11. Robins, Hernán and Brumback also 
demonstrated the application of the propensity score to the construction of the 
marginal structured model 12. This estimated the marginal effect, the inverse 
probability treatment weight estimator, from an analysis weighted by the inverse 
of the propensity score. Stabilisation of the weights could also be achieved by 
adjustment in the numerator of the weights for the expected probability of 
treatment group membership, thereby reducing the influence of extremely large 
weights from a few subjects. However interpretation of the marginal estimate 
requires caution in the presence of consequential heterogeneity 13, where the 
estimated effect on the treated group will be different from that of the controls. 
1.3 Causal inference framework 
Central to the framework is Rubin’s condition of ignorability, using notation in 
Rosenbaum and Rubin’s work on propensity scores 11: 
(𝑌0, 𝑌1) ⊥ 𝐴 
which gives the joint independence of potential outcomes Y0 and Y1, and 
treatment assignment, A. Hernán deploys a useful and more succinct notation 
14 for expressing causal effect in the context of potential outcomes. For the 
outcome Y, and a binary exposure or treatment A, each individual provides a 
pair of counterfactual outcomes Ya: 
𝑌𝑎⨆𝐴 
This implies the property of exchangeability to be true so where the potential 
outcome a of outcome Y is independent of the actual exposure or treatment A. 
This may at first seem counterintuitive, but more simply it states that 
membership of exposure group A should have no effect on the potential 
outcomes, Ya, of each individual. Put another way, this means that for any 
individual, if A=1 is assigned, potential outcome Ya=0 will equal the observed 
outcome under A=0, and vice versa. 
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Knowledge about the potential outcome of each individual, i.e: knowledge about 
a=0 when a=1 is observed and vice versa, renders the cause identifiable. 
Simply, causation cannot be attributed if only Y=1 is observed under A, since 
the counterfactual outcome Y of A could either be 1 or 0 15. Similarly the same 
argument is true, if Y=0 is observed under A. Hence causation can be inferred 
when: 
𝑌𝑎=1 ≠ 𝑌𝑎=0 
However, the impossibility of observing both potential outcomes of each 
individual under A should be clear, so that it is impossible to estimate the 
individual causal effect, δ: 
𝑌𝑎=1 − 𝑌𝑎=0 = 𝛿 
but, if the property of ignorability can be assumed, then causation can be 
inferred from association: 
𝑌𝑎 = 𝑌|𝐴 
Under this property, the group comprising individuals under one level of the 
exposure are exchangeable with those under the other level. This enables the 
effect of exposure, say T, to be estimated from individuals that are different in 
each level of exposure. Therefore while the outcome for the exposed individual, 
Ya=1, from set of individuals from population A under exposure level T=1 is 
observed, its counterfactual can be observed as the outcome, Yb=0, under 
exposure level T=0 comprising a different set of individuals from population B. 
This property of exchangeability assumes E[Ya=0] = E[Yb=0] (and conversely, 
E[Ya=1] = E[Yb=1]) in the population of individuals. While the true average causal 
effect for individuals in group A is expressed as risk difference as 
𝐴𝐶𝐸 = 𝐸[𝑌𝑎=1|𝑇 = 1] − 𝐸[𝑌𝑎=0|𝑇 = 0], 
the observed effect is the difference between the outcomes in group A under 
T=1 and outcomes in group B under T=0, and can be expressed as 
𝐴𝐶?̂? =  𝐸[𝑌𝑎=1|𝑇 = 1] − 𝐸[𝑌𝑏=0|𝑇 = 0] 
= (𝐸[𝑌𝑎=1|𝑇 = 1] − 𝐸[𝑌𝑎=0|𝑇 = 0]) + (𝐸[𝑌𝑎=0|𝑇 = 0] − 𝐸[𝑌𝑏=0|𝑇 = 0])   
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This is expressed equivalently, and perhaps more succinctly, as the outcome 
parameters of populations A and B, using Greenland and Morgenstern’s 
notation2: 
𝜇𝐴1 − 𝜇𝐵0 = (𝜇𝐴1 − 𝜇𝐴0) + (𝜇𝐴0 − 𝜇𝐵0) 
where the true effect is μA1 – μA0 , and μA0 – μB0 is the potential bias between 
populations A and B (where  denotes the population mean for the 
counterfactual of a particular group indicated by the subscript). The true effect 
can also be expressed analogously as a ratio: 
𝜇𝐴1
𝜇𝐵0
=
𝜇𝐴1
𝜇𝐴0
∙
𝜇𝐴0
𝜇𝐵0
 
There are of course other assumptions required in the identification of causal 
pathways. The exposure or intervention has to necessarily be well-defined, and 
not subject to multiple interpretations or versions 16. There has to be 
independence between individuals with respect to the intervention, and also the 
outcome, as in robust experimental design 17, referred to in the observational 
sense as the stable-unit-treatment assumption 18. Mediation has not been 
discussed and in the discourse so far, has been assumed to be absent, yet the 
causal mechanism may not be properly identified without information on any 
mediators present 19. This consideration links causal inference of the average 
causal effect to structural equation modelling, in which the interactions and the 
heterogeneity of the average causal effect are also considered. Causal 
inference in the presence of interactions was a topic of interest for this PhD 
project, and results from this are presented in later chapters. It should be noted 
in the presence of interactions, the exposure effect, when expressed as a ratio, 
will be different for the marginal effect and the conditional effect within strata of 
the covariate2. Whether the marginal and within-stratum conditional risk or odds 
ratios are equivalent is an issue of collapsibility. This sometimes gives rise to 
marginal and conditional ratios that are in the opposite direction, known as 
Simpson’s paradox 20,  which is dependent on the measure of association. This 
is sometimes mistakenly identified as confounding, i.e: missing information on 
covariate imbalance. 
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1.4 Causal inference and unmeasured confounding 
The development of causal inference for observational data with methods 
based on the property of conditional ignorability assumes the availability of 
information on confounders within the data, so that individuals in the exposed 
and unexposed groups of A are conditionally exchangeable given confounder(s) 
C: 
𝑌𝑎 ∐ 𝐴|𝐶 
Without the tool of randomisation and experimental control over endogenous 
factors in a randomised controlled trial (RCT), unbiased causal inference from 
observational data relies not only on the correct specification of confounders in 
the inferential models, but also on the confounders , C, being identified and 
recorded in the data in the first place. Reliance on the availability of information 
on all confounders is likely to be unrealistic with retrospective observational 
data. Even when data collection can be planned for prospective studies, there 
may be practical difficulties in collecting data for all primary confounders, and a 
failure to either identify or correctly model the confounders leading to persistent 
bias 21,22. 
There are different approaches offered by a raft of methods that could be best 
described collectively as quasi-experimental methods. Developed in parallel to 
those methods based on propensity scores found in medicine, QE methods 
largely have their origins in the disciplines of social sciences and econometrics 
23–25, where randomised experiments are not practicable. A more 
comprehensive review of these methods is given in the published paper 
comprising chapter two. 
The implication in the discourse on, and history of, causal inference by Cook 
and Campbell 26 is that the answer to the question regarding what has caused 
an event will depend on the philosophy that is followed in seeking the answer. 
In their own framework for causal inference, the distinction between “molar“ and 
“micromediation” is appropriate for medicine and biology, in which causality may 
be observed at the molar level (e.g: human physical activity leads to energy 
expenditure), but ultimately occurs at a micromediational level (e.g: the complex 
system of biochemical pathways involved between physical activity and energy 
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expenditure). Additionally, the comparison between open and closed systems 
helps underpin understanding of causal inference in medicine and human 
health. In observational data, the systems are decidedly “open”, easily leading 
to the “essentialist” view of cause and effect, in which all causal pathways are 
necessarily considered together. RCTs therefore attempt to emulate a closed 
system, in which stratification may control any endogenous relationships 
between known confounders and the outcome, and randomisation attempts to 
stochastically control for any remaining unmeasured confounding. The RCT 
therefore leads to a more experimentalist view of causal inference: 
 
What will happen if I change what I think is the cause? 
 
or perhaps more inferentially: 
 
Will changing what I think is the cause explain the cause of an observed 
event? 
 
While causal relationships need to be considered in designing an RCT to limit 
chance confounding relationships due to imperfect randomisation and/or non-
compliance, the open system representing observational data relies more 
heavily on understanding the causal pathways for the correct estimation of 
cause-and-effect in subsequent modelling. In this context, Pearl 27 considered 
causal inference to be a “nonparametric generalisation of the linear structural 
equation models” first developed for research in Economics 28. It was proposed 
that this could be helpfully illustrated through diagrammatic representation such 
as directed acyclic graphs (DAGs). Pearl considered an understanding of the 
underlying deterministic data-generation process to be essential for identifying 
true confounders as well as cause-and-effect 29. Paradoxically, such an 
understanding may be difficult to achieve in the open system of observational 
data 30. To that end, DAGs merely represent a hypothetical relationship, and the 
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risk oversimplifying causal pathways at the micromediational level of an open 
system. 
After nearly a century since Jerzy’s Master’s thesis, it is surprising that the 
potential outcomes approach is still challenged today 31. Questions have been 
raised over its relevance to description and surveillance within the spectrum of 
epidemiological investigation that extends to the aetiological 32. While criticism 
of the formal approach to quantitative causal inference in epidemiology has 
been shown to be misguided 33,34, another debate has highlighted the danger of 
oversimplifying or mis-specifying causal relationships, which DAGs are merely 
purposed to illustrate 30,35. Disagreements over the exact role of causal 
inference in epidemiology may in part be down to the RCT paradigm as the gold 
standard and exemplar of causal inference, which as already noted, may not sit 
well within the essentialist understanding of the open system that is human 
biology. Aalen, Roysland et al. perhaps best diagnose the role of RCTs in the 
confusion over causal inference by pointing out the limitations of RCTs in 
understanding causality: “Intervention and manipulation exhibit causality, but do 
not necessarily define it” 36. This is understood to acknowledge the inadequacy 
of the one-variable-at-a-time approach under the idealised conditions of an RCT 
for understanding complex biological networks of cause-and-effect particularly 
under homeostatic equilibrium, where observed variables may act as mediators 
and moderators of other effects. Beside their excellent treatise on the 
development of causal inference, Aalen, Roysland et al. argued a compelling 
case for explicitly including direction of effect relative to time in the causal 
inference framework, a property that is missing from much of the literature 
discussing causation, including DAGs. They argued that the time direction of a 
relationship can simply determine whether or not to condition on a variable 
rather than relying on identification of variables as possible colliders. It is in this 
context of time in causal inference, that the argument is made for inclusion of 
longitudinal information in the QE adjustment of longitudinal data in the method 
review of chapter two, which in turn supports the review of the PERR and 
Pairwise methods in chapter four and understanding of the analyses conducted 
in chapters five and six. 
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1.5 Confounding bias and quasi-experimental methods 
The problems posed by identifying potential confounders and correctly 
specifying the causal pathways of the confounders and other variables have 
contributed to the need for what is defined for the purposes of this PhD project 
as a QE approach to causal inference from observational data. Missing 
observations and missing information on key variables in the causal pathway 
are common problems with observational data. Variables that are associated 
with both the outcome and the exposure will confound any causal relationship 
between the outcome and exposure. (Paradoxically, if the confounder is 
measured without error and correctly specified in the inferential model then it is 
no longer a confounder, but just another adjustment variable. Therefore, the 
extra clarification of confounders as unmeasured or otherwise may be regarded 
as superfluous in the context of statistical modelling). In medicine, where 
interest is in the risk from exposure to a disease or in the effectiveness of a 
particular health intervention, the exposure or treatment is likely to be discrete 
and represented as a binary indicator variable. Therefore, potential confounders 
are any prognostic variable or a predictor of the outcome, which is distributed 
unequally between the exposed groups. Where the exposure or intervention is 
continuous, such as in the case of blood pressure or drug dosage, then 
prognostic variable would be distributed unevenly across the spectrum of the 
exposure to qualify as a confounder. Consequently, this creates uncertainty 
over how much of the difference in outcome between exposed groups should 
be attributed to the exposure itself or the confounding variable, which is wholly 
or partially aliased with the exposure. Age, which may commonly determine the 
prognosis of a disease in patients, may be balanced between intervention 
groups in an RCT either deterministically through stratification or stochastically 
through randomisation. Away from the controlled allocation of the intervention in 
an RCT, patients are likely to be selected for treatment on important prognostic 
variables such as age. Therefore in an observational study of any real-world 
scenario, the distribution of age may be different in each treatment group, 
leading age to potentially confound any observed effect of treatment. If the 
estimated effect of an exposure or treatment is not adjusted for confounding 
variables, then the effect of the confounding remains in the residual of any 
regression, biasing the estimates of the variables that are confounded. This 
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creates a threat to what is termed as the internal validity of the model and its 
estimates. If a variable is causally linked to only one of either the exposure or 
the outcome, then the variable is no longer an endogenous variable and a 
potential confounder, but an exogenous variable. If causally linked exclusively 
to the exposure, it can be considered an instrument of the exposure. If a causal 
determinant of the outcome only, then it is just another adjustment variable to 
be included in the regression model to reduce the error of the estimates. 
QE methods obviate the need to identify and correctly model all confounding 
relationships, although such methods often require meeting certain sets of 
assumptions. The assumptions required of analytical methods, that can be used 
in comparative effectiveness studies, are detailed in the method review of 
chapter two. Additionally, each method requires the data to either be configured 
in a certain way, such as having a longitudinal dimension for before-and-after 
designs, or exhibit certain properties, such as the availability of instrument(s) of 
the exposure in instrumental variable analysis. Collectively when data 
conveniently provide such properties that may accommodate a QE  approach, 
the data are said to provide a “natural experiment”. 
Applying QE methods to observational data to control for confounding bias 
obviously benefits the internal validity of the resulting estimates. However, there 
are also advantages to using observational data over experimental data, as will 
be explained in the following section on data and real-world evidence.  
1.6 Routinely collected data 
The aim of this PhD project was to research, apply and extend the use of 
particular QE methods to facilitate causal inference from observational data, 
primarily routinely-collected data (RCD) or administrative data. In medicine, this 
data is frequently encountered as patient information, collected and stored in 
the UK for the purpose of maintaining continuity of care. Since these data are 
routinely stored and accessed digitally, they are often referred to as “electronic 
health records” (EHRs), and henceforth will be referred to as such, although 
they may also be referred to as electronic medical records, electronic patient 
records and personal health records in the literature 37. Such data may also 
include claims against health insurance, particularly in the US. Primarily 
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recorded for actuarial and administrative purposes in the reimbursement of 
claims by the insurance industry, these can also be considered as EHRs, since 
they track healthcare usage and have been used to facilitate studies into health 
and health service utilisation, as evidenced in the systematic review of chapter 
two. 
The data for this PhD project were provided by the Clinical Practice Research 
Datalink 38, formerly the General Practice Research Database. The database 
collects primary-care data from GP surgeries using the Vision/EMIS IT systems, 
but began life as a useful record-keeping system in the management of a single 
General Practice 39.  With development by information technology specialists 
and linkage to data from other databases including the Office of National 
Statistics and Hospital Episode Statistics, this had grown into a data brokerage 
service, providing observational data for research into epidemiology, pharmaco-
economics, pharmacovigilance and risk-monitoring 40 . A review of its resources 
estimated it had records on over 11.3 million patients from 674 practices 41. 
Other sources of EHR data in the UK are Q-Research, ResearchOne, The 
Health Improvement Network and the Secure Anonymised Information Linkage 
databank. 
More recently, the boundary between RCD and trial data has become 
increasingly blurred as large-scale trials are integrated with RCD 42–45. The 
integration between trial and RCD is ideally suited for conducting pragmatic, 
open-label randomised trials. Dubbed point-of-care trials in the context of EHR 
data, the Randomised Evaluations of Accepted Choices in Treatment (REACT) 
trial recently explored the feasibility of using the CPRD system as a data 
collection service, and a real-time recruitment tool, randomising at the point of 
care 46. This was in part motivated by the paradox of “research exceptionalism”, 
which describes the contradiction between guidelines informing clinical good 
practice and regulations governing trials 47. Where there is an absence of 
sufficient evidence from comparative effectiveness studies, the choice in 
prescribing one out of set of similar drugs may entirely arbitrary and so the 
clinician may rely on his or her own judgement. However, should the clinician try 
to conduct research for determining the comparative effectiveness of the drugs, 
then paradoxically, this would be subject to rules that are far more stringent 
than those regulating clinical practice. The expansion beyond the merely 
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observational has been reflected in the changes to the services offered on the 
CPRD website, which now promises electronic Case Report Forms to facilitate 
point-of-care and phase III trials, in addition to the more commonly encountered 
use of EHR data for ecological, descriptive studies and for phase IV safety-
monitoring. In parallel, there has been a commensurate growth in 
methodological innovation to facilitate conducting trials using EHRs, particularly 
in clustering to accommodate treatment allocation at the general practice level 
48. 
The shift in the use from descriptive epidemiological and risk-monitoring studies 
to including more inferential studies and trials has been supported in the UK by 
funding calls into research based on EHRs, primarily from a consortium of 
funding bodies led by the Medical Research Council, and also by collaborations 
with the pharmaceutical and healthcare industries, such as the EU-wide Get 
Real, a three-year project initiated in 2013. In the US, the greater integration of 
EHRs into research can partly be evidenced in legislative changes such as the 
introduction of the Health Information Technology for Economic and Clinical 
Health (HITECH) Act of 2009 in the US. This mandated a process for improving 
the “privacy and security provisions” in the exchange and use of EHRs and set 
out a program for incentivising a “meaningful use of certified EHR technology”. 
In the UK too, the use of EHRs are more and more an integral part of public 
health policy 49,50. Overall, the view of stakeholders in the UK healthcare system 
would seem to vindicate the huge interest in using EHRs to improve clinical 
care, although there are some concerns about the quality of the data. From the 
report entitled Future of Health: Findings from a Survey of Stakeholders on the 
Future of Health and Healthcare in England 51, these concerns have tended to 
be over linkage to other useful data; uniformity and coherence between 
datasets; and reliability of the recorded data. 
As witnessed by the view of stakeholders, it is perhaps a commonly held view 
on EHRs that there are many issues to resolve around linkage and data quality 
52, and that next to RCTs, that the data are messy, plagued with missingness, 
noncompliance and the incorrect recording of observations. However, it was a 
view expressed by Tjeerd van Staa at the NIHR Statistics Group annual 
meeting in Sheffield 2016, that data are not necessarily error free because they 
are found on a trial’s case report form (CRF). A CRF presents a pristine view of 
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the real-world mess that is evident through EHRs, and that the underlying data 
could so easily be messy and imperfectly collected. However, internal validation 
at the CPRD aims to ensure an acceptable standard of data quality 40,53. The 
availability of up-to-standard (UTS) dates is one measure of assurance about 
the quality of the data. This is the date from which the data from a particular 
practice are determined by the CPRD to be of research quality based on the 
practice’s death recording and gaps in the data. The UTS date was used in this 
PhD project in the selection of patient cohorts to exclude any patients registered 
to GPs, whose practices were not up-to-standard at the index date of the 
cohort. Likewise, patients were also excluded if the last-collection date for data 
at their GP’s surgery fell short of the observed timespan for the cohort. 
Although overcoming confounding bias is one of the main challenges of using 
EHR data, there are advantages to using these data for causal inference, and in 
trials in partnership with bodies like the CPRD as a broker in the recruitment of 
General Practices and provider of an electronic CRF service. The advantages 
of the large, observational studies based on EHRs are often compared to those 
based on RCT data: 
1. EHRs typically provide much larger datasets than do RCTs, and the 
costs inextracting EHR data are typically lower too than the costs 
involved in running a trial. 
2. The costs may also limit the length of follow-up for a trial, whereas for 
EHRs, once the data are abstracted, the follow-up lasts as long as the 
records for each patient. 
3. Evidence from EHRs may complement existing trial evidence, especially 
where it may be unethical to randomise between treatment and control. 
Importantly, evidence from robust analysis of EHR data may also be 
used as pilot work for supporting future clinical trials. 
4. A greater amount of information is also potentially available from EHRs 
across a wider variety of clinically interesting sub-groups than may be 
possible from a clinical trial giving rise to a more heterogeneous dataset, 
from which more patient-specific outcomes may studied  
5. Besides larger sample sizes and affording greater statistical power, 
EHRs also potentially offers investigators the opportunity to observe the 
effect of an intervention as it happens in practice (so-called “real-world” 
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settings) away from the idealised settings of clinical trials. Clinical trials 
are often constrained by ethics and the practical considerations of 
recruiting to trial. Furthermore, patients may behave differently under 
observation in a trial than they would in real-world conditions (the so-
called Hawthorne effect). Hence, the results from trials might not 
necessarily represent what might happen under real-world conditions. 
This may limit or even invalidate their generalisability, or external 
validity, or restrict their applicability to a much narrower section of the 
population than intended. 
 
The last three points, and last two in particular, may be described as the basis 
for “real-world effectiveness”, which is a recurrent theme of this PhD project and 
other studies that use EHRs and routinely-collected data. It must also be 
considered that the very participation in a trial, patients may behave differently, 
in some reacting to the knowledge that they are being observed, giving rise to 
what is known as the Hawthorne effect. The absence of this effect is therefore 
implied in “real-world effectiveness”.  
According to records, the controlled trial has a history extending all the way 
back to ancient history 54. Notably James Lind is commonly acknowledged as 
being one of the first to conduct a controlled trial in recent history 55, but 
perhaps it is with the first randomised controlled trial of streptomycin in 1946 
that truly marked the 20th century as the era of the RCT. RCTs, through design, 
randomisation and delivery, may reduce the impact of bias to deliver high 
quality evidence by anticipating and mitigating for information loss or imbalance 
of potential confounders. However, we should perhaps not underestimate the 
impact on medicine and clinical practice with the arrival of big data, and in 
particular RCD. Data rich sources such as CPRD may be utilised to broaden the 
scope beyond continuity of care for the individual to prevention and informing 
health policies at the population level 56,57. It may be that the 21st century will be 
seen as the era of big data in medicine as well as in other disciplines. However, 
to maintain the quality of evidence, it is essential tools are developed to address 
the problem of confounding bias commonly associated with such data. It is 
towards this objective that this PhD project was directed. 
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1.7 Vaccination in older adults 
As this PhD was in part supported by the NIHR School for Public Health 
Research Ageing Well programme, of particular interest was outcomes 
research in older adults, a population that has been identified as being under-
represented in trials 58,59. The reasons for their under-representation are multi-
faceted, unclear and sometimes without justification, but at a practical level, 
impaired mobility and cognition may play a part in exclusion. The availability of 
EHR data on the population was therefore an ideal basis for addressing clinical 
questions that either cannot be realistically resolved through an RCT, or that 
seek real-world evidence of an intervention, whose efficacy may have 
previously been reported in an RCT. Studies, for which RCTs may not be 
appropriate, can be those investigating long-term adverse events and research 
into secondary unintended outcomes. Other possible investigations included 
research into the discontinuation of treatment and medication. 
Vaccination against influenza and pneumococcal infection in older adults is a 
key public health policy intended to reduce the disease burden and associated 
public healthcare costs. An investigation of vaccine effectiveness would not only 
provide real-world evidence in this clinically important risk group, but would also 
supplement existing trial evidence for a clinically important risk group that may 
be under-represented in randomised trials due to ethical and practical barriers, 
such as gaining informed consent from older adults with dementia, or other 
cognitive impairments 58. The scope for this investigation can be found in the 
protocol (Appendix C), which I co-authored as part of the PhD project, providing 
the major contribution to the statistical design and proposed analysis, and also 
the context in terms of current research. This protocol was submitted along wth 
that from another project using the same Gold Access to the CPRD data, and 
was approved by the Independent Scientific Advisory Committee of CPRD in 
December 2014. As the “oldest old” was one of the themes of Prof. David 
Melzer’s “Ageing well” investigations, the study on immunisation programmes in 
older adults was a logical extension of this package of work. This also 
presented an opportunity to build on the group’s work on polypharmacy in the 
elderly 60,61, and to complement the parallel work that had used the same data 
extraction 62. 
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A review of the literature on the vaccinations against influenza and 
pneumococcal pneumonia is incorporated in the chapters five and six in which 
the studies are presented. Further investigation of the real-world effectiveness 
of these vaccines was prompted by the problem of persistent bias that has 
affected previous observational research into vaccine effectiveness. Analyses 
relying on conventional regression models struggle to fully adjust for 
confounding bias, which is often unmeasured, and is compounded by decline in 
the functional status and age-related frailty in this older population 63. The 
phenomenon of ageing and age-related frailty in older adults is well-
documented 64–67, although presentation and causes are complex and 
multivariable 68,69. Given the implicit vagueness of its definition, yet the 
complexity of its causes and effects, frailty could be thought of as a collection of 
complex latent variables. It is therefore uncertain whether enough of the 
variables, through which such latent effects may be manifest, could be identified 
and measured to control for confounding through an adjusted-regression 
approach to the analysis of nonrandomised data. As explained in previous 
sections, quasi-experimental methods may offer a way of adjusting, or rather 
mitigating for (given that no direct adjustment is made) unmeasured 
confounding. 
A noticeable consequence of ageing and frailty is immunosenescence 70,71 - the 
age-related decline in immune function that is thought to explain the increasing 
susceptibility to infection from respiratory diseases, the vaccines for which were 
the subject of investigation in this project. It is immunosenescence and 
susceptibility to influenza and the pneumococcal infection that has directed the 
policy of vaccinating the older population. However, while vaccination may seek 
to counteract the age-related decline in the immune system, the problem of 
immunosenescence may weaken the intended immune response 
(immunogenicity) to the vaccine itself. The question of vaccine effectiveness in 
older adults is therefore comprised of two enquiries: is the vaccine effective in 
this population, and are there any trends with age that may suggest a 
weakened immune response to vaccination? This was the clinical question that 
motivated the study into the effectiveness of the pneumococcal vaccine in 
chapter five. 
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In chapter six, the effectiveness of the influenza vaccine was studied. However, 
rather than solely investigating its effect on influenza, greater interest lay in the 
potential benefits as a prophylaxis in preventing coronary disease. As will be 
discussed in the literature review of clinical findings, previous research has 
suggested that the influenza vaccination may be beneficial in helping to reduce 
rates of myocardial infarctions in the population of older adults. In seeking 
evidence for the existence of this effect, the study did not seek to explain the 
precise nature of the complex causal pathway that may exist between 
vaccination and outcome, but rather it acknowledged crucially the open system 
of causation that is human biology, as discussed in the previous section on 
causal inference. 
1.8 Summary of objectives 
The aim of this PhD project was to use routinely collected EHR data to evaluate 
the effectiveness of the pneumococcal and influenza vaccines in older adults. 
Retrospective recruitment to each study was different, reflecting the nature of 
the particular vaccine: The pneumococcal vaccine is considered to confer long-
term immunity and the years, 2002 to 2005, over which the vaccine was 
introduced formed a natural experiment for this particular study. In contrast, 
older patients are recommend for revaccination against influenza every year, 
due to the annual changes in the virus mix and pathogen evolution, and so 
annual effectiveness was studied as far back as 1997, the year before the first 
wave in the introduction of the policy to vaccinate older adults. 
Making use of the large data, the moderating effect of age on vaccine 
effectiveness was investigated in both vaccines. However, while the 
pneumococcal pneumonia was the primary outcome in the pnuemococcal-
vaccine study, in the influenza-vaccine study, the primary outcome was 
myocardial infarctions, with influenza as a secondary outcome. In both interest 
also centred on detecting any change in effectiveness with age. However, as 
the data were observational, the studies also served as the basis for 
understanding the performance and limitations of a recently developed set of 
methods for dealing with confounding, called the prior event rate ratio (PERR) 
and Pairwise methods. This necessitated a full review of the methods, their 
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performance using simulated data, and their application in other studies. The 
method was also reviewed in the wider context of quasi-experimental methods. 
Succinctly, the aims of this PhD were summarised as: 
 Conduct a systematic methodological review of QE methods and their 
application to longitudinal data as the context for the application of the 
PERR and Pairwise methods to the longitudinal data of EHRs, to 
understand the relative performance of each method and the strengths 
and weakness of using different QE methods that could be applied to 
EHR data [chapter 2] 
 Conduct a review of sensitivity analyses, as a complementary approach 
to dealing with unmeasured confounding. The literature search for this 
was conducted in tandem with that for the methodological review 
[chapter 3]. 
 Perform a full review of the PERR and Pairwise methods, focussing on 
their relative performance from simulation studies, their assumptions and 
their application in studies since their development. Common settings 
using in subsequent chapters focussing on the methods’ clinical 
application in vaccination studies will also be reported [chapter 4]. 
 Investigate the effectiveness of the pneumococcal vaccine in older adults 
using EHRs, and study effectiveness by age [chapter 5] 
 Investigate the effectiveness of the influenza vaccine in older adults 
against myocardial infarctions and influenza. Again the effectiveness by 
age was also be investigated [chapter 6] 
 In addition to the clinical findings from the vaccination studies, the 
relative performance of the PERR and Pairwise methods was also 
studied with a view to understanding the relative strengths and limitations 
that could lead to further methodological development [chapters 5, 6 & 7] 
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2.1 Abstract 
2.1.1 Objective 
Motivated by recent calls to use electronic health records for research, we 
reviewed the application and development of methods for addressing the bias 
from unmeasured confounding in longitudinal data. 
2.1.2 Design 
Methodological review of existing literature 
2.1.3 Setting 
We searched MEDLINE and EMBASE for articles addressing the threat to 
causal inference from unmeasured confounding in nonrandomised longitudinal 
health data through quasi-experimental analysis. 
2.1.4 Results 
Among the 121 studies included for review, 84 used instrumental variable 
analysis (IVA), of which 36 used lagged or historical instruments. Difference-in-
differences (DiD) and fixed effects (FE) models were found in 29 studies. Five 
of these combined IVA with DiD or FE to try to mitigate for time-dependent 
confounding. Other less frequently used methods included prior event rate ratio 
adjustment, regression discontinuity nested within pre-post studies, propensity 
score calibration, perturbation analysis and negative control outcomes. 
2.1.5 Conclusions  
Well-established econometric methods such as DiD and IVA are commonly 
used to address unmeasured confounding in non-randomised, longitudinal 
studies, but researchers often fail to take full advantage of available longitudinal 
information. A range of promising new methods have been developed, but 
further studies are needed to understand their relative performance in different 
contexts before they can be recommended for widespread use. 
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What is new? 
What is already known 
 Unmeasured confounding is a threat to the validity of observational studies based on 
data from non-randomised longitudinal studies 
 
Key findings 
 Longitudinal information that can be used to mitigate for unmeasured confounding in 
observational data is not always fully or properly utilised in health research. 
 Instrumental variable analysis and difference-in-differences were the most commonly 
encountered methods to adjust for unmeasured confounding in a review of the health 
literature. 
 There are a range of promising new methods, some of which utilise longitudinal 
information to relax the assumption of time-invariance for unmeasured confounders, 
but these are yet to be widely adopted. 
 
What is the implication? 
 All available methods rely on strong assumptions and more research is needed to 
establish the relative performance of different methods for particular problems and 
empirical settings. 
 
 
Figure 1: “What is new?” summary of contribution to research 
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2.2 Introduction 
In the era of “big data” in medicine, the increasing availability of large, 
longitudinal patient databases is creating new opportunities for health 
researchers.  A particular focus is on electronic health records (EHR) with 
routinely collected data collated from multiple care sites, often linked to external 
databases (e.g. death certificates). Built up over time, EHRs provide a 
sequential history of each patient’s encounter with the healthcare system. 
Examples of EHRs include The Clinical Practice Research Datalink (CPRD), 
The Health Improvement Network (THIN), QResearch and ResearchOne in the 
UK, and the Kaiser Permanente Northern California Oracle Research Database 
in the US. The value of large medical data recorded for administrative purposes 
in national registries is already recognised 72,73, with the provision of funds to 
expand the adoption of EHRs in research for patient benefit in the US with the 
Health Information Technology for Economic and Clinical Health (HITECH) Act 
of 2009, and in the UK, with a consortium of funding bodies led by the Medical 
Research Council. Another important source of information for health care 
analysis is databases of insurance claims, such as Medicare in the US, and in 
this review we do not differentiate between EHRs and claims data. 
A strength of EHRs and claims data is that they make it possible to study the 
comparative effectiveness of interventions and the associated risk of side-
effects in a real-world setting. Although randomised trials provide the gold 
standard of evidence, observational studies based on observational patient 
databases offer the potential to study more patients from a wider variety of risk 
groups with a longer follow-up period at a fraction of the cost. However, in the 
absence of randomisation, selection for treatment is often knowingly based on 
specific characteristics, such as frailty, disease severity or the risk of an 
outcome. If the indication for treatment is also related to prognosis, confounding 
by indication arises leading to biased estimation of effectiveness.  There is a 
large pharmacoepidemiologic literature on this topic and current best practice is 
to use design-based approaches such as the Active Comparator, New User 
Design to help mitigate bias where possible 74.However, residual differences 
between the treatment arms other than the treatment itself may still confound 
the intervention effect under study whether or not such an approach is used. If 
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the confounding variables are both known to the study investigators and 
measurable, then these could potentially be adjusted for in prospective non-
randomised studies. With retrospectively recruited subjects, however, the 
recording of such variables is outside the control of the investigator.  Analyses 
of non-randomised studies that fail to account for relevant confounders may 
have important negative consequences for health policy and patient safety. 
Methods described as the quasi-experimental (QE) approach 26, can be 
deployed to account for confounding by unobservable characteristics. These do 
not attempt to directly adjust for resulting bias, but use available information to 
achieve this indirectly under certain conditions and assumptions.  The aim of 
this systematic review is to review current practices in dealing with unmeasured 
confounding in individual-level longitudinal health data and to capture 
methodological developments in this area. While previous systematic reviews 
have been conducted to look at use of propensity score methods for measured 
confounders 75,76, we are unaware of any systematic review comparing use of 
methods for addressing unmeasured confounding in non-randomised, 
longitudinal data. We were particularly interested in how an individual’s history 
could be leveraged to evaluate the effects of unmeasured confounding and how 
the extra longitudinal information could be incorporated to improve adjustment 
for confounding bias. We intend for this review to contribute to the development 
of best practice in addressing unmeasured confounding in longitudinal data. 
The results should therefore help inform researchers intending to utilise “big 
data” from electronic health records. 
2.3 Methods 
2.3.1 Search strategy 
Our search strategy was informed by, but not limited to, known methods for 
addressing unmeasured confounding. The search strategy is recorded in 
Appendix A – methodological review search terms. The following electronic 
databases were searched: MEDLINE (via OvidSp including In-Process & Other 
Non-Indexed Citations) and EMBASE (via OvidSp 1996 to 2015 Week 21). We 
included all citation dates from database inception to May 2015. All references 
were exported into Endnote X7 (Thomson Reuters). 
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2.3.2 Inclusion and exclusion criteria  
The review included any non-randomised comparative studies that sought to 
adjust for unmeasured confounding in longitudinal data with repeated 
observations on identifiable individuals. In the interests of good practice, eligible 
papers had to explicitly identify the problem of bias arising from the selection on 
unobservable characteristics in the data, rather than routinely apply a QE 
design without this justification. For estimates of comparative effectiveness, 
eligible studies had to have independent control arms for each treatment of 
interest. Therefore, single arm studies were excluded. Studies based on case-
only designs, including the case-crossover design and the self-controlled case-
series design, in which confounding is controlled by making comparisons 
between exposed and unexposed periods for the same individual were also 
excluded.  Observational studies were not excluded based on the exposure 
under study so studies into the effects of passive exposures (medical 
conditions, environmental exposures etc) were included alongside studies of 
both the intended and adverse effects of active interventions. We note that good 
proxies for unmeasured confounding, or observed variables that sufficiently 
describe a latent variable such as frailty, would be preferable to dealing with the 
bias resulting from unmeasured confounders. If suitable proxies are identified 
and recorded, then there are in effect no unobserved confounders and the 
proxies could simply be adjusted for in the analysis, obviating the need for 
methods to adjust for the unobserved confounders. For this reason, 
adjustments for proxies of unmeasured confounders, including high-dimensional 
propensity scores, did not fall within the scope of this study. To be consistent 
with the “big data” theme of EHRs, a minimum sample size of 1000 participants 
was applied. This also set a minimum condition for the application of 
Instrumental Variable (IV) and Regression Discontinuity (RD) designs stipulated 
in the Quality of Effectiveness Estimates from Non-randomised Studies 
(QuEENS) checklist. Finally, we only accepted analyses of individual level data. 
We were aware that some studies may use analytical methods, such as 
difference-in-differences that aggregate the data at a treatment-group level. We 
therefore only included those studies, in which the same patients could be 
tracked over the time-frame of the sample. Conversely, some methods, such as 
instrumental variable analysis, make no explicit demands for longitudinal data at 
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the patient level. However, we included such studies where the sample was 
based on the availability of patient-level longitudinal information, with a history 
possibly but not necessarily preceding the time of exposure. We did not 
discriminate between data sources, as patient-level data will often arise from 
medical insurance claims in the US, as opposed to clinically-purposed 
databases in other countries. 
Only studies written in English were included. The following publication types 
were excluded from the review: 
systematic reviews of primary studies. 
randomised controlled trials 
cross-sectional data  
preclinical and biological studies 
narrative reviews, editorials, opinions 
2.3.3 Study selection 
Studies retrieved from the searches were selected for inclusion through a two-
stage process according to the inclusion/exclusion criteria specified above. 
First, abstracts and titles returned by the search strategy were screened for 
inclusion independently by two researchers. In case of doubt, the article in 
question was obtained and a subsequent judgement on relevance was based 
on the full article. Disagreements were resolved by discussion, with involvement 
of a third reviewer when necessary. Following the initial screening, full texts of 
identified studies were obtained and screened firstly by a single reviewer. In 
case of doubt, a second reviewer decided on the suitability of a paper. Where 
multiple publications of the same study were identified, data were extracted and 
reported as a single study. 
2.3.4 Evidence synthesis 
The details of each study’s design and methodology and the key characteristics 
of the data source were tabulated and discussed. We present a summary of the 
methods we found that can mitigate for confounding, or its synonyms as 
unmeasured, unobserved, hidden or residual. We note the historical frequency 
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and context of the application of those methods, to comment on progress in 
causal inference and identify directions for future research. 
2.4 Results 
2.4.1 Included studies 
Our searches returned 734 unique titles and abstracts, with 275 papers 
retrieved for detailed consideration Of the 275 studies eligible for a full-text 
review, 154 were excluded (see flow diagram: Figure 2).  
 
 
Figure 2: Flow diagram for method review 
A total of 121 studies were identified as performing a QE analysis on non-
randomised longitudinal data on human subjects, identifiable at an individual 
level, and so included for a full review of the text (Appendix B – table of studies 
included in the methodological review). 
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The QE methods identified in the review are summarised in Table 1. The most 
frequent method was instrumental variable analysis (IVA) found in 86 of the 
studies (Figure 3) – a method that uses an unconfounded proxy for the 
intervention or exposure. For successful adjustment, the proxy or instrument 
should be strongly, causally associated with the exposure or intervention, and 
the instrument should only affect the outcome through the exposure. In addition 
to IVA, three of these also applied difference-in-differences (DiD) – a method 
that typically uses pre-exposure outcomes to adjust for unmeasured 
confounding and assumes any trends unrelated to the exposure are the same in 
both groups. Seven more studies derived estimates from a combination of both 
IVA and DiD, two of which assumed an absence of higher order autocorrelation 
to use lagged observations of the treatment variable as an instrument. Beside 
the 11 studies applying DiD either in conjunction with or in addition to IVA, we 
identified a further 21 studies, in which the sole QE method was recognised as 
a DiD approach. 
We found five studies applied the prior event rate ratio method, a before-and-
after approach that can be aggregated to the treatment level for survival or rate 
outcomes and analogous to DiD. In all five cases the methods were applied to 
longitudinal, individual patient data. Similarly regression discontinuity (RD) was 
used for such data in three of the studies included for review. Another three 
focused on propensity score calibration (PSC). One study introduced 
perturbation testing and perturbation analysis, while another discussed the use 
of negative control outcomes.  
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Method Description Obstacles to implementation 
Frequency 
of methods 
Instrumental variable 
analysis (IVA) 
Upon identification of a suitably strong instrument, the influence of bias may be reduced 
through post-hoc randomisation. The instrumental variable should be highly determinant of 
the intervention or treatment received, while satisfying the exclusion assumption of being 
independent of the outcome other than through the treatment (Wright 1928; Angrist 1991). 
In practice, finding an instrument with a sufficiently strong treatment association is a stumbling 
block in many analyses (Bound, Jaeger, and Baker 1995; Baser 2009). Association of the instrument 
with the outcome exclusively through the treatment is an untestable assumption, particularly if an 
indirect association exists through an unmeasured covariate. 
79 
Difference-in-
differences (DiD) 
A biased effect estimate between two treatment groups may be corrected by the same 
estimates from a treatment-free period prior to the exposure, which should be a measure of 
the confounding bias contributed to the treatment effect (Ashenfelter and Card 1984). 
Aggregated at the treatment group level, this is operationalised in regression as a period-
treatment interaction. At an individual level, demeaning, first-differencing or dummy 
variables for each individual may yield bias-free fixed effects, contingent on assumptions. 
The method is contingent on the availability of repeated outcomes in both periods and  invokes a 
time-invariant confounding assumption: that the confounding bias as captured by the estimated 
treatment effect in a treatment-free period prior to exposure is constant through to the study 
period. 
24 
Prior event rate ratio 
(PERR) 
Analogous to the DiD method for time-to-event or rate data, a biased estimate of the hazard 
ratio or the incidence rate ratio is adjusted through its ratio with that from a treatment-free 
prior period (Tannen et al. 2008). 
As with the assumption for DiD, repeatable outcomes and a constancy of the unmeasured 
confounding bias is required across both periods, before and after the exposure.  Prior event 
occurrence should not influence the likelihood of future treatment. 
5 
Fixed effects 
instrumental variable 
analysis (FE IVA) 
IVA may be applied to DiD estimation to mitigate for second-order endogeneity: the time-
varying part of the bias that may not have been adjusted for by DiD. 
Assumptions of IVA apply 5 
Dynamic panel model, 
or Instrumental variable 
- generalised method of 
moments (IV-GMM) 
Lagged observations of the confounded (endogenous) explanatory variable are introduced in 
a first-differences fixed effects analysis so that the differences of the lags become the 
instrumental variables in a generalised method of moments estimation. 
Assumptions of IVA apply. Here the differenced lags should not be correlated with the differences 
in the error terms. 
2 
Regression 
discontinuity (RD) 
RD is a design for analysis based on a treatment assignment determined by a cut-off applied 
to a continuous variable that is preferably measured with some random noise (as many 
clinical tests may be). The outcome can then be modelled on treatment for individuals within 
a certain interval from the cut-off of the assignment variable to ensure exchangeability 
between individuals for robust causal inference (Thistlethwaite and Campbell 1960) 
Where assignment is not sharply determined by the cut-off, an increase in the probability of 
treatment may be observed leading to a "fuzzy" version of RD. Continuity in the assignment 
variable is assumed, otherwise manipulation of assignment and reverse causality may be 
suspected. Assignment should be locally random around the cut-off and makes the weak 
assumption that no unobserved covariates are  discontinuous around the assignment cut-off. 
3 
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Propensity score 
calibration (PSC) 
PSC adjusts for residual confounding in the error-prone main dataset by importing 
information about the unmeasured confounders from a smaller, external “gold-standard” 
dataset (Stürmer et al. 2005). Analysis in the main dataset is adjusted using a single 
dimension propensity score of the measured corrected for unmeasured confounding by 
regression calibration against the gold-standard propensity score. 
Successful adjustment is wholly dependent on the availability of another dataset containing the 
exposure variable and error-free predictor,  with individuals that are relevant enough to those in 
the main dataset and under similar enough conditions to assure sufficient overlap between the 
two datasets. 
3 
Perturbation 
testing/analysis (PT/PA) 
This data mining approach aims to mitigate for unmeasured confounding by adjusting for 
many measured variables that are weakly associated with the unobserved confounding 
variables (Lee 2014). Simulation in the single reviewed example demonstrated this may 
require 100's, if not 1000's of perturbation variables (PV). 
This requires a very highly dimensional dataset, which may ultimately obviate the need for indirect 
adjustment if the most or all of the confounders are captured. Simulation demonstrated the bias 
may be exaggerated if a confounder is inadvertently identified as a PV, requiring many more true 
PVs to correct the bias. The number of PVs may exceed the available degrees of freedom 
necessitating clustering. 
1 
Negative control 
outcome / exposure 
(NCO/NCE) 
A negative controls causally related to measured and unmeasured confounders affecting the 
exposure and main outcome, but not directly causally related to exposure and outcome 
themselves. As such, the negative control may be used to detect confounding bias in the 
main study, and potentially to indirectly adjust for this (Richardson et al. 2014) 
This assumes that the effect of the unmeasured confounders on the main outcome is similar to 
that affecting the negative control. 
1 
Table 1: Summary of methods to mitigate against unmeasured confounding captured by systematic review, and the frequency of their 
use amongst the captured papers 
  
   
 
 55 
 
Figure 3: Plot of frequency of reviewed methods for mitigating for unmeasured confounding by: difference-in-differences [black]; 
Instrumental variable analysis (IVA) [mid-grey]; Other [light grey] includes regression discontinuity, prior event rate ratio method, 
propensity score calibration, perturbation analysis, negative control outcomes, fixed effects with IVA and dynamic panel models. Note: 
the low frequencies in 2015 was attributable to the May cut-off for inclusion in that year  
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2.4.2 Studies excluded at full text 
The principal reason for exclusion in 94 of the studies, according to our eligibility 
criteria, was the absence of longitudinally observed, non-randomised outcomes on 
all individually identifiable persons, although other characteristics may also have 
justified their exclusion. No particular method was associated with the absence of 
longitudinal data on identifiable individuals with studies in this exclusion category 
comprising 59% DiD and 28% instrumental variable analyses compared, 
respectively, to 53% and 32% of all 154 of the rejected studies. Having fewer than 
1000 longitudinally observed individuals excluded 23 studies, among which those 
using instrumental variable analysis (IVA) numbered 15. Seven were excluded for 
not employing a QE method for unmeasured confounding. Five studies presented 
exploratory analyses without a focused clinical question; five were either method 
reviews or commentaries without an application of methods to data; one study 
duplicated a dataset already marked for inclusion, while another failed to specify the 
instrumental variable used. Of particular note were the 18 studies using the DiD 
approach that were excluded because no explicit justification was made for using the 
method to address unmeasured confounding, or any of its synonyms. In these 
studies, justification of the method was centred more on econometric concerns over 
time trends, and presented in terms of controlling for those trends rather than pre-
existing differences between the control and exposed group. 
2.4.3 Results of the included studies 
So far studies have been categorised according to their identified QE method. 
However, certain properties are shared across some of the methods, and can be 
classified according to how they reconcile their specific assumptions with the 
information offered by the structure of big, longitudinal data that typifies EHRs. In 
particular, we organised our results around how each method had incorporated 
longitudinal information, and the assumptions required. The stable of before-and-
after methods, that includes PERR and DiD, implicitly incorporates longitudinal 
information. Thereafter the challenge is how to relax the assumption of time-invariant 
confounding. Conversely, IVA is not uniquely applicable to longitudinal data, but we 
were able to broadly classify the types of instruments used (Table 2), some of which 
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did utilise longitudinal information. We found out of the total 121 studies, 77 
incorporated some element of longitudinal information into their analysis. 
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IV type Explanation/ Example No. of papers 
Total 
frequency 
Mendelian 
Genetic characteristics :Single 
nucleotide polymorphisms 
11 11 
Geographic 
Differential distance between 
patient's postcode and nearest 
health facility 
19 
1 
 
1 
21 
Time 
Time-based characteristic of 
treatment such as date of therapy 
6 
2 
10 
Historical 
Usually prescribing preference of 
physician or facility based on 
historical records of previously 
administered therapies 
31   34 
Lagged 
Previous therapy or outcome of 
patient 
6 6 
Randomisation Original randomisation 1 1 
Other 
Characteristics of individual 
e.g: age of patient, weight of 
offspring 
e.g: age of patient, weight of 
offspring 
8 8 
Table 2: Frequency of instruments categorised by type used in instrumental variable 
analyses 
2.4.3.1 Incorporation of external/additional data 
The propensity scores (PS), the predicted probability of exposure or treatment 
conditioned on measured confounders,were used in the seminal work on propensity 
score calibration (PSC) by Stürmer to calibrate an error-prone PS against a gold-
standard PS and hence arrive at an inference for the level of unmeasured 
confounding bias 77. The two subsequent PSC papers examined the tenability of the 
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method’s assumptions, firstly using simulated data to evaluate the conditions 
necessary to violate the surrogacy assumption 78. The second primarily used 
simulated data and applied the results to registry data to demonstrate a framework 
for determining size and direction of bias from one measured and one hidden 
confounder 79. 
2.4.3.2 High-dimensional data 
Since PSC collapses multiple, potential confounding variables down to the single 
dimension of a propensity score, the three PSC papers can also be considered a 
means of dealing with high-dimensional data. In addition to these, our review also 
included a novel data-mining approach that proposed to exploit the many factors 
(perturbations) that may be weakly associated with the unmeasured confounders 
from a high dimension dataset 80, for which longitudinal data may mitigate for 
incorrect adjustment of a collider. Perturbation analysis was successfully 
demonstrated on simulated data, although accidental inclusion of a measured 
confounder required many more perturbations to correct the resulting bias. Both the 
perturbation method and PSC were also proposed as sensitivity analyses. 
2.4.3.3 Quasi-experimental adjustment without longitudinal assumptions 
Those studies characterised as using a QE method without any longitudinal 
dimension were PSC and PT as described above. We also added to this category 11 
examples of Mendelian IVA 81–91 plus 32 other IVAs without historic or lagged 
instruments 92–123. While time-based instruments may at first seem longitudinal, 
these instruments, such as date of therapy, would need to be related to previous 
exposures or outcomes to be considered longitudinal. In some cases, survival times 
or rate data were used, but such outcomes do not intrinsically imply longitudinal 
adjustment for confounding. In spite of these “cross-sectional” approaches, all 
studies were based on some form of longitudinal data at the person level, as 
demanded by our inclusion criteria. Among the 43 non-Mendelian IVA papers in this 
non-longitudinal category, one study adjusted for non-longitudinal fixed effects within 
twins 101. In another three, discussed below, the analysis was supplemented with 
DiD 100,110, and with IVA applied to first-differences 124. 
One study examined the effect of lagged, cumulative exposure to radiation on lung 
cancer in uranium miners and nuclear workers 125. The problem of unmeasured 
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confounding was addressed using a method developed in earlier work that proposed 
negative control outcomes and exposures as a means of both detecting and 
potentially resolving confounding bias 126. Here the choice of death due to chronic 
obstructive pulmonary disorder as a negative control outcome was informed by 
clinical knowledge of there being no direct relationship with the exposure  except 
through the possible confounder, smoking. Given a plausible negative control 
outcome or exposure, the method offers at least a means of testing for confounding, 
and potentially a method of adjustment under the assumption that the association 
between the unmeasured confounder and the negative outcome is similar in 
magnitude to that between the same confounder and the outcome of interest. 
2.4.3.4 Quasi-experimental adjustment assuming time-invariant 
longitudinal information 
We found 36 IVA studies that used lagged information or history about the 
individuals’ exposure as instruments 124,127–162. One study had recourse to the 
random assignment from a previous study, and used this as an instrument 131. 
Except for that and four other different exceptions, the instruments were all based at 
least in part on the previous intervention, or history of interventions, of the clinician or 
healthcare facility. Characteristics of the clinician or facility may be chosen as 
instruments as they are more likely to affect the treatment only. This avoids direct 
associations with the individual and their outcome, and so better enforces the 
exclusion restriction – the exclusion of the instrument’s association with the outcome 
except through the treatment under study. While no assumptions are made about the 
dependence of confounding on time, the strength of the instrument clearly rests on a 
significant association between previous treatment(s) and the current treatment 
under investigation. In this regard, if the strength of an instrument varies with time, 
this may undermine its utility. 
In total, 24 studies also incorporated longitudinal information through the stable of 
methods that, in an abuse of terminology, we collectively referred to as the DiD 
approach. These included the 18 examples cited as using DiD regression 163–180 
alone, and four fixed effects (FE) 181–184. Either through fixed effects at the individual 
level or through aggregate-level regression operationalizing the DiD approach, these 
methods “ignore” the effect of confounding, which is assumed to be time-invariant. At 
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the individual level, time invariant confounding can be ignored by assigning nuisance 
dummy variables for each individual, or cancelled out through demeaning the 
observations, or through the first differences of observations on each individual. Two 
of the studies also extended DiD to allow different exposure effects and trends 
across two-level sub-groups in the higher-order contrast of difference-in-difference-
in-differences 168,173. Fourteen studies also adjusted for individual-level fixed effects 
either through direct inclusion of their covariates, or through matching or weighting 
on the propensity score of the covariates. This was perhaps a more rigorous and 
precise approach, accounting for known confounders, and yielding smaller standard 
errors for the estimated treatment effect. However, an assumption of time-invariant 
confounding was still required, with a null difference between exposure groups in the 
prior period being evidence of adjustment for time-invariant confounding only. Two of 
the 24 DiD studies also re-analysed their data using IVA 100,110, which provided an 
albeit limited opportunity to compare the relative performance of these methods. In 
the study by Schmittdiel et al.  of how statins delivered by mail order affects 
cholesterol control 110, the intervention coefficient from modelling the single main 
outcome was larger through DiD analysis and its standard error smaller than those 
from IVA, large standard errors being a feature of weak instruments. The study by 
Lei and Lin investigated the effect of exposure to a new medical scheme on 15 
health outcomes and rates of health-service utilisation 100. The effects were either 
not significantly different from the null or were significant and of similar magnitude 
with similar standard error except for two outcomes, where the effect size was 
significantly larger for IVA. 
Time-invariant confounding, also known as the parallel trends assumption, was 
relaxed by including dummy variables for the year and its interaction with the 
treatment dummy in a fixed-effects analysis, which allowed the unobserved trend to 
vary between exposure groups 183 using methods developed in economics and 
therefore not captured by this review 185,186. The results from this DiD with differential 
trend model were presented alongside those from the simple pooled DiD model and 
DiD with individual fixed-effects for the effect of financial incentives in care services. 
Tests confirmed parallel trends could be assumed in three outcomes, but out of the 
five outcomes presented, four were statistically significant and in all, the estimated 
effect size by differential trends was greater. 
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Our review also included six studies applying the prior event rate ratio method, a 
before-and-after analogue applicable to survival and rate data 187–192. The first two 
published were the seminal presentation of the method applied to registry data. Also 
included was a comprehensive evaluation by Uddin et al. of the performance of 
PERR under a wide array of simulated, theoretical settings, under which bias was 
shown to increase with a greater effect of the prior events on subsequent exposure 
or intervention.  When prior events strongly influence the likelihood of treatment, the 
exposure effect from the PERR method can be more biased than estimates from 
conventional methods121. The problem was re-examined in a recently published 
study, which provided a more general statistical framework for PERR adjustment and 
considered the potential for generalising the method to allow more flexible modelling 
192.  
2.4.3.5 Dynamic, longitudinal quasi-experimental methods and time-
varying information 
While regression discontinuity (RD) could suggest a longitudinal design, this is not 
exclusively so, and two RD studies were excluded because of this (one applied to 
spatial data while the other data was not longitudinal). Of those included all three 
could be said to accommodate time varying trends 193–195, and two of these were 
nested within a pre-post design: Zuckerman et al. were explicit in their 
methodological study in identifying the robustness to time-varying confounding, in 
which inhaler use in asthmatic patients was served as both the outcome variable in 
the post-test period as well as the assignment variable in the pre-test period 195. In 
the study of the effect school-leaving age on mortality by Albouy, different slopes 
were modelled for the assignment variable, year of birth, after the cut-off date 193. 
This acknowledged different maturation rates after assignment. However, as long as 
the assumptions of the method were met, assignment should have been as good as 
randomised, and so no further assumptions about the temporality of confounding 
was required. 
We also picked up six examples where IVA had been combined with either DiD or a 
fixed effects model, first appearing in our review with example from 2003 196. In 
Fortney’s 2005 study of treatment for depression 197, this combination method was 
justified as a control for time varying confounding, referred to as second-order 
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endogeneity. Further examples of the fixed-effects instrumental variable model were 
found 198,199. The roles of lagged treatments and outcomes as possible IVs and 
predictors were extensively considered in O’Malley’s study of whether the 
introduction of more expensive medication could have led to improved cost-
effectiveness in the long term 124. The author cautioned that the exclusion restriction 
may be difficult to satisfy when using the lagged treatment as an IV after first 
differencing. However, two studies 200,201 used differences in the lagged explanatory 
variable as the IVs to adjust for second-order endogeneity in a first-differences 
analysis following methods, not captured by our review, but developed in the realm 
of Economics 202–204. Referred to as the dynamic panel model or IV-GMM, this 
method was implemented efficiently through generalised method of moments. In 
their report on healthcare expenditure in patients with rheumatoid arthritis, Kawatkar 
et al. found the yielded estimates were further from the null with larger standard 
errors when compared to those from FE alone 200. 
 
2.4.4 Implementation of methods 
While choice of method in each study often rested on which extra information was 
available to address the issue of unmeasured confounding, method selection may 
also have been informed by the research area. The negative control method had its 
origins in epidemiology, with applications to occupational health policy. Likewise, the 
PERR method was developed exclusively on health data, with applications to drug 
safety and public health policy. Reflecting their origins in health econometrics, some 
studies were published in journals partially or entirely dedicated to the subject, with 
15 published 100,124,163–166,173,176,181–184,196,197,200 in this field out of the 32 studies using 
DiD and 29 93–95,98,103,104,109,111,112,114,116,120–122,128,131–134,140,144,147,150,205 out of the 86 
using IVA. Under the inclusion criteria, all studies had health outcomes or 
interventions. Mendelian IVA necessarily includes genetic information, and all were 
published in health-related journals. In contrast, all three studies using RD were 
published in health econometric journals. 
Before implementing one of the proposed methods, a natural first step is for the 
researcher to try to assess how much bias from unmeasured confounding is likely to 
be present.  While many of the included studies reported raw or unadjusted 
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descriptive estimates, bias estimation was limited either to considering the 
contribution from known confounders, including those summarised as a propensity 
score, or to methods, such as perturbation testing/analysis and negative controls 
methods, in which bias evaluation is an incremental step in adjustment. Under the 
assumption of time-invariant confounding, the difference-in-differences method may 
potentially offer a way of evaluating bias by modelling group differences in the pre-
exposure period. However, few studies evaluated hidden bias in this way 110,174,182. 
The regression formulation of the DiD method effectively by-passes separate 
analysis of the prior period. Instead studies often discussed the within-group 
changes over time. Similarly, the prior-period estimate from the PERR method 
implicitly offers an evaluation of confounding bias under the same assumptions, yet 
none of the studies presented information on outcomes in the prior period in this 
way. A direct evaluation of unmeasured confounding is less straight-forward in IVA, 
with further diagnostic tests only recently developed for the association between 
instrument and confounders 206,207 . 
2.5 Discussion 
This review examined the application of methods to detect and adjust for 
unmeasured confounding in observational studies, and was motivated by recent calls 
to utilise EHRs. Most of the reviewed studies used more established methods such 
as DiD and particularly IVA. We summarised how studies exploit the longitudinal 
information afforded by EHRs. 
It may be tempting to view electronic health records and medical insurance claims 
data as a problem of large observational data, and hence search for solutions 
through data mining. However, ethics governing patient data collection, plus limited 
clinician time is likely to preclude data with very large dimensions. For that reason, it 
is doubtful there would be enough dimensions for a method like Perturbation 
Analysis (PA) to be a practical solution. In addition, a greater number of variables 
would likely include enough information about the confounders to obviate the need 
for further adjustment through PA. More generally, the purpose of EHRs primarily as 
an administrative tool limits the scope for data mining of known confounders. 
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Similarly, limited availability of gold-standard datasets may have confined the use of 
external data, as in PSC, to but a few examples. 
We were surprised by the number of studies using IVA alone. While Mendelian 
randomisation has its advantages for many studies as a reasonable guarantor of the 
exclusion restriction, in general IVA typically suffers from the weak-instrument 
problem, resulting in large standard errors and wide confidence intervals. 
Longitudinal data offer an opportunity to reinforce the exclusion criteria by choosing 
historical or lagged instruments. However in doing so, the causal structure needs to 
be understood to avoid opening up “back door” paths and inducing further bias 124. 
DiD arguably offers advantages over IVA in being more intuitive and easier to 
conceptualise, and with the longitudinal data in EHRs it should be inherently easier 
to work with prior observations than to identify strong instruments. Even though 
before-and-after methods are not subject to the imprecision of weak instruments, the 
resulting estimates are only unbiased if the unobserved confounders exert a 
constant effect over the observation windows before and after exposure. Where 
multiple observations per individual exist, time may be paramaterised and different 
trends between exposure groups can be accommodated in DiD with differential 
trends, but a time invariant assumption about confounding must still be made. To 
partially or wholly relax this particular assumption, instrument variable analysis can 
be incorporated into the fixed effects model. Assuming the instrument’s exclusion 
restriction is satisfied then this doubly-robust approach affords the advantage of DiD 
over possibly weak instruments, while mitigating for some or all of the time-
dependent confounders ignored by DiD alone. Similarly, where multiple previous 
treatments or exposures are recorded, the differenced lagged treatments can be 
utilised as IVs in a fixed effects model to accommodate time-dependent confounding 
bias using the generalized method of moments system, referred to as IV-GMM or the 
dynamic panel model. 
Another potentially robust approach to unmeasured confounding would be the RD 
design, although the small number of examples in our review probably reflects the 
limited number of scenarios where this can be reasonably applied. Another concern 
over and above the usual technical challenges of applying the RD method is that in 
spite of heath records promising ample data, the sample would need to be reduced 
to an interval around the cut-off that ensures exchangeability of the two treatment 
   
 
 66 
groups. In this case generalisability would be restricted to individuals with 
characteristics found in the interval. As with RD, PERR was another method that was 
found in relatively few studies. This may have been in large part due to its recent 
development, rather than any technically demanding aspect of its application, since it 
simply extends the before-and-after approach of DiD to survival and rate data - 
outcomes that are common enough in health research.  However, the PERR 
approach does require strong assumptions including time-invariant confounding and 
the absence of an effect of prior events on likelihood of future treatment 192.   
Methods such as IVA and DiD have their origins in the sphere of econometrics, 
where randomised experiments are rare. We found that in importing DiD, some of 
the studies failed to explicitly acknowledge the problem of confounding bias. Instead 
justification for the method was presented in terms of the common trends 
assumption. Discussion of possible confounding bias is regarded as essential by 
most QA toolkits for observational data, and it is important that health researchers 
explicitly recognise this threat to the internal validity of non-randomised studies. 
Conceptually a non-temporal analogue of DiD would be the NCO method, which 
itself was presented foremost as a method for detecting unmeasured confounding. 
Given doubts over satisfying necessary assumptions for their implementation, 
authors of this method along with propensity score calibration and perturbation 
analysis have suggested that, as sensitivity analyses, these can at least offer an 
insightful complement to QE adjustment.  
Choosing between methods to reduce unmeasured confounding bias is challenging 
and we found few studies that directly compare methods. The performance of 
different methods will depend on factors such as the nature of the underlying 
confounding, the type of exposure and outcome, and the sample size 208  The type of 
data available will also guide the choice of method.  For example, the instrumental 
variable method requires a suitable instrument and DiD / PERR require data on at 
least two periods. In practice, no one method is likely to be best suited to all 
problems, and it is essential for investigators to carefully assess the potential biases 
in each proposed study, where possible tailoring the methods or combination of 
methods to address these biases 209.  Our review has highlighted how use of 
longitudinal information is one additional and potentially important consideration in 
this process.    
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While our review focussed on the problem of adjustment using analytic methods, 
many problems associated with observational data may be pre-empted by use of an 
appropriate study design 210.  Before choosing an appropriate analytic method, it is 
recommended that investigators carefully identify and match individuals for the 
control and intervention groups in order not to exacerbate any bias 74. The 
importance of study design is often discussed with a view to minimising confounding 
bias from unmeasured sources, with the subsequent adjustment accounting for 
observed confounders only 211, usually through the matching, weighting or 
adjustment of propensity scores 212. Where the success of the design remains in 
doubt, or its criteria cannot be fully met, then investigators will inevitably need 
recourse to some of the alternative methods reviewed in this report.  
The reviewed studies did not seek to distinguish between the different mechanisms 
of bias. Confounding by indication, deemed intractable by many researchers using 
the observed data 213,  was seen to create additional sources of bias in two separate 
simulation studies applying the “longitudinal” method of PERR, when an association 
was modelled between prior events and treatment status in the study period 121,122. 
Another common form of selection bias in pharmacoepidemiologic studies is the 
healthy user bias and this works in the opposite direction to confounding by 
indication, distorting treatment-outcome associations towards the treatment looking 
beneficial3.  Further research is needed to understand how each of the methods in 
this review is affected by the different types of confounding. 
An inherent limitation of this large, wide-ranging review is that it precluded 
meaningful data synthesis due to the mix of different data and study types.  
Furthermore, we could only find a few examples where the performance of different 
methods was compared within the same study. We also stipulated in the inclusion 
criteria that unmeasured confounding, or any of its synonyms, should be given as 
justification for methods in its adjustment. This may have inadvertently excluded 
some papers, where justification was implicit, but good practice in health research 
demands acknowledgement of this source of bias where applicable. While our 
search terms were specific to the scope of our review, we accept that this may have 
inadvertently excluded relevant methods and studies. Some methods, such as 
negative control outcomes, that were identified in the original search were not 
included as explicit terms in the search strategy, and further secondary searches 
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may have uncovered additional studies using these methods. We also acknowledge 
that there may be other relevant methods for addressing unmeasured confounding 
that have been missed by the search strategy. Consequently, we made inferences 
about the relative application of methods with caution. However, we were surprised 
so many studies focussed solely on IVA as the sole means of adjustment. A similar 
conclusion was echoed by a different review on regression discontinuity designs that 
found interest was growing in RD only as recently as 2014 214. 
By choosing to focus on methods with an independent control arm for each 
treatment, our review excluded case only designs including case-crossover designs 
(CCO) and the self-controlled case-series design.  This class of methods addresses 
unmeasured confounding by making comparisons within individuals so that each 
individual acts as his or her own control.  Another case-only design, the case-time 
control design, is an extension of the CCO design that uses information from a 
historical control group in a similar way to the PERR method.  These approaches are 
reviewed by Uddin et al 208 and Nordmann et al 215. 
This review has considered a range of promising new methods for addressing 
unmeasured confounding in non-randomised studies. However, consistent with prior 
research on dissemination and uptake of statistical innovations146, the rate of 
knowledge translation has been slow and we found that most studies in our review 
used established methods such as IVA and DiD.  A recent study by Cadarette et al 
has shown how Rogers’ Diffusion of Innovations model can be used to describe the 
adoption of novel methodologies in pharmacoepidemiology147 and this provides a 
useful resource for interpreting the uptake of methods in this review.  Cadarette et al 
proposed five principles for authors of methodological innovations that may improve 
translation into practice 147: (1) clearly describing the methods using foundational 
principles; (2) comparing results to established methods; (3) providing sample data, 
code or calculation examples; (4) early communication, support and testing; and (5) 
providing methodological and reporting guidance. These recommendations offer a 
useful checklist for researchers developing methods for addressing unmeasured 
confounding in observational studies. Of particular relevance in the context of this 
review is the need for more extensive evaluation and comparison of the emerging 
methods in a range of settings.   The review also addresses the need for 
methodological guidance through highlighting the potentially important role of 
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longitudinal information in addressing confounding bias and has identified this as an 
area for further development. 
2.6 Conclusions 
Our review showed how seminal work in econometrics has influenced practice in 
dealing with unmeasured confounding in clinical and epidemiological research. 
Although the issue of unmeasured confounding is widely acknowledged, we found 
that longitudinal information in observational studies appears under-utilised. Lagged 
and historical characteristics associated with the treatment may help enforce the 
exclusion restrictions of instrumental variables under the appropriate causal 
structures, while before-and-after methods, such as DiD and PERR, afford an 
intuitive approach without the imprecision of weak instruments. Furthermore, they 
offer a direct evaluation of time-invariant confounding bias. The most robust methods 
we found applied instrumental variable analysis to the fixed effects difference-in-
differences method, where such suitable instruments or difference lagged variables 
could be assumed to satisfy the exclusion restriction.  While there are sometimes 
good technical reasons for choosing one mode of analysis over another, many 
questions remain over the most appropriate methods.  All methods rely on 
assumptions, but little guidance is available to applied researchers as to the 
empirical settings in which particular methods can be safely used.  Few studies 
directly compare different methods and more research is needed to the establish the 
relative performance of the methods in realistic settings.    
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Chapter 3  -  Sensitivity analysis for addressing 
unmeasured confounding: a methodological 
review 
3.1 Introduction 
Both SA and QE methods take an indirect approach to the problem of confounding. 
The QE methods of chapter 2 make an adjustment, or rather a mitigation for 
unmeasured confounders, by invoking assumptions and utilising other available 
information, such as longitudinal observations available on patients in EHRs. Where 
uncertainty exists over the tenability of the assumptions or the precision of the 
estimates, such methods can be presented as SAs to postulate how much of the 
observed effect could potentially be attributed to residual confounding. In this way, 
the distinction between QE methods and SAs is not entirely clear. Therefore, it was 
important to also consider QE methods in the context of SAs, and so the search 
terms for SA were also included in the search strategy for methodological review of 
chapter two (Appendix A). 
Typically, an SA is either performed over a range of plausible settings for the 
confounding effect, or empirically discovers the degree of confounding required to 
move an observed effect to the null. Information on the direction and strength of 
association between the confounder and the outcome and key explanatory variables 
may be inferred from the data, or be imported from a source other than the dataset 
under analysis. If a high degree of imbalance of the confounder(s) across the 
treatment groups, or an implausibly high association of the confounder(s) with the 
outcome, is needed to change or explain treatment effect, then the results can be 
assumed to be reasonably robust to realistic levels of unmeasured confounding. 
Cornfield et al. 216 are often cited as the authors of seminal work on this approach. In 
this respect, adjustment methods and SA are very much complementary approaches 
to the problem of unmeasured confounding. 
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3.2 Methods 
The search strategy for the SAs followed the same as that for the methodological 
review, already outlined in chapter two. The study selection process also followed 
that of the review. The search term for sensitivity analysis can be found amongst the 
terms for the methodological review in Appendix A – methodological review search 
terms.  
3.2.1 Inclusion and exclusion criteria 
The definition and implementation of SA can vary from study to study. For the review 
an SA was defined to be a method by which a conventionally adjusted estimate for 
an intervention is challenged by the introduction of a hypothetical confounding 
variable(s) for a range of associations between the outcome, exposure and 
confounder(s). This did not include covariate substitution or restriction to a range of 
covariates or sub-group analysis, approaches which were excluded from the review. 
An additional consideration in managing the size of the review results was the 
expectation that the results from the literature search would be dominated by 
observational studies routinely following good practice in applying SA to test the 
robustness of results from inferential models. For that reason, I focussed on studies 
that sought to either develop SA methods using either simulated or observed data of 
any size, or explicitly focussed on the application of SA. 
3.3 Results 
In all, 23 papers on sensitivity analysis were eligible for review, including three 
studying propensity score calibration (PSC), one on perturbation testing and one on 
negative control outcomes (Table 3).  Some studies were based on seminal work not 
captured in the literature search for this review, which were nonetheless included for 
reference and discussion. One such was Greenland’s review of SA 217, which applied 
the basic formulation for the “external† adjustment” of a single binary confounder 
affecting the odds ratio of the association between a binary exposure and outcome. 
This involves choosing a plausible range over which to vary the confounder-outcome 
association and the odds of confounder prevalence in each exposure arm, but 
                                            
† “external” denotes manipulation by the author rather than external data 
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requires simultaneous interpretation of the confounder parameters. Margolis et al 218 
deployed this method and compared it to another by Rosenbaum 219, which 
summarised the imbalance of confounder prevalence as single parameter to predict 
the observed outcome due to the exposure. Margolis et al. advocated a combination 
of both approaches to reduce the number of computations. A study by Cabral 
captured in this review 220 also followed this principle. 
In their study, Arah et al 221 provided simplified formulae for uncontrolled confounding 
bias for different effect scales (risk difference, risk ratio and odds ratio) under a 
common framework, which can also accommodate polytomous unmeasured 
confounders. Formulae for SAs were subsequently extended to interaction analysis 
by VanderWeele et al. 222, who present bias formulae for interactions on both the 
additive and multiplicative scales. 
As a complement to finding a corrected point estimate for a set of parameters 
describing the confounder relationship, MacLehose et al. 223 reviewed a method for 
deterministic nonparametric bounds for the causal effect identified by the potential 
outcomes model and implemented this through linear programming, a procedure 
more widely used in operations research and econometrics. 
The general regression-based formulation developed by D. Lin et al. 224, which could 
accommodate censored survival times as well as continuously distributed 
unmeasured confounders, was the basis for the study by N. Lin et al 225. This 
provided a general framework for characterising the contribution to bias from missing 
covariates and censoring in the Cox model. As a special case of this framework, the 
method of D. Lin et al. was found to perform less precisely as the magnitude of bias 
increases. The work by N. Lin et al. would inform later work, presenting the Pairwise 
framework 192, which also included a test for the presence of confounding. 
Our review also picked up studies that sought to address the problem of uncertainty 
over the distribution of externally adjusted confounders. Steenland and Greenland 226 
present Bayesian sensitivity analysis (BSA), and the analogous Monte Carlo 
sensitivity analysis (MCSA) as methods for acknowledging both uncertainty from 
random sampling and confounding bias in a single interval estimate. The BSA 
approach was adapted by De Vocht et al. 227 under the full Bayesian framework to 
adjust for smoking history as the residual confounder in a study of the risk of lung 
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cancer in a cohort study of workers within the European asphalt industry. With the 
advantage of extra processing power afforded by advances in computer technology, 
the authors were able to specify the confounder prevalences without approximation 
from the more realistic Dirichlet process as originally suggested by Steenland and 
Greenland. Later Carrao et al. 228 also expanded on the SA method by Steenland 
and Greenland 226 through their study of mono- and combination therapies and 
cardiovascular disease, using health records. Here the exposure-confounder 
association was evaluated using an external dataset, reflecting this random 
uncertainty through Monte Carlo sampling for three different hypothesised outcome-
confounder associations.  
The review also captured two papers developing BSA from the same authors. 
McCandless et al. 229 used both simulated data and health records in their study into 
treatment for heart failure to demonstrate the advantage of acknowledging 
uncertainty over the prior distribution of an unmeasured confounder. In a following 
paper 230, using the same illustrative example, the authors demonstrated that 
uncertainty over a single binary unmeasured confounder could be reduced using 
hierarchical prior distributions in BSA, by assuming the confounder originated from 
the same distribution as the measured confounders. Subsequently, Gustafson et al. 
231 developed a simple prior distribution for a SA, requiring only a small number of 
hyperparameters, to model both poorly measured and unmeasured confounding. 
The intention was that this simplified approach, referred to as the simplified Bayesian 
sensitivity analysis, could be more easily adopted in practice. 
A propos of poorly measured confounding, Brunelli et al. 232 studied a problem 
specific to retrospective cohort data, such as EHRs. Baseline data and patient 
histories are often gathered from information from the prior period preceding the 
index date of the study, here referred to as the “look-back window”. The authors, 
examining the sensitivity of results to the length of look-back window, found that all-
available information resulted in less bias with lower mean square error compared to 
a fixed-interval window. 
In their seminal work on PSC as a QE method, Stürmer et al 233 also presented this 
as a sensitivity analysis. Besides importing information about confounding from an 
external source, this also confers the advantage reducing the dimensionality of 
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multiple confounders to a single score for adjustment of the exposure effect. The 
PSC approach was presented in a subsequent paper by Schneeweiss 234 captured 
by our literature search, which presented PSC along with MCSA, the “rule-out” 
approach (the level of confounder imbalance and confounder-outcome association 
required to account for the observed effect) and what the author dubbed the “array 
approach”, which estimates the response surface of the outcome risk ratio after 
adjustment across a constellation of confounder parameters. Further work by Lunt et 
al. 79 presented a framework for advancing PSC as an SA method through the use of 
DAGs. Testing one of its key assumptions, surrogacy, they confirmed earlier work 78 
that PSC was unbiased conditional on the effects of the unmeasured confounders 
being in the same direction as that of the observed. 
The problem of dimensionality in representing an array of potential unmeasured 
confounders was explored in the study by Li et al. 235, which proposed the propensity 
score as the sensitivity function of unmeasured confounders, developed by Robins et 
al. 236 and Brumback et al. 237 in their SA for inverse-probability weighted estimators. 
This approach also demonstrated some robustness against the misspecification of 
the functional form of the propensity score. Again through inverse-probability 
weighting, but more pertinent to modelling repeated outcomes with time-dependent 
confounding from longitudinally observed data, Ko et al. 238 performed an SA to a 
plausible range of the selection-bias parameter in the marginal structural model, as 
developed by Robins 239 and Hernán 240. 
The concept of perturbation 80, already discussed as an adjustment method in the 
review of QE designs, intuitively seems better suited as an SA, as it tests for 
unmeasured confounding through weak associations of 100’s, if not 1000’s of 
observed variables. This data mining approach should in theory be applicable to the 
big data of EHRs, but its implementation may be impeded by the method’s 
assumptions and the need for so many observed variables, presumably just a subset 
of which would comprise enough confounders to sufficiently adjust for bias. 
In contrast to perturbation testing, which relies on the availability of non-confounding 
covariates associated with confounders, the study by the Richardson et al. 125 
applied the negative control outcome (NCO) method, which takes a more 
parsimonious approach to utilising internal information from the dataset (as opposed 
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to external adjustment or external calibration data). Their study was based on earlier 
work by Lipsitch et al. 126, not captured in the literature search, which proposes 
finding another outcome unrelated to the outcome of interest and only causally 
related to the exposure through the confounders of exposure and outcome. This 
way, confounding bias may be detected through an effect of the exposure on the 
NCO, assumed to be through the unmeasured confounder, when conditioned on the 
measured confounder. 
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Table 3: Summary of studies on sensitivity analysis, returned by the literature search. 
Authors Year Title Summary 
Margolis, D. J. 
Berlin, J. A. 
Strom, B. L. 
Berlin, J. A. 
Strom, B. L. 
1999 A comparison of 
sensitivity analyses of 
the effect of wound 
duration on wound 
healing 
Effect of dichotomised wound duration on failure to heal in 
chronic leg ulcers comparing two approaches to SA, one of 
Rosenbaum 219 & one of Greenland 217, of estimates to 
unmeasured confounders. An important methodological 
statement on a complementary approach in using 2 SA methods 
together 
Du, X. L. 
Key, C. R. 
Osborne, C. 
Mahnken, J. D. 
Goodwin, J. S. 
Key, C. R. 
Osborne, C. 
Mahnken, J. D. 
Goodwin, J. S. 
2003 Discrepancy between 
consensus 
recommendations and 
actual community use 
of adjuvant 
chemotherapy in 
women with breast 
cancer 
Study investigated whether chemotherapy varies with age in 
women, and tested sensitivity of results to unknown confounders 
using method by Greenland 217: This was expanded for eight-
level exposure groups of age, and tested sensitivity to a 
confounder dichotomised around different age cut points. 
Ko, H. 
Hogan, J. W. 
Mayer, K. H. 
2003 Estimating causal 
treatment effects from 
longitudinal HIV natural 
history studies using 
marginal structural 
models 
Investigation of effect of highly active antiretroviral therapy 
regimens on CD4 cell counts in 871 HIV-infected women 
recruited for the HIV Epidemiology Research Study, using 
Marginal Structural Models / G-estimation. It implements (in 
what is posited as the first example) of Robin's approach 239 to 
SA by estimating the bias as the difference between the 
counterfactual means, given observed confounders, but here for 
a plausible range of selection bias in prescribing. 
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Steenland, K. 
Greenland, S. 
2004 Monte Carlo sensitivity 
analysis and Bayesian 
analysis of smoking as 
an unmeasured 
confounder in a study 
of silica and lung 
cancer 
Authors discuss the advantages of Monte Carlo (MC) sensitivity 
analysis (MCSA). Ordinary sensitivity analysis only allows 
postulation of a point estimate of bias, usually when only the 
direction of bias can be ascertained with any certainty. Bayesian 
and MC approaches can generate a range of plausible adjusted 
effect estimates for a given distribution of bias. However, while 
the implementation of a Bayesian sensitivity analysis (BSA) can 
be involved, requiring complex understanding, MCSA 
approximate BSA methods under certain conditions. This was 
demonstrated on a cohort of workers' silica exposure and lung 
cancer outcomes, adjusting for bias from smoking habits, the 
distribution for which is based on 1987 survey data. 
MacLehose, R. F. 
Kaufman, S. 
Kaufman, J. S. 
Poole, C. 
2005 Bounding causal 
effects under 
uncontrolled 
confounding using 
counterfactuals 
A nonparametric approach is presented in this study as a 
complement to sensitivity analysis, through linear programming 
for determining the bounds, or absolute limits, of the true effect 
of the exposure in the presence of unmeasured confounding. 
This was done using the observed table of observed data and 
counterfactuals, under realistic assumptions about the potential 
outcomes. Method applied to exemplar of effect of beta-blockers 
on mortality. 
Stürmer, T. 
Schneeweiss, S. 
Avorn, J. 
Glynn, R. J. 
2005 Adjusting effect 
estimates for 
unmeasured 
confounding with 
validation data using 
propensity score 
calibration 
Seminal paper on propensity score calibration (PSC) used to 
adjust for unmeasured confounding in study of effect of NSAIDs 
(non-steroidal anti-inflammatory drugs) on 1-y mortality in 
elderly, through use of a calibration dataset to complete 
adjustment for unmeasured confounders in main error-prone 
dataset. Here the main data is the Medicaid register of adults 
aged >= 65y with hospitalisations 1995-97, calibrated with 
Medicare Current Beneficiary Survey. PSC was proposed as a 
SA until method limitations & validity assessed  
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Malay, D. S. 
Margolis, D. J. 
Hoffstad, O. J. 
Bellamy, S. 
Margolis, D. J. 
Hoffstad, O. J. 
Bellamy, S. 
2006 The Incidence and 
Risks of Failure to Heal 
After Lower Extremity 
Amputation for the 
Treatment of Diabetic 
Neuropathic Foot Ulcer 
The study comprised an exploratory analysis of risk factors and 
treatments in failure to heal of extremity amputation in the 
diabetic foot. The sensitivity of the results to unmeasured 
confounders was tested by Greenland's SA 217: Estimates were 
concluded to be robust to confounding 
Schneeweiss, S. 2006 Sensitivity analysis and 
external adjustment for 
unmeasured 
confounders in 
epidemiologic 
database studies of 
therapeutics 
This study presents a tutorial-like review of SA methods the 
selection of which will be dependent on the availability of 
information about the (binary) confounders (affecting binary 
outcomes): 
The array approach estimates adjusted relative risks (RR) & 
bias  across parameters for RR of the confounder-outcome 
association and  confounder prevalence in each group 
Rule-out: equation allows estimation of RR of the confounder-
disease association and confounder prevalence in groups to 
move the apparent RR to the null. 
External adjustment: This allows a more straight-forward 
estimate of RR confounder-disease association when the 
confounder prevalence is known from an external validation data 
External adjustment for multiple confounders: describes PSC. 
Simulation via MCSA 
The array approach estimates adjusted relative risks (RR) & 
bias  across parameters for RR of the confounder-outcome 
association and  confounder prevalence in each group 
Rule-out: equation allows estimation of RR 
External adjust 
External adjustment for multiple confounders: describes PSC. 
Simulation via MCSA 
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McCandless, L. C. 
Gustafson, Paul 
Adrian, Levy 
2007 Bayesian sensitivity 
analysis for 
unmeasured 
confounding in 
observational studies  
Using real and simulated data, the study looks at the 
consequences of non-identifiability of the prior distribution and 
the effect of prior misspecification on the estimated interval of 
Bayesian SA.  By acknowledging uncertainty about unmeasured 
confounding, the authors demonstrated that credible Intervals 
achieve approximately nominal coverage probability if prior 
distribution is similar to sampling distribution of the model 
parameters. According to average coverage probability, it is 
better to acknowledge uncertainty about unmeasured 
confounders, even if model for BSA is unidentifiable. 
Arah, O. A. 
Chiba, Y. 
Greenland, S. 
2008 Bias Formulas for 
External Adjustment 
and Sensitivity 
Analysis of 
Unmeasured 
Confounders 
The authors review and present a simple set of bias expressions 
for SA of effects on different scales (risk difference, risk ratio, 
odds ratio), and demonstrate how this can be extended to 
polytomous confounders, exposures and outcomes. 
Cabral, M. D. 
Luiz, R. R. 
2008 Use of sensitivity 
analysis to assess the 
effects on anti-hepatitis 
A virus antibodies of 
access to household 
water supply 
The study used two approaches to SA, citing Rosenbaum 219 
and then Greenland's 217 external adjustment to evaluate the 
plausibility of results from investigation into the effects of access 
to household water on hepatitis A prevalence, and found the 
odds ratio between confounder and outcome would need to be 
>=4 to explain the observed effect. 
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McCandless, L. C. 
Gustafson, P. 
Levy, A. R. 
Gustafson, P. 
Levy, A. R. 
2008 A sensitivity analysis 
using information 
about measured 
confounders yielded 
improved uncertainty 
assessments for 
unmeasured 
confounding 
Using external data on unmeasured confounding might not 
narrow the uncertainty over confounding. However, the authors 
proposed using existing associations between the measured 
confounders and prognosis to better inform the interval 
estimates of the treatment effect by assuming a similarity of the 
unmeasured confounders and treating the coefficients of 
measured and unmeasured confounders as random samples 
from a normal distribution. Shrinkage estimates can then take 
account of the similarities in a Bayesian treatment of hierarchical 
models. 
De Vocht, F. 
Kromhout, H. 
Ferro, G. 
Boffetta, P. 
Burstyn, I. 
Kromhout, H. 
Ferro, G. 
Boffetta, P. 
Burstyn, I. 
2009 Bayesian modelling of 
lung cancer risk and 
bitumen fume 
exposure adjusted for 
unmeasured 
confounding by 
smoking 
Authors adopted & expanded Steenland & Greenland's 226 BSA 
to assess the effect of smoking, identified as the unmeasured 
confounder in the risk of lung cancer to bitumen exposure 
The study assumed informative priors based on a Dirichlet 
distribution. The posterior distribution was generated by Gibb's 
sampling using Metropolis MCMC. The association of lung 
cancer with bitumen exposure was still supported after SA, but 
with reduced certainty.The study assumed informative priors 
based on a Dirichlet distribution. The posterior distribution was 
generated by Gibb's sampling using Metropolis MCMC. The 
association of lung cancer with bitumen exposure was still 
supported after SA, but with reduced certainty. 
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Fung, T. T. 
Van Dam, R. M. 
Hankinson, S. E. 
Stampfer, M. 
Willett, W. C. 
Hu, F. B. 
Van Dam, R. M. 
Hankinson, S. E. 
Stampfer, M. 
Willett, W. C. 
Hu, F. B. 
2010 Low-carbohydrate 
diets and all-cause and 
cause-specific 
mortality: Two cohort 
studies 
In their study on the effects of low-carbohydrate diets (LCD) on 
cause-specific mortality using two cohorts of data, the authors 
cited Lin et al 224 in their SA, and found that the confounder 
imbalance would unlikely be strong enough to entirely explain 
the apparent effect of higher mortality from animal-sourced 
LCDs and lower mortality from plant-based LCDs. 
Gustafson, P. 
McCandless, L. C. 
Levy, A. R. 
Richardson, S. 
2010 Simplified Bayesian 
Sensitivity Analysis for 
Mismeasured and 
Unobserved 
Confounders 
Simple Bayesian Sensitivity Analysis (SBSA) is developed from 
the authors' previous work, and aims to incorporate poorly 
measured confounders, as well as unmeasured confounders, 
that are realistically likely to be available in most data. Focus is 
on simplifying the specification of the prior and hyperparameters 
involved 
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Li, L. 
Shen, C. 
Wu, A. C. 
Li, X. 
Shen, C. 
Wu, A. C. 
Li, X. 
2011 Propensity score-
based sensitivity 
analysis method for 
uncontrolled 
confounding 
The authors propose a 1-dimensional function of the propensity 
score, referred to as the sensitivity function, to quantify bias due 
to hidden confounders, and as an alternative SA for IPW 
estimators by Robins et al. 236 and Brumback et al 241. The SF 
was used to correct IPW estimators. Advantage of method is it 
reduces dimensions of confounders and polynomial forms of PS 
function can be reasonably approximated by lower order 
polynomials. The method is demonstrated on study of 
medication frequency in asthmatics. 
Corrao, G. 
Nicotra, F. 
Parodi, A. 
Zambon, A. 
Soranna, D. 
Heiman, F. 
Merlino, L. 
Mancia, G. 
Nicotra, F. 
Parodi, A. 
Zambon, A. 
Soranna, D. 
Heiman, F. 
Merlino, L. 
Mancia, G. 
2012 External adjustment for 
unmeasured 
confounders improved 
drug-outcome 
association estimates 
based on health care 
utilization data 
The authors applied SA to a nested case-control study of the 
effect of different drug regimens of mono and combination 
antihypertensive therapies on cardiovascular outcomes. 
Steenland & Greenland's Monte Carlo SA 226 was also applied to 
acknowledge the uncertainty over the distribution of bias and to 
incorporate external information about the confounders from 
other data sources. The results explained the apparent different 
in risk between two drugs administered extemporaneously and 
in combination, but not between combination and mono-
therapies. 
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Lunt, M. 
Glynn, R. J. 
Rothman, K. J. 
Avorn, J. 
Sturmer, T. 
2012 Propensity score 
calibration in the 
absence of surrogacy 
Authors present a framework by way of directed acyclic graphs 
for using PS calibration to adjust for confounding through an 
external, cross-sectional validation dataset in the simple 
scenario of one measured and one unmeasured confounder. A 
formula can be utilised to predict the presence and magnitude of 
bias in PSC. Under the assumption of independence between 
the observed & unobserved confounders, only one parameter 
needs to be substituted in the bias formula. Simulated cohorts 
were analysed and the effectiveness of NSAIDs on survival 
times of older adults estimated, using influenza vaccination 
status and age as gold-standard and error-prone PS's 
respectively 
Vanderweele, T. J. 
Mukherjee, B. 
Chen, J. 
2012 Sensitivity analysis for 
interactions under 
unmeasured 
confounding 
This technique was developed for assessing the sensitivity of 
interaction analyses to unmeasured confounding, with 
presentation of the bias formulas. This was demonstrated using 
data on the interaction between passive smoking and 
glutathione S-transferase M1 (GSTM1) on the risk for 106 lung 
cancer cases among non-smokers. 
Brunelli, S. M. 
Gagne, J. J. 
Huybrechts, K. F. 
Wang, S. V. 
Patrick, A. R. 
Rothman, K. J. 
Seeger, J. D. 
2013 Estimation using all 
available covariate 
information versus a 
fixed look-back window 
for dichotomous 
covariates 
SA of the differential effects of missing information on covariates 
from medical records, which results in unmeasured confounding 
bias. Simulations compare the benefits of fixing the window of 
time for collecting the information from all subjects to collecting 
all available information as determined by the subjects' historic 
contact and registration with the medical system. The simulation 
derives estimated bias for a range of probabilities for binary 
covariates, exposures and outcomes, for which recorded 
healthcare utilisation is a probability dependent on a binary 
frailty variable. The conclusion is that less bias is introduced 
when all available information is introduced rather than over a 
common fixed window. 
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Lin, N. X. 
Logan, S. 
Henley, W. E. 
2013 Bias and sensitivity 
analysis when 
estimating treatment 
effects from the cox 
model with omitted 
covariates. 
This study extends the formula for bias due to confounding in 
the Cox model by Lin D et al 224 to a general framework for other 
potential sources of bias, applying this to randomised and 
observational studies and simulated data. It concludes that the 
results from a Cox model are biased by missing covariates, 
even if those covariates are balanced, and that censor bias is 
maximised at 50% censoring. 
Lee, W. C. 2014 Detecting and 
correcting the bias of 
unmeasured factors 
using perturbation 
analysis: a data-mining 
approach 
Presentation of proposed method to test for unmeasured 
confounding (perturbation test) and to adjust for it (perturbation 
adjustment) where very large data exist through a data mining 
approach by accounting for the weak associations with any 
unmeasured confounders of multiple perturbation variables 
(PV), possibly 100's, if not 1000's. However the large number of 
PVs may exceed the available df's, so clustering of PV levels 
may be necessary. Longitudinal data may mitigate against 
incorrect adjustment of collider. Inadvertent adjustment of a 
measured confounder, however, exacerbates the bias, which 
may be eventually attenuated with many more PVs. More work 
needed to explore continuous PVs. 
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Richardson, D. B. 
Laurier, D. 
Schubauer-Berigan, 
M. K. 
Tchetgen, E. T. 
Cole, S. R. 
2014 Assessment and 
indirect adjustment for 
confounding by 
smoking in cohort 
studies using relative 
hazards models 
This cites earlier work on negative control outcomes (NCO) 
126.The study of lung cancer risks in occupational cohort studies, 
usually with unverifiable confounding effects from unmeasured 
smoking status, is used as the exemplar in this presentation of 
the use of an NCO in the SA and adjustment for unmeasured 
confounders such as smoking status. Here the measured 
confounders and the unmeasured confounders are common 
causes of the NCO. Adjustment for NCOs are an improvement 
on ordinary SAs, which make unverifiable assumptions about 
the prevalence of smoking among exposure groups, but the 
method imposes other unverifiable assumptions including that 
the exposure does not cause the NCO. Here COPD was used 
as the NCO in the study of the occupational risk of lung cancer 
in Colorado miners and French nuclear workers. 
  
   
 
 86 
 
3.4 Discussion 
SA often relies on assessing whether a hypothesis about the size of the confounding 
effect required to explain the observed effect of exposure is credible. However, an 
implausibly large confounding effect does not completely rule out bias, the size of 
which may still be clinically meaningful. In this way, BSA and MCSA have proved to 
be useful in acknowledging the uncertainty over the distribution of confounding bias. 
External data sources may be also useful in yielding more information about 
confounders as in the propensity score calibration methods. Many confounders are 
likely to be associated so basing hypotheses about unmeasured confounders on 
those observed will likely be informative. Propensity scores may also be useful as a 
sensitivity function, reducing the dimensions of many different confounders into a 
single summary. 
In contrast to external adjustments, the method of negative control outcomes stands 
out as one that makes use of available information within the same dataset. Another, 
source for information on unmeasured confounding may be found within the patient 
histories of the dataset. Indeed, many of the before-and-after methods reviewed in 
chapter 2 rely on the longitudinal information from patient histories, as well as the 
longitudinal adjustment for measured confounders using weighted methods (broadly 
known as G-methods). In this respect, the study by Brunelli et al is highly informative 
in determining the look-back window for patient histories.  
Where the ability to capture information about confounders is in doubt, many of the 
QE methods may be regarded as SAs themselves, as has been suggested for the 
method of propensity score calibration. As will be discussed in the next chapter, the 
prior period of the PERR method and the control arm of the Pairwise method may 
offer a window onto the direction and size of confounding. In a comparison of the two 
methods, the performance of the PERR and Pairwise methods will be greatly 
informed in chapter 4 by the work of Lin, Logan and Henley 225. 
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3.5 Conclusion 
Sensitivity analyses aim to indirectly characterise the relationship between exposure, 
outcome and unknown confounder(s). From the reviewed literature, the approach 
taken to SA will be informed by the characteristics describing assumptions about the 
unmeasured confounder: 
• Hypothesised confounders vs. information on confounders from external data 
sources vs. indirect internal information on confounders 
• Single or multiple confounders vs. single dimensional summary 
• Point estimates for SA vs. methods to integrate uncertainty over unmeasured 
confounders 
• Modelling vs explicit formulation for SA 
Hypothesising a range of confounders, or deliberating over the size of confounding 
required to move the observed effect to the null may be akin to plucking numbers out 
of the air, unless there is some reference. If knowledge about the unobserved 
confounders can be gleaned from another dataset, then these may serve as a 
reference. If the information on these is complete, then a calibration may be possible 
using PSC, although this may prove to be quite rare in practice. However, in a 
dataset sufficiently rich in information, finding an NCO would obviate the need for an 
external dataset, as might patient histories, if the degree of confounding bias may be 
gleaned from the longitudinal information. Many of the methods, such as NCO and 
PSC, may be characterised as an empirical, model-based approach. However, 
explicit formulae exist for re-calculating the odds ratio or relative risk adjusted for a 
hypothesised confounder. Here, the effect of a single confounder may be 
represented, but in reality, confounding bias is likely to be from multiple sources. 
Propensity scores and dimension reducing functions of multiple confounding effects 
may offer a means of modelling realistic scenarios. However many confounders may 
be unobserved, the resulting bias can only be unidimensional. Yet, uncertainty will 
inevitably exist over the true degree of bias. Here, this can be accommodated as a 
hypothesised distribution of the bias through Bayesian and Monte Carlo SA 
methods. The need for positing a distribution for the confounding bias may be 
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obviated, however, by the availability of indirect information about the bias within the 
same dataset.  
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Chapter 4  -  The PERR and Pairwise methods: review and 
implementation 
4.1 Development of the PERR and Pairwise methods 
Attempts to replicate trials in a 2008 study using the observational data of EHRs 
prompted the authors, Tannen, Weiner and Xie, to develop a new method to address 
unmeasured confounding 242,243. The prior event rate ratio (PERR) method was an 
intuitive before-and-after approach, analogous to differences-in-differences, that 
could be applied to both survival and rate data. Although, quasi-experimental 
methods are available for continuous and binary outcomes, there are few, if any, 
methods suitable for survival data. While rate and survival data are two possible 
measurements of the outcomes generated by the same process, the attraction of 
using survival data is that it is possible to analyse the data without modelling the 
underlying distribution of survival times by applying the popular Cox regression 
model (also known as the proportional hazards model) 244. Extensive literature exists 
on the theory and application of the Cox model. Briefly, the effect of an exposure or 
other variables of interest may be estimated from the maximum likelihood of the joint 
probability of the events as a function of the variables’ coefficients for individuals 
ordered by their survival times observed over a prescribed period. As the method 
relies only on the rank of the ordered survival times rather than the length of the 
survival times themselves, this is also known as the partial likelihood, expressed as 
the likelihood of the exponent of the linear predictor of a vector of coefficients, β, for 
x covariates, observed at the kth ordered event of i times: 
𝐿(𝜷) = ∏
𝑒𝑥𝑝(𝜷. 𝒙(𝑖))
∑ 𝑒𝑥𝑝(𝜷. 𝒙𝒍)𝑙∈ℜ(𝑡(𝑖)
𝑘
𝑖=1
 
Equation 1 
where the denominator is the set of individuals at risk at the ith ordered event as 
stated in Cox 244. The times may terminate with an event, in which case the time of 
that individual is present in both the numerator of the probability and in the 
denominator as part of the risk set of all survival times lasting up to that point in time. 
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The times that do not terminate in an event are censored and are only in the 
denominator of the joint probability function as part of the risk set for all survival 
times of individuals at risk at the time of the event in the numerator. This approach 
avoids direct estimation of the underlying baseline hazard function.  
Outside actuarial sciences and process monitoring in manufacturing, survival data 
are perhaps mostly commonly encountered in medicine. Therefore the arrival of the 
PERR method, was key to the development of more inferential studies using 
routinely collected data at a time of growing interest in using EHRs for health 
research 245.  
4.1.1  The PERR method 
The PERR method proposes that if the hazard (or rate) ratio of the exposure in a 
period of study is biased by confounding, this may be adjusted by the hazard (or 
rate) ratio between the two exposed groups from a period prior to the exposure 
(Figure 4). This, therefore, demands an exposure (treatment)-free period prior to the 
period under study, and assumes that the hazard (or rate) ratio from the exposure-
free prior period is a measure of the pre-existing confounding bias between the two 
exposure groups. While the PERR method offers a possible route for addressing 
unmeasured confounding, like all quasi-experimental methods, it is appropriate for 
certain types of data, and its reliability rests on meeting certain assumptions (see 
below). Since information on the outcome from an exposure-free prior period is key 
to the correction for confounding bias, then the outcome needs to be repeatable. 
Implicit in the assumption of the prior period offering a correction for confounding 
bias, is that the bias is constant from one period to the next. Upon meeting these 
conditions then the PERR estimate is provided by either the hazard from a survival 
model or the incidence rate from a suitable model, such as the Poisson, in the study 
period divided by the corresponding estimate from the prior period. In this way, the 
estimate from the prior period should provide an estimate of the magnitude and 
direction of confounding that may be present in the study period, if the assumptions 
are correct. 
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Figure 4: Diagram of the adjustment made across two periods in the prior event rate 
ratio (PERR) method. The hazard ratio (HR) of intervention is calculated from 
survival times (ST) from the study period and adjusted with that from the exposure 
(treatment)-free prior period. The shaded cell denotes the exposure arm in the study 
period. The PERR adjustment can also be applied to rate data. 
4.1.2 The PERR-Alt or Pairwise method 
In a follow-up to the seminal paper, an alternative formulation of the PERR method, 
the PERR-ALT method, was first presented by Yu et al 246. In contrast to adjusting 
the Cox estimate from the study period with that from the prior, the PERR-Alt method 
is based on a paired Cox analysis, in which an adjustment for a period effect is made 
within each subject. Under the large sample approximation, the difference between 
the PERR and PERR-ALT method is clear: The adjustment for confounding using 
the PERR-ALT method is made within each of two exposure groups. The hazard 
ratio of treatment effectiveness is then the ratio of the hazard ratios from each 
adjusted exposure group. Conversely, the PERR method first finds the hazard ratio 
of the exposure effect in the study and prior period and then adjusts the hazard ratio 
of exposure in the study period with that from the prior period. Results from a limited 
array of simulations in the study by Yu et al. demonstrated no bias in the PERR-ALT 
and little bias in the PERR method relative to exposure effect assuming equal 
confounding effects in both study intervals.  Further work was also discussed, but not 
presented for the effects of prior events on those in the study period. 
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HRSTUDY
HRPERR
= HRSTUDY/HRPRIOR
HRPRIOR
Time
ST
ST
ST
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Figure 5: Diagram of the adjustment made within each exposure arm between two 
periods using the PERR-ALT approach. The hazard ratio (HR) of the exposure in the 
study period relative to the prior period is calculated from the survival times (ST) for 
the exposed group and then adjusted with the analogous ratio for the unexposed 
group. The shaded cell denotes the exposure in the study period. The PERR-ALT 
adjustment can also be applied to rate data. 
Further results from simulations were presented in another method paper by Uddin 
et al.247, under a variety of scenarios, which will be discussed in more detail below. 
Simulations also examined the relative performance of the PERR and PERR-ALT 
methods together in the method paper by Lin and Henley that presented a 
generalised formula for the Pairwise likelihood method 192, of which the PERR-ALT 
method is a special case. The formula extended the Pairwise method to 
accommodate time-varying covariates as well as multiple periods, and demonstrated 
superiority in dealing with time-varying baseline hazards, although a greater 
sensitivity to confounder-treatment interactions. Furthermore, the authors 
demonstrated that the problem of bias will stubbornly afflict estimates from the 
application of the PERR method. This is due to problems of bias with the underlying 
Cox models in the presence of missing covariates as demonstrated in earlier work 
225. The problem of bias in the PERR estimates was shown to be exacerbated in the 
presence of censoring. Only when the missing covariate is a confounder does the 
bias in the Cox model reduce under the PERR method. 
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group
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HRPERR-ALT
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4.2 Clarification of types of confounding 
In order to examine the assumptions around the two methods, it is first necessary to 
clarify some the terminology around confounding. Two terms for confounding bias 
are frequently encountered, sometimes within the same study. These are 
“confounding by indication” and “selection bias”. It would be interesting, but, perhaps 
not especially worthwhile given the work involved, to conduct a systematic review to 
study consistency of usage of these terms. However, there can only be one effect of 
confounding: bias. The two terms simply describe the mechanism, by which 
confounding might arise, and it is important to clarify the motivation for using either 
“confounding by indication” or “selection bias” instead of “confounding bias”. As 
established in the introduction chapter, the first condition for a confounder in 
Statistics is that it must be any other variable, other than the variable(s) of interest, 
which may affect the outcome(s) of interest. In medicine and health, this is likely to 
be referred to as a prognostic variable. As variables of interest are often binary 
exposure or treatment variables, then any potential prognostic variables will 
confound the exposure variable if these are imbalanced between exposure groups. 
Patients may be selected for a particular treatment based on prognostic factors, or 
characteristics associated with these. In this way, the second condition for a 
confounder is met by association of the prognostic variable either through imbalance 
between exposure groups or through selection for treatment based on it. In the UK, 
the patients may seem to fare badly and be worse off under particular treatments, if 
these are prioritised for those most in need. In countries like the USA, access to 
healthcare largely depends on income. Better health may be seen to be enjoyed by 
those with a higher socioeconomic status, and so this confounding may lead to a 
healthy patient bias. In both cases, some form of selection bias has occurred. 
Confounding by indication is subtly different. A risk of bias still exists from what is a 
form of selection, but here “by indication” is taken to mean selection on the outcome 
or associated event, which subsequent treatment is intended address. This is an 
important distinction in the context of the PERR and Pairwise methods applied to 
longitudinal EHR data, as the definition implies that confounding-by-indication can 
only occur when an outcome is repeatable – an essential feature of data required for 
the application of the PERR and Pairwise methods. In the case of presentation of a 
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disease, “by indication” would therefore be the prescribing of a treatment intended to 
prevent future recurrence of the disease. 
4.3 Assumptions of the PERR and Pairwise methods 
The assumptions have variously been presented and tested through simulation in 
the seminal studies discussed above. For clarity, these are consolidated and 
discussed below, and each simulation study critiqued where necessary: 
1. The same net effect of confounding in the prior as in the study 
This refers to the condition of there being no difference in the underlying bias 
between the study and prior periods. This does not explicitly require the same 
confounders to be present in both periods, but rather the same effect is exerted. In 
the simulation study of Uddin et al.247, different symbols were used to represent the 
confounders (C11 for the prior and C12 for the study period) in order to simulate 
different period-specific effects of confounding. The implication from the arrow from 
C11 to C12, that confounders in one period “cause” those in the other may be 
contentious, especially where these are asserted to be equal. Such an issue could 
be treated as further evidence of problems in using DAGs to illustrate observed 
epidemiological relationships 35. Theoretically, a different set of confounders for each 
period could by chance exert the same effect with one causing the other, which may 
warrant different symbols, although in practice it is difficult to conceive a situation 
where this would happen to be the case. In practice, it would be necessary to accept 
no significant difference between the periods’ confounding effects, given some non-
significant differences may persist as a result of modelling instability and random 
variation. If the same confounders are present throughout, then their effect is 
assumed to be constant over the prior and study periods. In their presentation of the 
PERR-ALT method, Yu et al. demonstrated that the bias from the period-confounder 
interaction relative to the exposure effect was “well-controlled” at less than 5% when 
the exposure was small, and less than 10%, when the exposure effect was 
“moderate to large”246. If the confounding effect is stable then this suggests time-
invariant confounding between the two periods. The property of time-invariant 
confounding may be reasonable when: 
a. the population characteristics are stable over time. 
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The underlying latent factor that broadly encapsulates prognostic factors and 
susceptibility to disease could be described as frailty. The precise definition of frailty 
and the variables that measure it may change according to the disease, but the rate 
of change in frailty over time may differ according to the population under study. 
Among the very old, or ill patients with a poor prognosis, the rate of change in some 
“frailty” variables may be great enough to consider restriction of the observation time 
if any of these are confounders. If the change in the confounding effect is too great 
between the periods, then the prior period will be a poor adjustment for confounding 
in the study period. 
b. the prior and study periods are adjacent to each other: 
The proximity of the start of the prior period to that of the study period depends in 
part on the length of the prior period. In the case of certain annual vaccinations, such 
as those for influenza, the proximity will also be determined by any seasonality in the 
treatment and follow-up. The proximity of the periods may also depend on the 
availability of an exposure-free sample for recruitment. If in the case of the phased-in 
introduction of health policies, such as vaccination, a larger cohort may be assured 
by looking back far enough to maximise the availability of treatment-free individuals. 
However, this will need to be balanced against the stability of confounders, and that 
of frailty as discussed in (a), as over time the relationships with any confounding 
variables are likely to change. 
c. the prior and study periods are short: 
For reasons discussed in (a), the length of the study and prior periods will impact on 
their proximity as noted in (b). However, longer periods will likely allow more events 
to observed as well as a longer recruitment period, both of which would increase the 
power of a study, so a balance invariably needs to be struck between these 
considerations and the violation of time-invariant confounding. 
2. No moderating effects of confounders on exposure or treatment 
In their presentation of the Pairwise method and evaluation of the relative 
performance, Lin and Henley presented results for the PERR and Pairwise methods 
compared against the Cox model under simulation of an interaction between the 
confounders and exposure effects 192. Under parameters of unity, the PERR 
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adjustment was seen to perform better than the Cox model, while the Pairwise 
method only seemed to be less biased than the Cox model when the magnitude of 
the interaction effect was less than that of the main effect in this particular scenario. 
However, it was not clear how this might be attenuated under different parameters. 
3. Independence between outcomes 
The occurrence of events should be independent so that any event should not 
change the probability of any subsequent events. More specifically to the PERR and 
pairwise methods, events in the prior period should not directly influence those in the 
study period. This may be more of a problem when events are common enough to 
occur more than once within the same patient. However, for the scenario presented 
by Uddin et al. 247, the bias was relatively small compared to the conventional risk 
ratio. Nevertheless, this may be questionable if, say, in the case of infectious 
diseases, infection in a prior period conferred immunity in the study period.  
4. No causal effect of the prior outcome on exposure 
As explained in the section above, where the outcome in the prior period determines 
the exposure in the study period, this can be regarded as confounding by indication. 
The implication for the two-period study design analysed by the PERR method is that 
the effect on the outcomes from the imbalanced prognostic variables (i.e. 
confounders) is accompanied by a causal effect of the outcomes in the prior period 
on exposure. In this matter DAGs can seemingly both clarify and confuse 
understanding of this concept.  To understand how this might arise, it is helpful to 
first consider indication (effect of prior outcome on exposure) in the absence of 
confounding. This was presented, but not fully explained, in scenario 3 of the study 
by Uddin et al (Figure 6) 247. The scenario of a direct causal effect without any 
prognostic or confounding variables is arguably unrealistic in any observed biological 
system, yet this explains the problem of indication. In scenario 3, the exposure is 
determined by event Y1, which must therefore occur entirely at random in the prior 
period since it has no cause or confounder. Since the causal path X  Y2 is 
unconfounded, then adjustment with what is a randomly generated process Y1, 
where treatment X is wholly or partly determined by Y1 would induce bias in the 
estimate of the effect of X on Y2. Therefore the problem with confounding by 
indication in the PERR and Pairwise methods is that it comprises two effects, and an 
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adjustment is made not only for confounding, but also indication (Figure 7). In this 
way, adjusting for Y1 as an indicator in the regression of X on Y2 is akin to adjusting 
for an instrument in which X becomes the mediator rather than the cause of Y2. 
 
Figure 6: Recreation of figure 4a from scenario 3 in the study by Uddin et al., where 
the causal effect in the study period between X and Y2 is unconfounded, but X is 
indicated by prior event Y1 
 
 
Figure 7: Representation of figure 4c from scenario 3 in the study by Uddin et al., 
where the causal effect in the study period between X and Y2 is confounded by C, 
but X is indicated by prior event Y1, which is also caused by confounders C. 
 
The idealised relationship for the application of PERR is represented in Figure 8, 
which shows the prior outcome Y1 and the causal effect of X on Y2 confounded by C. 
In many clinical scenarios, one could expect the actual relationships to be 
somewhere between this idealised scenario and that with indication in Figure 7. An 
example could be where patients receive an invitation for routine vaccination based 
on age and irrespective of health status, but following an illness close to their 
appointment, some patients, who otherwise would ignore the invitation, might elect to 
be vaccinated.  This demonstrates the confusion that DAGs may cause, as they can 
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falsely represent a dichotomisation of a relationship that may exist on a continuous 
scale between Y1 acting as a proxy for confounders C and Y1 as an instrument for X. 
Certainly, the strength of Y1 as a proxy for confounders C would be stronger in some 
clinical scenarios, for instance, in a study of the side-effects of a treatment.  Uddin et 
al. showed under simulation that the logarithm of the hazard ratio moves linearly 
away from the point of no bias with an increasing effect of indication. 
  
Figure 8: PERR is applied ideally to a causal relationship between exposure, X, and 
study outcome, Ys, confounded by C. Prior outcome, YP, is also predicted by 
confounders, C, but crucially there is no indication between Yp and X. 
The simulation of Lin and Henley showed a more complicated relationship for a 
different range of settings192. Overall the PERR estimates performed better than 
those from those from the Cox model, although for a wider range of values the 
Pairwise estimates were affected the least by bias. 
5. No differential effect of dropout or censoring 
The condition for censoring and dropout in applying the PERR and Pairwise methods 
depends on which of the two methods is used. Censoring is a potential problem in 
survival analysis, if this is deemed to be informative and imbalanced between 
exposure levels. Censoring may include death if this is not an outcome, although due 
to the unrepeatable condition of death, this would not be a valid outcome under the 
PERR approach in any case. The potential sensitivity of the survival model to 
informative censoring may be evaluated by inspecting the distribution of censored 
times relative to event times and by comparing the results from reassigning the 
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censors as events with those from assigning the longest times to censored times248. 
Inverse probability of censor weighing may be possible if there are a sufficient 
number of censored times. Irrespective of informativeness, however, the problem 
posed by dropout/mortality is that this is an unrepeatable condition in the prior 
period, as patients are necessarily alive up to the point of recruitment in the study 
period. If dropout is imbalanced between treatment groups, as simulated in Uddin et 
al. and Lin and Henley, then this is likely to be commensurate with an imbalance in 
the associated confounders, creating a problem akin to the violation of assumption 1 
above: that the net effect of confounding should be equal in both periods, or at least 
similar enough to lead to no significant practical difference. In the simulation by 
Uddin et al., it was not entirely clear how imbalanced was mortality between 
exposure groups, but the results suggested a downward bias with increasing 
mortality rates. They also reported that excluding mortality in the study period 
numerator of the PERR method was more biased than the PERR that included all 
patients. Lin and Henley dubbed the difference in mortality between periods, and the 
potential resulting confounder imbalance, as the differential case fatality (DCF), in 
reference to an abstract by Gallagher 249 (there was no subsequent peer-reviewed, 
published study, so this was not included in the method review). Their simulation 
confirmed that DCF arises from imbalance in confounders, but also demonstrated 
that DCF can decrease as well as increase the bias of the PERR method. 
Interestingly, they also showed that in the extreme case of all patients at one level of 
a binary confounder dying before the study would result in no bias. Crucially, the 
results from the Pairwise method were also unbiased, since the comparisons are 
always paired within each patient. Reflecting the concern over imbalanced 
censoring, Lin and Henley’s steps for detect confounding in the prior period of the 
PERR method took account of possible bias from imbalanced censoring. They first 
proposed a test of significance between exposure groups having swapped the 
censor and event indicators, following a similar method proposed by Collett for 
testing the imbalance in censoring 248. However, censoring in the prior period is 
unlikely to be anything other than administrative censoring of patients, who have 
reached the end of the prior period without an event, and so must necessarily be 
alive for the study period, for which they were recruited. 
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4.4 PERR and Pairwise methods in the context of general 
approaches to confounding 
In chapter two a variety of methods were reviewed, which leveraged the longitudinal 
information of EHRs to adjust for unmeasured confounding. Many of these relied on 
longitudinal information from an exposure-free period prior to the period of study 
itself. While this type of before-and-after adjustment could be described as an 
“approach” or method, it also intrinsically determines the “shape” and features of the 
data and the way, in which these are analysed. Hence, study design and the method 
used are not mutually exclusive for many of the approaches. In this way, it would be 
misleading to consider the PERR and Pairwise methods in isolation of all other 
potential strategies for minimising confounding bias. 
 
Figure 9: Venn diagram of possible approaches to reduce or mitigate for confounding 
bias with examples (not exhaustive) of each. 
 
In practice, it is useful to consider how different approaches may overlap and be 
combined to minimise the risk of bias due to confounding (Figure 9). For example, 
some form of restriction to a particular sub-group or within strata of the population 
may control for confounding by aiming to reduce the difference in prognostic 
characteristics between exposure groups and may be deployed as a form of 
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sensitivity analysis of the reliability of the main unrestricted result 250. This is a 
common approach, and recently there has been a growing interest in the test-
negative case-control design particularly for monitoring annual vaccine effectiveness 
251–255. This is a form of restriction applied to the outcome, and in the case of 
influenza studies, it seeks to mitigate for health seeking behaviour by studying only 
patients, who have reported symptoms akin to influenza-like illness. A case-control 
design then analyses effectiveness based on laboratory-confirmed infections, which 
mitigates against disease misclassification 255. A poorly defined outcome may evade 
attempts to control for confounding, in the same way a poorly defined intervention 
may prove problematic for inferential consistency from the research question and 
data to a wider population 16. However, restriction necessarily reduces the external 
validity of the results. With regards to the test-negative case-control design in study 
of influenza effectiveness, the size of the study and the generalisability is restricted 
by access to laboratory-confirmed outcomes 255. As in the UK and other countries, 
the absence of widespread laboratory testing to confirm cases of influenza would 
significantly reduce the sample size. After the initial screening of outcomes, the 
method still relies on adjustment, through matching on measured confounders, and 
as a type of case-control study, cannot deal with unmeasured sources. 
Another design type is the active comparator new-user study. Because the 
comparison is between two treatments for the same disease, it can assume the 
same indicators for treatment with the only difference being the therapy. This 
ensures a similar distribution of prognostic variables between therapy groups 74. For 
that reason, this design could be the optimum design for comparative effectiveness 
studies, although it is difficult to conceive a wider application of the design beyond 
such studies. There is no adjustment using longitudinal information per se, but rather 
eligible patients are selected based on their history of medication use as determined 
through longitudinal EHRs. 
The methodological review of chapter two was scoped to include only studies with at 
least two exposure levels. In this way, participants would have been recruited 
according to exposure status. However, this excluded a set of other before-and-after, 
single-arm, case only designs that recruit according to outcome, in which cases 
serve as their own controls in a period prior to exposure. One such method is the 
case series or self-controlled case series, in which cases are selected and their 
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exposure status retrospectively studied relative to the timing of their outcome 256,257. 
Conditional upon the assumption of no effect of a recurrent event altering the 
probability of subsequent exposure, this approach lends itself well to studying 
adverse events for drug and vaccine safety. The safety of the mumps, measles and 
rubella vaccine (MMR) has often been cited as an example of its application 258. The 
case series design may be extended to accommodate transient exposures, for which 
multiple exposure and control periods are possible. This constitutes a case-
crossover design 259. The use of either method depends on the historic pattern of 
medication use, but both approaches require a well-defined period of exposure and 
control 215. For example, after vaccination, there may be a limited window of time 
during which outcomes could be assumed to be adverse reactions. As the case-
crossover design may analyse multiple windows then it is also essential that the 
baseline rate of such outcomes does not change, and that there are no time trends 
in the exposure windows. Since individuals in a case only design act as their own 
controls (“crossover” is within individuals), then this mitigates for fixed confounding 
effects, but susceptibility to bias from time-varying confounders cannot be ruled out. 
Furthermore, case-only studies ask a subtly different question of the data, by 
recruiting cases only. The effect on cases only may be slightly different from the 
effect adjusted for confounding between exposed individuals and controls, and the 
results may not be as widely generalisable as those from PERR and Pairwise. 
Crucially the availability of controls and an exposure-free prior period under the 
assumption of temporally stable bias allows an investigation of the source and size 
of bias, in a direct way that is not possible with case only studies. 
The methodological review of chapter two broadly considered how longitudinal 
information could be utilised in the adjustment for unmeasured confounding and was 
motivated by the growing interest in routinely collected datasets, where such 
information is likely to be available. Longitudinal information may facilitate the use of 
“before-and-after” methods, in which longitudinal comparisons are made to 
temporally adjust for unmeasured confounding. A summary of these methods is 
listed in Table 4. The inclusion of single-arm, case only methods along with the 
PERR, Pairwise and other methods reviewed in chapter two further illustrates the 
overlap between method or study design in adjusting for unmeasured confounding 
and how design is integral to this adjustment. 
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Quasi-experimental methods typically invoke extra assumptions to adjust for 
unmeasured confounding, and before-and-after approaches demand longitudinal 
information and particular study designs (i.e: cohort) to yield that information. In this 
way, there is an unavoidable overlap between design and method. Similarly 
adjustment for unmeasured confounding does not necessarily preclude explicit 
adjustment for measured confounders (Figure 9). Moreover, since it has been shown 
that the PERR method cannot entirely remove bias from effect estimates 192, then 
inclusion of covariates and potential confounders, where available, would be 
desirable. On this basis, it would be good practice to try and adjust for common 
confounders, such as age and gender, in any given model first. This would minimise 
the degree of confounding bias, and leave the PERR method to adjust for residual 
bias. Furthermore, it would allow assessment of the sources of bias, and of how 
much is due to unmeasured confounders through comparison of the results from the 
model adjusted for measured confounders with the PERR-adjusted model. 
Alternatively, adjustment may take the form of inclusion of a propensity score, rather 
than adjustment by each variable. Propensity scores were calculated for the studies 
in this project and more details can be found below in section 4.6.3. Propensity 
scores may be implemented as an adjustment for observed confounders by more 
than one approach 212. For example, inverse probability treatment weights (IPTW) 
can be derived from propensity scores (PS) to provide estimates from a weighted 
model. This was the approach followed for explicit adjustment in this project (for 
more details about the advantage of IPTW over other PS methods, see below in 
section 4.6.3). Models that re-weight according to measured confounders are also 
known as marginal structural models 12, although throughout this project, this 
application has mostly been referred to as IPTW. Weighting may also be applied 
through a raft of methods broadly known as G-methods to adjust for time-dependent 
effects if there is information available on past covariates and treatment states 260,261. 
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Method Description How method controls for unmeasured confounding 
Prior event rate 
ratio (PERR) 
Adjustment of the study incidence or hazards rate for rate or survival data, 
by exposure group, using the equivalent estimate from an exposure-free 
prior period. 
The method relies on individual level data from both periods to control 
for unmeasured confounding, but adjustment is made at the group 
level. 
PERR-Alt / 
Pairwise 
Estimates for survival data the hazard rate for an exposure from the 
paired likelihood of the within-individual comparisons of the study period 
with an exposure-free prior period. 
Adjustment is made within each individual and offers more flexibility in 
accommodating proportional differences between the period-specific 
baseline hazards, modelled as a nuisance variable, with the potential to 
expand the Pairwise formula to more than one period, as well as to 
model time-dependent covariates. 
Difference-in-
differences 
(DiD) 
Estimates the effect on two groups from the coefficient of the interaction 
between the group and period variables from a regression of outcomes for 
each group at each time point. 
The data look back to an exposure-free period, although DiD does not 
exclusively require longitudinal data (i.e: may use repeated cross-
sectional panel data), and the adjustment is between exposure group. 
Therefore within-individual data may benefit from including variable 
specific covariates in the regression, or using the first differences or 
fixed effects approach. 
Fixed effects 
and first 
differences 
Estimates the effect on a continuous outcome from regression on a binary 
exposure having either demeaned the data across time (fixed effects) or 
by finding the differences (fixed effects method is equivalent to first-
differences for two time points). 
Requires individual-level data. By regressing the first differences or 
demeaned data, time-invariant individual-specific confounders are 
eliminated within each individual. Suitable for continuous outcomes. 
Regression 
discontinuity 
The effect of an intervention may be estimated through the pretest-
posttest design, for which a cut-off on the pretest value of a continuous 
outcome determines membership of a binary intervention group. The 
effect is estimated as the degree of discontinuity by a dummy variable for 
treatment in a regression model. For individuals close enough to the cut-
off, exchangeability and a lack of confounding bias is assumed. 
The method intrinsically requires individual level data to regress post-
test on pre-test outcomes. Unmeasured confounding is controlled by 
assuming that individuals are similar in all potential confounding 
variables for pretest values within a certain distance from the cut-off. 
This is best achieved if there is random noise in the pretest 
measurements, and there is a sharp cut-off in treatment assignment. 
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Interrupted 
time series 
(ITS) 
Studies the effect of an intervention at a point in time in a population by 
estimating any discontinuity in the response or change in time-related 
trends of the response. 
ITS may be applied to individual-level longitudinal data or population-
level data collected over time, but yields population-level estimates. 
Accuracy may depend on modelling trend, seasonality or any 
periodicity within the data, but does not require explicit adjustment for 
confounders or a control group, although the availability of a control 
group would allow confirmation of a reported effect. Suitable for 
studying policy implementations in time, which do not coincide with a 
concomitant change in any other determinants of outcome. 
Self-controlled 
case series 
(SCCS) 
Single-arm case only design that recruits on outcomes, and adjusts within 
individual. 
As a single-armed study design, individuals act as their own controls. 
An observation window should be clearly defined within which it should 
be possible to identify any possible exposures, which should not be 
exclusively distributed among cases (i.e: possible to have exposed and 
unexposed cases). Controls are any events occurring outside a well-
defined exposure risk-window. 
Case-
crossover 
Same as the SCCS, but can accommodate multiple exposure-risk 
windows for transient exposures. 
Same as SCCS, but for multiple exposure-risk windows. 
Table 4: A list of before-and-after methods for adjusting for unmeasured confounding with a brief description of each method and 
how the adjustment is made for unmeasured confounding. 
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4.5 Applications of PERR and Pairwise methods in the 
literature 
Weiner et al. began the first of two studies in 2008 introducing the PERR method by 
replicating as many aspects as possible of the Scandinavian Simvastatin Survival 
Study (dubbed the 4S RCT), except for randomisation, using data from the CPRD 
(then known as the GPRD) 242. For two of the four outcomes, that the authors were 
able to replicate, the results of all analyses of MI outcomes showed reasonable 
concordance with the RCT results. In the case of coronary revascularisation, the 
PERR-adjusted estimate was not significant and was different from the RCT result, 
which had demonstrated a beneficial effect. However the PERR-adjusted result was 
closer to the RCT estimate than the unadjusted results, which indicated a harmful 
effect. The study published immediately after by Tannen et al., in the following pages 
of the same issue of the journal replicated two RCTs (HOPE and EUROPA) 
analysing the effects of angiotensin-converting enzyme inhibitors on five outcomes 
243. Two of the outcomes, death and coronary heart failure could not be PERR 
adjusted, as such outcomes could not logically be repeated in the period prior to 
study. Of the three remaining outcomes (myocardial infarctions, strokes and 
coronary revascularisation) studied in the two trials, the PERR adjustment was 
demonstrated to be reasonably successful in bringing the estimates into close 
agreement with the RCT results, although perhaps less for that of stroke under the 
exclusion criteria used in the HOPE trial. 
Later, in 2009, Tannen et al. published the results from the application of PERR to 
the data from their previously replicated studies 245. Three of these were the 4S, 
HOPE and EUROPA replications, which had had the PERR method applied, in 
previous published work 242,243. Of the remaining, the PERR method could not be 
applied to the replication of the Syst-Eur trial 262 studying the effect of 
antihypertensive therapy because of the method of patient selection, while the PERR 
adjustment of the replication of the Womens’ Health Initiative 263,264 (both those with 
an intact uterus and the hysterectomy sub-group) was relatively inconclusive 
because of imprecision and wider confidence intervals. Furthermore, for the point 
estimates of the effect on strokes, the PERR-adjusted results were further away from 
those of the RCT and the naïve Cox estimates. 
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Following up their PERR-adjusted replications of RCTs, Tannen et al. conducted one 
more study applying the PERR method in comparative effectiveness research of 
adverse cardiac events under two different thiazolidinedione, antidiabetic drugs: 
pioglitazone (PIO) and rosiglitazone (ROS) 189. While the effect of PIO on cardiac 
outcomes did not differ significantly from published RCT estimates, there was some 
evidence of deviation from the RCTs in the adjusted HRs and PERR-adjusted HRs 
for ROS on myocardial infarction (MI). However, there was no statistical evidence of 
difference in the rate of adverse events between the two drugs, although a direct 
comparison of the exposed groups revealed a hazard of MI that was higher in the 
ROS group and borderline significant. 
Since the publication of the PERR method and its application in seminal and 
subsequent papers by its authors, other examples of its application by other authors 
have only just begun to be published, while the literature review found no examples 
citing the Pairwise method (Table 5). The first by Brophy et al., captured in the 
method review of chapter two, examined the effect of proton pump inhibitors (PPIs) 
on survival times until infections by campylobacter and salmonella 190. Using the 
prior event rate, the authors were able to determine that patients, who were 
prescribed PPIs, were prone to such infections, and not significantly improved by 
treatment. Since the methodological review of chapter two, Othman et al. have also 
published a study into PPIs, which through the application of the PERR method 
showed a reduced risk of pneumonia among the PPI patients 265. Results were also 
presented alongside those from an adjusted model, revealing the extent of 
unmeasured confounding. However, a recently published investigation by Zirk-
Sadowski et al. into the effect of PPIs on pneumonia showed an elevated risk of 
pneumonia in the second year after PPI prescription among adults aged at least 60y 
using both weighted and PERR-adjusted models 266. Similar results in the same 
study were also achieved through the first example outside the seminal study of Yu 
et al. of the application of the PERR-ALT method. 
A novel application of the PERR method was found in Dennis et al.’s study of 
adverse events following antipsychotic prescribing in older patients with dementia 
267. This was one such example of how the PERR method could be applied to 
observational, registry data to study a clinical question regarding adverse events in a 
population that would otherwise be difficult to recruit to trial. Another later study by 
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Brophy et al. reported higher rates of hospital admissions for respiratory illnesses in 
children, who were prescribed antipsychotic medication, having applied the PERR 
method to Welsh EHR data from the SAIL databank 268. 
The first example of the application of the PERR method to the estimation of vaccine 
effectiveness was published in a study by Young-Xu et al. 269. Using the PERR 
approach, a beneficial relative effectiveness of high dose vs. standard dose influenza 
vaccination was reported against influenza and pneumonia-associated outcomes 
and against all-cause outpatient visits in adults from an US database aged at least 
65y, but not against laboratory-confirmed influenza. The point estimate of the latter 
result would suggest a beneficial effect, but the effect suffered from imprecision and 
wider confidence intervals. With the availability of laboratory-confirmed results, the 
data perhaps could have been analysed using a test-negative case-control design, 
but the PERR method was nevertheless utilised, perhaps justified by the sparsity of 
laboratory outcomes. However, the authors’ use of the period of low circulating 
influenza viruses immediately before the peak season for the prior period rather than 
the previous season is questionable. The low-circulation period may be used in the 
calculation of excess deaths during the peak influenza season 270, and has 
previously been used in a case-centred model resembling a case control study 271, 
but in the application of the PERR method, the prior period should be similar in 
conditions to the study period in order for the analysis to be properly valid as stated 
above in paragraph 1 of section 4.3. Given the difference in rates and the 
seasonality of other factors as well as influenza, it is difficult to conceive that the 
effect of confounders and any interactions with the intervention would be the same 
between low and high influenza-circulation periods. It is therefore difficult to be 
assured that the low circulation period would necessarily be representative of the 
bias during high circulation. If nothing else, then the point estimate from a period with 
low levels of influenza in circulation would likely be subject to a greater degree of 
relative imprecision that could lead to an inaccurately adjusted PERR estimate, when 
a previous influenza season might have be used instead. 
Latterly, further work based on the PERR method was presented by Tannen and Yu, 
called the post-treated event rate ratio (PTERR) 272. This sought to widen the 
applicability of the PERR method to studies where mortality is an outcome. As 
already discussed in section 4.3, being a once-only event, death violates the 
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condition of repeatability in PERR. The method relies on a post-treatment unexposed 
duration being available for the exposed group, so may not suit curable conditions 
requiring single treatment. The authors proposed limiting the as-treated durations of 
the unexposed group to those of their matched exposed subjects, which could be 
adjusted using the “post-treated” period when the exposed transition to an 
unexposed state. While this method with its adjustments for analysis time may at first 
seem less intuitive than the PERR method, the extensive comparisons of results 
from database studies to RCTs and simulation results seem supportive of the 
method as an adjustment for unmeasured confounding in mortality studies. However, 
the method seems to rely on a low mortality rate and on the bias due to differential 
case fatality being close to zero or relatively negligible compared to the bias in the 
as-treated period. These assumptions and the condition of an exposure-free period 
being available for the exposed group following treatment is likely to limit the 
applicability of the method. Also, the assumption of temporally stable confounding 
still applies, and the authors’ emphasis was on the method as a sensitivity analysis 
and evaluation of unmeasured confounding, rather than as a quasi-experimental 
method for estimating treatment effects without confounding bias. 
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Title Authors Year Journal Adjustment methods 
Replication of the Scandinavian Simvastatin 
Survival Study using a primary care medical 
record database prompted exploration of a 
new method to address unmeasured 
confounding 
Weiner MG 
Xie D 
Tannen RL 
Xie D 
Tannen RL 
2008 Pharmacoepidemiology 
and Drug Safety 
PERR applied to replicated studies of 
matched patients 
Replicated studies of two randomized trials 
of angiotensin-converting enzyme inhibitors: 
further empiric validation of the “prior event 
rate ratio” to adjust for unmeasured 
confounding by indication.  
Tannen RL 
Weiner MG 
Xie D 
Weiner MG 
Xie D 
2008 Pharmacoepidemiology 
and Drug Safety 
PERR applied to replicated studies of 
matched patients 
Use of primary care electronic medical 
record database in drug efficacy research 
on cardiovascular outcomes: Comparison of 
database and randomised controlled trial 
findings. 
Tannen RL 
Weiner MG 
Xie D 
Weiner MG 
Xie D 
2009 BMJ PERR applied to replicated studies of 
matched patients 
Prior event rate ratio adjustment: numerical 
studies of a statistical method to address 
unrecognized confounding in observational 
studies. 
Yu et al. 2012 Pharmacoepidemiology 
and Drug Safety 
PERR and PERR-Alt applied to simulated 
data 
A new “Comparative Effectiveness” 
assessment strategy using the THIN 
database: Comparison of the cardiac 
complications of pioglitazone and 
rosiglitazone 
Tannen RL 
Wang X 
Yu M 
Weiner MG 
Wang X 
Yu M 
Weiner MG 
2013 Pharmacoepidemiology 
and Drug Safety 
PERR applied to replicated studies of 
matched patients compared with 
propensity-score matched analysis 
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Incidence of Campylobacter and Salmonella 
Infections Following First Prescription for 
PPI: A Cohort Study Using Routine Data 
Brophy et 
al. 
2013 The American Journal 
of Gastroenterology 
PERR applied to the unadjusted Cox 
model 
Community acquired pneumonia incidence 
before and after proton pump inhibitor 
prescription: population based study. 
Othman F 
Crooks CJ 
Card TR 
Crooks CJ 
Card TR 
2016 BMJ PERR applied to unadjusted Cox models, 
but compared to adjusted analysis and 
results from self-controlled case series 
study design 
A new method to address unmeasured 
confounding of mortality in observational 
studies 
Tannen RL 
Yu M 
Yu M 
2017 Learning Health 
Systems 
The PTERR results are compared to 
results from the unadjusted and adjusted 
Cox regression as well as those reported 
from trials 
Characteristics of Children Prescribed 
Antipsychotics: Analysis of Routinely 
Collected Data 
Brophy et 
al. 
2018 Journal of child and 
adolescent 
psychopharmacology 
PERR applied to unadjusted Cox models 
and compared to results from adjusted 
logistic models 
Proton-Pump Inhibitors and Long-Term Risk 
of Community-Acquired Pneumonia in Older 
Adults 
Zirk-
Sadowski J 
et al. 
2018 Journal of the 
American Geriatrics 
Society 
The PERR and PERR-Alt method applied 
to unadjusted Cox models and compared 
to models adjusted by weighting (inverse 
probability treatment weighted) 
Relative Vaccine Effectiveness of High-
Dose versus Standard-Dose Influenza 
Vaccines among Veterans Health 
Administration Patients. 
Young-Xu 
et al. 
2018 The Journal of 
Infectious Diseases 
PERR applied to the ratio of incidents 
calculated before and after matching, and 
compared to the same results without the 
PERR adjustment 
Table 5: List of published studies applying the PERR and Pairwise/PERR-Alt methods
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4.6 Settings and implementation of PERR and Pairwise 
methods in this project 
The research question was to investigate the effectiveness of the two vaccines that 
were the subject of a major health-policy implementation in the UK, of World Health 
Organisation recommendations at the beginning of the millennium. These were the 
pneumococcal and influenza vaccine, which are the subject of chapters five and six, 
respectively. A protocol for these studies, which was submitted to the CPRD, is 
available in Appendix C – ISAC protocol. Following on from the work of Tannen et 
al., the intention was to apply the PERR method, and the lesser known Pairwise 
method, to mitigate for unmeasured confounding in the estimation of vaccine 
effectiveness. This was compared against an adjusted analysis, using an efficient 
weighting method in preference to matching, the more commonly encountered 
method of adjustment used in the replications of RCTs from routinely collected data. 
The exposure-free prior period would also allow an evaluation of the source and 
degree of confounding bias. 
Comparing the results of the PERR and Pairwise methods is crucial to 
understanding their relative performance. Furthermore, it is only in the application of 
such methods that further areas may be identified for future methodological 
development. In this way, where the interaction of vaccination and age was found to 
be significant in the study period, the moderating effect of age was also adjusted for 
confounding bias using the PERR and Pairwise methods. In light of the existing 
literature, this may be a novel application of the PERR and Pairwise methods. 
Pneumococcal and the influenza vaccines have been recommended for adults aged 
at least 65y, and are intended to ameliorate a major healthcare burden in this age 
group. However, recent evidence for the effectiveness of the pneumococcal vaccine 
against coronary disease, and the overlap in the pathophysiology of the diseases 
that the vaccines are intended to prevent, justifies the multi-faceted approach to the 
research 273. There are of course major differences in the pathology of the diseases 
targeted by vaccination: Streptococcus pneumoniae is a bacterium, against which 
vaccination is intended to confer long-lived immunity. Influenza is caused by a mix of 
viruses, which can evolve and change every year and against which the vaccine has 
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to be matched annually. These differences have ramifications for the study design, 
and so the vaccine studies require different settings for implementation, which are 
discussed here. Further information and details in the context of the research, to 
which they each pertain, can be found in their respective chapters (five and six). 
However, the common layout of the data from CPRD and similarities in the 
population, study design and settings justify an initial discussion of these aspects 
and a description of the workflow that this entails. 
4.6.1 Study design 
In the context of the data, the PERR and Pairwise methods constitute a before-and-
after approach to the problem of unmeasured confounding using data, in which 
longitudinal information is available for the patients selected according to their 
exposure group, and other prognostic variables. As such, only a cohort study design 
is applicable. Longitudinal information is arguably available from repeated cross-
sectional studies, but in its original form, the PERR method demands that this 
information is within-patient. Nested case-control studies or test-negative case 
control studies, as well as case-only studies, also rely on longitudinal information 
within patients, but here this is from the look-back (purely retrospective) from an 
outcome as opposed to follow-up (retrospective or prospective) after an exposure. 
4.6.2 Recruitment and follow-up 
Common to both the pneumococcal and influenza vaccine studies, as set out in the 
method section for each, the minimum age of recruitment was 65y and older at the 
time of the index date for each study. The date was chosen to coincide with the start 
of the seasonal rise in vaccination rates, thereby capturing the majority of the  
vaccinations early on in the study. In this way, most of the follow-up time would take 
place before the start of the next ‘flu season. For both vaccination studies, 
recruitment lasted one year. For the influenza vaccine study, follow-up was limited to 
one year to help retain consistency between the vaccine and the circulating influenza 
strains. For the pneumococcal vaccine study, however, pathogen evolution was less 
of an issue, so follow-up was extended to two years, to capture more outcomes 
whilst still limiting the time during which the effects of confounding might change (see 
point 1 in section 4.3 on equal net effect of confounding across periods). The follow-
up in the prior period was the same as that for the study period, and immediately 
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preceded the study period. Both studies imposed a vaccine-free period preceding 
the prior period to allow for wash-out of any previous vaccinations. 
In the study of influenza, an estimate of annual vaccine effectiveness was sought 
over from 1997, which included the first wave of the phased introduction of the 
vaccine in 1998. Interpretation of the results might therefore accommodate inference 
about the annual variation in the matching between vaccine and circulating 
pathogens. In contrast, recruitment to the pneumococcal study utilised the growth in 
vaccination coverage between 2003 and 2005. Choosing this time period exploited 
the rapid increase in vaccination rates in a natural experiment to maximise the size 
of the three annual cohorts (Figure 10). The stepwise introduction of vaccination by 
age group also facilitated the study effectiveness by these sub groups. 
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Figure 10: Graph of cumulative percentage vaccinated (e.g: pneumococcal 
vaccination) over time illustrating the advantage for optimal recruitment from growth 
in vaccine recipients in a population starting with a low vaccination coverage.  
 
The start of the observation times among the vaccine recipients was their date of 
vaccination. However, no such date exists for the controls. Attributing the cohort 
index date as a survival start date for all controls would create an imbalance in the 
distribution of start dates between exposure groups with unforeseen consequences 
from any time-dependent phenomena or exogenous variables. It is quite possible 
that some form of immortal time bias could occur among the controls if they all 
started their observation time much earlier than the vaccine recipients and before 
any seasonal increase in circulating pathogens. In order to have an approximately 
equal distribution of observation start times between exposure groups, it was 
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decided that the start dates for follow-up of the vaccine-free controls should come 
from the vaccination dates of the vaccine recipients. This was done through 
matching, at first exactly on age, gender and GP practice, and then iteratively on 
ever coarser age groups and combinations of gender and GP practice. Where 
several matches were possible, vaccine dates were randomly allocated as 
observation start dates to the controls. No further matching was performed, for 
example, to balance confounders (see below in section 4.7 on the Workflow of 
computer code). 
4.6.3 Adjustment for known confounders and effect modification 
As a basic adjustment for fundamental patient characteristics, all Cox models, to 
which the PERR method was subsequently applied, were adjusted for patient age 
and gender. As such variables are likely to be confounders in their own right, as well 
as be associated with other potential confounders, this demonstrated good practice, 
as detailed in section 4.4, in reducing that part of the bias, which the PERR method 
may fail to adjust. Notwithstanding confounding, the effects of age and gender were 
of intrinsic interest as prognostic variables. Therefore, these were included in the 
Pairwise models too. 
Since the population under study in this project was older adults, whose life status 
and disease prognoses are dependent in part on age and age-related frailty, it was 
of clinical interest to analyse how the effectiveness of vaccination might be 
moderated by the age of the patients. This entailed fitting an interaction between 
vaccination and age to the models, and adjusting this using the PERR and Pairwise 
methods. This was an important and novel aspect of the research, and to my 
knowledge had not previously been explored using quasi-experimental methods 
applied to EHRs in this way. 
In addition to the quasi-experimental adjustment, it was important to gauge the 
success, or otherwise, of this through a comparison of a more complete adjustment 
for the confounders available in the data. To achieve this end, all possible 
confounders were selected in a logistic regression of vaccinaton status. The 
predicted probabilities of exposure, or propensity scores, provided a summary of the 
effect of confounders on exposure, reducing potentially many confounders down to a 
single variable for each individual. However, conditioning on propensity scores in 
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survival models can lead to biased estimates 274. Matching introduces minimal bias 
275, but relies on the choice of matching algorithm and likely requires more 
computation to implement. Inverse probability treatment weighting (IPTW) also 
introduces minimal bias and is recommended for survival models 275, but is easier to 
implement as this avoids the extra step of matching. IPTW models provide an 
estimate of the marginal effect of an exposure, which is arguably more readily 
interpretable than an effect that is conditioned on a variety of prognostic variables. 
Further details on the prognostic variables selected for the propensity score models, 
and how these were built, are given in the sections on adjusted modelling within the 
studies of chapters five and six. 
4.6.4 PERR estimation 
The PERR method can be simply applied to estimate the hazard ratio of vaccine 
effevctiveness from the ratio of the hazard ratios for vaccination from the Cox model 
in the study period over that in the prior period. In the two vaccination studies, the 
Cox regression modelled the time until event on vaccination status adjusted for age 
and gender, the hazard function is expressed as: 
ℎ(𝑡) = exp(𝛽𝑥. 𝑋 + 𝛽𝑎𝑔𝑒 . 𝑎𝑔𝑒 + 𝛽𝑔𝑒𝑛𝑑𝑒𝑟 . 𝑔𝑒𝑛𝑑𝑒𝑟) ℎ0(𝑡) 
Equation 2 
where h0(t) is the baseline function and the natural exponent is applied 
to the linear predictor of the vaccination status indicator variable, X, 
with coefficients β’s for age and gender 
The linear predictor in the exponent of the hazard function was specified in the stcox 
command of Stata v.13, and estimated by maximum likelihood.  Where interactions 
between age, gender and vaccination were of interest, these were fitted up to the 
two-way level and the optimum model selected by comparing the Chi-squared 
statistics of each Cox model in the study period. In order to apply the PERR method 
to interactions, the same model specification was applied to the prior period data. 
Bootstrapping was used to obtain confidence intervals for the PERR-adjusted 
estimates. 
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4.6.5 Pairwise estimation 
Based on the paired Cox model 276 and Yu et al.’s development of the PERR-ALT 
model 246, Lin and Henley have provided the likelihood expression for the Pairwise 
model fitted to two periods 192, which was used to fit the model for vaccination status, 
x, adjusting for age and gender: 
𝐿(𝑋, 𝑎𝑔𝑒, 𝑔𝑒𝑛𝑑𝑒𝑟, 𝛼)
= ∏ (
1
1 + 𝑃𝑖𝑒
(𝛽𝑥.𝑥+𝛽𝑎𝑔𝑒.𝑎𝑔𝑒+𝛽𝑔𝑒𝑛𝑑𝑒𝑟.𝑔𝑒𝑛𝑑𝑒𝑟+𝛼)
)
∆𝑝𝑖𝑛
𝑖
(
𝑒(𝛽𝑥.𝑥+𝛽𝑎𝑔𝑒.𝑎𝑔𝑒+𝛽𝑔𝑒𝑛𝑑𝑒𝑟.𝑔𝑒𝑛𝑑𝑒𝑟+𝛼)
𝑒(𝛽𝑥.𝑥+𝛽𝑎𝑔𝑒.𝑎𝑔𝑒+𝛽𝑔𝑒𝑛𝑑𝑒𝑟.𝑔𝑒𝑛𝑑𝑒𝑟+𝛼) + 𝑆𝑖
)
∆𝑠𝑖
 
Equation 3 
where  is a nuisance parameter modelling the period effect,  is a 
binary indicator variable denoting whether a survival time for the ith of n 
patients in prior period, p, or study period, s, ended in an event, and P 
is a switch variable denoting whether the shortest survival time was in 
the prior period, or S, the complement of P (i.e. P = 1- S), for the 
shortest time in the study period. 
It can be seen when either a survival time does not end in an event or is not the 
shortest out of the two periods, then the corresponding term of that period in the 
likelihood will be unity, and therefore contribute no information to the likelihood. This 
means in order for a patient to contribute to the likelihood, then the shortest survival 
time out of the two periods must end in an event, otherwise the information for that 
patient is null. Effectively this means that the Pairwise estimate is derived from a 
subset of patients used to find the PERR estimate. This meant less storage and 
faster computation time when this was deployed in the vaccine studies. 
The Pairwise method was applied using R software 277, and the likelihood entered as 
its logarithm, transforming the product operators into sums. The log likelihood 
function was estimated using the non-linear minimisation function (nlm) in R, with 
zero starting values and outputting the Hessian matrix. The confidence interval for 
the Pairwise estimate of vaccination were subsequently derived from the square root 
of the corresponding diagonal element of the stored Hessian matrix.  
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4.6.6 Cox analysis with time-varying covariates 
As an alternative approach to modelling time, a common index date of 1st September 
of each year was chosen, and vaccination was modelled as a time-varying covariate 
(TVC). Modelling vaccination as a TVC offered not only insight into any time-
dependent effects, but also the advantage of circumventing the need for matching to 
map the vaccination dates onto the controls for their start times. In this way, chance 
imbalances in the observation start times between vaccine recipients and controls 
were avoided, as well as the need to run a computationally intensive matching 
algorithm in Stata. Cox regression of TVC’s first of all required a re-organisation of 
the data to split the data for the exposed group into two rows of observations, as 
might be found in the counting process format for the Andersen-Gill model of ordered 
survival times 278. For the first row, the exposure indicator variable would be set to 
zero, to represent the period in an unexposed state, ending in either an event or the 
time of exposure. The second row, therefore would represent the exposed state of 
the ordered survival times, with the indicator variable now set to one. The survival 
time for this second period re-starts from the time of exposure. The controls would 
remain as they are with one row of observations per individual. If PERR were to be 
applied, then the format of the prior data would remain as is, with one row of 
observations per patient. To proceed with TVC Cox analysis in Stata, the data had to 
be stset with the exit option specified as “.” to retain patient records after failure. The 
enter option was set as the start date for each individual survival time. This was often 
zero as this corresponded to the common index date, but for post-exposure times, 
was the time from the start date to exposure (e.g: days since the index date until 
vaccination). As exposed individuals would contribute two survival times to the 
likelihood, clustering by patient was accounted for in the covariance matrix of the 
estimates to account the lack of independence in the exposed observations and to 
adjust the standard errors accordingly.  
4.6.7 Sample size calculation 
The sample size calculated for both vaccine studies and submitted to the CPRD’s 
Independent Scientific Advisory Committee was partly informed by estimates from 
the 2012 edition of the Coronary Heart Disease Statistics, from the British Heart 
Foundation. Focussing on women aged over 84y, this clinically interesting subgroup 
experienced 139 incidences of acute myocardial infarction (a primary outcome for 
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ischemic heart disease) per 100 000 person-years.  As the meta-analysis into 
studies of influenza vaccination on cardiovascular disease found the effect could 
reduce the risk by about 35%, the power to detect a hazard ratio of 0.65 from a Cox 
model is sought at a power of 0.8 and significance level of 5%. Using the Schoenfeld 
approximation, this would require a sample size of 121 710 patients. If the power to 
detect a hazard ratio of, say, 0.70 were sought, this would increase to 177 550 
patients. 
An estimate of incidence for community-acquired pneumonia among adults aged 
over 65y put the rate at 7.99 per 1000 person-years from pilot CPRD data. 
Therefore, the probability of survival times ending in such an outcome over a three-
year study period of the pneumococcal vaccine would be approximately 0.024. 
Results from a meta-analysis of studies into the pneumococcal vaccine suggested 
that the risk of pneumococcal pneumonia could be reduced by approximately 16%. 
Therefore, to detect a hazard ratio of 0.85 at a power of 0.8 and significance level of 
5% would require 49 530 eligible patients.  
 
4.7 Workflow of computer code 
The processing of raw data is an essential part of any empirical study, whether a 
clinical trial or a project using routinely collected data. This involves not only the 
application of inclusion/exclusion criteria, but manipulation into an analysable form. 
In this project, as with most studies using CPRD and other routinely collected data, 
this involved merging together data from across different datafiles, whilst applying 
the inclusion/exclusion criteria. As both studies in this PhD project investigated 
vaccine effectiveness and required survival times in a cohort study design, I wrote 
core code that could be applied to each study with adjustment of files paths, 
inclusion criteria and the study settings. For clarity, adaptability and ease-of-
troubleshooting, this was modularised across a sequence of do-files (files containing 
program code in Stata), each purposed to apply the inclusion criteria to particular 
CPRD datafiles, or merge their derivatives and calculate new variables (Figure 11). 
The modularised do-files were organised in Stata’s project manager facility, from 
which they could be run in order. It should be noted that code writing was an 
   
 
 121 
evolutionary, learning process, so while all code should run without any detectable or 
undetectable errors, code written later may exhibit more efficiency and arguably less 
verbosity. While R was used to perform the Pairwise analysis, as it was relatively 
easy to specify a likelihood within a user-defined function in that particular software, 
Stata was used for all data preparation and the PERR analysis. This represented a 
challenge at times as the approach is different from R, plus Stata can only hold one 
dataset in memory at once, necessitating the specification of temporary datafiles in 
some instances. Temporary datafiles notwithstanding, many interim datasets were 
created and saved in between the modular do-files. Graph output was created using 
both Stata (initially version 12) and the ggplot2 package in R, depending on 
convenience. 
One particular challenge posed by the constraint of one dataset-at-a-time in Stata’s 
memory was in writing the matching routine stored in the do-file, Matchexh+dth 
(suffixed with the version number). This was used purely for mapping the vaccination 
dates of the vaccine recipients to the controls in order to assign a similar distribution 
of observation start dates. No further matching was involved in the analysis, nor as 
an adjustment for confounding. Thereafter, adjusted analyses were performed 
through weighting based on derived propensity scores. In the matching routine for 
observation start dates, the patients were grouped by ever fuzzier levels of grouping 
variables. First, these were on exact age, gender and practice id. For fuzzier 
grouping variables, age was categorised into ever coarser levels, until dropped. 
Practice id was then dropped and further fuzzier levels of grouping organised around 
just gender and age categorised into varying levels of coarseness, until just gender 
remained. The do-file routine then looped over the grouping variables, exhaustively 
matching patients by the finest degree of grouping until moving to the next level of 
fuzziness. Within the loop, Stata’s temporary files were invoked to separate those 
patients, who had been matched, and keep a tally of the patients remaining. As it is 
unusual for matching to be used in this way (i.e: just for mapping observation start 
times), it should be re-iterated that matching was not used in any of the analyes, 
rather explicit adjustment for confounding was approached through weighted 
regression. 
Stylistic differences may be noticed across the code, with different versions of the 
same code invoked, as there was an inevitable learning process throughout the 
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project, which gradually led to slightly more sophisticated use of syntax. In the case 
of the influenza study, predicting the propensity score for both periods of the 15 
cohorts required invoking Mata in the automated selection of the significant 
prognostic variables for the propensity score models (do file: autoselect_pscore_v2). 
However, the code writing for this project preceded my recent involvement in NIHR-
funded activity focussing on best practice in code writing and programming 
validation. While this was primarily intended for clinical trials units, there are obvious 
advantages in terms of traceability and reproducibility in applying the same 
standards to analysis of EHRs and RCD. Some version control was maintained and 
Stata’s project manager was utilised to run modularised code for this project, 
however, there are further potential advantages to be gained from using version 
control software, or uploading to GitHub with its own integrated version-control. 
The programming code used in this project accompanies this thesis in separate files. 
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Figure 11: Flowchart of data preparation workflow in Stata towards analysable 
dataset. Do-file names are in bold in square shapes, CPRD datafiles are indicated by 
rhombus shapes, and datafiles with inputted symptom codes in trapezoid.  
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5.1 Abstract 
5.1.1 Objective 
To determine the age-specific effectiveness of the 23-valent pneumococcal 
polysaccharide vaccine (PPV-23) in UK adults aged 65y and older. 
5.1.2 Design 
Quasi-experimental analysis of a retrospective cohort of 324,804 older primary care 
patients using the Prior Event Rate Ratio (PERR) method to adjust for measured and 
unmeasured confounding. 
5.1.3 Setting 
General practices registered to the Clinical Practice Research Datalink with linkage 
to Hospital Episode Statistics and the Office of National Statistics databases. 
5.1.4 Population 
Three annual cohorts from 2003 to 2005 coinciding with the introduction of the policy 
to recommend the vaccination against Streptococcus pneumoniae for adults aged 
65y and older. 
5.1.5 Intervention 
23-valent polysaccharide pneumococcal vaccination (PPV23) 
5.1.6 Main outcome measure 
Specific antibiotic treatment for lower respiratory tract infections or hospitalisation 
with symptoms consistent with pneumococcal Community Acquired Pneumonia 
(CAP). 
5.1.7 Results 
For all three cohorts, the rates of pneumococcal pneumonia in the year before 
vaccination were higher for patients who proceeded to be vaccinated with PPV23 
than for patients who remained unvaccinated, indicating the presence of confounding 
bias. Adjustment for this bias using the PERR method showed that PPV23 was 
moderately effective for two years after vaccination against CAP in all age sub-
groups with hazard ratios of 0.86 (95% confidence interval: 0.80 to 0.93), 0.74 (95% 
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CI: 0.65 to 0.85) and 0.65 (95% CI: 0.57 to 0.74) in patients aged 65-74, 75-79 and 
80+ respectively in the 2005 cohort.  The interaction between vaccination and age 
was statistically significant in the 2005 cohort, with predicted risk reductions of 4%, 
12% and 15% at ages 65y, 75y and 80y, respectively.  
5.1.8 Conclusions 
The UK programme for vaccinating patients aged ≥ 65y with PPV23 is effective at 
reducing CAP. The effectiveness increases with age in step with increasing 
susceptibility to CAP at older ages. Examining the risk of infection in the period prior 
to vaccination suggests that the vaccination is targeted towards those most likely to 
benefit long-term from immunity to pneumococcal infection. 
5.2 Introduction 
Pneumonia is a major cause of morbidity, hospitalization and associated mortality in 
older adults 279.  Since 2003, public health policy in the UK has recommended 
vaccination against streptococcus pneumoniae (pneumococcus) for adults aged ≥ 
65y using the 23-valent polysaccharide pneumococcal vaccine (PPV23). The 
vaccination programme began in August 2003 with the PPV23 vaccine offered to 
adults aged ≥ 80y. This was extended to adults aged ≥ 75y in April 2004 and then 
finally to all adults aged ≥ 65y in April 2005.  PPV23 is recommended as a standard 
intervention for the elderly in many other countries across Europe and elsewhere. 
However, there has been ongoing controversy about whether or not PPV23 is 
effective in preventing noninvasive pneumococcal infection: four systematic reviews 
have been published since 2016 with divergent conclusions 280–285. 
Recent evidence has come from two trials. One, a large-scale, population-based 
randomised trial (CAPITA) in the Netherlands, reported an efficacy of 46% against 
first episodes of vaccine-matched strains of community-acquired pneumonia and 
75% against invasive pneumococcal disease among 84 496 adults aged ≥ 65y 286. 
However, the study lacked the power to draw conclusions on how efficacy might vary 
with the age of the vaccine recipient. Furthermore, the intervention was protein-
conjugated polysaccharides from 13 serotypes (PCV13), a vaccine originally 
developed for young children but licensed since for use in adults primarily on the 
basis of immunogenicity studies. PPV23, the vaccine offered to adults in many 
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countries including the UK, was recently investigated in a prospective, multi-centre 
trial in Japan, in adults aged ≥ 65y 287. A significant effectiveness, of 23% and 34%, 
was reported against all-cause pneumonia and vaccine-matched strains, 
respectively. However, without randomisation, the trial relied on a test-negative 
design to mitigate against confounding, with subsequent adjustment in the analysis 
for confounding variables. The claimed increase in effectiveness in adults aged 
between 64 and 75y was small, and not supported by statistical evidence. Evidence 
from previous studies for how the effectiveness of PPV23 changes with age remains 
inconclusive, yet age is a critical cut-off in determining vaccination policy. Age-
related decline in immune function renders older adults susceptible to pneumococcal 
infection, yet the same decline may reduce the immunogenic response to 
vaccination. 
We conducted a retrospective cohort study using electronic health records (EHRs) to 
assess real-world effectiveness of the vaccine in adults aged ≥ 65y in the UK and to 
determine how effectiveness might change with age. The data were extracted from 
the Clinical Practice Research Datalink (CPRD) with linkage to Hospital Episode 
Statistics and Office of National Statistics data. Large EHR databases can afford 
larger sample sizes for the study of real-world effectiveness in small sub-groups than 
would typically be available in randomised trials, as well as facilitating the study of 
populations which, for ethical reasons, might otherwise be difficult to recruit into a 
trial. The rise in vaccination rates resulting from the vaccination programme for older 
adults provided the opportunity for a natural experiment. Furthermore the 
incremental introduction of the policy by age group from 2003 to 2005 facilitated 
estimation of the pneumococcal vaccine’s effectiveness within the key age sub-
groups. 
5.3 Methods 
5.3.1 Data source 
We used data from the UK Clinical Practice Research Datalink (CPRD) 53, a 
database of electronic medical records including information on demographics, 
consultations, diagnoses, drug prescriptions, immunisations, referrals, etc collected 
by participating general practitioners (family doctors) during their daily clinical 
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routines. Our datasets were also linked to hospital admission data  and death 
certificate data. The CPRD has been granted Multiple Research Ethics Committee 
approval (05/MRE04/87) to undertake purely observational studies, with external 
data linkages including HES and ONS mortality data. The work of CPRD is also 
covered by NIGB-ECC approval ECC 5-05 (a) 2012. Our study gained prior approval 
by the CPRD Independent Scientific Advisory Committee for MHRA database 
research (ISAC protocol 14-159). 
5.3.2 Recruitment and study population 
Three cohorts were studied, each relating to a single year of the phased introduction 
by age-group of the policy to vaccinate older adults with PPV23: adults aged ≥  80y, 
vaccinated for the first time from 1st September 2003 to 31st August 2004; adults 
aged  ≥  75y from 1st September 2004 to 31st August 2005; and adults aged ≥ 65y 
from 1st May 2005 to 30th April 2006. The dates for the start and end of recruitment 
for each cohort were chosen so as to capture the peak uptake of the vaccine during 
the relevant period. Patients had to be alive and registered at their general practice 
at the (index) date of vaccination.  All adults that remained unvaccinated for the 
duration of the study period were designated as controls and matched to vaccinees, 
to the nearest age, and where possible the same gender and practice, solely for the 
purposes of assigning an index date. The index date for each control was the 
vaccination date of the corresponding vaccinee. Each cohort was analysed 
separately. Any patients without any data in the six years preceding recruitment to 
the study were excluded from the cohort, as there was a considerable risk they had 
left the area, but failed to de-register with the practice (see flowchart in section 5.6 
Appendix A).  
5.3.3 Study design and follow-up 
Without randomisation, vaccination status in observational studies of this type may 
be influenced by unmeasured confounders, including variables related to the number 
and severity of diseases, and in this age group, latent frailty. Recent advances in 
quasi-experimental methods make it possible, under relevant assumptions, to 
address directly the unmeasured confounding bias that arises when relevant 
confounders are omitted 208,288. One such approach to enhancing the validity of 
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observational studies is the Prior Event Rate Ratio (PERR) method, proposed by 
Tannen and Weiner et al 187,242, and extended by Yu et al 246 and Lin and Henley 192. 
The PERR approach is becoming more widely adopted in clinical studies based on 
EHRs and, for example, was used recently to demonstrate that previously reported 
associations between the use of proton pump inhibitors and risk of community 
acquired pneumonia are likely to be due entirely to confounding factors 265. 
We made use of the PERR framework by considering the introduction of the 
pneumococcal vaccination policy as a natural experiment. Quasi-experimental 
analysis of vaccine effectiveness was conducted by using group differences before 
the introduction of the vaccine to adjust for unmeasured confounders. We adopted a 
two arm before-and-after design in which vaccinated and control patients were 
followed up during two periods: the study period, consisting of up to two years from 
the index date, and a prior period of up to two years starting from two years before 
the index date (Figure 12). Patients were censored upon death or being transferred 
out of their practice. The two year study follow-up period was chosen because two 
years is the time interval for which the effect of the vaccine was found to be stable in 
previous studies289 suggesting reasonable stability of unmeasured confounding 
effects over this period.  
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Figure 12: Schematic of paired design for PERR analysis of PPV23 effectiveness. 
Patients vaccinated during a 1y recruitment window are selected and matched to 
controls by age, gender and general practice. Index dates of controls are mapped 
from the vaccination dates of vaccine recipients. Event times are compared for 
vaccinated and control patients during a 2y study period and a 2y prior period. The 
start of the prior period precedes recruitment by exactly 2y. Survival times may end 
with an event or be censored before the end of either period. 
5.3.4 Vaccination 
Patients were identified as being vaccinated with PPV23 using relevant codes in the 
CPRD immunisation file, supplemented with codes from the therapy file (Appendix D 
– CPRD and HES codes). Similarly, the patients’ influenza vaccination status in each 
year was also retrieved, and included in the study. 
5.3.5 Outcomes and covariates 
As laboratory confirmation of suspected cases of pneumococcal pneumonia is not 
widely available, we utilized the clinical records to specify a composite outcome of 
either hospitalisation for suspected pneumococcal pneumonia, or the prescription of 
antibiotics of species typically used for treating pneumonia, and qualified by the 
coded symptoms consistent with those of the disease 290,291. Amoxicillin and 
doxycycline were the antibiotics selected for study as those most likely to be 
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prescribed to treat invasive pneumococcal disease and pneumonia-like LRTIs. A 
pharmacist and clinician independently identified the corresponding product codes 
(Appendix D – CPRD and HES codes) in the data. The antibiotic prescriptions were 
further qualified by the medical codes for symptoms consistent with pneumonia and 
LRTIs, which were independently selected by two clinicians (JM & AB), with input 
from a third (DM) where differences arose. Hospitalisations were coded according to 
their ICD-10 classification (Appendix D – CPRD and HES codes). Survival times for 
this endpoint were calculated for each patient in both the prior and study periods.  
Information was also collected on smoking history and comorbidities within the 
Quality Outcomes Framework (QOF), a scheme to incentivise general practitioners 
to register common morbidities of patients.  The corresponding codes were obtained, 
with reference to previous work on multimorbidity 60. 
For the purpose of building a high-dimensional propensity score predicting treatment, 
the QOF codes were supplemented with further codes for conditions identified in an 
electronic frailty index (eFI) 292. When the codes of a disease category from either 
QOF or the eFI overlapped with at least 80% of the other, then the source with the 
fewer codes was excluded to avoid unnecessary multicollinearity in specifying the 
propensity score model. 
5.3.6 Statistical analysis 
Patient characteristics and comorbidities were used to identify likely sources of 
measured confounding. Cox’s regression was used to model the effect of vaccination 
on the hazard function for the composite pneumococcal pneumonia outcome, both 
with and without adjustment for confounding variables (model fitting found in section 
5.7 Appendix B: Fitting the Cox model for pneumococcal investigation). For each of 
the three recruitment cohorts, separate Cox regression models were fitted to the 
data from the prior and study periods. For the 2003 recruitment cohort, models were 
fitted to the single age-group of over-79y olds. For 2004, the analysis was stratified 
by age-group with separate models fitted for over-79y olds and 75-to-79y old adults, 
while the 2005 cohort was analysed in three separate age-groups: 65 to 74y old 
adults, 75-to-79y old adults and over 79-y olds. The degree of confounding bias was 
assessed by the hazard ratio for the treatment effect from the Cox regression models 
fitted to the treatment-free prior period. Potential modifying effects of age and gender 
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on treatment effectiveness were considered through inclusion of age, gender and 
treatment and their interactions up to the 2-way level. The best-fit models for each 
cohort were selected through chi-square tests of the deviance between nested 
models. These models were used as the basis for quasi-experimental analysis using 
the PERR approach. Conventional adjustment for measured covariates, such as the 
QOF diagnoses, was undertaken as a sensitivity analysis (see below). 
5.3.7 Adjustment for unmeasured confounding 
We used the PERR adjustment to mitigate for hidden confounding, adjusting the 
hazard ratio (HR) of the study period with that from the prior period. Bootstrap 
resampling provided the 95% confidence intervals for the PERR estimate. Recent 
work has shown that the PERR method has a tendency to attenuate treatment 
estimates in the presence of hidden covariates and / or censoring 225, and so the 
quasi-experimental analysis was supplemented with the pairwise Cox likelihood 
approach (pairwise method) which removes this source of bias 192.  This approach is 
equivalent to the PERR-ALT method proposed by Yu et al 15. Initially, separate 
analyses were conducted for each age sub-group (65-74, 75-79, 80+) within each 
cohort. Further analyses were conducted for each cohort in which the age sub-
groups were combined and interactions between age and vaccination status were 
considered. 
5.3.8 Sensitivity analyses 
Results from methods mitigating for unmeasured confounding were compared with 
those adjusted by weighting using variables available in the data and identified as 
having confounding effect 12,293. This weighted approach as with all adjusted 
regression models, relies on potential confounders being fully observed and 
available in the data, with any bias from remaining unobserved confounders 
assumed to be negligible 12. The weights were obtained from a propensity score 
model, but first, the prognostic predictors of survival time were found through 
backwards elimination of potential confounders in a Cox regression. Eliminating 
weak prognostic variables that were poorly predictive of survival avoided potential 
inclusion of instruments of treatment in the propensity score model, which might 
otherwise inflate the error for the estimated effect 294. A high-dimensional approach 
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was taken, using up to 58 candidate variables, including key patient characteristics 
of age and gender, as well as diseases registered under the UK Quality Outcomes 
Framework 295, supplemented with variables used in the UK electronic Frailty Index 
292 (National Institute of Health Research), and the index itself. Variables in the frailty 
index were monitored over the five years preceding each patient’s study period. The 
propensity score was obtained as the predicted probability of vaccination from a 
logistic regression of vaccination status on the candidate variables, identified as 
potential confounders. Poor predictors of treatment were excluded through 
backwards elimination of the candidate prognostic variables at the 5% level of 
significance.  Subsequent adjustment of the analytic Cox model with stabilized 
inverse probability treatment weights (sIPTW) yielded an estimate of the marginal 
effect and avoided the bias arising from conditioning on the propensity score as has 
been demonstrated in simulation studies 275.  
The propensity score model used to obtain the weights in the study period was re-
estimated for the same variables using data from the prior period. The effectiveness 
in the prior period was then estimated through a weighted regression to ascertain the 
success of adjustment under the assertion of stable confounding. This was assessed 
by the proximity of the estimate to unity. However, such an assertion may not have 
been reasonable, so hazard ratio of effectiveness from the weighted regression of 
the prior period was re-estimated using weights based on propensity scores 
modelled on confounders specifically for the prior period data. The PERR analysis 
was then applied to the weighted-estimate from the study period, alternately adjusted 
with both versions of the weighted HR from the prior period. i.e.: the HR for the prior 
period weighted by  
 propensity scores specifically obtained for the prior period, but modelled on 
the same (static) confounders as already determined for the study period 
 propensity scores predicted from a model of confounders found to be 
significant in the prior period, but not necessarily the same confounders as 
those used for the study-period propensity score (dynamic). 
Further sensitivity analysis was also carried out for sub-groups of various influenza 
vaccination patterns to examine possible confounding between the effectiveness of 
this and pneumococcal vaccinations on the outcome. To address the impact of 
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concurrent or recent influenza vaccination on estimates of PPV23 effectiveness, 
patients were classified into one of four sub-groups based on whether they had been 
vaccinated against influenza in either the prior or study period alone or in both 
periods (never-FV, prior-FV, study-FV, always-FV). The potential moderating effect 
of influenza vaccination on PPV23 effectiveness by age was assessed by modelling 
an interaction between age and the PPV23 intervention effect in each flu-vaccine 
subgroup. 
5.4 Results 
Table 1 shows the trends in PPV vaccination coverage by age group, for the periods 
before and during the introduction of the national vaccination programme. There was 
good concordance between the PPV uptake achieved by the end of 2005 in the 
study data (see Table 6) and national vaccination rates reported by Public Health 
England (PHE - formerly the Health Protection Agency) for uptake by 31st March 
2006 (For age groups ≥ 65y; 75-79y; and 80y and older respectively: Extracted data 
64.8%, 70.6%, 68.4%; PHE 64.4%, 68.9%, 68.1%). A flowchart showing the 
numbers at key stages of selection from the data are shown in Figure 14 of section 
5.6 Appendix A. 
 Extracted data per 
year 
Each year by age group 
Year Number 
of 
patients 
% 
Vaccinated 
65 - 74y > 75y 75 - 79y > 80y 
patients %Vac'd patients %Vac'd patients %Vac'd patients %Vac'd 
2002 470657 25.7 234482 22.4 236175 28.9 94447 30.5 141728 27.9 
2003 504948 33.2 250851 24.0 254097 42.2 100334 33.7 153763 47.8 
2004 522963 42.5 260254 26.8 262709 58.1 102906 55.8 159803 59.5 
2005 541694 64.8 267984 60.2 273710 69.2 107089 70.6 166621 68.4 
2006 553627 69.3 272516 65.0 281111 73.4 109473 74.6 171638 72.7 
Table 6: Annual cumulative pneumococcal vaccination rates from 2002 to 2006 by 
age group (for patients alive and registered at the beginning of each year) 
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5.4.1 Cohort characteristics 
The cohort size increased with each study year as the vaccination programme was 
expanded; about half of each cohort comprised vaccinees with 47.1% in 2003, 
41.3% in 2004 and 53.2% in 2005. Nearly half the 2005 cohort were males, 
decreasing to about a third for the older 2003 cohort (Table 2). The controls were at 
least two years older on average and tended to have fewer males, and this 
imbalance appeared to be greatest in the 2004 cohort. The vaccination group was 
found to have a consistently higher prevalence of diseases registered under the 
Quality Outcomes Framework compared to the controls. The two leading registered 
comorbidities were hypertension and coronary heart disease. Hypertension 
prevalence in the vaccinees ranged from 46% in 2005 to 52% in 2004, and in the 
controls from 37% in 2005 to 41% in 2004. Similarly, coronary heart disease was 
more prevalent among the vaccinees with 18.5% compared to 15.6% for the controls 
from the 2003 cohort falling to 11.3% and 10.5%, respectively, in the 2005 cohort.  
The 2004 cohort exhibited the greatest imbalance in terms of QOF indices, age and 
gender. The proportion of identified smokers was similar between treatment groups, 
increasing slightly with each cohort. 
In all three cohorts, the majority of patients had been vaccinated against influenza at 
least once in both the prior and study periods (always-FV). Compared to those not 
vaccinated in either period (never-FV), the numbers vaccinated in both periods were 
31855 vs. 16500 in 2003, 37771 vs. 26667 in 2004, and 103293 vs. 64016 in 2005. 
The patients receiving the flu vaccine in the prior period only and in the study period 
only were relatively few in number ranging from 1911 for those in the 2003 cohort 
receiving a flu vaccine in the study period only, to 17425 in 2005 for the same flu-
vaccine subgroup. The rates of influenza vaccination were much higher in the 
pneumococcal vaccinees than in the controls: At least 80% of the pneumococcal 
vaccinees received an influenza vaccination in both periods, while for the controls 
this figure decreased from 30 to 20% with each cohort (Table 2). 
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Cohort 2003 2004 2005 
Treatment group Vaccinated Controls Vaccinated Controls Vaccinated Controls 
N  25870 29087 30028 42625 104969 92225 
% males  36.7% 28.5% 40.4% 31.8% 44.7% 40.3% 
Age 
Mean 84.5 85.9 79.3 82.3 71.6 75.1 
s.d. 4.0 4.8 4.3 5.8 5.4 8.1 
Disease 
registered 
under Quality 
Outcomes 
Framework 
AF 14.3% 11.9% 11.0% 10.6% 6.3% 6.9% 
Asthma 6.9% 5.2% 6.9% 5.5% 7.3% 5.6% 
Cancer 9.7% 8.2% 9.7% 8.8% 8.4% 8.0% 
CHD 21.9% 18.6% 19.4% 16.7% 13.3% 12.4% 
CKD 6.1% 3.1% 19.7% 12.1% 14.8% 11.8% 
COPD 5.4% 5.3% 5.9% 5.2% 4.4% 4.2% 
Dementia 6.7% 9.0% 4.7% 7.1% 1.8% 3.6% 
Depression 9.8% 9.0% 9.4% 8.7% 8.5% 7.9% 
DM 6.2% 4.2% 8.8% 6.4% 8.4% 6.9% 
Epilepsy 1.3% 1.2% 1.3% 1.2% 1.2% 1.2% 
HF 10.3% 10.7% 6.0% 7.3% 2.3% 3.9% 
Hypertension 48.5% 37.5% 52.1% 40.9% 46.2% 37.4% 
Hypothyroid 9.0% 7.9% 9.2% 8.2% 7.9% 7.2% 
Mental Health 1.0% 1.6% 1.2% 1.6% 1.1% 1.5% 
Stroke 14.1% 14.0% 10.7% 11.9% 5.8% 7.6% 
Smoking 
status 
Smoker 15.4% 16.4% 20.9% 20.6% 23.7% 25.3% 
Not smoker or 
n/a 
53.4% 61.4% 44.9% 54.1% 45.2% 49.3% 
Ex smoker 31.2% 22.2% 34.2% 25.3% 31.1% 25.4% 
Influenza 
vaccination in 
both periods 
 90.2% 29.3% 88.1% 26.6% 80.1% 20.8% 
Table 7: Characteristics of study population for each cohort by pneumococcal 
vaccination status at cohort entry into study period 
  
   
 
 137 
5.4.2 CAP and mortality rates in each cohort  
The overall risk of the composite CAP outcome decreased from 10.2% in the 2003 
cohort to 6.9% in the 2005 cohort, reflecting the younger age distribution for the later 
cohorts (Table 3). Patients were more likely to experience a CAP event in the study 
period than in the prior period for both vaccinated and control patients: In 2003, the 
incidence of CAP in the prior and study periods was 8% and 11% respectively for 
vaccine patients, and 7% and 10% respectively for control patients. These 
proportions decreased with later cohorts. The proportion of hospitalisations for 
pneumococcal pneumonia among patients experiencing a prior or study end point 
tended to be greater for the controls, as high as 49% for those in the older 2003 
cohort, while 31% for the vaccinees. As before, these proportions decreased with 
later cohorts. 
Control patients had higher mortality rates than vaccinated patients with 32% of the 
controls from the older 2003 cohort being censored on death compared to less than 
half that figure (15%) among the vaccinees. This imbalance increased with each 
year of recruitment, a trend that was tempered by the inclusion of younger patients in 
later cohorts, which saw the overall reduction in mortality fall from 19% to 7% per 
cohort by 2005.  Those hospitalised for pneumonia were at the greatest risk of death, 
particularly in the older 2003 cohort (68% and 81% following hospital admissions in 
vaccinees and controls, respectively). Consistent with the high mortality rate 
following pneumonia hospitalisation, the proportion of outcomes resulting in 
hospitalisation was lower during the prior period than the study period, as patients 
needed to be alive after the prior period for subsequent selection to the study. In 
comparison to deaths, there were far fewer censored survival times due to 
deregistrations from the general practices. 
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Cohort 2003 2004 2005 
Exposure group 
Vaccine 
recipients Controls 
Vaccine 
recipients Controls 
Vaccine 
recipients Controls 
Deaths 
Patients 
censored on 
death 
 9184 
(31.6) 
 3985 
(15.4) 
 9995 
(23.4) 
 2727 
( 9.1) 
12293 
(13.3) 
 4296 
( 4.1) 
Transfers 
out of 
practice 
Patients 
censored for 
transferring 
out of practice 
 3891 
(13.4) 
 1654 
( 6.4) 
 4388 
(10.3) 
 1316 
( 4.4) 
 7719 
( 8.4) 
 4227 
( 4.0) 
Outcomes 
in study 
period 
Patients with 
CAP outcomes 
 2816 
( 9.7) 
 2811 
(10.9) 
 3579 
( 8.4) 
 2734 
( 9.1) 
 6016 
( 6.5) 
 7625 
( 7.3) 
Hospitalised 
pneumonia (% 
of CAP) 
 1371 
(48.7) 
  858 
(30.5) 
 1569 
(43.8) 
  642 
(23.5) 
 1901 
(31.6) 
 1055 
(13.8) 
Deaths during 
study among 
hospitalised 
pneumonia 
cases 
 1115 
(81.3) 
  584 
(68.1) 
 1190 
(75.8) 
  377 
(58.7) 
 1328 
(69.9) 
  528 
(50.0) 
Outcomes 
in prior 
period 
Patients with 
CAP outcomes 
 2125 
( 7.3) 
 2166 
( 8.4) 
 2836 
( 6.7) 
 2314 
( 7.7) 
 5143 
( 5.6) 
 7020 
( 6.7) 
Hospitalised 
pneumonia (% 
of CAP) 
  529 
(24.9) 
  269 
(12.4) 
  608 
(21.4) 
  233 
(10.1) 
  841 
(16.4) 
  428 
( 6.1) 
Table 8: Description, N (%), of composite CAP outcomes, death and censoring for 
each cohort from 2003 to 2005 
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5.4.3 Prior event rate ratio analysis  
For all three cohorts, and in each age sub-group, the rates of CAP in the year before 
vaccination (prior period) were higher for patients that went on to be vaccinated with 
PPV23 than for patients who remained unvaccinated, indicating the presence of 
confounding bias (Table 4). In patients aged 65-74 (2005 cohort), the rate of CAP in 
the study period was higher for patients that had been vaccinated than for patients 
that had not: HR=1.28 (95% confidence interval: 1.22 to 1.34). However, the 
imbalance between vaccinated and control patients was even greater in the prior 
period before either group had received PPV23: HR=1.37 (95% CI: 1.30 to 1.44). 
Adjustment for measured and unmeasured confounding bias using the pairwise 
PERR method gave a significant protective HR of 0.86 (95% CI: 0.80 to 0.93) (Table 
4 and Figure 2). Similar protective effects of vaccination were seen in the older age 
sub-groups within the 2005 cohort with HR of 0.74 (95% CI: 0.65 to 0.85) and 0.65 
(95% CI: 0.57 to 0.74) respectively in the 75-79 and 80+ age groups respectively.   
Results for the 2003 and 2004 cohorts were similar for each age sub-group. 
Estimates from the standard PERR method were consistent with the pairwise 
estimates but effect sizes tended to be closer to the null, as expected. 
 
Cohort 
year 
Age group 
Hazard ratios (95% CI) of Treatment term 
Prior Study PERR Pairwise 
2003 80+ 1.20 (1.13, 1.27) 1.00 (0.95, 1.06) 0.84 (0.77, 0.91) 0.68 (0.63, 0.74) 
2004 75-79 1.23 (1.14, 1.34) 1.12 (1.03, 1.20) 0.90 (0.82, 1.00) 0.82 (0.72, 0.93) 
2004 80+ 1.34 (1.23, 1.45) 1.07 (0.99, 1.15) 0.80 (0.72, 0.88) 0.61 (0.54, 0.69) 
2005 65-74 1.37 (1.30, 1.44) 1.28 (1.22, 1.34) 0.94 (0.89, 0.99) 0.86 (0.80, 0.93) 
2005 75-79 1.27 (1.16, 1.39) 1.08 (0.99, 1.17) 0.85 (0.76, 0.94) 0.74 (0.65, 0.85) 
2005 80+ 1.31 (1.20, 1.42) 1.07 (0.99, 1.15) 0.82 (0.73, 0.91) 0.65 (0.57, 0.74) 
Table 9: Hazard ratios, adjusted for age and gender, presented for sub-group 
analysis of the prior and study periods, and the PERR-adjusted estimates. Sub-
groups correspond to the age groups, which were incrementally targeted for 
pneumococcal vaccination from 2003 to 2005, namely adults aged over 79y; from 75 
to 79y; and from 65 to 74y.  
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Figure 13: Pairwise-adjusted  hazard ratios of vaccination for each annual cohort 
(2003-005) by sub-groups of age (65 to 74y – light grey circle; 75 to 79y – mid-grey 
triangles; 80+y – black squares). 
Further analysis of the 2005 cohort, modelling age as a covariate in an interaction 
with vaccination, identified an increasing protective trend with age (p-value=0.01).  
The interaction HRs for the PERR and pairwise models, respectively, were 0.99 
(95% CI: 0.99 to 1.00) and 0.98 (95% CI: 0.98 to 0.99) indicating that the estimated 
reduction in the rate of CAP in the vaccinated patients from each model improved by 
4%  and 8%, respectively, for every 5 year increase in age. 
One of the central assumptions of the PERR adjustment approach is that the 
occurrence of prior events does not influence the likelihood of future treatment. We 
note that in this study, outcomes in the prior period did not greatly differentiate 
subsequent vaccination status, with 50.5% of patients with CAP being vaccinated, 
compared to 46.8% of those without CAP in the same period. 
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5.4.4 Sensitivity analysis 
5.4.4.1 Propensity score weighted regression 
The list of confounders found to be significant in the study period of each cohort is 
given in Table 10, as well as those (dynamic), which were found specifically for the 
prior period. The balancing variables found not to be significant, and therefore 
excluded as potential confounders, in models in any period for any of the cohorts 
were: cancer, mental health, stroke, aspirin count. In addition to these, there were 
inconsistent confounders, which appeared no more than once in the study period of 
any of three cohorts: QOF-registered atrial fibrillation, QOF-registered chronic kidney 
disease, epilepsy, hypothyroidism. More confounders were found in the study 
periods. In 2003, the disparity in the number of confounders was 47 in the study 
period compared to 44 in the prior of the 2003 cohort, but this grew to 49 compared 
to 30 for the same respective periods in the 2005 cohort. 
Density plots of the propensity scores (section 5.8 Appendix C: propensity score 
density graphs) revealed sufficient overlap for valid inference for the 2004 (Figure 22) 
and 2005 cohorts (Figure 23), but a slight disparity in overlap towards the higher 
scores and a concern about the positivity of controls, with many scores close to zero, 
raised caution about inference from the IPTW analysis of the 2003 cohort (Figure 
21). The success of the IPTWs to balance the confounders was judged by 
comparison of the unweighted and weighted standardised mean differences (SMD) 
of the variables used to predict the propensity score (Plotted as Figure 24, Figure 25 
and Figure 26 in section 5.9 of Appendix D: plots of standardised mean differences 
of balancing variables, for the 2003, 2004 and 2005 cohorts, respectively). Notably, 
age, then the number of historic consultations and prescriptions, were consistently 
the variables with larger imbalances, indicating these as the primary confounder 
variables. For the 2003 and 2004 cohorts, the electronic frailty index was also one 
the largest sources of confounding. Weighting achieved good balance for the 2005 
cohort, with no weighted SMDs exceeding six units (pooled weighted standard 
deviations), and the largest imbalance due to age being substantially reduced. 
Reasonable balance was achieved for all confounders in the 2004 cohort, except 
age, for which the SMD remained relatively high at 30 units, although this was half 
the unweighted SMD. For the 2003 cohort, the weighed SMD for age was also half 
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that of the unweighted SMD, but remained high at 70 units. Although the unweighted 
SMDs indicated the largest imbalances in the 2003 cohort, following weighting the 
SMDs remained high, though still reduced for many variables. 
When analysing the study period data through an IPTW regression (using weights 
based on the propensity scores predicted from the logistic regression of 
confounders), the greatest effect of vaccination occurred in the 2003 cohort among 
the 80+y age group with a HR of 0.72 (95% CI: 0.67 to 0.78). By 2004, this had 
increased to 0.84 (95% CI: 0.77 to 0.92) for the same age group, but by comparison 
to the 75-79y age group (HR 0.93; 95% CI: 0.85 to 1.17), there was an apparent 
age-related effect. By 2005, this direction of effect in the study period has 
disappeared, with the 75-79y group have the lowest HR at 0.90 (95% CI: 0.83 to 
0.98). ( 
Cohort 
Age 
group 
N 
vaccinated 
N 
controls 
HR for each period 
PERR HR 
Prior Study 
2003 80+ 25870 29087 0.89 (0.83, 0.96) 0.72 (0.67, 0.78) 0.81 (0.74, 0.89) 
2004 75-79 19409 16632 1.07 (0.98, 1.17) 0.93 (0.85, 1.01) 0.86 (0.78, 0.96) 
2004 80+ 10619 25993 1.09 (0.99, 1.19) 0.84 (0.77, 0.92) 0.77 (0.68, 0.87) 
2005 65-74 79812 49879 1.16 (1.10, 1.22) 1.03 (0.98, 1.09) 0.89 (0.84, 0.95) 
2005 75-79 15784 16403 1.07 (0.98, 1.17) 0.90 (0.83, 0.98) 0.85 (0.76, 0.94) 
2005 80+ 9373 25943 1.22 (1.11, 1.33) 0.96 (0.86, 1.08) 0.79 (0.69, 0.91) 
Table 11). 
The weighted HRs of the treatment groups in the two-year prior period were used to 
evaluate the degree of unmeasured confounding that might still remain after the 
weighted adjustment. Comparing the estimates using weights based on (dynamic) 
confounders specific to the prior (Table 11) and those based on the same (static) 
confounders found in the study period ( 
Cohort 
Age 
group 
N 
vaccinated 
N 
controls 
HR for each period 
PERR HR 
Prior Study 
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2003 80+ 25870 29087 0.87 (0.79, 0.96) 0.72 (0.67, 0.78) 0.83 (0.75, 0.94) 
2004 75-79 19409 16632 1.08 (0.99, 1.18) 0.93 (0.85, 1.01) 0.86 (0.78, 0.96) 
2004 80+ 10619 25993 1.10 (1.00, 1.21) 0.84 (0.77, 0.92) 0.76 (0.68, 0.86) 
2005 65-74 79812 49879 1.17 (1.11, 1.23) 1.03 (0.98, 1.09) 0.89 (0.83, 0.94) 
2005 75-79 15784 16403 1.09 (1.00, 1.19) 0.90 (0.83, 0.98) 0.83 (0.74, 0.93) 
2005 80+ 9373 25943 1.26 (1.15, 1.38) 0.96 (0.86, 1.08) 0.77 (0.66, 0.87) 
Table 12), the results were similar across the two different approaches to weighting 
for the prior period, indicatingreasonable stability in the modelling of confounders. 
The deviation from the null of the prior period HRs indicated that some residual 
confounding could be assumed and were greater than unity except for 2003, which 
indicated a bias towards healthy vaccine recipients. Once the PERR-adjustment had 
been applied to the weighted study-period estimates, an age effect was consistently 
observed across the cohorts: The HRs for the 80+y group ranged from 0.77 to 0.81 
based on dynamic confounders, and from 0.76 to 083 for the static confounders. The 
point estimate for the 75-79 y age group varied between 0.85 and 0.86 for both the 
2004 and 2005 cohorts modelled on dynamic confounders, and between 0.83 and 
0.86 modelled on static confounders. For the youngest age group, 65-74y, in 2005, 
the point estimates were both 0.89 (to the nearest 2 d.p.) regardless of the type of 
confounders used. 
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Disease 
2003 2004 2005 
Prior Study Prior Study Prior Study 
Asthma ✓ ✓ ✓ ✓ ✓ ✓ 
Atrial fibrillation   ✓    
Cancer       
Coronary heart disease ✓ ✓ ✓ ✓ ✓ ✓ 
Chronic kidney disease      ✓ 
Chronic obstructive pulmonary 
disorder 
✓ ✓ ✓ ✓ ✓ ✓ 
Dementia ✓ ✓ ✓ ✓ ✓ ✓ 
Depression ✓ ✓ ✓ ✓ ✓ ✓ 
Diabetes  ✓    ✓ 
Epilepsy   ✓ ✓   
Heart failure ✓ ✓ ✓ ✓  ✓ 
Hypertension    ✓  ✓ 
Mental health       
Stroke       
Hypothyroidism   ✓ ✓   
Activity limited ✓ ✓ ✓ ✓  ✓ 
Anemia ✓ ✓ ✓ ✓ ✓ ✓ 
Arthritis ✓ ✓ ✓ ✓ ✓ ✓ 
Atrial fibrillation ✓ ✓  ✓  ✓ 
Carer required ✓ ✓  ✓  ✓ 
Cerebrovascular disease ✓ ✓ ✓ ✓ ✓ ✓ 
Chronic kidney disease    ✓  ✓ 
Diabetes ✓ ✓ ✓ ✓ ✓ ✓ 
Dizziness ✓ ✓ ✓ ✓  ✓ 
Dyspnoea ✓ ✓ ✓ ✓  ✓ 
Falls ✓ ✓ ✓ ✓  ✓ 
Foot problems ✓ ✓ ✓ ✓  ✓ 
Fracture ✓ ✓ ✓ ✓  ✓ 
Hearing impaired ✓ ✓ ✓ ✓ ✓ ✓ 
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Heart failure ✓ ✓ ✓ ✓  ✓ 
Heart valve disease  ✓  ✓  ✓ 
Housebound ✓ ✓ ✓ ✓ ✓ ✓ 
Hypertension ✓ ✓ ✓ ✓ ✓ ✓ 
Ischaemic heart disease ✓ ✓ ✓ ✓  ✓ 
Mental / cognitive problems ✓ ✓ ✓ ✓ ✓ ✓ 
Mobility ✓ ✓ ✓ ✓ ✓ ✓ 
Osteoporosis ✓ ✓ ✓ ✓ ✓ ✓ 
Peptic ulcer ✓ ✓ ✓ ✓  ✓ 
Peripheral vascular disease ✓ ✓ ✓ ✓ ✓ ✓ 
Polypharmacy       
Respiratory disease ✓ ✓  ✓ ✓  
Skin ulcer ✓ ✓ ✓ ✓ ✓ ✓ 
Sleep disturbed ✓ ✓ ✓ ✓  ✓ 
Social vulnerability ✓ ✓ ✓ ✓ ✓ ✓ 
Syncope ✓ ✓ ✓ ✓ ✓ ✓ 
Thyroid disease ✓ ✓ ✓ ✓ ✓ ✓ 
Tremors ✓ ✓ ✓ ✓  ✓ 
Urinary incontinence ✓ ✓ ✓ ✓ ✓ ✓ 
Urinary system disease ✓ ✓ ✓ ✓ ✓ ✓ 
Visual impairment ✓ ✓ ✓ ✓ ✓ ✓ 
Weightloss and anorexia ✓ ✓ ✓ ✓  ✓ 
Yearly drug count ✓ ✓ ✓ ✓ ✓ ✓ 
Electronic frailty index ✓ ✓ ✓ ✓ ✓ ✓ 
Age ✓ ✓ ✓ ✓ ✓ ✓ 
Gender ✓ ✓ ✓ ✓ ✓ ✓ 
Aspirin count       
Number of consultations  ✓ ✓ ✓ ✓ ✓ 
Smoking status ✓ ✓ ✓ ✓ ✓ ✓ 
Table 10: List of balancing variables used to predict propensity scores for each 
cohort 2003-2005. The number of consultations and aspirin prescriptions were 
counted, respectively, over three and two years preceding the start of each patients 
follow-up in the study period 
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Cohort 
Age 
group 
N 
vaccinated 
N 
controls 
HR for each period 
PERR HR 
Prior Study 
2003 80+ 25870 29087 0.89 (0.83, 0.96) 0.72 (0.67, 0.78) 0.81 (0.74, 0.89) 
2004 75-79 19409 16632 1.07 (0.98, 1.17) 0.93 (0.85, 1.01) 0.86 (0.78, 0.96) 
2004 80+ 10619 25993 1.09 (0.99, 1.19) 0.84 (0.77, 0.92) 0.77 (0.68, 0.87) 
2005 65-74 79812 49879 1.16 (1.10, 1.22) 1.03 (0.98, 1.09) 0.89 (0.84, 0.95) 
2005 75-79 15784 16403 1.07 (0.98, 1.17) 0.90 (0.83, 0.98) 0.85 (0.76, 0.94) 
2005 80+ 9373 25943 1.22 (1.11, 1.33) 0.96 (0.86, 1.08) 0.79 (0.69, 0.91) 
Table 11: PERR-adjusted analysis of pneumococcal vaccine effectiveness in the 
2003-2005 cohorts, based on the inverse probability treatment weighted hazard 
ratios, with the weights estimated for each period from propensity scores predicted 
from period-specific (dynamic) confounders. 
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Cohort 
Age 
group 
N 
vaccinated 
N 
controls 
HR for each period 
PERR HR 
Prior Study 
2003 80+ 25870 29087 0.87 (0.79, 0.96) 0.72 (0.67, 0.78) 0.83 (0.75, 0.94) 
2004 75-79 19409 16632 1.08 (0.99, 1.18) 0.93 (0.85, 1.01) 0.86 (0.78, 0.96) 
2004 80+ 10619 25993 1.10 (1.00, 1.21) 0.84 (0.77, 0.92) 0.76 (0.68, 0.86) 
2005 65-74 79812 49879 1.17 (1.11, 1.23) 1.03 (0.98, 1.09) 0.89 (0.83, 0.94) 
2005 75-79 15784 16403 1.09 (1.00, 1.19) 0.90 (0.83, 0.98) 0.83 (0.74, 0.93) 
2005 80+ 9373 25943 1.26 (1.15, 1.38) 0.96 (0.86, 1.08) 0.77 (0.66, 0.87) 
Table 12: PERR-adjusted analysis of pneumococcal vaccine effectiveness in the 
2003-2005 cohorts, based on the inverse probability treatment weighted hazard 
ratios, with the weights estimated for each period from propensity scores predicted 
for each period, but based on those (static) confounders found to be significant in the 
study periods only. 
5.4.4.2 Impact of current or recent influenza vaccine 
Separate analysis of the 2005 cohort by influenza-vaccine sub-group indicated that 
PPV effectiveness was maintained at age 80 irrespective of whether patients 
received the influenza vaccine in either one or both of the prior and study periods 
(HR for the pairwise models: 0.69, 0.74, 0.61 and 0.82 for the never-FV, prior-FV, 
study-FV and always-FV sub-groups respectively in Table 13). The increasing 
protective effect of the PPV with age seen for the overall 2005 cohort was 
maintained, irrespective of the confounding-adjustment method, in all flu-vaccine 
subgroups with very similar gradients (HR for the interaction in the pairwise models 
ranged from 0.97 to 0.98 in Table 13). We noted that there were inconsistent results 
for the main effect of vaccination across the 2005 influenza-vaccine sub-groups: 
patients only receiving the influenza vaccine in the study period (post-FV) was the 
only sub-group with a protective effect of PPV23 at age 65. The main effects for the 
other three sub-groups were all above one. Analysis of the 2003 and 2004 cohorts, 
provided further support for the effectiveness of the PPV23 vaccine at the oldest 
ages across all four influenza vaccine sub-groups, although the precision of the 
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estimates was affected by the small number of PPV23 recipients in the never-FV and 
prior-FV sub-groups, and the small number of controls in the post-FV.  
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FV sub 
group 
years 
N  Hazard ratios 
vaccine 
control
s 
 Vac lcl ucl Vac*age lcl ucl 
Vac 
@65y 
lcl ucl 
Vac @ 
75y 
lcl ucl 
Vac @ 
80y 
lcl ucl 
Never 
FV 
2003 859 15641  0.73 0.49 1.09                         
2004 1484 25183  0.74 0.54 1.01                         
2005 5386 58630  1.08 0.81 1.44 0.97 0.95 1.00 1.08 0.81 1.44 0.80 0.66 0.97 0.69 0.54 0.88 
Prior 
FV 
2003 527 4164  0.48 0.30 0.76                         
2004 667 5023  0.64 0.41 0.99                         
2005 2760 9880  1.26 0.82 1.91 0.97 0.93 1.00 1.26 0.82 1.91 0.88 0.68 1.13 0.74 0.53 1.02 
Post 
FV 
2003 1141 770  0.57 0.35 0.93                         
2004 1425 1100  0.44 0.28 0.68                         
2005 12698 4547  0.70 0.51 0.96 0.99 0.96 1.02 0.70 0.51 0.96 0.64 0.51 0.80 0.61 0.45 0.82 
Always 
FV 
2003 23343 8512  0.69 0.60 0.79                         
2004 26452 11319  0.76 0.67 0.86                         
2005 84125 19168  1.17 1.00 1.35 0.98 0.97 0.99 1.17 1.00 1.35 0.92 0.84 1.01 0.82 0.74 0.92 
Table 13: Results from pairwise regression of survival times adjusted for age and gender, modelling main effects of vaccination 
(Vac) for the 2003-2004 cohorts, and their interaction (Vac*age for the 2005 cohort, by sub groups according to flu vaccination in 
the prior and study periods. For the interactions of the 2005 cohorts, the predicted hazard ratios at ages 65, 75 and 80y are 
presented, along with the bootstrapped lower (lcl) and upper (ucl) 95% confidence intervals for all hazard ratios. Number (N) of 
patients less than 1000 are highlighted in red to draw attention to the small numbers in some cases 
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5.5 Discussion 
5.5.1 Statement of principal findings 
The results from this study have shown that vaccination with PPV23 is effective in 
protecting older adults aged 65 and above against pneumococcal community-
acquired pneumonia in routine clinical practice. The conclusion was based on 
concordance between results, having taken a robust approach to confounding bias, 
applying different methods to adjust for confounding. To the best of our knowledge, 
this is the first population study to establish that vaccine effectiveness is maintained, 
and may even increase, in the oldest age groups: the reduction in risk due to PPV23 
vaccination was estimated to be about 15% in adults aged 65-74 and increased to 
35-40% in adults aged 80 or above. Aggregating the number of events and the time 
at risk over the three consecutive years for the group aged 80 or above, the average 
percentage risk over 365 years in the control group was calculated to be 7.1%. 
Treating this as the baseline risk, and assuming a relative risk of 0.65 among the 
vaccinated as estimated for 2005 cohort, this corresponded to a reduction in 
absolute risk of 2.5%. Hence, the vaccine may be expected to prevent 25 cases of 
PPV every year among every 1000 adults aged at least 80y. 
5.5.2 Strengths and weaknesses of the study 
Our study has several strengths: firstly, our data source, the Clinical Practice 
Research Datalink, with current coverage of about 11 million patients, is 
representative of the general population of patients in the UK 296. Using this 
database and adequate sample selection strengthens generalizability of our findings 
from 324,804 elderly patients. We believe that risks estimated in this study represent 
actual real-world events during the study periods.  Our selection criteria allowed for 
inference on the general population of older patients aged 65 years and over rather 
than only those who were at risk of pneumonia. The study therefore has high 
external validity.  The introduction in August 2003 of the UK policy of vaccinating 
older adults against Streptococcus pneumoniae created a natural experiment. By 
sampling patients during the early years of this programme when uptake of PPV23 
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was high, we were able to select sufficiently large numbers of patients receiving 
PPV23 in order to study vaccine effectiveness by age sub-group. 
We believe this study is the first example of using Prior Event Rate Ratio 
methodology to control for unmeasured confounding in a vaccine effectiveness 
study. We have used a recent formulation of the PERR approach, the pairwise 
method (also equivalent to the PERR-ALT method) that overcomes a source of bias 
in the original PERR adjustment method, by fitting a paired Cox model to the prior 
and study periods. It has been demonstrated that applying PERR methods to 
retrospective cohorts, under certain conditions, can reproduce results from 
randomised clinical trials 187–189,242. However, PERR methodology is limited by the 
need for stronger and more complex assumptions than randomisation. Firstly, 
vaccination should not be determined by presentation of the outcome in the prior 
period. This assumption is likely to have been met given that we found little 
difference in vaccination status between patients with a suspected pneumonia event 
in the prior period and those without. The second main assumption is the lack of 
substantive time-dependent confounding. We tried to address this by limiting the 
follow-up to two years post-vaccination and by replicating results for the 74-79 and 
80+ age sub-groups across multiple recruitment cohorts. We also made comparisons 
with estimates from standard Cox regression models weighted by high-dimensional 
propensity scores, a well-established approach to dealing with measured 
confounding in observational studies. The gold standard for evidence remains a well 
powered RCT, as trials are able to remove both the influence of time-invariant 
confounders (e.g. associated with genetic variance) and time-variant confounding 
(e.g. associated with a temporary health state) from the analyses. However, RCTs 
are not always representative of the clinical populations of interest, especially the 
oldest old and frail patients that may be the target for a health intervention. 
Another concern was over the potential repeatibility of the outcomes. While repeated 
pneumonia infections may be possible, particularly among frail, older adults in this 
population, infection may provoke an immune response, that may confer some 
immunity against later infection, and so change the risk. If this were the case, then 
one could expect to see a reduced hazard of further infection relative to the prior 
period, particularly in the unvaccinated patients of the control group. This would 
represent a violation of the assumption of period-invariant confounding. In the case 
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such as this where there is a greater, pre-exisiting risk among the vaccine recipients, 
then the PERR-adjusted effects would be exaggerated. 
An important limitation of our study was the lack of information on pneumococcal 
pneumonia serotypes. The choice of a composite outcome measure based on 
antibiotic prescriptions or first hospitalization for suspected pneumococcal 
pneumonia was less specific than in some previous studies but was developed with 
clinician input to reflect the manifestations of pneumococcal disease in clinical 
practice. 
While our study addresses real-world effectiveness of pneumococcal vaccination up 
to two years post-vaccination, questions remain over the long-term immunity 
afforded by PPV23. Although stability of confounding factors may be reasonable 
over the short term, a longer follow-up of more than two years would inevitably 
capture declining health and increases in frailty. Where changes in the confounding 
relationships are time-dependent, the assumptions of many quasi-experimental 
analysis methods, including the PERR approach, would be violated.  
5.5.3 Strengths and weaknesses in relation to other studies 
Until recently, much of the evidence for the efficacy of the PPV23 vaccine has been 
based on studies in younger, healthier adults. Of two reviews in 2016/2017 focusing 
on older adults, the review by Schiffner and colleagues concluded that there was no 
evidence that PPV23 can prevent CAP in a general, community-dwelling elderly 
population284 . In contrast, the review by Falkenhorst and colleagues reported 
significant vaccine efficacy/effectiveness against both IPD and pneumococcal 
pneumonia285. The two reviews identified the same RCTs and the difference in 
findings relates to decisions over inclusion criteria and the quality of evidence 
provided by each study. This lack of consistency between systematic reviews has 
led to ongoing controversy surrounding the effectiveness of the PPV23 vaccine.  
Although the recent CAPITA trial has shown the efficacy of the 13-valent 
pneumococcal conjugate vaccine against pneumococcal pneumonia and invasive 
pneumococcal disease in adults aged 65 years or older, it did not resolve 
uncertainties surrounding effectiveness of PPV23 286. The recent multicentre, 
prospective study conducted in Japan by Suzuki and colleagues found low to 
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moderate effectiveness of PPV23 against vaccine serotype pneumococcal 
pneumonia287. Compared with conventional case-control or cohort designs, their 
test-negative study design  was less susceptible to bias caused by differences in 
health-care-seeking behaviour among cases and controls, and the use of non-
specific outcome measurements. However, it is not clear how well this approach 
controls for general sources of unmeasured confounding. The generalisability of the 
results was also restricted to those patients presenting with symptoms of CAP, for 
whom laboratory confirmation was available, and the study lacked the power to look 
at the important question of how PPV23 effectiveness varies by age group. In 
contrast, our study employed two methods to adjust for unmeasured confounding, 
and compared these with a high-dimensional adjustment for measured confounders, 
across subgroups of age. Ours is the largest study to date and made it possible to 
compare the effectiveness of PPV23 across age sub-groups. The finding that 
vaccine effectiveness may increase with age reflects the increased vulnerability to 
infection of the oldest old. In contrast, Suzuki et al found that vaccine effectiveness 
was greater in patients under 75 but this effect was not statistically significant. 
5.5.4 Unanswered questions and future research 
Although vaccination with PPV23 reduced risk of pneumococcal CAP in elderly 
patients, the absolute reduction in rate of disease and hospitalization was moderate. 
Determining an effective adult pneumococcal vaccination policy is complex because 
none of the available vaccines covers all serotypes and the proportion of vaccine-
covered serotypes has been declining since the introduction of PCVs in children 287. 
Our study was unable to look at the impact of a combined policy based on PPV23 
and PCV13. In practice, the optimal adult vaccination policy will need to be flexible 
and adaptive, requiring monitoring of the latest available data. We showed how 
effectiveness of PPV23 was maintained at the oldest ages but questions remain 
about how the effectiveness of the vaccine varies in other population sub-groups. 
5.5.5 Meaning of the study: possible explanations and implications 
for clinicians and policy makers 
We found that vaccinated patients tended to be younger and experienced higher 
rates of comorbidity than control patients, suggesting vaccine take-up was higher 
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amongst patients in closer contact with the health-care system and more likely to 
benefit from the long-term immunity to pneumococcal disease. 
The control of pneumococcal pneumonia is a public health priority in countries with 
an ageing population, such as the UK, because of the higher risk in older age groups 
and the associated health costs.  Our study demonstrated a clear reduction in 
disease burden following the introduction of the UK policy of vaccinating older adults 
with PPV23. Contrary to suggestions in the literature, we found that the vaccine 
remained effective, and may even increase in effectiveness, at older ages, 
supporting the targeting of the oldest old and most frail patients for PPV23 
vaccination in order to reduce the burden of pneumococcal disease. Other research 
would suggest vaccine efficacy declines with age in the elderly due to the age-
related fall in immune response 297,298. However, this has to be set against the 
increased susceptibility of the oldest age groups when assessing vaccination 
effectiveness in real world populations: rates of CAP increase with age in the 
absence of vaccination indicating the potential for benefit from immunisation may be 
maximised by prioritising the  oldest age groups. At least in the two years after 
vaccination, the benefits of vaccinating the oldest adults with PPV23 to reduce 
susceptibility were shown to outweigh any deleterious effect of immunosenescence. 
These findings have implications for the formulation of future pneumococcal 
vaccination policy in the UK and other countries.  
5.5.6 Conclusions 
Vaccination with PPV23 has been shown to be effective in reducing risk of 
pneumococcal disease in patients aged 65 and older in clinical practice. The burden 
of disease increases with age and, despite concerns that immunosenescence may 
weaken immune response, we found the vaccine was most effective in the oldest 
old. Our study illustrates how real-world effectiveness studies with appropriate 
control for unmeasured confounding can provide valuable insights into the population 
impact of vaccination policies. 
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5.6 Appendix A 
 
Figure 14: Flowchart of patient selection in study of pneumococcal vaccination 
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5.7 Appendix B: Fitting the Cox model for pneumococcal 
investigation 
5.7.1 Model building 
The best-fit Cox models of survival study times were found from both forwards and 
backwards selection. All models had to include the variable of interest: the treatment 
variable, trt, denoting vaccination [0,1]. The maximum level of interaction was 2-way 
for all interactions of the 3 main variables (gender, age, treatment). A forward 
selection process was used to find the best-fit model of the survival times from the 
prior period. The best fit was decided from the (chi-square) testing of deviance 
(difference in -2* log likelihood) for the additional term between two otherwise 
identical models. In all cases the best-fit model of the study survival times was found 
to apply to those from the prior period: 
2003 cohort (over 79y only). 
The main effect of treatment was not significantly different from the null, but the most 
significant model included the terms: 
 Main effects: Age; gender; vaccination status 
 Interactions: Age * gender 
2004 cohort (over 74y only). 
 Main effects: Age; gender; vaccination status 
 Interactions: Age * gender 
2005 cohort (over 65y) 
 Main effects: Age; gender; vaccination status 
 Interactions: Age * gender; Age * vaccination status  
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5.7.2 Diagnostic tests of PH 
A test of proportional hazards through a generalised linear regression of the scaled 
Schoenfeld residuals on time299, using Stata’s estat phtest, revealed some violation 
of the assumption, mostly in the models applied to the prior period for study years 
2003 and 2004. For those years there was evidence of non-proportionality in the test 
of the hazards of treatment. Given the large data size, tests were deemed significant 
at the 1% level. There was no evidence of non-proportionality for model of the 2005 
study period, although the test of the age and the age*treatment terms in the prior 
period suggested some non-proportionality. With large data it is possible to detect 
violations that are not practically significant. However, violations in the proportionality 
of the hazards for the variable of interest, that of vaccination, would be of particular 
concern.  While the test statistics for the treatment term were large enough in the 
prior periods of 2003 to 2004 and large enough for its interaction with age for 2005 to 
be flagged as statistically significant violations of the PH assumption, the regression 
coefficients, ρ, denoting the extent of non-proportionality were small. The negative 
natural logarithm of the cumulative hazard function were plotted against the natural 
logarithm of the analysis time to inspect the extent of any PH violation.  
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Study period Prior period 
 
Term ρ χ2 d.f. Prob>χ2 Term ρ χ2 d.f. Prob>χ2 
2003 
(>=80y) 
gender -0.00665 0.24 1 0.624 gender -
0.00656 
0.18 1 0.6737 
 
age -0.01172 0.74 1 0.3893 age 0.00726 0.23 1 0.6311 
 
trt 0.0254 3.64 1 0.0565 trt -
0.07586 
24.72 1 0 
 
gender*age 0.01276 0.88 1 0.3476 gender*age 0.00961 0.38 1 0.5383 
 
global test   9.81 4 0.0437 global test   28.42 4 0 
2004 
(>=75y) 
gender 0.02082 2.71 1 0.0995 gender 0.00909 0.42 1 0.5188 
 
age 0.01001 0.64 1 0.4222 age 0.03222 5.48 1 0.0193 
 
trt 0.02982 5.59 1 0.0181 trt -
0.05709 
16.97 1 0 
 
gender*age -0.01572 1.54 1 0.2143 gender*age 0.00436 0.1 1 0.7575 
 
global test   10.42 4 0.034 global test   40.47 4 0 
2005 
(>=65y) 
gender 0.01904 5.08 1 0.0242 gender 0.00489 0.3 1 0.5837 
 
age -0.00428 0.27 1 0.6049 age 0.02548 8.23 1 0.0041 
 
trt 0.01096 1.7 1 0.192 trt -
0.00075 
0.01 1 0.9324 
 
gender*age -0.00426 0.26 1 0.6124 gender*age 0.01053 1.42 1 0.233 
 
age*trt 0.00653 0.63 1 0.4283 age*trt -
0.02251 
6.69 1 0.0097 
 
global test   23.76 5 0.0002 global test   38.32 5 0 
Table 14: Table of results Stata’s estat test of proportional hazards for each of the 
best-fit models for each year 2003-2005 (trt is the variable name for vaccination 
effect) 
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5.7.3 Diagnostic plots 2003 
5.7.3.1 Study period 
  
 
Figure 15: Graphs of observed (vaccinated – red; controls – blue) vs. predicted 
(vaccinated – orange; controls – green) survival times against analysis time, and of 
the negative logged hazards (vaccinated – red; controls – blue) from the study period 
of the 2003 cohort 
While the log-log plot indicates some violation with converging lines, this would 
appear to occur for the relatively few short survival times (Figure 15). For the 
majority of the data corrresponding to the logged survival time values  greater than 
about three (corresponding to 20 days), the hazards would appear to be reasonably 
proportional. The plotted  predicted and observed survival curves appear reasonably 
close with a small descrepancy for those values corresponding to  survival times of 
less than a year. 
5.7.3.2 Prior period 
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Figure 16: Graphs of observed (vaccinated – red; controls – blue) vs. predicted 
(vaccinated – orange; controls – green) survival times against analysis time, and of 
the negative logged hazards (vaccinated – red; controls – blue) from the prior period 
of the 2003 cohort 
The predicted survival times from the Cox model appeared to be overestimated for 
the vaccines and underestimated for the controls by the second year of observation 
(Figure 16). The log-log plot indicated that the hazards were mostly proportional for 
survival  times greater than about 60 days. 
5.7.4 Diagnostic plots 2004 
5.7.4.1 Study period 
  
 
Figure 17: Graphs of observed (vaccinated – red; controls – blue) vs. predicted 
(vaccinated – orange; controls – green) survival times against analysis time, and of 
the negative logged hazards (vaccinated – red; controls – blue) from the study period 
of the 2004 cohort 
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Both the survival curves plot and the log-log plot indicated little if any violation of the 
proportional hazards assumption in the study period (Figure 17). 
5.7.4.2 Prior period 
  
 
Figure 18: Graphs of observed (vaccinated – red; controls – blue) vs. predicted 
(vaccinated – orange; controls – green) survival times against analysis time, and of 
the negative logged hazards (vaccinated – red; controls – blue) from the prior period 
of the 2004 cohort 
While the survival curves appeared to be overestimated  for the vaccinees and 
underestimated for the controls, the log-log plot indicated little non-proportionality 
over the logged times (Figure 18). 
5.7.5 Diagnostic plots 2005 
5.7.5.1 Study period 
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Figure 19: Graphs of observed (vaccinated – red; controls – blue) vs. predicted 
(vaccinated – orange; controls – green) survival times against analysis time, and of 
the negative logged hazards (vaccinated – red; controls – blue) from the study period 
of the 2005 cohort 
From the plots it was difficult to distinguish between the predicted and observed 
hazards for both treatment groups , indicating little effect of treatment in the study 
period (Figure 19). The log-log survival plots would appear to be not entirely parallel, 
although small differences may be exagerrated by the plots being almost overlaid. 
5.7.5.2 Prior period 
  
 
Figure 20: Graphs of observed (vaccinated – red; controls – blue) vs. predicted 
(vaccinated – orange; controls – green) survival times against analysis time, and of 
the negative logged hazards (vaccinated – red; controls – blue) from the prior period 
of the 2005 cohort 
The predicted and observed survival times appear to closely agree and the log-log 
plots are broadly parallel (Figure 20). 
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5.7.6 Investigation of time-invariance assumption 
Without prior knowledge, it is difficult to determine the optimum functional form over 
time of any potentially time-varying covariates, but the time-dependency of the 
variables was tested through the regression of survival times on the covariates, 
allowing for time-dependency of the coefficients on the natural logarithm of time. 
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Term 
varying with 
ln(time) 
Study period Prior period 
  
Hazard 
ratio 
Standard 
error z P>|z| 
Hazard 
ratio 
Standard 
error z P>|z| 
2003 
Treatment 1.076268 0.025331 3.12 0.002 0.939274 0.027669 
-
2.13 0.033 
Age 1.00013 0.002375 0.05 0.956 1.003576 0.003148 1.14 0.255 
Gender 1.044615 0.02522 1.81 0.071 1.010374 0.030738 0.34 0.734 
2004 
Treatment 1.042504 0.025705 1.69 0.091 0.921118 0.026561 
-
2.85 0.004 
Age 0.99933 0.001996 
-
0.34 0.737 1.005543 0.002554 2.18 0.029 
Gender 1.025801 0.024707 1.06 0.29 1.0536 0.030307 1.82 0.07 
2005 
Treatment 1.072364 0.018199 4.12 0 0.958765 0.017848 
-
2.26 0.024 
Age 0.998434 0.001068 
-
1.46 0.143 1.001681 0.001244 1.35 0.176 
Gender 1.034018 0.016828 2.06 0.04 1.026603 0.018214 1.48 0.139 
Table 15: Hazard ratios of the interaction between the independent variables and the 
natural logarithm of survival times from the models allowing for time dependency. 
The hazard ratios and their standard errors indicate the extent to which the hazards 
change over the logarithm of time from their time-invariant HRs (not shown) that 
were estimated in the same model. 
According to the time-varying covariate (TVC) model, there was some evidence of 
time dependency of the treatment effect for the study period of 2003, while for the 
prior period, there was little evidence of this. This was contrary to the conclusions 
from the regression-based test of the PH assumption (above) for the same cohort, 
which indicated the greatest violation of proportionality occurring in the prior rather 
than the study period. The situation is reversed for the 2004 cohort with significant 
time-dependency occurring in the prior period. For the 2005 cohort, there appeared 
to be a highly significant time-dependent effect of treatment in the study period, 
although this was not so clearly evident in the diagnostic plots of survival times. 
While the time-invariant HRs indicated that the direction of vaccine effectiveness with 
age was maintained, the time-varying estimates indicated a small convergence over 
time between the vaccination groups in the prior period. Conversely, in study period, 
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the time-varying estimates indicated a divergence over time, which could be 
interpreted as the waning effect of vaccination. 
5.7.7 Conclusions 
The test of proportional-hazards based on Schoenfeld residuals revealed some 
violations, particularly for the 2003 and 2004 cohorts, although the predicted and 
observed survival plots indicated that the resulting biases were likely to be small. 
However, the detection of such violations were powered by the size of the data. 
Furthermore, the results did not align with those from the investigation into the time 
dependency of the hazards. The PERR adjustment was applied to the time-invariant 
Cox models, noting the relatively minor violation of the proportional hazards 
assumption. 
Unlike the pairwise model, the PERR adjustment very much depends on, amongst 
other conditions, the fit of the underlying survival model. In the case of the Cox 
model, proportional hazards have to be assumed. The sensitivity of the PERR 
method to non-proportional hazards arising from time-varying hazards was illustrated 
by Lin and Henley192, which the pairwise method can avoid by specifying a time-
dependent period effect. However, it would not be clear how the PERR method could 
be applied to survival times in the prior and study periods with differing time 
dependencies. Furthermore, this would considerably complicate the reporting of 
subsequent PERR results, as the hazards would have to be estimated for an array of 
time-points from the study and prior periods. 
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5.8 Appendix C: propensity score density graphs 
 
Figure 21: Density plot of the propensity scores for the vaccine recipients and 
controls in the 2003 cohort 
 
Figure 22: Density plot of the propensity scores for the vaccine recipients and 
controls in the 2004 cohort 
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Figure 23: Density plot of the propensity scores for the vaccine recipients and 
controls in the 2005 cohort 
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5.9 Appendix D: plots of standardised mean differences of 
balancing variables 
 
Figure 24: Plots of the weighted (by propensity scores) and unweighted standardised 
mean differences for balancing variables - 2003 cohort 
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Figure 25: Plots of weighted (by propensity scores) and unweighted standardised 
mean differences for balancing variables - 2004 cohort 
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Figure 26: Plots of weighted (by propensity scores) and unweighted standardised 
mean differences for balancing variables - 2005 cohort 
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6.1 Abstract 
6.1.1 Objective 
This study aimed to adjust for unmeasured confounding in the estimation of the real-
world effectiveness of the influenza vaccine against influenza and also myocardial 
infarction (MI) in adults aged 65y and older in the UK.  
6.1.2 Design 
Quasi-experimental (QE) cohort study of patients in the UK from general practices 
registered to the Clinical Practice Research Datalink. 
6.1.3 Setting 
Adults aged 65y and over, recruited in annual cohorts, starting in September, from 
1997 to 2012, with no record of a previous influenza vaccination. 
6.1.4 Intervention 
Influenza vaccination 
6.1.5 Outcome measures 
Hospitalisation for MI, influenza, and prescriptions for antibiotics for symptoms 
consistent with lower respiratory tract infections during a follow-up period of one 
year. 
6.1.6 Results 
After adjustment using the (prior event rate ratio) PERR method, the HRs for 
vaccination against MI from the Cox model adjusting for age and gender were 
significantly less than unity, varying between 0.40 (95% confidence interval: 0.30, 
0.55) and 0.74 (95% CI: 0.57, 0.92), except in 2001 (HR=0.89, 95% CI: 0.68, 1.17). 
The same annual trend was closely mirrored in the pairwise-adjusted results, the 
point estimates for which varied between 0.38 and 0.80.  Interaction analysis for all 
years apart from 1997, 1998 and 2005 indicated a waning effect of vaccination with 
age. The weighted estimates were greater than unity in most of the cohorts. 
However, upon applying the PERR adjustment, the weighted results were in 
accordance with those from the PERR of the adjusted Cox models. Annual 
differences in the mix and virulence of influenza may have given rise to the variability 
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between the cohorts’ esimates. However, the global estimate of vaccine 
effectiveness across all cohorts was found to reduce the risk of MIs by 39% (95% CI: 
34, 44). 
Applying the same PERR method, the data demonstrated vaccination to be 
moderately effective against influenza in all cohorts (Pairwise HRs ranging from 0.63 
in 1999 to 0.90 in 2001), although there were no significant interactions with age. 
Differences in effectiveness between the subgroups of pneumococcal vaccination 
(PPV) status were not consistent, with smaller sizes and large variability in the PPV 
group before 2003. 
6.1.7 Conclusions 
In spite of potential seasonal pathogen evolution and vaccine mismatches, the 
influenza vaccination broadly demonstrated effectiveness in older UK adults, whose 
annual pattern broadly followed that for effectiveness against MIs, suggesting the 
prevention of MIs by the vaccine may be partly mediated by influenza. 
6.2 Introduction 
The influenza vaccine is currently recommended for adults aged ≥ 65y, the age 
group with the highest risk of mortality from influenza viruses 300. While  vaccination 
is intended to protect against influenza 301, ecological data have revealed potential 
benefits against possible complications of the disease 302,303. Increased 
hospitalisation rates for myocardial infarction (MI) and related cardiovascular 
conditions have long been observed to coincide with influenza epidemics 304 with an 
elevated risk of acute MI within seven days of laboratory-confirmed influenza 
infection in adults aged ≥ 65y  305. It is thought that the influenza virus acts to 
increase the risk of MI both directly by provoking an inflammatory response in the 
heart, and indirectly by activation of inflammatory pathways and atherosclerosis, 
potentially exacerbated by an increased metabolic response to the virus 306,307. The 
most recent Cochrane review 308 of randomised controlled trials investigating the 
prevention of cardiovascular events either as primary or secondary outcomes 
included two large studies that had investigated MI outcomes, but did not detect a 
significant effect 309,310. However, the findings were based on a range of ages, and 
were not restricted to the elderly population. 
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Population-studies using electronic health records (EHR) have previously been 
utilised to demonstrate a protective effect of influenza vaccination, reducing the odds 
of MI in the year following vaccination by 20% in elderly Taiwanese patients 311. 
However, EHRs are not purposed for research, and without the observations on all 
confounders of vaccination and MI, unmeasured confounders will likely bias an 
analysis that relies on adjustment for measured confounders alone. It is therefore 
important to diagnose and accommodate unmeasured confounding when using EHR 
data for inferential investigations 288. 
This study therefore proposed to investigate the real-world effectiveness of influenza 
vaccinations against the risk of MI, as well as influenza, in the adults aged ≥ 65y 
registered to General Practices in UK Primary Care, using data extracted from the 
Clinical Practice Research Datalink. Effectiveness was examined for each annual 
cohort of new recipients of the influenza vaccine from 1997 to 2011, that would 
encompass the introduction of the policy to recommend for vaccination adults aged 
at least 75y in 1998, extended to those aged at least 65y in 2000. In this way, the 
influence of the policy itself on any trends in vaccine effectiveness could be studied. 
We also investigated issues with immunogenicity in this age group by analysing 
effectiveness with age and by sub groups of pneumococcal vaccination status.  
6.3 Methods 
6.3.1 Data source 
The data were from the UK Clinical Practice Research Datalink (CPRD) 53, a 
database of electronic medical records including information on demographics, 
consultations, diagnoses, drug prescriptions, immunisations, referrals, etc collected 
by participating general practitioners during their daily clinical routines. The data 
analysed were from English practices, which had linkage available to hospital 
admissions and death certificate data. The CPRD has been granted Multiple 
Research Ethics Committee approval (05/MRE04/87) to undertake purely 
observational studies, with external data linkages including HES and ONS mortality 
data. The work of CPRD is also covered by NIGB-ECC approval ECC 5-05 (a) 2012. 
This study gained prior approval by the CPRD Independent Scientific Advisory 
Committee for MHRA database research (ISAC protocol 14-159). 
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6.3.2 Study population 
Annual cohorts were recruited from 1997 to 2011. Recruitment began on the 1st 
September, the index date for each year. Patients had to be HES-linked, alive and at 
least 65y of age on the index date, and were excluded if not registered at their 
practice at least five years before. An absence of any clinical consultation in the five 
years before the index date was regarded as unlikely for patients in this age group 
and so such cases were excluded. The general practices also had to be up-to-
standard at least five years before the index date.   
6.3.3 Vaccination 
Patients receiving the influenza vaccine in each annual cohort were identified 
according instances of influenza vaccination found under their relevant medical 
codes in the immunisation file and their product codes in the therapy file (Appendix D 
– CPRD and HES codes). 
6.3.4 Study design and follow-up 
The study comprised individual annual cohorts of eligible patients, who had not 
received the influenza vaccine in the two years prior to the index date. In each 
cohort, patients were selected for the exposed group if they had received a 
vaccination between the index date and the following 31st January, inclusive. Any 
patients receiving a vaccination during follow-up after this date were excluded from 
the study cohort, and any remaining unvaccinated were designated as controls for 
the vaccine recipients. While vaccination date determined the start of follow-up 
among recipients of the vaccine, obviously no such date was available for the 
controls. In order for there to be an approximately equal distribution of follow-up start 
dates among the controls as the vaccine recipients, the start dates were mapped 
onto the controls from the dates of vaccine recipients, either exactly matched on age, 
gender and GP practice, or on ever broader categories for where no exact match 
could be found. Matching was used solely for this purpose and played no further role 
in the analysis. Fourteen days were added to the vaccination dates of the recipients 
to allow time for full immunogenicity, and also to the start dates of the controls so 
that they remained commensurate with those of vaccine recipients. Any patients, for 
whom an MI event occurred before the attainment of full immunity, were censored 
and assigned a zero survival time, and so effectively did not contribute to the 
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likelihood of the survival model. All patients were then followed up for a year, 
censoring on death and transferrals out of the registered practice. 
6.3.5 Outcomes 
The primary outcome was admissions to hospital for myocardial infarction, coded 
according to ICD-10 (Appendix D – CPRD and HES codes), serving as the endpoint 
in the primary survival analysis. Where MI was not the primary reason, but an event 
during a subsequent episode of the same spell, admissions were not counted as 
endpoints. Where an admission for MI spanned the start date of either period, the 
start date for follow-up was adjusted to the discharge date of their hospital spell. This 
ensured that follow-up did not begin while already under observation in hospital for 
one or multiple MI events. 
The secondary outcome was a composite of either hospitalisation or treatment for 
suspected influenza cases. Possible instances of treatment were prescriptions for 
antiviral drugs used to treat influenza, or lower respiratory tracts infections requiring 
treatment with antibiotics (Appendix D – CPRD and HES codes). Antibiotic 
prescriptions were identified in the data by their corresponding codes, and qualified 
by codes for symptoms that had previously been validated by two clinicians as being 
consistent with those for lower respiratory tract infections (Appendix D – CPRD and 
HES codes). Hospitalisations for influenza were indicated in the HES data by their 
corresponding ICD10 codes describing the reason for admission.  
6.3.6 Statistical analysis 
The effect of influenza vaccination on survival times until the first MI was analysed 
using Cox’s regression adjusting for age (centred on 65y) and gender, censoring on 
death. Any patients found to have vaccination dates occurring after their date of 
death were dropped from the cohort. Any negative survival times resulting from the 
addition of 14 days (reflecting the period for immunogenicity) to the vaccination date 
were assigned zero times, with the corresponding events coded as right-censored 
events. As a guide to possible effect sizes, results for each annual cohort were 
presented with 95% confidence intervals, and so inference was carried out at the 5% 
significance level. The same approach was used for the secondary outcome of 
influenza events. 
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As an alternative approach to modelling time and understanding the effect of 
vaccination relative to a common index date, the data were also expressed as a 
counting process for analysis of vaccination as a time-varying covariate (TVC). By 
initiating follow-up from a common index date of 1st September, this simplified the 
analysis, but also could account for the time at risk in the vaccine recipients before 
their vaccination. Patients in the intervention group, therefore, had two possible 
survival times in the study period and were coded as vaccine-free up until 
vaccination, but vaccinated thereafter. In doing so, data preparation was greatly 
simplified, and the analysis could be run without the need for matching and assigning 
controls a start date based on vaccination dates. Follow-up for those patients, who 
were still in hospital from a previous MI at the time of the index date, began from the 
date of discharge. For the vaccine recipients, follow-up re-continued from the 
vaccination date plus 14 days, with the vaccination indicator variable set to one. 
6.3.6.1 Adjustment for confounding 
An adjustment on measured confounders available in the data was attempted 
through an inverse probability treatment weighted (IPTW) analysis of each individual 
cohort. For this, the propensity score summarising the probability of vaccination for 
every patient had to be derived for each cohort from a logistic regression model of 
vaccination status on gender, age, indices of the Quality Outcomes Framework 295 
and deficits in the electronic Frailty Index (eFI) 292, as well as the eFI itself . To 
manage the size of the task, and avoid individually fitting a model for every cohort, a 
program was written in Stata to fit an optimum model for each cohort according to 
the significance of the Wald statistics of each regressor at the 5% level. 
To mitigate for confounding bias, both measured and hidden, the prior event rate 
ratio (PERR) method 242,243 was applied to the survival data. For comparison, 
confounding was also adjusted through an alternative approach to the PERR, 
applying the likelihood framework of the Pairwise method 192. 
The PERR method was applied to the data presented in the counting process 
format, modelling vaccination state as a time-varying coefficient 278. Adjustment 
comes from dividing the estimate for the vaccination effect in the study period by that 
from the vaccine-free prior period. This required following up the patients from the 
date one-year prior to their start date in the study period, until either the defined MI 
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event or the index date of the study period. The PERR method was applied to the 
Cox regression estimates for vaccine effectiveness and also to those from the TVC 
model for each annual cohort. In both applications, the format of data from the prior 
period was the same, as no vaccinations occurred in the prior period, and therefore 
each patient had only one survival time. 
The PERR method was also applied to the IPTW results. In order to derive the 
weights for the prior period, the automated logistic model selection was run for the 
prior periods to each cohort, as done for the study period. 
As well as analysing each individual cohort, the data from all cohorts were 
aggregated into a single, global dataset, and analysed using PERR-adjusted Cox 
models adjusting for age and gender. Because this approach would likely aggregate 
the data on the same patients from across several cohorts, the same patients could 
be represented across several cohorts. To account for a potential lack of 
independence between observations, these were analysed using robust standard 
errors, clustered on patient id. 
6.3.6.2 Sub-group analysis 
Further analysis tested for any moderating effect of age, by modelling the interaction 
between age and vaccination status and their main effects, to which the PERR 
adjustment was applied. In a sensitivity analysis of the effectiveness of the influenza 
vaccine was re-analysed according to polysaccharide pneumococcal vaccination 
(PPV) status. Both the PERR and pairwise analyses were repeated for subgroups of 
PPV, classified into patient, who have had a record of PPV in both study and the 
prior period (ever), and those with no record of PPV (never). 
6.4 Results 
6.4.1 Cohort characteristics 
There was an overall increase in the size of the annual cohorts from 62 644 in 1997 
to 130 460 in 2011, while the annual percentage rate of influenza vaccinations 
among the 65+ year old patients of each cohort fluctuated around 15% from 1997 to 
1999 (Table 16). However, the rate increased to 39.5% in 2000 with the introduction 
of the policy to increase vaccine coverage in the adults aged at least 65y. The 
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exclusion of patients with an influenza vaccination in the two years prior to 
recruitment likely contributed to the reduction of uptake in vaccination in the following 
cohorts to a minimum of 56370 in 2002. Thereafter the cohort size steadily 
increased, while the vaccination rate fluctuated between 12.9% in 2007 and 24.5% in 
2005. 
The mean age of each cohort remained at around 74y until 2003, decreasing very 
slightly to below 73y by 2010. While vaccine recipients were the same age or slightly 
older than the controls up until 2000, their mean age decreased with each year to 
about 70y in 2011, eventually about 3.4y younger than the controls. Patients with at 
least one QOF-registered disease comprised 68.2% of the vaccine recipients 
compared to 54.1% of the controls in the 1997 cohort, but by 2011 this disparity had 
steadily reduced to 60.6% and 58.1%, respectively. This trend in disparity may have 
been driven at least by the most commonly diagnosed condition, hypertension, the 
prevalence of which in the vaccine recipients and controls stood, respectively, at 
32.6% and 27.3% in 1997 increasing to similar levels, 36.3% and 35.3%, by 2011. 
The difference between vaccination groups in the prevalence of the next most 
frequent morbidity, coronary heart disease, also narrowed from 19.3% and 13.4%, in 
vaccine recipients and controls respectively in 1997, to similar levels, 7.3% and 
8.8%, in 2011. Similar declining trends were seen in atrial fibrillation, asthma, chronic 
obstructive pulmonary disease, depression and strokes. The remaining diseases had 
relatively low levels, except for chronic kidney disease, which increased from no 
recorded diagnoses before 2001 to 14.2% of the controls and 11.3% of vaccine 
recipients in 2011.  
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Table 16: Table of each annual cohort’s characteristics describing vaccination status, hospital admissions for myocardial infarctions, age, 
gender and proportions of diseases monitored under the Quality Outcomes Framework. 
 
  
Year N
N 
vaccinate
d
% 
vaccinated
Vaccine 
status
N MI 
admissions
Mean age
% 
males
% patients 
with QOF 
diseases
Atrial 
fibrillatio
n
Asthma Cancer CHD CKD COPD Dementia Depression Diabetes Epilepsy HF
Hyper-
tension
Hypo-
thyroid
Mental 
health
Stroke
Controls 369 74.1 41.9 54.1 4.4 5.7 4.6 13.4 0 3.9 1.4 8.7 1.2 0.9 5.3 27.3 3.9 0.8 6.7
Vaccinated 71 74.3 41.9 68.2 6.4 10.4 5.4 19.3 0 7.5 2 11.6 2.5 1.1 8 32.6 5.4 0.7 9.2
Controls 431 74 42.3 54.4 4.4 6 4.6 13.6 0 3.9 1.3 8.2 1.4 0.9 4.9 28.3 4.1 0.8 6.4
Vaccinated 55 76.1 42.3 71.6 7.5 10.3 6 21.3 0 7.3 3.2 11.7 3.6 1.3 9.3 35.8 5.2 0.7 9.8
Controls 437 73.9 42.8 54.3 4.3 5.8 4.4 12.9 0 3.6 1.2 7.9 1.7 0.9 4.4 29.4 4.2 0.8 5.9
Vaccinated 102 75.3 42.8 70.2 7.3 10.3 5.6 21.3 0 7.7 2.3 11.2 3.4 0.9 7.8 36.3 5.5 0.9 9
Controls 356 74.5 42.8 53.5 4.5 5.6 4.4 12.4 0 3.5 1.5 7.5 2 0.9 4.3 29.2 4.3 0.9 5.9
Vaccinated 250 72.9 42.8 61.7 5 7 5.1 15.3 0 4.1 1.2 8.3 2.9 1 4.2 35.4 5 0.7 6.2
Controls 337 74.6 41.6 53.1 4.3 5.6 4.3 12 0 3.5 1.4 7.2 2.4 0.9 4 29.6 4.7 0.9 5.7
Vaccinated 146 73.2 41.6 62.6 5.4 6.8 4.9 15.5 0.1 4.3 1.6 8.1 3.9 1.1 4.4 35.6 5.7 0.8 6.7
Controls 361 74.4 41.7 52.6 4.4 5.4 4.3 11.5 0.1 3.2 1.5 6.9 3 0.9 3.6 30 5 0.9 5.4
Vaccinated 95 71.9 41.7 63.2 4.7 6.7 5.8 14.1 0.1 4.1 2 8.4 5 1.2 3.8 36.8 5.9 0.8 6.1
Controls 395 74.4 42.1 53.5 4.6 5.5 4.5 11.1 0.1 3.2 1.6 6.6 3.9 0.9 3.1 31.5 5.2 0.9 5.3
Vaccinated 73 71.5 42.1 62.1 5 6.7 5 12.6 0.1 4.4 2.1 8.5 5.6 1.2 3 37 6.2 0.9 5.6
Controls 379 74.2 42.7 53.6 4.6 5.4 4.6 10.4 0.3 3.1 1.5 6.1 4.8 0.9 2.7 32.5 5.6 0.9 5
Vaccinated 90 71.3 42.7 65.4 5.2 7.5 5.6 12.9 0.3 5 2.2 7.8 7.1 1.1 3 39.6 6 1.1 6.1
Controls 406 74.4 42.8 53.9 4.9 5.4 4.7 10.1 3.2 3.3 1.6 5.6 5.6 0.9 2.5 32.7 5.9 1 5.1
Vaccinated 132 71 42.8 60.3 4.3 5.8 5.8 10.1 3.2 3.8 1.8 6.9 6.4 1.1 1.9 36.9 6.3 0.9 4.6
Controls 410 74.1 43.2 54.9 4.9 5.3 4.8 9.8 9.6 3.3 1.6 5.7 6.3 0.8 2.1 33.4 6.2 1.2 4.7
Vaccinated 68 70.6 43.2 61.3 5.1 4.9 5.6 9.8 10.4 4.4 2.6 7 6.7 1.2 2.3 36.8 6.4 1.1 5.2
Controls 460 73.8 44.1 55.1 5 5.2 5 9.2 11.6 3.3 1.6 5.4 6.4 0.8 1.8 33.7 6.3 1.2 4.4
Vaccinated 65 69.9 44.1 61.6 4.6 5.1 6 8.9 11.2 4 2.6 7.5 6.6 1 1.8 36.9 6.7 1.4 4.3
Controls 555 73.6 44.4 55.9 5 5.2 5 9 12.7 3.4 1.6 5.4 6.8 0.8 1.7 34.2 6.5 1.2 4.2
Vaccinated 90 69.7 44.4 60.7 4.5 5 6.2 7.6 11 3.7 2.2 6.9 6.3 1 1.4 36.5 7 1.3 3.5
Controls 537 73.3 44.8 56.1 5 5 4.9 8.6 12.8 3.5 1.5 5.2 7 0.8 1.5 34.6 6.5 1.1 4
Vaccinated 93 69.6 44.8 61.5 4.3 5.6 5.9 7.7 12.1 4.2 2.2 6.7 6.5 1.1 1.4 36.9 6.8 1.1 3.8
Controls 601 73.5 45 57.3 5.1 5.2 4.7 8.7 13.7 3.7 1.6 4.9 7.6 0.8 1.4 35.2 6.8 1.1 3.7
Vaccinated 66 69.7 45 61.2 4.9 5.3 6.2 7.8 11.4 4.4 2.6 6.4 7.2 1.2 1.3 36.3 7.2 1.3 3.8
Controls 696 73.4 45.2 58.1 5.2 5.5 4.3 8.8 14.2 4 1.6 4.4 8.2 0.8 1.3 35.3 7 1.1 3.4
Vaccinated 101 70 45.2 60.6 4.9 4.9 5.7 7.3 11.3 4.3 2.4 5.9 6.7 0.9 1.3 36.3 7.3 1 3.2
2011 130460 20302 15.6
2010 113666 15197 13.4
2009 103538 14839 14.3
2008 97355 16225 16.7
2007 87388 11286 12.9
2006 77136 10635 13.8
2005 81591 20027 24.5
2004 69285 11896 17.2
2003 59851 10943 18.3
2002 56370 9875 17.5
2001 58998 13753 23.3
2000 73527 29058 39.5
1999 72288 8686 12
1998 68421 5801 8.5
1997 62644 7687 12.3
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6.4.2 Effectiveness of influenza vaccination on MI 
6.4.2.1 Cox models and PERR adjustment 
The Cox model in both the study and prior periods of every cohort were adjusted for 
age and gender (diagnostic log-log plots for the fitted Cox models in Appendix E). 
The hazard ratios (HRs) for gender in every cohort were significantly greater than 
unity, varying between 1.40 and 1.87, indicating a greater risk of MI in males 
compared to the reference level of females (Table 17). A greater than unity HR for 
the age variable indicated increasing risks with age too, that were statistically 
significant. Effects in the same direction and of similar size were seen in the prior 
period too for the age and gender variables of each cohort’s Cox model. 
The HR for vaccination was greater than unity in the study period of every cohort 
apart from 2003, 2008 and 2010. These were significantly different from unity in 
years 1997, 1999, 2001, 2002 and 2004. However, the HRs for the study-period 
vaccination status in the vaccine-free prior periods were all greater than unity and 
greater than the study HRs, suggesting the presence of a pre-existing confounding 
bias (Figure 27). There was no discernible similarity in the trends of the HRs over 
time of the prior and study periods. However, there was noticeably more variability of 
the prior-period point estimates, ranging from 1.43 to 2.67, (orange circles in Figure 
27) compared to those for the study period, ranging from 0.93 to 1.57 (blue circles in 
Figure 27). With fewer events in the prior, the confidence intervals were wider too. 
After the PERR adjustment, the estimated HR of influenza vaccination varied mostly 
between 0.40 in 2010 and 0.74 in 2000 and 2002 (Table 17; Figure 28). All PERR-
adjusted estimates were all significantly different from unity, except for 2001, for 
which the HR was 0.89 (95% CI: 0.70, 1.17). Therefore, the results would indicate a 
reduction in the risk of MI by as much as 60% might be possible following an 
influenza vaccination. 
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Figure 27: Plot of hazard ratios of the effect of influenza vaccination on MIs from the 
Cox regression models adjusted for age and gender for the prior (orange) and study 
(blue) periods of each annual cohort with error bars representing the bootstrapped 
95% confidence intervals. 
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Figure 28: Plot of hazard ratios for the estimated effect of influenza vaccination on MI 
hospital admissions from the PERR-adjusted model (grey dots), the pairwise model 
(blue triangles) and the PERR-adjusted time-varying covariate model (green dots) 
with errors bars representing the bootstrapped 95% confidence intervals. 
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Recruityear Period 
No of MI 
HR gender HR age HR FV group 
Vaccinated Controls 
1997 Prior 48 174 1.61 (1.24, 2.11) 1.01 (1.00, 1.03) 1.96 (1.42, 2.70) 
1997 Study 72 386 1.55 (1.29, 1.87) 1.03 (1.02, 1.04) 1.31 (1.02, 1.68) 
1997 PERR     0.67 (0.44, 0.99) 
1998 Prior 69 342 1.82 (1.50, 2.22) 1.03 (1.02, 1.04) 2.05 (1.58, 2.66) 
1998 Study 57 461 1.75 (1.47, 2.08) 1.04 (1.03, 1.05) 1.23 (0.94, 1.63) 
1998 PERR     0.60 (0.41, 0.84) 
1999 Prior 116 319 1.51 (1.25, 1.83) 1.02 (1.01, 1.03) 2.59 (2.09, 3.20) 
1999 Study 105 452 1.87 (1.58, 2.21) 1.04 (1.03, 1.05) 1.57 (1.27, 1.94) 
1999 PERR     0.61 (0.46, 0.80) 
2000 Prior 224 244 1.87 (1.55, 2.25) 1.03 (1.02, 1.04) 1.43 (1.19, 1.72) 
2000 Study 260 382 1.84 (1.57, 2.15) 1.04 (1.03, 1.06) 1.06 (0.90, 1.24) 
2000 PERR     0.74 (0.57, 0.92) 
2001 Prior 136 296 2.02 (1.67, 2.46) 1.04 (1.03, 1.05) 1.55 (1.26, 1.90) 
2001 Study 149 365 1.84 (1.54, 2.19) 1.05 (1.04, 1.06) 1.38 (1.14, 1.67) 
2001 PERR     0.89 (0.70, 1.17) 
2002 Prior 92 263 1.61 (1.30, 1.99) 1.05 (1.04, 1.06) 1.90 (1.49, 2.41) 
2002 Study 99 382 1.70 (1.42, 2.04) 1.06 (1.05, 1.07) 1.31 (1.04, 1.64) 
2002 PERR     0.74 (0.58, 0.99) 
2003 Prior 114 292 1.45 (1.19, 1.77) 1.06 (1.04, 1.07) 2.02 (1.62, 2.52) 
2003 Study 79 421 1.73 (1.44, 2.07) 1.05 (1.04, 1.07) 0.93 (0.73, 1.19) 
2003 PERR     0.46 (0.34, 0.61) 
2004 Prior 134 347 1.63 (1.36, 1.96) 1.05 (1.04, 1.06) 2.09 (1.71, 2.56) 
2004 Study 100 417 1.67 (1.40, 1.99) 1.07 (1.06, 1.08) 1.32 (1.06, 1.64) 
2004 PERR     0.63 (0.48, 0.83) 
2005 Prior 154 334 1.48 (1.24, 1.78) 1.05 (1.04, 1.06) 1.67 (1.37, 2.03) 
2005 Study 141 456 1.53 (1.30, 1.80) 1.07 (1.06, 1.08) 1.15 (0.95, 1.40) 
2005 PERR     0.69 (0.53, 0.88) 
2006 Prior 108 367 1.56 (1.30, 1.88) 1.06 (1.05, 1.07) 2.21 (1.78, 2.74) 
2006 Study 73 449 1.73 (1.45, 2.07) 1.08 (1.07, 1.09) 1.26 (0.98, 1.62) 
2006 PERR     0.57 (0.42, 0.77) 
2007 Prior 112 353 1.64 (1.36, 1.98) 1.06 (1.05, 1.07) 2.67 (2.15, 3.32) 
2007 Study 70 516 1.70 (1.44, 2.00) 1.07 (1.06, 1.08) 1.16 (0.90, 1.50) 
2007 PERR     0.44 (0.31, 0.59) 
2008 Prior 111 401 1.52 (1.27, 1.82) 1.06 (1.05, 1.07) 1.74 (1.41, 2.16) 
2008 Study 94 606 1.48 (1.27, 1.73) 1.07 (1.06, 1.08) 0.98 (0.79, 1.23) 
2008 PERR     0.56 (0.41, 0.75) 
2009 Prior 133 476 1.42 (1.21, 1.67) 1.06 (1.05, 1.07) 2.06 (1.69, 2.50) 
2009 Study 97 597 1.40 (1.20, 1.63) 1.07 (1.06, 1.08) 1.24 (1.00, 1.54) 
2009 PERR     0.60 (0.45, 0.80) 
2010 Prior 141 500 1.42 (1.21, 1.67) 1.07 (1.06, 1.08) 2.34 (1.93, 2.83) 
2010 Study 76 678 1.62 (1.40, 1.88) 1.08 (1.07, 1.09) 0.94 (0.74, 1.19) 
2010 PERR     0.40 (0.30, 0.55) 
2011 Prior 177 570 1.72 (1.48, 1.99) 1.06 (1.05, 1.07) 2.09 (1.76, 2.48) 
2011 Study 111 773 1.82 (1.59, 2.08) 1.08 (1.07, 1.08) 1.00 (0.82, 1.22) 
2011 PERR     0.48 (0.39, 0.60) 
Table 17: Results for the number of admissions for myocardial infarction (MI); and 
the prior, study period and PERR-adjusted hazard ratios (95% CIs) of gender, age 
and influenza vaccination group for each annual cohort 
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6.4.2.2 Weighted results and PERR adjustment 
From the IPTW analysis, adjusting for measured confounders, the results were 
variously distributed around unity (Table 18). No results for any cohort’s study period 
(blue circles in Figure 29) were significantly different from the null, but the greatest 
protective effect was seen in 2003 with an HR of 0.78 (95% CI: 0.59, 1.04), 
respectively. From 2004 onwards, all HRs were above unity indicating a harmful 
effect with HRs as high as 1.28 (95% CI: 0.95, 1.74) in 2009. Once the PERR 
method had been applied, the weighted results (blue triangles in Figure 29) were 
more commensurate with those from the PERR-adjusted unweighted-Cox models 
(grew triangles in Figure 29), including the non-significant effect estimated for the 
2001 cohort. The diagnostic plots in 6.6 Appendix A of the standardised and 
unstandardised mean differences of potential confounders in the study periods 
revealed better balanced was generally achieved for the earlier cohorts, noting that 
not all the variables contributed to the propensity score. It was also apparent that 
after 2001, age became the leading variable with the greatest imbalance between 
vaccination groups. This seemed to coincide with the shift from risk-based 
vaccination prior to the policy introduction to the age-based eligibility criterion for 
vaccination. 
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Cohort 
HR for each period 
PERR HR 
Prior Study 
1997 1.63 (1.17, 2.28) 1.00 (0.65, 1.55) 0.61 (0.36, 1.03) 
1998 1.86 (1.41, 2.44) 0.88 (0.62, 1.25) 0.48 (0.31, 0.73) 
1999 2.25 (1.80, 2.81) 0.99 (0.79, 1.24) 0.44 (0.32, 0.58) 
2000 1.22 (1.02, 1.47) 0.86 (0.72, 1.01) 0.70 (0.55, 0.91) 
2001 1.36 (1.10, 1.67) 1.09 (0.88, 1.34) 0.80 (0.60, 1.07) 
2002 1.61 (1.25, 2.08) 1.04 (0.81, 1.33) 0.64 (0.47, 0.88) 
2003 1.79 (1.42, 2.27) 0.78 (0.59, 1.04) 0.44 (0.29, 0.61) 
2004 1.77 (1.42, 2.22) 1.22 (0.94, 1.59) 0.69 (0.48, 0.93) 
2005 1.66 (1.34, 2.04) 1.08 (0.86, 1.35) 0.65 (0.48, 0.90) 
2006 2.07 (1.62, 2.64) 1.17 (0.85, 1.61) 0.57 (0.39, 0.79) 
2007 2.55 (1.92, 3.38) 1.11 (0.81, 1.52) 0.44 (0.29, 0.66) 
2008 1.61 (1.24, 2.09) 1.07 (0.77, 1.50) 0.67 (0.44, 0.99) 
2009 2.05 (1.61, 2.59) 1.28 (0.95, 1.74) 0.63 (0.42, 0.89) 
2010 2.76 (2.14, 3.55) 1.24 (0.88, 1.75) 0.45 (0.29, 0.65) 
2011 2.09 (1.70, 2.58) 1.00 (0.78, 1.28) 0.48 (0.34, 0.64) 
Table 18: Inverse probability treatment weighted hazard ratios (95% CIs) for the 
study and prior periods of each cohort from 1997 to 2011. The PERR results are 
those from the adjustment of the weighted HR for the study adjusted with that of the 
prior periods, presented with 95% booststrapped confidence intervals. 
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Figure 29: Plots for the cohorts from years 1997 to 2011, comparing the inverse 
probability treatment weighted hazard ratios from the study periods (blue circles) of 
each, from the PERR adjustment for the weighted HRs (blue triangles) and from the 
PERR results of the unweighted survival analyses (grey triangles). 
6.4.2.3 PERR adjustment of aggregated results 
Having aggregated the data from across the annual cohorts, the PERR-adjusted HR 
of 0.61 (95% CI: 0.56, 0.66) for vaccination against MIs from the global model 
indicated that the average reduction in risk from 1997 to 2011 was 39% (95% CI: 
34%, 44%) (Table 19). In the global model, the confounding effect of age and gender 
was seen to be more stable in the prior and study periods, with the point estimates 
for the HR for age being around 1.05 to 1.06 and that of gender ranging only from 
1.60 in the prior to 1.67 in the study period. 
Period No. of MI HR gender HR age HR FV group 
Prior 7828 1.60 (1.52, 1.69) 1.05 (1.05, 1.05) 1.93 (1.83, 2.04) 
Study 9871 1.67 (1.59, 1.75) 1.06 (1.06, 1.07) 1.18 (1.12, 1.25) 
PERR    0.61 (0.56, 0.66) 
Table 19: Number of myocardial infarctions (MI) and hazard ratios (95% confidence 
intervals) for MI by influenza vaccination group from the global model aggregating all 
annual cohorts, allowing for clustering around patient 
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6.4.2.4 Pairwise estimates 
The HRs of vaccination effect from the pairwise model, in which age, gender and 
period were adjusted for, were all further from unity than the PERR estimates (HR of 
0.38 in 2003) (Table 20; Figure 28). This would indicate a marginally greater overall 
protective effect of vaccination against MI than that estimated through the PERR 
method, although the overlap of confidence intervals would suggest this to be non-
significant. 
Cohort PERR-TVC 
Pairwise 
cohort 
Pairwise HR 
1997 0.55 (0.30, 1.07) 656 0.51 (0.33, 0.79) 
1998 0.59 (0.33, 0.99) 888 0.56 (0.38, 0.83) 
1999 0.54 (0.34, 0.78) 960 0.55 (0.40, 0.76) 
2000 0.78 (0.58, 1.08) 1053 0.64 (0.49, 0.83) 
2001 0.80 (0.56, 1.13) 894 0.80 (0.59, 1.08) 
2002 0.64 (0.38, 1.03) 797 0.70 (0.49, 1.01) 
2003 0.48 (0.27, 0.75) 874 0.38 (0.27, 0.54) 
2004 0.62 (0.41, 1.05) 933 0.53 (0.38, 0.72) 
2005 0.67 (0.47, 0.99) 1020 0.53 (0.40, 0.71) 
2006 0.66 (0.38, 1.04) 938 0.49 (0.34, 0.70) 
2007 0.43 (0.25, 0.67) 995 0.39 (0.27, 0.56) 
2008 0.63 (0.40, 0.91) 1137 0.46 (0.33, 0.64) 
2009 0.65 (0.42, 0.98) 1241 0.53 (0.39, 0.72) 
2010 0.41 (0.26, 0.63) 1278 0.38 (0.27, 0.52) 
2011 0.48 (0.32, 0.71) 1566 0.44 (0.33, 0.58) 
Table 20: Hazard ratios (bootstrapped 95% CIs) for each annual cohort for the effect 
of influenza vaccination on MI hospital admissions from the pairwise model and the 
PERR-adjusted TVC model. As the data are analysed using the pairwise method for 
a subset of patients from each annual cohort with outcomes in either the prior or 
study period, then the size of this subset is given in the table as “Pairwise N”. The 
size of the PERR-TVC cohort remains the same as that of the standard PERR-
adjusted models. 
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6.4.2.5 Time-varying covariate models 
The estimates from the PERR-adjusted TVC model broadly followed the same trend 
as those from the PERR-adjusted Cox and the Pairwise models, and were closer to 
the null than the Pairwise results in all, but four of the years (Table 20; Figure 28). 
However, there was greater imprecision around the estimates, with confidence 
intervals that were wider than those from the PERR and Pairwise methods. 
6.4.3 Effectiveness of vaccination on influenza 
The HRs for age in the Cox model of every cohort’s study period were significantly 
and consistently greater than unity, indicating an increasing risk of hospitalisation or 
treatment for influenza with age (Table 21). Conversely, the HR for males was 
significantly greater than unity up to 2002, after which it decreased to below one, but 
not significantly so - indicating at least parity in the risks between the genders. The 
HR for vaccination status was significantly in excess of one in every cohort, ranging 
between 1.31 in 2005 and 1.82 in 2011. The HRs in the vaccine-free prior periods 
were greater than the study periods, indicating pre-existing bias, except for the 2001 
cohort, which with an HR of 1.48 was only 0.02 greater than that of the study period ( 
Cohort Period 
No. 
events 
Hospital 
admissions 
as % of 
events 
Hazard ratios 
Gender Age FV group 
1997 Prior 2747 5.8% 1.02 (0.94, 1.10) 1.02 (1.01, 1.02) 2.01 (1.84, 2.20) 
1997 Study 2548 15.0% 1.12 (1.03, 1.21) 1.03 (1.02, 1.03) 1.53 (1.38, 1.69) 
1997 PERR     0.76 (0.67, 0.86) 
1998 Prior 2692 13.2% 1.06 (0.98, 1.14) 1.02 (1.02, 1.03) 2.07 (1.87, 2.29) 
1998 Study 2627 23.9% 1.17 (1.08, 1.26) 1.04 (1.03, 1.04) 1.46 (1.30, 1.64) 
1998 PERR     0.71 (0.61, 0.82) 
1999 Prior 2748 17.0% 1.16 (1.07, 1.25) 1.03 (1.02, 1.03) 2.12 (1.94, 2.32) 
1999 Study 2780 27.4% 1.10 (1.02, 1.19) 1.04 (1.03, 1.04) 1.48 (1.34, 1.63) 
1999 PERR     0.70 (0.62, 0.79) 
2000 Prior 2741 17.7% 1.06 (0.98, 1.15) 1.03 (1.03, 1.04) 1.65 (1.53, 1.78) 
2000 Study 2621 22.8% 1.12 (1.03, 1.21) 1.04 (1.03, 1.04) 1.37 (1.27, 1.48) 
2000 PERR     0.83 (0.74, 0.93) 
2001 Prior 1831 16.5% 1.01 (0.92, 1.11) 1.03 (1.02, 1.04) 1.48 (1.34, 1.63) 
2001 Study 2000 29.2% 1.12 (1.02, 1.22) 1.04 (1.04, 1.05) 1.46 (1.33, 1.61) 
2001 PERR     0.99 (0.87, 1.12) 
2002 Prior 1722 17.8% 1.02 (0.93, 1.13) 1.03 (1.03, 1.04) 1.87 (1.68, 2.08) 
2002 Study 1759 33.1% 1.02 (0.92, 1.12) 1.04 (1.04, 1.05) 1.44 (1.28, 1.61) 
2002 PERR     0.77 (0.67, 0.90) 
2003 Prior 1856 19.7% 0.88 (0.80, 0.97) 1.03 (1.03, 1.04) 2.00 (1.81, 2.22) 
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2003 Study 1911 32.9% 0.98 (0.89, 1.07) 1.04 (1.04, 1.05) 1.46 (1.31, 1.63) 
2003 PERR     0.73 (0.64, 0.84) 
2004 Prior 2187 20.8% 0.90 (0.83, 0.98) 1.04 (1.03, 1.04) 1.97 (1.79, 2.16) 
2004 Study 2420 32.0% 1.03 (0.94, 1.12) 1.04 (1.04, 1.05) 1.53 (1.39, 1.69) 
2004 PERR     0.78 (0.70, 0.89) 
2005 Prior 2735 18.5% 0.94 (0.87, 1.01) 1.03 (1.03, 1.04) 1.70 (1.57, 1.84) 
2005 Study 2697 32.3% 1.03 (0.96, 1.12) 1.04 (1.04, 1.05) 1.31 (1.20, 1.43) 
2005 PERR     0.77 (0.69, 0.86) 
2006 Prior 2553 20.6% 0.98 (0.91, 1.07) 1.04 (1.03, 1.04) 2.13 (1.94, 2.34) 
2006 Study 2597 31.6% 0.99 (0.91, 1.07) 1.04 (1.04, 1.05) 1.58 (1.42, 1.74) 
2006 PERR     0.74 (0.66, 0.83) 
2007 Prior 2867 18.5% 0.95 (0.88, 1.02) 1.03 (1.02, 1.03) 1.76 (1.60, 1.93) 
2007 Study 2793 32.3% 1.02 (0.94, 1.10) 1.04 (1.04, 1.05) 1.47 (1.33, 1.64) 
2007 PERR     0.84 (0.73, 0.96) 
2008 Prior 3280 18.8% 0.92 (0.86, 0.99) 1.03 (1.03, 1.04) 1.80 (1.66, 1.96) 
2008 Study 3291 35.7% 0.96 (0.89, 1.03) 1.04 (1.04, 1.05) 1.35 (1.23, 1.47) 
2008 PERR     0.75 (0.66, 0.83) 
2009 Prior 3586 21.5% 0.94 (0.88, 1.01) 1.03 (1.03, 1.03) 1.92 (1.77, 2.08) 
2009 Study 3144 34.8% 0.97 (0.90, 1.04) 1.04 (1.04, 1.05) 1.47 (1.34, 1.62) 
2009 PERR     0.77 (0.69, 0.86) 
2010 Prior 3561 23.9% 0.91 (0.85, 0.97) 1.03 (1.03, 1.04) 1.92 (1.77, 2.09) 
2010 Study 3490 37.5% 0.97 (0.90, 1.03) 1.04 (1.04, 1.05) 1.80 (1.66, 1.97) 
2010 PERR     0.94 (0.85, 1.05) 
2011 Prior 4025 24.3% 0.95 (0.89, 1.02) 1.04 (1.03, 1.04) 2.24 (2.09, 2.41) 
2011 Study 4127 48.6% 0.98 (0.92, 1.04) 1.05 (1.05, 1.05) 1.82 (1.69, 1.96) 
2011 PERR         0.81 (0.73, 0.89) 
Table 21; Figure 30). The PERR-adjusted HRs ranged from 0.70 in 1999 reaching 
the maximum of 0.99 in 2001. The HRs from the pairwise method, while always 
further below the null, tracked very closely with the PERR-adjusted results, and 
ranged from 0.63 in 1999 to 0.90 in 2001 (Table 22; Figure 31). While the prevalence 
of influenza outcomes remained relatively stable varying between 3 and 4% in each 
cohort, the number of hospital admissions as a proportion of the composite influenza 
was 15% in 1997 and after a temporary fall in 2000, eventually rose to 48.6% in 
2011 (Table 21). While this increase  was quite marked, it seemed to  bear no 
relation to the trends in the effect of vaccination, either before or after PERR 
adjustment (Figure 31). 
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Figure 30: Plot of hazard ratios of the effect on the composite influenza outcome of 
influenza vaccination from the Cox regression models adjusted for age and gender 
for the prior (orange) and study (blue) periods of each annual cohort. 
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Cohort Period 
No. 
events 
Hospital 
admissions 
as % of 
events 
Hazard ratios 
Gender Age FV group 
1997 Prior 2747 5.8% 1.02 (0.94, 1.10) 1.02 (1.01, 1.02) 2.01 (1.84, 2.20) 
1997 Study 2548 15.0% 1.12 (1.03, 1.21) 1.03 (1.02, 1.03) 1.53 (1.38, 1.69) 
1997 PERR     0.76 (0.67, 0.86) 
1998 Prior 2692 13.2% 1.06 (0.98, 1.14) 1.02 (1.02, 1.03) 2.07 (1.87, 2.29) 
1998 Study 2627 23.9% 1.17 (1.08, 1.26) 1.04 (1.03, 1.04) 1.46 (1.30, 1.64) 
1998 PERR     0.71 (0.61, 0.82) 
1999 Prior 2748 17.0% 1.16 (1.07, 1.25) 1.03 (1.02, 1.03) 2.12 (1.94, 2.32) 
1999 Study 2780 27.4% 1.10 (1.02, 1.19) 1.04 (1.03, 1.04) 1.48 (1.34, 1.63) 
1999 PERR     0.70 (0.62, 0.79) 
2000 Prior 2741 17.7% 1.06 (0.98, 1.15) 1.03 (1.03, 1.04) 1.65 (1.53, 1.78) 
2000 Study 2621 22.8% 1.12 (1.03, 1.21) 1.04 (1.03, 1.04) 1.37 (1.27, 1.48) 
2000 PERR     0.83 (0.74, 0.93) 
2001 Prior 1831 16.5% 1.01 (0.92, 1.11) 1.03 (1.02, 1.04) 1.48 (1.34, 1.63) 
2001 Study 2000 29.2% 1.12 (1.02, 1.22) 1.04 (1.04, 1.05) 1.46 (1.33, 1.61) 
2001 PERR     0.99 (0.87, 1.12) 
2002 Prior 1722 17.8% 1.02 (0.93, 1.13) 1.03 (1.03, 1.04) 1.87 (1.68, 2.08) 
2002 Study 1759 33.1% 1.02 (0.92, 1.12) 1.04 (1.04, 1.05) 1.44 (1.28, 1.61) 
2002 PERR     0.77 (0.67, 0.90) 
2003 Prior 1856 19.7% 0.88 (0.80, 0.97) 1.03 (1.03, 1.04) 2.00 (1.81, 2.22) 
2003 Study 1911 32.9% 0.98 (0.89, 1.07) 1.04 (1.04, 1.05) 1.46 (1.31, 1.63) 
2003 PERR     0.73 (0.64, 0.84) 
2004 Prior 2187 20.8% 0.90 (0.83, 0.98) 1.04 (1.03, 1.04) 1.97 (1.79, 2.16) 
2004 Study 2420 32.0% 1.03 (0.94, 1.12) 1.04 (1.04, 1.05) 1.53 (1.39, 1.69) 
2004 PERR     0.78 (0.70, 0.89) 
2005 Prior 2735 18.5% 0.94 (0.87, 1.01) 1.03 (1.03, 1.04) 1.70 (1.57, 1.84) 
2005 Study 2697 32.3% 1.03 (0.96, 1.12) 1.04 (1.04, 1.05) 1.31 (1.20, 1.43) 
2005 PERR     0.77 (0.69, 0.86) 
2006 Prior 2553 20.6% 0.98 (0.91, 1.07) 1.04 (1.03, 1.04) 2.13 (1.94, 2.34) 
2006 Study 2597 31.6% 0.99 (0.91, 1.07) 1.04 (1.04, 1.05) 1.58 (1.42, 1.74) 
2006 PERR     0.74 (0.66, 0.83) 
2007 Prior 2867 18.5% 0.95 (0.88, 1.02) 1.03 (1.02, 1.03) 1.76 (1.60, 1.93) 
2007 Study 2793 32.3% 1.02 (0.94, 1.10) 1.04 (1.04, 1.05) 1.47 (1.33, 1.64) 
2007 PERR     0.84 (0.73, 0.96) 
2008 Prior 3280 18.8% 0.92 (0.86, 0.99) 1.03 (1.03, 1.04) 1.80 (1.66, 1.96) 
2008 Study 3291 35.7% 0.96 (0.89, 1.03) 1.04 (1.04, 1.05) 1.35 (1.23, 1.47) 
2008 PERR     0.75 (0.66, 0.83) 
2009 Prior 3586 21.5% 0.94 (0.88, 1.01) 1.03 (1.03, 1.03) 1.92 (1.77, 2.08) 
2009 Study 3144 34.8% 0.97 (0.90, 1.04) 1.04 (1.04, 1.05) 1.47 (1.34, 1.62) 
2009 PERR     0.77 (0.69, 0.86) 
2010 Prior 3561 23.9% 0.91 (0.85, 0.97) 1.03 (1.03, 1.04) 1.92 (1.77, 2.09) 
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2010 Study 3490 37.5% 0.97 (0.90, 1.03) 1.04 (1.04, 1.05) 1.80 (1.66, 1.97) 
2010 PERR     0.94 (0.85, 1.05) 
2011 Prior 4025 24.3% 0.95 (0.89, 1.02) 1.04 (1.03, 1.04) 2.24 (2.09, 2.41) 
2011 Study 4127 48.6% 0.98 (0.92, 1.04) 1.05 (1.05, 1.05) 1.82 (1.69, 1.96) 
2011 PERR         0.81 (0.73, 0.89) 
Table 21: Results for the number of (composite influenza) outcomes; percentage of 
outcomes that were hospital admissions for suspected influenza; and the prior, study 
period and PERR-adjusted hazard ratios (95% CIs) of gender, age and influenza 
vaccination group for each annual cohort. 
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Cohort N % vaccinated Pairwise HR vaccination 
1997 4859 19.5% 0.73 (0.63, 0.84) 
1998 4869 14.4% 0.65 (0.55, 0.77) 
1999 5096 19.5% 0.63 (0.54, 0.72) 
2000 4920 48.3% 0.76 (0.68, 0.86) 
2001 3540 29.7% 0.90 (0.78, 1.05) 
2002 3200 23.7% 0.71 (0.60, 0.84) 
2003 3455 25.2% 0.64 (0.55, 0.76) 
2004 4227 23.9% 0.72 (0.62, 0.84) 
2005 5003 29.9% 0.72 (0.63, 0.81) 
2006 4732 20.2% 0.70 (0.60, 0.81) 
2007 5216 17.2% 0.79 (0.68, 0.92) 
2008 6023 21.5% 0.69 (0.61, 0.79) 
2009 6193 19.9% 0.72 (0.63, 0.82) 
2010 6486 19.3% 0.86 (0.75, 0.98) 
2011 7537 23.8% 0.76 (0.68, 0.85) 
Table 22: Results (hazard ratios (95% CIs)) from the pairwise analysis of the effect 
of influenza vaccination on the composite influenza outcome for each cohort. Note 
that each cohort is a reduced subset of patients with an outcome in either the prior or 
study period as demanded by the pairwise likelihood. 
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Figure 31: Plot of hazard ratios for the estimated effect of influenza vaccination on 
influenza outcomes from the PERR-adjusted model (grey dots) and the Pairwise 
model (blue triangles) with errors bars representing the bootstrapped 95% 
confidence intervals. 
6.4.4 Sub-group analysis 
No significant effect on the influenza outcome was detected from the interaction 
between age and vaccination status with all the 95% CIs for all HRs including unity 
(not shown). For the MI outcome, however, there was a significant effect of 
interaction between vaccination and age in years 2004 and 2008 with HRs above 
unity and marginal significance in 2010 and 2011 (Table 23 ). All other interactions 
were above unity, but not significantly so, apart from the 1997, 1998 and 2005 
cohorts, for which the main effects of vaccination were also weakest out of all the 
cohorts. Given that all the point estimates for the vaccination main effect were below 
one, then the interpretation of the interactions for the 13 cohorts with interaction HRs 
above one is that for those years, the effectiveness of vaccination appeared to wane 
with age. For example, the hazard of an MI after vaccination in 2009 was estimated 
to be 0.55 at 65y, but according to the interaction this had increased to 0.67 at 85y. 
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Cohort HR vaccination HR vaccine*age 
1997 0.85 (0.23, 1.48) 0.98 (0.92, 1.04) 
1998 0.71 (0.18, 1.24) 0.99 (0.93, 1.04) 
1999 0.44 (0.20, 0.68) 1.03 (0.99, 1.08) 
2000 0.60 (0.39, 0.80) 1.02 (0.99, 1.05) 
2001 0.80 (0.46, 1.13) 1.01 (0.98, 1.04) 
2002 0.62 (0.33, 0.92) 1.02 (0.99, 1.05) 
2003 0.40 (0.22, 0.58) 1.01 (0.98, 1.05) 
2004 0.43 (0.25, 0.62) 1.04 (1.01, 1.07) 
2005 0.85 (0.51, 1.20) 0.98 (0.95, 1.01) 
2006 0.46 (0.24, 0.68) 1.02 (0.99, 1.06) 
2007 0.35 (0.19, 0.50) 1.03 (0.99, 1.06) 
2008 0.42 (0.24, 0.59) 1.04 (1.00, 1.07) 
2009 0.55 (0.35, 0.76) 1.01 (0.98, 1.04) 
2010 0.29 (0.17, 0.40) 1.03 (1.00, 1.06) 
2011 0.37 (0.24, 0.51) 1.03 (1.00, 1.05) 
Table 23: PERR-adjusted hazard ratios (95% CIs) of vaccination main effect and its 
interaction with age on myocardial infarctions for annual cohorts, from the model 
including age and gender main effects and interaction. 
 
In the analysis of influenza vaccine effectiveness by PPV subgroup, a high degree of 
uncertainty characterised the results from 1997 to 2002 with relatively wide 
confidence intervals for those years and the point estimates for the HRs for 
influenza-vaccine status were greater than unity among the PPV recipients in 1998, 
2000 and 2001 (Table 24; Figure 32). In 2001, the PERR-adjusted hazard of an 
influenza outcome following influenza vaccination was significantly greater among 
the PPV recipients, and greater than unity, indicating evidence of a harmful effect of 
influenza vaccination in the PPV subgroup. The pairwise-estimated HR for PPV 
recipients in 2001, however, while greater than the subgroup without PPV, was not 
significantly greater than unity (Table 24; Figure 33). In contrast the variability in the 
HRs for influenza vaccination among patients with no record of PPV, whilst 
fluctuating and of variable significance, were more stable and consistently below 
one, indicating a protective effect of the influenza vaccine in this sub-group. 
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In terms of the confounding-adjustment method, there were no appreciable 
differences in the results after 2001, with consistent overlap thereafter between the 
95% confidence intervals of the PERR and Pairwise estimates for vaccination effect. 
According to both methods, the Pairwise HRs were lower than the PERR-adjusted 
analogues after 2000 in both PPV subgroups. However, before 2001 the small 
sample sizes likely led to the large variability and lack of stability in the estimates 
from both methods for the PPV subgroup.  
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Cohort 
PPV 
subgroup 
N 
% 
vaccinated 
PERR-adjusted HR 
vaccination 
Pairwise-adjusted 
HR vaccination 
1997 PPV 432 32.2% 0.78 (0.28, 1.88) 0.67 (0.24, 1.91) 
1998 PPV 1065 26.2% 1.39 (0.67, 2.67) 1.44 (0.67, 3.07) 
1999 PPV 1905 37.4% 0.70 (0.43, 1.10) 0.57 (0.32, 1.01) 
2000 PPV 2208 60.3% 1.12 (0.72, 1.77) 1.09 (0.66, 1.81) 
2001 PPV 2054 58.8% 1.95 (1.20, 3.27) 1.77 (0.97, 3.26) 
2002 PPV 1234 31.2% 0.88 (0.46, 1.55) 0.79 (0.37, 1.68) 
2003 PPV 1349 31.7% 0.60 (0.31, 1.07) 0.56 (0.28, 1.14) 
2004 PPV 2633 30.0% 0.83 (0.57, 1.26) 0.92 (0.57, 1.50) 
2005 PPV 7882 44.4% 0.73 (0.55, 0.96) 0.68 (0.48, 0.95) 
2006 PPV 9265 23.6% 0.85 (0.63, 1.16) 0.81 (0.56, 1.16) 
2007 PPV 10984 19.1% 1.01 (0.74, 1.37) 0.90 (0.64, 1.27) 
2008 PPV 15653 24.4% 0.72 (0.58, 0.90) 0.62 (0.47, 0.81) 
2009 PPV 17154 20.5% 0.93 (0.74, 1.17) 0.96 (0.73, 1.26) 
2010 PPV 19832 17.1% 1.11 (0.89, 1.39) 0.98 (0.73, 1.33) 
2011 PPV 14587 21.3% 0.93 (0.72, 1.21) 0.88 (0.66, 1.18) 
1997 no PPV 60009 10.7% 0.77 (0.68, 0.90) 0.73 (0.62, 0.85) 
1998 no PPV 64466 6.9% 0.68 (0.58, 0.81) 0.63 (0.52, 0.77) 
1999 no PPV 65944 9.4% 0.69 (0.59, 0.80) 0.63 (0.53, 0.74) 
2000 no PPV 65715 35.5% 0.86 (0.76, 0.95) 0.77 (0.68, 0.88) 
2001 no PPV 53861 19.3% 0.94 (0.80, 1.10) 0.81 (0.68, 0.95) 
2002 no PPV 51031 14.8% 0.81 (0.69, 0.94) 0.74 (0.61, 0.89) 
2003 no PPV 49184 13.1% 0.80 (0.67, 0.95) 0.67 (0.55, 0.81) 
2004 no PPV 47730 7.0% 0.97 (0.79, 1.20) 0.77 (0.63, 0.94) 
2005 no PPV 55233 9.0% 1.01 (0.82, 1.22) 0.86 (0.70, 1.06) 
2006 no PPV 56996 5.6% 0.77 (0.63, 0.96) 0.70 (0.56, 0.88) 
2007 no PPV 64105 5.9% 0.76 (0.61, 0.95) 0.73 (0.58, 0.92) 
2008 no PPV 68699 8.1% 0.83 (0.69, 1.00) 0.78 (0.64, 0.95) 
2009 no PPV 72342 6.7% 0.74 (0.61, 0.87) 0.67 (0.55, 0.83) 
2010 no PPV 76005 6.8% 0.87 (0.73, 1.07) 0.86 (0.68, 1.09) 
2011 no PPV 83377 9.0% 0.80 (0.69, 0.94) 0.79 (0.67, 0.93) 
Table 24: PERR-adjusted and Pairwise-estimated hazard ratios (95% CIs) of the 
effect of influenza vaccination on influenza outcomes by sub-groups of 
pneumococcal vaccination (PPV) status for each cohort. 
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Figure 32: Plot of PERR-adjusted hazard ratios of effect of influenza vaccination on 
influenza outcomes for recipients of the pneumococcal (PPV) vaccination (blue) and 
patients without PPV (orange). 
 
0
0.5
1
1.5
2
2.5
3
H
az
ar
d
 r
at
io
Cohort
   
 
 200 
 
Figure 33: Plot of Pairwise-estimated hazard ratios of effect of influenza vaccination 
on influenza outcomes for recipients of the pneumococcal (PPV) vaccination (blue) 
and patients without PPV (orange). 
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6.5 Discussion 
By accounting for pre-existing confounding biases, the overall effectiveness of the 
influenza vaccine in reducing the probability of myocardial hospital admissions was 
estimated on average to be 39% (95% CI: 34, 44) among patients aged at least 65y 
in UK primary care for years 1997 to 2011. This was reasonably consistent with the 
estimate of 33% for the effectiveness against MI reported by the FLUCAD 
randomised study 310 captured in the most recent Cochrane review, although their 
precision was affected by having fewer patients and therefore fewer outcomes. The 
results from our study are also broadly in line with the conclusion of a protective 
effect against major adverse cardiovascular events as estimated in a recent 
systematic review 312. Other sources of evidence are available, but using different 
approaches, in which confounding bias may not have been addressed 303,311. 
Aggregating the number of events and the time at risk over all cohorts, the average 
percentage risk over 365 years in the control group was calculated to be 0.80%. 
Treating this as the baseline risk, and assuming a relative risk of 0.61 among the 
vaccinated given by the aggregated PERR results, this corresponded to a risk 
difference of 0.31% - the small difference a consequence of the low incidence of MI 
in this selected group of older adults. Although the reduction in the hazard of MI 
indicated at least moderate effectiveness of the vaccine, expressed as a difference, 
the vaccine may only be expected to prevent about 3 cases in every 1000 person-
years. Having mitigated for unmeasured confounding through the PERR method, the 
estimated annual vaccine effectiveness varied between 11% in 2001 and 60% in 
2010. The results from the Pairwise method followed a broadly similar pattern in the 
trend over time, but estimated greater effectiveness for all years ranging from 20% in 
2001 to 62% in 2003. 
The degree to which the hazard ratios from the prior periods deviated from unity was 
inferred to be an estimate of the size of pre-existing confounding bias between the 
exposure groups. If there were no confounding bias, and no missing covariates in 
the Cox model, then the hazard ratios of the prior periods would be all aligned with 
unity under the assumption of time-invariant confounding. However, these were in 
excess of unity, suggesting that vaccinated patients in this population newly 
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vaccinated patients were at a considerably higher risk of both MI and influenza in the 
prior period. 
The results from the IPTW analysis, fluctuated around unity up to 2003, but 
afterwards, were consistently above unity, indicating an elevated risk of MI as much 
as 40% and a potentially harmful effect of vaccination. In the context of a one-sided 
hypothesis, that the vaccination is unlikely to be harmful, this would indicate the 
presence of residual confounding bias, that had not been resolved through weighing. 
The presence of bias, however, was more apparent in the weighted estimates for the 
prior periods, which were all above unity, and significantly so, except for that 
pertaining to the study in 2000. While these estimates in the prior period were closer 
to the null than those from the unweighed analysis, the significant difference from the 
null would suggest considerable bias remained unadjusted by the weighted method. 
As the modelling was involved in deriving the weights, then the bias could 
concievably have been further exacerbated by misspeficiation of the propensity-
score model, from which the weights were predicted. Once the PERR was applied to 
the IPTW results, these fell below unity and into close agreement with those from the 
PERR-adjusted results of the unweighted survival analyses. 
Estimates derived through PERR method have been shown to be susceptible to bias 
from missing covariates  225, and this is in contrast to the within-patient comparison 
of the Pairwise method. Relative to the Pairwise method, the PERR-adjusted results 
were consistently closer to  the null, but with considerable overlap in their confidence 
intervals for most years. This may suggest a relatively minor impact from missing 
covariates and differences in performance, although comparison of the methods 
without information on all key covariates is complex, and the presence of confounder 
interactions and strong indication by prior events may have equally led to bias in the 
Pairwise method. 
Instability in the degree of confounding was apparent from the fluctation in the prior 
estimates over the years of the study. This was also evident in the weighted 
estimates for the prior periods, which followed a similar trend. This could have been 
due either to variation in the source of unmeasured confounding, or exogenous 
fluctuations in the outcomes, due to, say, influenza virulence. If the latter were the 
case, then this could represent a serious departure from the assumption of a time-
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invariant, stable effect of confounding between the prior and study period. A global 
estimate of vaccine effectiveness was presented as a crude average over year-to-
year variability in the confounders and also in vaccine effectiveness. This was 
derived from using the PERR method to adjust the estimate from the aggregated 
study period data with the aggregated prior periods, having adjusted simply for age 
and gender. Robust variance estimates clustered by patients were specified in the 
Cox models to accommodate a lack of independence between the observations, due 
to multiple observations from the same patients over different cohorts. 
The same between-cohort variability in the prior periods was also manifest in the 
models of the vaccine effectiveness against influenza outcomes. This, too, indicated 
instability in the degree and source of confounding bias over time. However, 
compared to the MI outcomes, the effect of gender on influenza outcomes was less. 
Effectiveness against influenza varied between 30% in 1999 and no effect in 2001 
for the PERR estimates, and between 37% and 10% for the pairwise estimates of 
the same years, respectively. However, the pattern in effectiveness against influenza 
exhibited over time broadly agreed with the effectiveness against MIs, including the 
apparent reduction in the vaccine effectiveness in 2001. If MI is a hypothesised 
consequence of influenza infection then it would be reasonable to expect to see the 
same trends in effectiveness against MI and influenza. Since the pattern of the 
trends in vaccine effectiveness against both outcomes over time were observed to 
be remarkably similar, this provides further evidence to support the hypothesis that 
the vaccine may offer a secondary protection against MIs through its mediation of 
influenza infection.  
The reduction in vaccine effectiveness against influenza and MI observed in 2001 
was the local minimum of a trend that began in 1998. This coincided with the change 
from recommending the vaccine according to risk to the introduction of the age-
based policy in 1998 and 2000 - a likely cause of the instability in the confounding 
adjustment for that period. A previous study found no evidence of an effect on 
excess mortality due to influenza in the age groups that were the subject of the 
change in policy 313. However, patient characteristics in the vaccination group would 
have changed as a result of the policy, which may explain the subsequent reduction 
of effectiveness in 2001. Certainly, changes in the differential prevalences between 
vaccine recipients and controls of major cardiovascular diseases were evident in the 
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data. The greatest differences in hyptertension and coronary heart disease rates 
were seen in the earlier cohorts, but the prevalences were nearly equalised by the 
later cohorts. Simultaneously, the differences in age between vaccine recipients and 
controls grew with each annual cohort. Additionally the diagnostic statistics of the 
balancing variables used in the weighted analyses revealed that after 2002, age 
became the most imbalanced variable. These patterns perhaps further reflected the 
change from the ad-hoc practice of recommending the vaccine based on risk group 
to the age-based policy. After the period of transition to the age-based policy, the 
hierarchy of balancing variables, ordered by mean differences, stabilised. Therefore, 
variability in confounding bias for those years were perhaps more likely determined 
by antigen evolution and the changes in the mix of influenza viruses, rather than 
changes in the strength of confounding. 
Analysis of effectiveness by PPV sub-groups revealed the influenza vaccine to be 
protective against influenza in the PPV-free sub-group to varying degrees of 
statistical significance that were not noticeably dissimilar to influenza-vaccine 
effectiveness regardless of PPV status. However, there were relatively far fewer 
patients in the sub group of PPV recipients, especially before 2005. With this in 
mind, the estimates, which indicated a harmful effect of vaccination (significant for 
the PERR-adjusted estimate in 2001), could be subject to false-positive, type 1 
errors, exacerbated by instability in the confounding adjustments for that period. 
Furthermore, if such a deleterious drug interaction between vaccines were to exist, it 
is unlikely that it would be constrained to a few select years. 
6.5.1 Limitations of this study 
The effect of vaccination may partly be determined by the degree of antigenic 
mismatch between vaccine and virus in any particular season 314. A weakness of the 
analysis is that the models did not account for this, although determining the activity 
of the circulating pathogens and the degree of mismatch between virus and vaccine 
would likely require further work 315. This would pose an even greater challenge in 
operationalising the resulting change in confounding bias, and in how this could be 
incorporated into the models. In particular, adjustment relies on the conditions for 
confounding being the same from one year to the next. Using the year before the 
study to adjust for confounding may be unreasonable, particularly if there was a 
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large enough change in the type or mix of circulating viruses between the two 
periods. In addition, determining the true effectiveness against MI may be further 
complicated 306 by mediation of receptor proteins and differential cardioprotective 
effect of vaccine strains 316. Therefore, this presents a potential limitation in applying 
the before-and-after approach of the PERR to vaccination studies of a seasonal 
disease such as influenza. 
A condition for the validity of the PERR and Pairwise methods is the repeatibility of 
the outcome. The pathology and treatment for subsequent MIs may be different from 
the initial MI, which could require a more sophisticated approach to the analysis, 
stratifying the model for each ordered event, such as in the Prentice-Williams-
Peterson model 317. However, this would not induce repeatability, but it could further 
encumber adjustment for unmeasured confounding through the PERR method, as 
the models for each stratum of the ordered events could be different, and therefore, 
necessarily different between the prior and study periods. Furthermore, although the 
data are large, there would be a greater chance of model misspecification as there 
would then be multiple events counted from periods of just one year. 
Another potential limitation is the threat to the external validitiy of the cohort from the 
exclusion criteria that were imposed to strengthen the internal validity of the results: 
The criterion of selecting only patients with no record of vaccination in the five years 
preceding the study period was chosen to provide a sufficient washout period for 
contamination from previous vaccinations, but this may have been too long and may 
consequently encumbered the generalisability of the results by excluding those 
patients who had been vaccinated more regularly. 
6.5.2 Strengths of this study 
A strength of this work was the robust approach taken to confounding and the use of  
real-world data to estimate the effectiveness of the influenza vaccine against MI. The 
use of such data is ideally suited to discovering secondary benefits to existing 
treatments and new prophylaxes. Such studies offer an opportunity to observe the 
effectiveness of an intervention in practice away from the idealised settings of a 
randomised clinical trial (RCT). Although the tool of randomisation in a properly 
designed and compliant RCT is widely accepted as the best guarantor against 
confounding bias, quasi-experimental methods and study designs offer a means of 
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adjusting for confounders that may not always be fully observed. The application of 
two QE methods avoided relying on a single set of assumptions, allowing further 
insights into the data and the nature of the confounding bias. Studying the periods 
prior to vaccination also offered an evaluation of the size of confounding bias under 
the assumption of time-invariance. The QE approach was further supplemented with 
a high-dimensional adjusted analysis, which not only offered further insight into the 
bias due to unmeasured confounding, but also allowed diagnoses of the degree of 
imbalance in the measured confounders. 
Another strength of the study was the analysis of influenza as an outcome and 
possible mediator for MI. The concomitant effect against influenza was further 
evidence of the causal pathway to MI from influenza, the primary target of the 
vaccine. Previous studies have suggested using outcomes observed in months 
outside the influenza season to control for confounding 318–320. While this may help 
identify the presence of bias, the conditions for confounding before, during and after 
the influenza season are unlikely to be the same. Furthermore, circulating pathogens 
outside the influenza season are likely to exist at such low levels as to introduce 
further variability and imprecision.  
A potentially important finding was that in all but three of the years, the results 
suggested vaccine effectiveness may wane with age against MI in this population of 
older adults. However, there was no indication of a consistent age effect on 
vaccination against influenza, which was in accordance with findings from a test-
negative study conducted in the same age group 321. It is important to note the 
distinction in this regard between this and previous work on the pneumococcal 
vaccine, in which a net benefit was apparent in older age groups. 
6.5.3 Conclusions 
In every year from 1997 to 2011, evidence was found of a protective effect against 
MIs, having accounted for the hazard of MIs in the prior period of each cohort. For 
most of those years, there was some evidence that this effectiveness may decrease 
with age. The agreement between adjusted effectiveness estimates against 
influenza and MIs in each year would suggest that prevention of MIs is at least 
mediated by prevention of influenza infection. By relying on QE adjustment using 
prior periods, annual changes in pathogen virulence may threaten the validity of the 
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estimates from some years. However, in aggregate the estimated vaccine 
effectiveness of 39% was in reasonable concordance with available trial evidence. 
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6.6 Appendix A – IPTW diagnostic plots 
 
Figure 34: Plots of weighted (by propensity scores in red) and unweighted standardised (blue) mean differences for balancing 
variables – 1997 -1999 cohorts 
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Figure 35: Plots of weighted (by propensity scores in red) and unweighted standardised (blue) mean differences for balancing 
variables – 2000 - 2002 cohorts 
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Figure 36: Plots of weighted (by propensity scores in red) and unweighted standardised (blue) mean differences for balancing 
variables – 2003 -2005 cohorts 
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Figure 37: Plots of weighted (by propensity scores in red) and unweighted standardised (blue) mean differences for balancing 
variables – 2006 -2008 cohorts 
   
 
 212 
 
Figure 38: Plots of weighted (by propensity scores in red) and unweighted standardised (blue) mean differences for balancing 
variables – 2009 -2011 cohorts 
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Chapter 7  -  Discussion and conclusions 
7.1 Summary of thesis 
This project was partly motivated by the need for further evidence on vaccination in 
older adults from the routinely collected data stored in electronic health records. 
Vaccination of this age group is a key component of public health policy against 
infectious diseases, although studies have raised concerns that this age group is 
under-represented in clinical trials. Evidence from EHRs may be useful in 
supplementing existing evidence from RCTs, or even in informing the design of 
future trials. Therefore, in addtion to addressing the clinical question, this PhD 
necessarily focussed on the methods for deriving this evidence in the wider context 
of the growing interest in analysing routinely-collected data, such as electronic health 
records. However, in order to elicit inferential-quality evidence, such methods need 
to address the problem of confounding in observational data. Confounding is a 
problem for inference even from the “gold standard” data of clinical trials, where 
drop-out, non-compliance, poor randomisation, and even poor design, may lead to 
bias, if treatment groups become imbalanced in any prognostic factors. The bias 
may be corrected by modelling known confounders. However, this relies on having 
information about the relevant confounders, and in the absence of randomisation, it 
may not be reasonable to expect to identify and observe all potential confounders. 
This is none more so the case than with observational data, such as EHRs, where 
adjusted regression alone might not entirely account for unmeasured confounding. A 
greater focus is required on the use of quasi-experimental methods to deal with 
unmeasured confounding to better enable EHRs as a data resource in research. 
Acknowledging this issue was a major part of this project as I conducted a 
methodological review of QE methods in the context of EHRs and other similar data 
with longitudinal information on individual patients. This study, published in the 
Journal of Clinical Epidemiology, searched for published studies that applied QE 
methods to such data, and examined how each may have utilised the available, 
patient-level, longitudinal information to adjust for, or rather mitigate for, unmeasured 
confounding 322. In this study, I aimed to draw attention to the different QE methods 
that leverage longitudinal information to adjust for confounding, some of which may 
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be underutilised due to the lag between development and widespread adoption in 
research. 
To address the problem of confounding in vaccination studies, I focussed on the 
application of the prior event rate ratio method, and the framework of the Pairwise 
model. The PERR and Pairwise models have been an essential innovation in 
enabling the use of EHR data for replicating clinical trials studying survival and rate 
data. In this project, I applied these to address the clinical questions posed in the 
vaccination studies. I also reported on the relative performance of these methods to 
provide guidance for future work. The results from the PERR and Pairwise 
approaches may be compared to those from trials as a form of sensitivity analysis of 
the degree of unmeasured confounding. Therefore, as complementary and useful 
approach to the problem of confounding, the search strategy for the methodological 
review of chapter 2 was scoped to include sensitivity analysis too, the results for 
which were presented in the following chapter. As such, QE methods, like the PERR 
and Pairwise methods, may offer an alternative approach to sensitivity analysis and 
the issues over the transportability of external data on, and assumptions about, 
unmeasured confounders, by invoking a different set of assumptions to utilise 
longitudinal information within the same dataset. 
Following the methodologial review of QE methods and sensitivity analyses as wider 
context for the PERR and Pairwise methods,  I then conducted a review of these two 
methods, and presented a summary of their assumptions aggregated from different 
methodological studies, discussing their relative performance under different types of 
confounding bias. I also presented my literature review of studies that had utilised 
the PERR and Pairwise methods since publication of the seminal studies. As such, 
chapter four may offer further guidance to utilisation of the PERR and Pairwise 
methods, and will be submitted for publication. 
Thereafter, the PhD focussed on applying the PERR and the recently developed 
Pairwise framework to the study of the real-world effectiveness of vaccination in 
older adults, an age group that may present many issues in the recruitment to trials . 
This was the first known example of the application of the Pairwise method outside 
the seminal work on this and the PERR-ALT method, and the first comparison of its 
performance relative to the PERR method in an applied setting. Moreover, the larger, 
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real-world data enabled analysis of interesting sub groups with surprising results. 
Both pneumococcal and influenza vaccines were studied, and the conditional 
estimates from the PERR and Pairwise methods were compared with the marginal 
estimates from a regression weighted by high-dimensional, propensity score based 
on observed confounders. This robust approach not only compared the success of 
adjustment, but served to gain further insight into the source and size of confounding 
bias, informing recommendations for good practice. 
The investigation of pneumococcal vaccination presented somewhat controversial 
results in showing an increase in effectiveness with age. This runs counter to the 
hypothesis that immunosenescence may reduce effectiveness. However, while the 
degree of bias may be disputed, the direction of effect with age persisted to varying 
degrees in the results from all the methods used to address confounding. Whether or 
not immunosenescence leads to weaker immune response in older adults, or a 
shorter duration of immunity, the study found older adults to be at greater risk of 
infection. On that basis, vaccination still seems to confer immunity, with the real-
world evidence suggests we should expect to see a net benefit from immunisation at 
the population level in older age groups in spite of immunosenescence. I presented 
these results at an oral session at the 33rd International Conference on 
Pharmacoepidemiology 323, and the report, which is included as chapter 5, is 
prioritised for submission to a suitable journal. 
Complementing the work on pneumococcal vaccination, the project also investigated 
the effectiveness of the influenza vaccine as a secondary prevention against 
myocardial infarctions. The results for this were presented over two oral sessions at 
the 34th International Conference on Pharmacoepidemiology 324,325. With influenza 
infection designated as a secondary outcome in this study, the study found 
consistent evidence for the effectiveness against MI with the influenza outcome as a 
possible mediator. However, gender was a much stronger prognostic variable for MI 
outcomes. Furthermore, while there was evidence that effectiveness against 
influenza waned with age, no moderating effect was found for MI. These results were 
confirmed by both the PERR and Pairwise methods, although the latter tended to be 
further from the null, estimating a greater protective effect from vaccination. In 
contrast to the QE methods, the adjusted survival models produced hazard ratios 
that were for most years greater than unity. This ran counter to expectation, and 
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would suggest that adjustment on observed confounders was incomplete. After 
application of the PERR method, the adjusted estimates closely agreed with those 
from the PERR-adjusted naïve Cox models. 
7.2 Limitations 
In the novel application of the PERR and Pairwise methods to vaccination studies, it 
was important to understand the limitations as well as the relative performance of 
each method, particularly in relation to the assumptions and conditions detailed in 
section 4.3 of chapter four. It was also important to acknowledge the limitations in 
the application to studying vaccine effectiveness to inform future work. Comparing 
the two methods together and against methods adjusting for measured confounding   
raised some wider methodological considerations and in some cases highlighted 
unresolved issues in the application of the PERR and Pairwise methods: 
1. Limit to scope of method review: The scope was restricted to methods with a 
control arm as an analogue to RCTs. Furthermore, the review did not consider 
study designs, but rather it focussed on analytical methods for longitudinal, 
observational data, which in many cases, such as cohorts for before-and-after 
comparisons, may be a necessary pre-condtion for the application of the 
method, such as PERR or difference-in-differences. The focus on comparative 
studies meant excluding single-arm, self-controlled studies, although these were 
later considered as part of the specific review of the PERR and Pairwise 
methods in chapter four. The role of sensitivity analysis in dealing with 
unmeasured confounding was also reviewed, but in order to keep the report to a 
publishable size, this was abstracted into its own chapter. 
2. Verification of stable confounding assumption: In the application of the PERR 
and Pairwise models, the stability between the prior and study periods of the net 
effect of confounding was emphasised as a necessary assumption in section 
4.3. It is likely that if the influence of individual confounders changes between the 
periods then this would lead to a violation of the constant bias assumption. 
Although it is not possible to directly ascertain a violation of this assumption by 
hidden confounding, some clues may found by inspecting the stability of 
observed confounders under the assumption that changes in these may be 
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associated with changes in the unmeasured confounders. In the vaccine studies, 
the diagnostic tools used for the IPTW analysis were employed for this purpose, 
as well as for determining the success of weighting. Here, the weighted and 
unweighted mean differences in the measured confounders between exposure 
groups in the study period were compared to those in the prior period. As with 
vaccination studies, any change in the rank of the mean differences of the 
confounders over the annual cohorts and between the study and prior periods 
may be evidence of unstable confounding. In the pneumococcal vaccination 
study, the changing set of confounders between the prior and study periods 
instilled caution in the interpretation of the results. For the influenza-vaccine 
study, where there were 15 cohorts to consider, there was a notable shift in the 
ranked mean differences, with age being the largest following the introduction of 
the policy to vaccinate the elderly against influenza. Where anomalous changes 
in the results of a series of cohorts are considered over time, as with the 
influenza study, it may also be helpful to inspect the between-cohort variation in 
the confounders over a longer time period to make inferences about the stability 
of confounding, and potentially explain any incongruity. 
3. Repeatability of outcomes: Following application of the PERR and Pairwise 
methods to investigating vaccine effectiveness, further clarification is needed 
about satisfying the basic condition for a repeatable outcome in order to apply 
these methods. Firstly, in the influenza vaccine study, there was a potential 
problem over the independence of multiple MI events in the same patient. If 
there was dependence between successive events then each MI may be 
determined by different confounding effects, or different confounders altogether. 
Stratifying survival analyses by different orders of the event was discussed as a 
way of mitigating against order dependence within each period, but this alone 
would not invoke repeatability between periods of the PERR and Pairwise 
methods as the strata in one period would necessarily be different from that in 
the other. Secondly, the independence, and therefore, repeatability of events 
may be threatened in the study of infectious diseases, where an outcome in the 
prior period of a patient provokes an immune response that carries over into the 
study period. 
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4. Prior period as estimate of confounding: Whilst the size of the group effect in the 
prior period of the pneumococcal and influenza studies was taken as an 
indication of the size of confounding bias, it was not possible to exactly estimate 
this in the presence of potential assumption violations such as missing, but 
otherwise balanced covariates in the Cox model 225. Although conformance to 
the proportional hazards assumption was broadly satisfied through inspection of 
diagnostic plots, minor deviations would have also affect the precision of the 
estimates. While important prognostic variables are unlikely to be perfectly 
balanced in real-world data and the prior period will be a reasonable indicator of 
the pre-existing bias between levels of the exposure variable, some caution may 
be required in using this as an unbiased estimate of the confounding effect. 
5. Determining successful adjustment against assumption violations: The 
vaccination studies offered an opportunity to re-examine the relative 
performance and limitations of the PERR & Pairwise methods using real data 
rather than simulated data. The models in both vaccination studies were 
adjusted for the common confounding variables of age and gender. However, 
simulation studies have demonstrated that bias can still affect the PERR method, 
if significant, yet balanced covariates are excluded from the model 225. Therefore, 
the results from the PERR and Pairwise analyses were compared to IPTW 
regression. It was noted that the IPTW results were generally closer to the null. 
However, in the influenza vaccination study, many of these exceeded unity by a 
large degree, which prompted speculation about the correct specification of the 
model and terms used in the propensity score. Previous research has warned 
about model misspecification exacerbating the imbalance in other confounders 
and the use of propensity scores in practice 22. Without full information regarding 
the unobserved confounders, it was not possible to distinguish between bias 
from model instability, model misspecification and unmeasured covariates, but 
by identifying as many measured confounders as possible, the degree of 
unmeasured confounding could be better ascertained. This exemplifies the 
challenge in using observational data. However, once the PERR method was 
applied to the IPTW results from the influenza study, these closely resembled 
the Pairwise and unweighted PERR results. From this it could be concluded that 
the PERR and Pairwise methods may have successfully corrected for residual 
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confounding error, and that any potential misspecification in the propensity score 
was either minor, or cancelled out by similarly misspecified prior periods. Best 
practice should therefore be to compare the QE results against the best 
available non-QE method that explicitly adjusts for measured confounders. The 
PERR method should then be applied to the adjusted results from the 
multivariable or weighted analysis. In this way, interpretation of the results needs 
to balance the potential problem of model misspecification against the 
assumptions of any applied QE methods. 
6. Severe confounding between vaccines: Neither vaccination study was able to 
fully disentangle the effects from one vaccination in the presence of the other. 
This could certainly be explained in part by the size of the sub-groups. The 
pneumococcal study was divided into four sub-groups of influenza vaccination, 
classified by vaccination states in the prior and study periods. However, there 
were few patients in three of the four sub groups, with the attendant wider 
confidence intervals and uncertainty over the point estimates. In the influenza 
study, interest was in pneumococcal sub groups, dividing patients into never and 
ever having received the pneumococcal vaccine. However, there were far fewer 
patients, who had had a record of pneumococcal vaccination before 2002. This 
led not only to wider confidence intervals, but also spuriously high hazard ratios 
suggesting an unexpected harmful effect of the influenza vaccine in this sub 
group. It is possible that either by chance, confounding bias is less stable 
between the prior and study periods in a small sub group, or the sub group was 
an intrinsically less stable set of patients of rapidly increasing frailty. While EHR 
may offer the opportunity to study clinically interesting sub groups, no method 
can disentangle the effects of severely confounded exposures or treatments.  
7. Season-specific outcomes: Specific to seasonal diseases, such as influenza, the 
approach in some studies has been to restrict analysis to outcomes that have 
occurred within a period defined as high pathogen circulation 270,326. This would 
increase the specificity of the disease identification and reduce the inclusion of 
false positives in inferential studies. This may have been a reasonable strategy 
to follow, although in this project, the pneumococcal study was designed to span 
multiple years to maximise the collection of outcomes and so afford more 
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statistical power. The same approach was applied to the multiple cohorts of the 
influenza study, following up patients for a year rather than during individual flu 
seasons. Other before-and-after studies were noted in chapter six as having 
suggested the low-circulation periods outside of the influenza season as an 
adjustment period 318–320, and this was the strategy used in a recently published 
study 269 into influenza effectiveness using the PERR. However, choosing to 
adjust with an outcome from a low circulation period may be ill-conceived, as it 
could risk decreasing the specificity of the outcome since without laboratory 
confirmation, some cases may have been incorrectly identified. Also fewer 
outcomes would lead to less precision and wider confidence intervals. More 
importantly, the confounders affecting a low circulation study period are not 
necessarily the same as those affecting a high circulation prior period, and 
therefore may not offer a reliable basis for adjustment.  
8. Pathogen evolution: While pneumococcus, like all bacterium, are known to 
evolve, particularly in response to treatment, vaccination and targeting by the 
immune system, constant surveillance by sentinel laboratories is required to 
respond to annual changes in the mix and type of influenza viruses, and update 
the vaccine accordingly. So, while the conclusions for the pneumococcal study 
remain reasonably robust to pathogen evolution over a short peroid of time, this 
was a potential weakness of the influenza study. Accounting for viral potency, 
antigenic drift and any subsequent mismatch between viruses and vaccine could 
improve the accuracy of the results, and potentially stabilise confounding 
between the prior and study periods. As noted in chapter six, operationalising an 
adjustment would be complex, and antigenic drift and viral activity would need to 
be quantified. In determining the effect on MI outcomes, this would also likely 
involve accounting for mediation by receptor proteins and potentially a 
differential cardioprotective effect of vaccine strains. 
9. Viable alternatives: The scope of this PhD project was limited to a review and 
application of the PERR and Pairwise methods in the context of other QE 
methods. While this precluded focussing on other possible methods, such as 
those reviewed in chapter two, these should not be entirely overlooked as viable, 
alternative analytic methods for addressing the clinical questions of chapters five 
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and six. The test negative case control design is popular in the monitoring of 
influenza vaccine effectiveness 251,252,254,327. This seeks to minimise confounding 
from health-seeking behaviour through restriction to those patients, who have 
been diagnosed as having an influenza-like illness (ILI) 255. Cases of influenza 
are then confirmed among the ILI cohort by laboratory analysis, which facilitates 
the case-control analysis. However, generalisability of the results from such an 
analysis is arguably diminished by the restriction limiting the study cohort to ILI 
cases and the availability of laboratory testing to confirm cases. Because of the 
reliance on restriction, this method did not qualify as a QE method in the method 
review, but a review of its relative performance would be informative. 
10. Survival data vs. rates: Although the focus in the project was on specific 
outcomes expressed as survival data, it is worth mentioning that the PERR could 
have been applied to events as rates as a Poisson-like process. This, however, 
would have required parametric modelling and would have lacked the flexibility 
of the Cox models. 
11. Estimation of time-varying covariates: The expression of vaccination in the Cox 
model as time-varying covariate was found to greatly facilitate the derivation of 
survival times for the cohort. Without this tool, the survival start times would start 
relative to the date of vaccination for the vaccine-recipients. However, to avoid 
disparity in the distribution of start times with the controls, who would otherwise 
commence from the same index date, it was necessary to map the vaccination 
dates onto the controls as their own start dates. To avoid unintentionally 
introducing further bias, this entailed writing a computationally intensive 
matching algorithm in the statistical software. Once the start times had been 
designated for the controls, the matching was no longer needed. Expression of 
the vaccination variable as a time-varying covariate obviated the need for 
matching, since both vaccine-recipients and controls started their follow-up from 
a common index date. With the extra pre-vaccination period for vaccine 
recipients in the study period, the point estimates seemed to be less stable over 
time and the confidence intervals were slightly inflated above those for the PERR 
and Pairwise estimates.  
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12. External validity/generalisability vs. selection criteria: Although one of the much 
cited advantages of using RCD over RCTs is the generalisability of the results to 
a wider population, some of the selection criteria used in applying the PERR 
method may have placed restrictions on the external validity of the findings. 
Some of the settings were the exclusion of patients based on previous 
vaccinations, and the exclusion of controls, whose follow-up may have included 
vaccination during the next vaccination season. 
7.3 Discussion of thesis 
At the beginning of this thesis, some time was spent setting the scene and 
describing the motivation for this project that had arisen from the growing interest in 
using routinely-collected data for clinical evidence. In spite of the challenges of 
deriving plausible evidence of causal relationships using such data, this interest has 
not diminished. Once the preserve of commercial interests and data mining in market 
research, the presence of big data in medicine is only likely to grow. A systematic 
review of methods for dealing with the problem of confounding was not only an 
obvious means of providing the necessary background required for this PhD project, 
but also served as a timely reference for other studies eliciting causal inference. For 
this purpose, the review was directed towards the application of EHRs for causal 
inference, with a specific interest in utilising the longitudinal information available for 
each patient. In this way, the PhD project would contribute to the growing interest in 
using quasi-experimental methods 322 
The methodological review of chapter two provided an essential broader context for 
the methods among which the PERR and Pairwise sit. It was also noted that many of 
the QE methods have their roots in econometrics, but that uptake of these methods 
in medical statistics might not entirely match the growing interest in EHRs. It would 
be interesting to ascertain the relative frequency of QE methods used to analyse 
EHRs against explicit adjustment methods that assume no unmeasured 
confounders, although this may involve undertaking a much larger review. However, 
it should not be assumed that conventional multivariable regression, matching or 
weighting will fully adjust for unmeasured confounding bias that has previously been 
described as “stubborn” and resistant to adjustment in EHR data 22,213, including 
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vaccination studies 318. This justified the recommendation in the conclusions of the 
method review to utilise the longitudinal information available in EHRs, where 
possible, as good practice when seeking causal inference from this data. Since 
causation exists as a temporal relationship, a longitudinal dimension is an often 
undeclared condition in the theory of causal inference that was discussed in the 
introductory chapter. Therefore, researchers using EHRs need to be thinking 
longitudinally about the threats to unbiased causal inference from unmeasured 
predictors of an outcome that may exist as part of a wider causal network, potentially 
confounded by past exposures and outcomes. For that reason, it makes sense to 
think longitudinally about adjusting for unmeasured confounders too. The method 
review of chapter two, the sensitivity analyses covered in chapter three and the 
discussion around the PERR and Pairwise methods in chapter four offer many 
strategies for dealing with unmeasured confounding and are presented as a 
collection of resources for improving causal inference from longitudinal, 
observational data. 
Faced with untestable assumptions about unmeasured confounders, it should be 
considered good practice to supplement adjustments for measured confounders with 
a sensitivity analysis, QE analysis, or QE adjustment based around a particular study 
design. A QE method may also be deployed as sensitivity analysis to test for the 
presence of no unmeasured confounders. In this respect, although each QE method 
invokes certain assumptions, QE methods generally may offer an advantage over 
traditional SA methods, which often rely on the transportability of external information 
about confounders and their applicability to the dataset under analysis. In contrast, 
the QE before-and-after methods, like the PERR and Pairwise, utilise within-dataset, 
longitudinal information. 
Where unmeasured confounding is readily acknowledged, and the primary analysis 
relies on a QE adjustment, then an analysis based on an explicit adjustment for 
observed confounders may be considered a sensitivity analysis and a check on the 
assumptions of the QE method. This robust approach was followed for vaccination 
studies with the PERR and Pairwise results firstly compared with each other. The 
underlying study and prior period  estimates of the PERR estimate may also 
diagnose the existance of bias. Covariates in the basic adjustment comprised the 
main confounders of gender and age, both of which are known to be main 
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determinants of frailty in the older population, and as such may partly account for 
other associated sources of bias. Contingent on the assumptions for the Cox model 
being met, the vaccine was expected to show no effect in the period prior to 
vaccination, so the size of deviation from the null in the hazard ratios for vaccination 
was interpreted as a measure of bias in the data due to unmeasured confounders. In 
Lin and Henley 192, a procedure was presented for testing for the presence of 
unmeasured confounding in the prior period and to differentiate this from imbalanced 
censoring. However, in the prior periods of the vaccination studies, survival times 
were administratively censored at the end of follow-up in the absence of an event. 
HRs for vaccination significantly greater than unity in the study period were 
considered inconsistent with existing evidence, and therefore implausible. Since 
selection bias in the vaccine studies was directed towards the frail, rather than 
exhibiting a healthy user bias, the degree to which the study period exceeded the 
null was also interpreted as an indicator for the presence of unmeasured 
confounding bias and its potential size. 
Finally, the results from the PERR and Pairwise methods were compared with those 
from an IPTW analysis, with weights based on propensity scores predicted from all 
observed variables determined to be confounders. The IPTW estimates offered a 
more easily interpretable marginal estimate of effectiveness unconditioned on any 
other variable, although this precluded estimation of interaction terms, instead relying 
on sub-group analysis. The direction and size of deviation of the IPTW HR from unity 
for the exposed group in the prior period could be informative about the size of 
residual confounding or at least indicate its potential presence in the study period. 
This is of course contingent on the propensity score model being correctly specified 
and on compliance with the proportional hazards assumption of the Cox model. The 
exposure HR for the prior period should then be interpreted as the bias having 
averaged over the effect of the observed confounders. 
As a further verification of the PERR and Pairwise results applied to an unadjusted 
or partially adjusted multivariable model, the PERR method could also be applied to 
the weighted estimates of the study period using weighted estimates from the prior 
period. In the pneumococcal study, some of the weighted prior-period estimates 
were greater than unity indicating the possible presence of residual confounding, 
although instability in the confounders between the periods could not be ruled out. 
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However, in the study on influenza vaccine effectiveness on MI outcomes, many of 
the weighted study period HRs exceeded unity. This suggested the potential 
presence of residual confounding due to unobserved and unadjusted confounders, 
although some proportion of the bias could still have been attributable to model 
misspecification. After applying the PERR adjustment to the weighted Cox estimates, 
the resulting point estimates were remarkably close to the PERR-adjusted estimates 
from the age and gender adjusted Cox model. This was a reassuring check on the 
performance of PERR demonstrating its ability to adjust to results that are consistent 
with each other, notwithstanding potentially misspecified, marginal and basic-
adjustment models. 
One of the challenges in applying the PERR and Pairwise to vaccination studies was 
the derivation of the survival start dates for the controls from the vaccine recipients 
through matching. Expressing vaccination as a time-varying covariate obviated the 
need for this, and the PERR was successfully applied to the influenza study with the 
vaccine effect as a time-varying covariate in the study period, although the 
confidence intervals were wider than the standard approach. Nonetheless modelling 
time-varying covariates is a highly adaptable approach to investigating comparative 
effectiveness studies, not just for accounting for time-varying effects, but also where, 
as in the vaccination studies, determining the start times for follow-up may involve 
complicated matching algorithms. 
Throughout the vaccination studies, the Pairwise estimates were consistently further 
from the null than the PERR estimates. This may have been due to missing, but 
otherwise balanced covariates, which can bias the PERR method, but not the 
Pairwise. However, other differences exist between the performance of each method 
under the same assumption, so it was difficult to determine the provenance of the 
differences. For instance, where there is an interaction between exposure and a 
hidden confounder, then the resulting bias has been shown to vary according to size 
of the confounding effect, although for most of the range in one scenario presented 
in Lin and Henley 192, this was shown to favour the PERR method. Further bias due 
to assumption violation may arise when the exposure or treatment is indicated by the 
event in the prior period. Here, the relationship between the bias and the strength of 
indication for each method differentially varies over the range or the effect of 
confounding. As discussed in paragraph 4 of 4.3 of chapter four, this is further 
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complicated by indication existing on a continuum rather than as a binary state. 
Furthermore, trying to diagnose confounding by indication may be difficult, given 
there would be nothing to differentiate between any treatment that may have been 
indicated by a prior event and those treatments that might have been administered 
coincidentally following an event (without actually being indicated by it). For instance, 
a patient could easily have had a chance pneumococcal infection in the period 
leading up to a routine appointment for vaccination against the disease, which may 
have appeared to have been indicated, but otherwise lacking any direct causal 
connection. 
This project has demonstrated the PERR and Pairwise framework to be more than 
just a QE method applied to unadjusted models to mitigate against unmeasured 
confounding. Rather, such methods could be an integral part of a best-practice 
approach to EHRs, especially when combined with the best available adjustment for 
observed confounders. Firstly, the direction and degree of unmeasured confounding 
bias may be inferred from the prior and study periods contributing to the PERR 
analysis, contingent on a correctly specified model for those periods. Where multiple, 
successive cohorts are analysed, as was done for the study of influenza 
effectiveness on MI outcomes, then inference about the stability of the confounders 
may be inferred from the year-to-year changes in the prior periods, since only 
confounders and unmeasured covariates will be solely affecting the estimates. For 
instance, relative to the exposure effect, the effects of confounding may be deemed 
unstable, if the year-to-year variation in the prior period seems excessive over time. 
Comparisons of the unweighted mean differences in confounders between exposure 
groups from each cohort, as found in the diagnostic plots for the IPTW method, may 
further shed light on the stability of the unmeasured component of confounding bias 
through potential associations with the measured confounders (the principle upon 
which perturbation analysis sits 80). Further comparison against methods attempting 
a full, explicit adjustment may help identify the proportion of bias that may be due to 
unmeasured confounding. However, caution is required as the accuracy of the 
results from the adjusted model will depend on the functional form of the adjusted 
variables and any potential interactions being correctly specified in the model. 
As was demonstrated in the study of PPV effectiveness, the PERR and Pairwise 
methods could potentially provide unbiased estimates of interactions and exposure 
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modifiers. The investigation of effect modification is often proposed as a secondary 
analysis, requiring division of the data into sub-groups of the effect modifier. 
However, this may lead to challenges of statistical multiplicity, and many statistical 
corrections are either overly conservative, producing type 2, false-negative 
conclusions, or too liberal leading to type 1, false-positive errors328. The procedure 
followed in this project was to model the interaction between exposure and potential 
modifier, as a global test of the sub-groups. The interaction, when found to be 
significant in the study period, was then adjusted using the PERR method, which as 
far as I am aware from the published literature, is the first example of deploying the 
PERR adjustment in this way. The need for further research into this particular 
application is acknowledged in section 7.4.3.1 below. The interaction could be 
interpreted directly through its PERR-adjusted effect, although interpretation for 
effectiveness at specific ages is complicated by also having to consider the PERR-
adjusted main effects and interaction simultaneously. Therefore, when the global test 
of the age and vaccination interaction was found to be significant in the 2005 cohort 
of the PPV study, the effect of age was interpreted through modelling three main 
effects for in the data, having divided it into age sub-groups. An advantage of this 
approach is that the marginal effect of vaccination could be estimated using IPTW for 
each age group for ease of interpretation. Furthermore, the PERR method was also 
applied to adjust for any residual confounding not controlled for by the propensity 
score used in the IPTW method. 
The authors of the seminal work on PERR, and subsequently PERR-ALT, applied 
the methods to replicated trials using EHRs as a means of validation, and 
comparison to the trial results. However, as reported in chapter four, the application 
of PERR varied in the subsequent studies. While few applied PERR to complete the 
adjustment for confounding, most applied the method to unadjusted models as a 
means of presumably adjusting for all confounding. Here, this particular chapter will 
be published as a review with a view to offering guidance and best practice in the 
application of the methods. A cautious approach was taken in this project, applying 
the PERR and Pairwise methods to models conditioned on the basic adjustment for 
age and gender. These were compared to models adjusted for measured 
confounders through weighting, although the two approaches offer different 
estimates of effect, one conditional on age and gender, and the other, marginal, 
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averaged across all the other effect effects and characteristics of the sample. Finally, 
the marginal models were adjusted with PERR to gauge the degree of bias due to 
unmeasured confounders. This robust approach was in contrast to many other 
studies applying the PERR method. The novelty of this work was also in the first ever 
application of the Pairwise, and PERR-ALT, model outside of the seminal studies. 
A notable difference in the approach to the application of the PERR method between 
the seminal studies of Tannen, Weiner et al and this project, was that here the 
methods were applied to the vaccine data without attempting to exactly replicate 
RCTs, and did not specifically consider an as-treated analysis. Without the tool of 
randomisation, one would reasonably expect the replication of a trial in RCD would 
produced biased results, but replication has been used primarily to help validate the 
PERR method in the seminal work. Hence, any differences between the replicated 
and original trials results could be attributed to bias rather than trial conditions with 
all other things, apart from randomisation, being equal. Trial replication was not 
repeated for the vaccine studies as the purpose was not to limit the generalisability 
and sample size by imposition of too many selection criteria. While some exclusion 
criteria may serve to hone a clinical question to a relevant population, the 
applicability of results from real-life practice relies in part on studying exposures 
away from carefully controlled trial conditions. With regards to the sample set, an as-
treated approach was unnecessary given that exposed individuals were necessarily 
compliant for the duration of the vaccination effect, unless they were censored on 
death or upon deregistering with their practice. In the case of influenza, the duration 
of vaccine effectiveness was for the year from the point of vaccination, while for 
PPV, which is not administered annually, the duration of effect was considered to be 
long enough to accommodate a follow-up of at least two years. 
Evidence for moderating effect of age on the effectiveness of the pneumococcal 
vaccination would appear to be reasonably robust given that this was observed in 
the naïve Cox model adjusting for age (a main effect of the interaction term) and 
gender; the marginal effects of the high-dimensional IPTW model by age group; and 
the PERR and Pairwise models applied to the former. The difference between the 
age groups of the IPTW model was less than that suggested by the interaction terms 
of the conditional models, but this may have been attenuation of an otherwise large 
interaction effect by residual confounding. The accuracy of the PERR and Pairwise 
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adjusted estimates still rested on the assumption of stable confounding, but these 
were arguably less exposed to changes in pathogen virulence than in the study of 
the influenza vaccine. Further simulation work may be needed to test the 
performance of the PERR and Pairwise methods in estimating interactions (see 
future work below). However the findings of the age-vaccine interaction could impact 
on the direction of future research 70, with the real-world evidence suggesting that 
the benefits of pneumococcal vaccination are not noticeably undermined by a poorer 
immune response in older ages. 
An important implication from applying the PERR and Pairwise methods to vaccine 
studies is that these methods may be more suited to studying non-infectious 
diseases, or adverse events where the outcomes are more likely to be independent 
and repeatable. However, the challenges of applying the methods to these studies 
allowed a thorough comparison of their performance using real-world data. In spite of 
these challenges, the evidence from the vaccination studies were supportive of their 
protective effect. For PPV, effectiveness increased with age, and for influenza, the 
protective effect against MI was mediated through its effectiveness against influenza. 
Furthermore, the results for the influenza vaccine aggregated over many cohorts 
suggest an effectiveness of 39% against MI, which was consistent with the evidence 
from one of the few trials conducted on this outcome. 
Lastly, while the results from this analysis of EHRs are compared to trial results, the 
evidence from real-world data should not necessarily be viewed as a challenge to 
RCT-generated evidence. Instead, real-world evidence tries to acknowledge the 
complexity of the greater causal network, in which the evidence from RCTs might sit. 
The findings from this project have not only contributed useful clinical evidence, but 
have also demonstrated the utility of routinely-collected data, as well as contributing 
to the research into methods that can analyse such data by mitigating for, or 
describing the sensitivity to unmeasured confouding. 
7.4 Future research 
Future research that may progress the work undertaken in this PhD project can be 
described as two-pronged. While interest may lie in further validating and extending 
PERR and Pairwise as viable methods in research using routinely collected data, 
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there is also a need to address some pressing clinical questions around drug-
vaccine interactions, which may be resolved by the advantages afforded by the real-
world data from EHRs. One of these questions follows on from discussions at the 
33rd International Conference on Pharmacoepidemiology prompted by my work on 
pneumococcal vaccination in this PhD project. Some pilot work has been undertaken 
to explore the viability of such a project, and more details are given in the protocol for 
this, which is presented below in section 7.4.1. In addition to the application of the 
methods in further clinical research, I identified during the course of this project, 
further ideas for developing and extending the methods. 
7.4.1 Future research: A protocol for the investigation of the 
influence of statins on influenza vaccine effectiveness 
7.4.1.1 Background 
An elevated risk of acute myocardial infarction has frequently been observed to 
coincide with high levels of influenza infection 302,304,305,329,330. It is believed this is a 
likely inflammatory response to infection and to the release of proinflammatory 
cytokines. Some studies have also found evidence of a reduction in the rates of 
myocardial infarction and heart failure following influenza vaccination 311,314,331–333. 
This, in turn, this has led to a proposed additional role for influenza vaccination in 
preventing acute cardiovascular diseases 306,316,334–336, although some of the 
observational evidence may be biased without adjustment for unmeasured 
confounding 311,314. Furthermore, estimation of the marginal effect may conceal 
differential effects between key sub-groups of patients, with some patients deriving 
great benefit from vaccination 332,337. Because statins may have anti-inflammatory as 
well as lipid-lowering effects, statins have been proposed as a possible prophylaxis 
against influenza as well as cardiovascular diseases on the basis of the 
proinflammatory stimuli, common to both diseases 338. However, recently published 
evidence has suggested that statins may impair immunogenicity, and therefore 
effectiveness, of the influenza vaccine 339–342. 
Building on previous work investigating pneumococcal vaccine effectiveness and the 
role of the influenza vaccine in protecting against myocardial infarctions in the 
elderly, this study proposes to investigate whether statins moderate vaccine 
effectiveness against influenza in the population of adults aged at least 65y. 
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Although the US data are subject to different biases and different prescribing 
patterns, to facilitate comparability, the settings for this project will largely be 
informed by the study of Izuerieta et al.342. By replicating those studies conducted on 
predominantly US populations, this project aims to uniquely contribute to the growing 
body of evidence on the immunomodulatory effect of statins using UK population 
data. Furthermore, while previous studies have adjusted for observed confounders, 
we will also investigate what role unmeasured confounding may have by using 
quasi-experimental techniques322. 
7.4.1.2 Cohort selection 
This project will use data collected on UK adults aged at least 65y available from the 
Clinical Practice Research Datalink. The study will start from 2002, avoiding the 
instability in treatment and potential confounders during the change from the risk-
based practice to an age-based vaccination policy, which completed in 2001. Annual 
cohorts will then be recruited to the latest annual cohort that can be guaranteed 
complete and up-to-standard by the CPRD. Recruitment will begin on the index date 
for each year, arbitrarily set to the 1st September as the date likely to precede 
seasonal vaccination (typically October) and the maximum number of patients 
recruited in the same period. Patients will be included if they have a record of 
vaccination against influenza between the index date and the 31st January of the 
following year. Follow-up will begin on the date of influenza vaccination, plus 14 days 
to allow for full immunogenicity, and end 30th April. 
For the purpose of applying a quasi-experimental adjustment for unmeasured 
confounding, a sub-cohort of patients will also be selected according to their 
vaccination status in the prior period, defined as the 1st September of the previous 
year to the 31st of the following January, during which follow-up will last until 30th 
April. In this way, the sub-cohort will be defined as patients, who have been 
vaccinated against influenza for two consecutive years. For example: the index date 
for the 2010 cohort would be defined as the 1st September 2010, and patients 
required to have been vaccinated between the index date and 31st January 2011. 
The study period would therefore be defined as the follow-up from the date of 
vaccination to 30th April 2011. Follow-up in the prior period would have ended on 30th 
April 2010 and begun with an influenza vaccination in the prior period between 1st 
September 2009 and 31st January 2010. 
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Patients should be HES-linked, alive and at least 65y of age on the index date, and 
excluded if not registered at their practice at least two years before. The General 
Practices will also have to be up-to-standard at least two years before the index 
date. An absence of any clinical consultation in the five years before the index date 
will be regarded as unlikely for patients in this age group and so such cases will be 
excluded. Instances of influenza vaccination will be determined by their relevant 
medical codes in the immunisation file and product codes in the therapy file 
(Appendix D – CPRD and HES codes) 
7.4.1.3 Intervention 
Statins listed under the relevant British National Formulary chapter code of 0212 can 
be identified in the CPRD therapy file by their product codes (all with CPRD BNF 
code = 02120400). Synthetic statins are Atorvastatin, Rosuvastatin and Fluvastatin. 
Non-synthetics are Simvastatin, both with and without Ezetimibe, and Pravastatin 
(see Appendix F – codes for statins in CPRD data, for full list of statins and product 
codes). For any given cohort, records of statin prescribing will be retrieved for the 
period between 30th April of the year before the index date and 16th January of the 
year after the index date (e.g: for the 2010 cohort, this would be from 30th April 2009 
to 16th January 2011). The end date for a prescribed course of statins can be 
calculated from the quantity supplied and the date of prescription. Courses will be 
counted as one, where prescriptions were renewed within two days of the previous 
one finishing. Patients will be excluded from the cohort if prescribed a spurious 
quantity of statins considered to be less than 7 or greater than 84. To ensure a 
statin-free prior period for the quasi-experimental adjustment of unmeasured 
confounders, patients will then be excluded if there is evidence of a statin 
prescription in prior period up to 15 days after vaccination in the prior period, and 
since the 30th April of the year preceding the index date. For example, given an index 
date of 1st September 2010, this would define a statin-free period from 30th April 
2009 to 15 days after an influenza vaccination in the period between 1st September 
2009 and 15th January 2010. 
Statin users shall be defined as patients with a sufficient supply of statins to cover 
the period 15 days before vaccination through to 15 days after vaccination for each 
study period, with a maximum allowable gap of 2 days. Adherent statin users will be 
those who are prescribed statins in the period from 30th April preceding vaccination 
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in the study period to 15 days after vaccination with a medication possession ratio 
(MPR) of ≥ 0.8. Non-users will be defined as beneficiaries with no evidence of 
receiving statins during the period extending from 6 months before to 15 days after 
vaccination. Patients who do not meet the criteria for either group will be excluded 
7.4.1.4 Outcomes 
Given the rarity of instances of antiviral drug prescribing in the dataset, the study will 
examine the effect on two outcomes: hospitalisation for influenza and a composite of 
a prescription for an antiviral drug or hospitalisation for influenza. As a sensitivity 
analysis, eligibility of the outcomes will also be restricted to those occurring during 
periods of high level influenza circulation periods as confirmed by PHE laboratory 
surveillance. Survival times will be calculated as the time from vaccination until date 
of one of the events of the composite outcome, less the 14 day period for developing 
immunity after vaccination. Influenza diagnoses in the HES data can be identified by 
their ICD-10 codes (Appendix D – CPRD and HES codes), and the date of influenza 
given by the date of admission to hospital. Antiviral drugs are identified by their 
product codes (Appendix D – CPRD and HES codes). 
7.4.1.5 Statistical analysis 
The effect of statins on survival times until the composite outcome will be analysed 
using Cox’s regression adjusting for age and gender, censoring on death. Any 
patients found to have vaccination dates occurring after their date of death will be 
dropped from the cohort. Any negative survival times resulting from the addition of 
14 days to the vaccination date (reflecting the period for immunogenicity) will be 
assigned zero times, with any corresponding events being coded as right-censored 
events. 
7.4.1.6 Adjustment of cohorts for unmeasured confounding 
To adjust for unmeasured confounding, the resulting hazard ratio from the study 
period for the sub-cohort of patients with two years of influenza vaccination will be 
adjusted with the hazard ratio for statin-free prior period, using the prior event rate 
ratio (PERR) method. Confidence intervals for the PERR-adjusted hazard ratio can 
be obtained through bootstrapped resampling. 
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7.4.1.7 Weighted analysis of 2010 cohort 
An inverse probability treatment weighted (IPTW) survival analysis will be performed 
to estimate the marginal effect of the statins, adjusting for measured confounders for 
the study period only. Stabilised IPTWs will be based on the propensity scores 
derived from a predictive model for statin treatment. Prognostic variables considered 
for the propensity score model will be those found to be significant at the 5% level in 
a Cox regression of the defined outcomes. Candidate variables will include age, 
gender, diseases recorded for the Quality Outcomes Framework 295 and symptoms 
and diseases derived for the electronic frailty index 292, as well as the index itself. To 
gauge the extent of unmeasured confounding, the IPTW estimates from the study 
period will be obtained for the sub-cohort of patients with two years of influenza 
vaccination, and additionally the PERR adjustment shall be applied. 
7.4.2 Future research: Development of the post event rate ratio 
method 
Investigation of vaccination rates during the recruitment to the pneumococcal 
vaccine study prompted an exploration of an alternative approach to the PERR 
method. The pneumococcal vaccine had been introduced into adults aged at least 
65y by age group over three successive years between 2003 and 2005. Vaccination 
rates before 2003 according to the data were below 30%. This was consistent with 
the data from the HPA, who reported a vaccination rate of 29% in 2003 based on 
monitoring over the previous 10y. According to the CPRD data, this had increased to 
72% in 2008, compared to 69% reported by the HPA for that year. 
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Figure 39: Plot of proportion of patients ever receiving a pneumococcal vaccination 
for each year in the CPRD data from 1999 to 2010, to illustrate potential for an 
adjustment of the study period using the all-vaccinated patients in the post period. 
Vaccinated patients up to the study start are excluded. The hazard ratio of treatment 
in the study period is estimated from the vaccinated group’s survival times (found in 
area 1 below the curve in study period) relative to those of the controls (dotted 
quadrant marked 2). The hazard ratio of treatment in the post period is estimated 
from the vaccinated group’s survival times (dotted quadrant marked 3) relative to 
those of the controls receiving the vaccine (found in area 4 below the curve in the 
post period). 
With the PPV vaccination policy achieving its aim of increasing vaccination 
coverage, a large part of the UK population of older adults had rapidly transitioned 
from an unvaccinated to a vaccinated state (Figure 39). This prompted the idea to 
use the event rate from a “post” period after the study period, in which all patients in 
the study period were eventually vaccinated. The confounding adjustment would 
come from the post period, during which all patients would have been vaccinated, 
and the only observed effect should have been from confounding bias. The post 
period could then replace the prior period as an adjustment ratio for the study period 
HR (or relative risks if using rate data instead of survival). The proposed idea is as 
simple and intuitive as the original PERR method. It is proposed that this may be 
tested on the vaccine effectiveness data and compared with the results from the 
PERR and Pairwise methods (Figure 40). 
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Figure 40: Diagram illustrating PostERR method relative to the prior period. As per 
the cumulative vaccination graph in figure 1, 100% coverage of treatment is rarely 
achieved at the population level, so there is likely to be a rump of patients, who will 
never be treated. 
This PostERR method, as I have dubbed it, may at a very superficial level seem 
similar to Tannen and Yu’s post-treated event rate ratio (PTERR) method. However, 
their PTERR method was developed to deal with confounding by unrepeatable 
events, like death. Rather than using a common all-treated period as with the 
PostERR method, the PTERR method exploits differences in the as-treated and 
intention-to-treat (ITT) periods for individual patients in order to adjust for 
confounding. This, of course, implies applicability to treatments, where non-
compliance is possible in the first place, and would preclude investigations into 
vaccinations and cures. The PTERR method also relies on matching exposed to 
unexposed patients for comparison of the as-treated and ITT periods, and so might 
not quite be considered a true quasi-experimental method. 
As alternative adjustment for confounding, the PostERR method may offer some 
advantages instead of, or as a complement to the PERR method: 
1. It offers an alternative measure of confounding bias for a sub-group within the 
PERR cohort, which eventually reaches an exposed state. A different 
confounding bias may manifest in the post period compared to the prior, so 
some simulation work will be necessary to investigate this. High-dimensional 
Treatment group
Control group
Study periodPrior period Post period
• Controls eventually treated.
• HRPOST is hazard in treatment group 
relative to treated controls
Never treated
HRSTUDYHRPRIOR
HRPostERR
= HRSTUDY / HRPOST
HRPOST
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adjustment methods, such as IPTW, should be used as a check and 
verification of the bias apportioned to observed confounding, as followed in 
this PhD. With the transition of the unexposed into an exposed state, this 
approach has parallels with the active-comparator new-user design, and 
similarly could be considered a form of restriction to patients, who will all 
eventually reach an exposed state. 
2. It is clear from the (pneumococcal) vaccination rates over time, there remains 
a proportion of patients, who are never vaccinated. This would also likely be 
true for other cures or long-lasting treatments. In the older population, some of 
these may be terminally ill, or may have died during that year of data 
collection. However, the never-treated patients may in some way be different 
from the remaining cohort, depending on the cut-off for determining those, 
who would never be treated. By considering the PostERR cohort, this should 
provide another useful insight into the nature of the confounders biasing the 
study-period results. 
3. For the PostERR cohort, inference could potentially be made about not only 
the size of confounding bias, but also its trend over time by comparing the all-
exposed post period with the unexposed prior period. An assumption of the 
PERR method, applicable to the PostERR method too, is that of time-invariant 
confounding bias. However, information from the prior and post periods not 
only offer insight into changes in the bias over time, but potentially an 
adjustment for it too. 
In the first instance, the PostERR method could be demonstrated on the 
pneumococcal vaccine investigation in chapter five. However, further simulation work 
would be needed to clarify the above ideas 1-3, as well as the assumptions of 
PERR, particularly in the presence of confounding by indication. 
7.4.3 Future research: Methodological development 
7.4.3.1 Validation of PERR and Pairwise applied to interactions 
As far as could be ascertained from the published literature, the vaccination studies 
were the first to apply the PERR and Pairwise methods to moderating effects. In 
clinical trials, the focus is usually on estimating the efficacy of an intervention as a 
main effect, with clinically interesting sub-groups subordinated as secondary 
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analysis. With routinely collected data, there is little justification for being restricted 
by this paradigm. Also, testing interactions are essential for investigating moderating 
effects, and for performing global tests of significance to avoid multiplicity across 
categories of patient characteristics divided into subgroups. With the size and depth 
of information available for patient histories in EHRs, QE methods, such as the 
PERR and Pairwise methods could be utilised in identifying responders to treatment 
and adverse events contributing to the development of personalised medicine. In this 
PhD project, the pneumococcal vaccination found effectiveness increased with age, 
contrary to some counter arguments based on the observed phenomenon of 
immunosenescence. This was verified across a variety of approaches including a 
non-QE, weighted regression, all reaching the same conclusion about the 
moderating effect of age. Clearly this has potential to impact on the decisions taken 
by policy makers. However, this and future work could benefit from further validation 
of the analysis in which interaction effects were adjusted using the PERR and 
Pairwise methods in the presence of confounding. It is known from previous 
simulation work that the Pairwise method, and to a lesser extent the PERR method, 
are biased in the presence of an interaction between the exposure and any hidden 
confounder. However, little is known about the performance of the methods when 
analysing an interaction in the presence of unmeasured confounders. In Figure 41, if 
M is the moderator, with which exposure X interacts to cause observed Y, then X 
and Y may be confounded by unmeasured confounders, U, or that U may be aliased 
with the interaction effect through M, or may directly moderate the effect of X on Y as 
an unmeasured moderator. All scenarios are also possible. Hence, a simulation is 
necessary to test the performance of the methods under these conditions. This could 
be presented in the context of the vaccination studies in the older population, in 
which age is often a key effect moderator, as well as confounder.  
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Figure 41: Causal diagram showing moderating effect of M on the effect of X on 
outcome, Y. U is an unmeasured variable and potential confounder and/or mediator. 
The dashed lines show possible causal pathways to be simulated in the study of the 
performance of the PERR and Pairwise methods in analysing an interaction. 
7.4.3.2 Sensitivity to timing of prior period 
As the prior period is key to the adjustment in the PERR and Pairwise methods, then 
further work might be undertaken to explore the sensitivity of results to varying 
timings and durations of the prior period. The period immediately prior to the study 
period was chosen in the vaccination studies as this seemed to afford the best 
assurance that the confounding bias would be representative of that in the study 
period. However, the timing of the prior period could be chosen to create a gap 
between the two periods. This could provide further insight into the stability of the 
confounding bias over time as well as potentially test the sensitivity to indication bias 
(effect of prior event on exposure). For interventions like vaccination, some caution 
would be necessary about inferences into the presence, or otherwise, of indication, 
as vaccines tend to be routinely offered during a specific season in the year (usually 
U
X Y
M
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October to December). In this case, events occurring in the previous season may still 
indicate vaccination, which would nevertheless be administered in the following 
season, and so a lag of a whole year may be necessary to entirely separate 
indication effects. However, as discussed in paragraph four of section 4.3 in chapter 
four, indication is unlikely in theory to operate completely independently of 
confounding variables, and so simulation work may be required to determine the 
point, at which the effect of indication “overtakes” the imbalance in prognostic 
factors. For other interventions independent of season, the lag between periods 
could be varied over months rather than in years. However, to study the stability of 
confounders over time, then the lags may need to be specified in years as well as 
months to study stability of long term and seasonal unmeasured confounders, 
respectively.  
7.4.4 Future research: Best practice guidelines 
Presentation of the study on pneumococcal vaccination led to an invitation from the 
International Society of Pharmacoepidemiology (ISPE) to review the 
pharmacoepidemiological extension to the pre-existing guidelines for the reporting of 
studies conducted using observational routinely-collected health data (RECORD), 
thus creating the RECORD-PE guidelines. This has now been published on the ISPE 
website 343. The RECORD guidelines were themselves an extension of the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
guidelines adapted for RCD such as EHRs. The RECORD guidelines presented 
timely recommendations for maintaining good practice in reporting studies based on 
RCD, justified by the growing interest in using this data in health research. While it 
was entirely logical to build upon these existing guidelines, there is an argument for 
starting afresh, and use the opportunity to review and renew existing items, rather 
than append to them. One of my primary concerns was the separation of items 4 
(study design), 9 (bias) and 12 (statistical methods). While EHRs of RCD may form 
the basis for many ecological studies (e.g: vaccination coverage; changes in 
prescribing patterns over time), there is an increasing focus on how to tackle the 
problem of confounding bias and improve the robustness of causal inference from 
evidence based on EHRs. In this way, study design and statistical methods have 
been shown (section 4.4 of chapter four) to be two integral strategies for dealing with 
confounding bias. As confounding bias is arguably the greatest threat to causal 
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inference from observational data, then this perhaps warrants greater focus in any 
guidelines for using RCD. This certainly figured prominently in the objective the PE 
extensions were intended to serve. However, the danger of separating the two 
complementary strategies in items 4 and 12 for dealing with the property of bias 
listed in 9, is that that focus becomes too diffuse. While it is helpful to break down the 
problem into numbered steps in order of reporting, there is an argument for 
reorganising the guidelines and starting again, perhaps tailoring these for inferential 
studies, given that adjustment for bias will determine both simultaneously the study 
design and analytical method used. 
An important contribution in the PE-extension to the guidelines was the expansion of 
the section on study design to focus on how this could be used to mitigate for 
confounding bias. The explanation included, as an example, the relatively recent 
development of the active-comparator new-user design, which, as already described, 
controls for confounding by restricting the study to a comparison between two drugs 
for the same disease, and therefore, to patients with the same prognosis. However, 
the examples also included interrupted time series, which it could be argued is an 
analytical method rather than design, relying as it does on longitudinally collected 
data, but not necessarily within individuals. The explanation also offered risk-
minimisation interventions as an example of study, which was perhaps better suited 
as an example of a study’s purpose rather than its design. 
It was further noted that in the explanation for the “Methods (bias)” section that this 
seemed to overlap with the following explanation for item 12 on statistical methods 
by including comments on adjustment for observed confounders through propensity 
score methods. The explanation for item 12a also exclusively focussed on case-only 
designs, which may erroneously give the impression of being the only acceptable 
design and method. Future collaboration may be needed for further iterative 
improvements on the guidelines. However, it is clear that if a contribution is to be 
made to RCD methodologies, then further work is first required to develop best 
practice in the application of the PERR and Pairwise methods, building on the work 
presented in this PhD project. Besides publication of the studies on vaccination, a 
review based on chapter 4 will also published, which will include the 
recommendations for best practice in applying the PERR and Pairwise methods, 
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along with examples where the conditions for the application of the methods may be 
met. 
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7.5 Conclusions 
Through the investigation of vaccine effectiveness in older adults using electronic 
health records, my work for this PhD project has demonstrated how evidence from 
routinely collected data can been used to complement the results from clinical trials 
to build a more complex understanding of a potential clinical effects in real-world 
settings. I demonstrated how this involved quasi-experimental methods to adjust for 
confounding bias, and in the application to the vaccination effectiveness studies, I 
developed a strategy for understanding the source and size of the bias. In these 
studies, I was able to compare the performance of two related and recently 
developed methods for adjusting for unmeasured confounding. I also reported on the 
limitations of these methods, the PERR and Pairwise, and their performance in their 
application to vaccine effectiveness studies. I also demonstrated the usefulness of 
these methods in studying populations, such as older adults, that may be under-
represented in trials. 
My contribution to research into these specific methods is that by drawing together 
existing research, I was able to report on the relative performance of the PERR and 
Pairwise methods, and offer guidance for their future application. In a wider context 
of adjusting for unmeasured confounding, I have also provided published guidance 
for using quasi-experimental methods in studies using routinely-collected data, and 
how the available longitudinal information can be leverage to adjust for unmeasured 
confounding. For future research, I have identified avenues for improving the 
applicability of the PERR approach, and potentially its robustness against time-
varying confounding. 
My research also had a clinical impact. Through the novel application of the PERR 
and Pairwise methods to estimating effect modification, I presented evidence for an 
increase in effectiveness of the pneumococcal vaccine with age in older adults, 
during the implementation of the UK vaccination programme. In my study of the 
influenza vaccine in the same population, I presented evidence for the protective 
effect of the influenza vaccine against myocardial infarction, and how this is likely to 
be mediated through its protective effect against influenza. I also highlighted the 
challenges in applying these methods to vaccination studies, but identifed another 
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area for its application, studying the drug interaction between statins and the 
influenza vaccine and presented my protocol for this, based on my pilot work.  
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Appendix A – methodological review search terms 
1. ("prior event" and ratio).ti,ab. 
 
2. "paired cox model".ti,ab. 
 
3. 1 or 2 
 
4. instrumental variables.ti,ab. 
 
5. instrumental variable analysis/ 
 
6. propensity score calibration.ti,ab. 
 
7. regression discontinuity design.ti,ab. 
 
8. "difference in differences".ti,ab. 
 
9. (difference adj1 differences).ti,ab. 
 
10. "ratio of ratios".ti,ab. 
 
11. (ratio adj1 ratios).ti,ab. 
 
12. interrupted time series.ti,ab. 
   
 
 246 
 
13. segmented regression.ti,ab. 
 
14. (sensitivity analysis/ or sensitivity analysis.ti,ab.) and ((unmeasured or residual or hidden) and 
(confounding or confounder*)).ti,ab. 
 
15. or/4-14 
 
16. ((unmeasured or residual or hidden or unobserved or omitted) and (confounding or confounder*)).ti,ab. 
 
17. confounding variable/ 
 
18. covariates.ti,ab. 
19. bias.ti,ab. 
 
20. selection bias/ 
 
21. 16 or 17 or 18 or 19 or 20 
 
22. observational study/ 
 
23. (observation* adj (stud* or data)).ti,ab. 
 
24. ((before adj after) and (study or studies)).ti,ab. 
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25. (nonrandomi?ed or non randomi?ed).ti,ab. 
 
26. case crossover.ti,ab. 
 
27. case control.ti,ab. 
 
28. case control study/ 
 
29. cohort study.ti,ab. 
 
30. (quasi experiment* or quasiexperiment*).ti,ab. 
 
31. quasi-experimental study/ 
 
32. cross sectional study.ti,ab. 
 
33. cross-sectional study/ 
 
34. simulation.ti,ab. 
 
35. case time control.ti,ab. 
 
36. ("before and after" and (study or studies)).ti,ab. 
 
37. or/22-36 
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38. 16 and 19 and 37 
 
39. 3 or 15 
 
40. 39 and 37 and 21 
 
41. 38 or 40 
 
42. 21 or 37 
 
43. 39 and 42 
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Appendix B – table of studies included in the methodological review 
Table 25: Table of included studies denoting QE method used and type of instrument, if applicable, where: IVA = instrumental 
variable analysis; RD = regression discontinuity; DiD = difference-in-differences; DiDiD = difference-in-difference-in-differences; 
PSC = propensity score calibration; PERR = prior event rate ratio 
Author Title Year QE method If IVA, IV type 
Bryson, W. C.; McConnell, J.; 
Krothuis, T.; McCarty, D. 
Extended-release naltrexone for alcohol 
dependence: persistence and healthcare 
costs and utilization 
2011 DiD 
 
Cheng, L.; Liu, H.; Zhang, Y.; 
Shen, K.; Zeng, Y. 
The impact of health insurance on health 
outcomes and spending of the elderly: 
Evidence from china's new cooperative 
medical scheme 
2015 DiD 
 
Gebel, M.; Vosemer, J. The impact of employment transitions on 
health in Germany. A difference-in-
differences propensity score matching 
approach 
2014 DiD 
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Goetzel, R. Z.; Roemer, E. C.; Pei, 
X.; Short, M. E.; Tabrizi, M. J.; 
Wilson, M. G.; Dejoy, D. M.; 
Craun, B. A.; Tully, K. J.; White, J. 
M.; Baase, C. M. 
Second-year results of an obesity 
prevention program at the dow chemical 
company 
2010 DiD 
 
Higgins, S.; Chawla, R.; Colombo, 
C.; Snyder, R.; Nigam, S. 
Medical homes and cost and utilization 
among high-risk patients 
2014 DiD 
 
Kausto, J.; Viikari-Juntura, E.; 
Virta, L. J.; Gould, R.; Koskinen, 
A.; Solovieva, S. 
Effectiveness of new legislation on 
partial sickness benefit on work 
participation: a quasi-experiment in 
Finland 
2014 DiD 
 
Kelly, Y.; Kelly, J.; Sacker, A. Changes in bedtime schedules and 
behavioral difficulties in 7 year old 
children 
2013 DiD 
 
Lin, W. C.; Chien, H. L.; Willis, G.; 
O'Connell, E.; Rennie, K. S.; 
Bottella, H. M.; Ferris, T. G. 
The effect of a telephone-based health 
coaching disease management program 
on medicaid members with chronic 
conditions 
2012 DiD 
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Lyon, S. M.; Wunsch, H.; Asch, D. 
A.; Carr, B. G.; Kahn, J. M.; 
Cooke, C. R. 
Use of intensive care services and 
associated hospital mortality after 
massachusetts healthcare reform 
2014 DiD 
 
Menon, J.; Paulet, M.; Thomas, Iii 
J. 
Wellness coaching and health-related 
quality of life: A case-control difference-
in-differences analysis 
2012 DiD 
 
Moran, J. R.; Short, P. F.; 
Hollenbeak, C. S. 
Long-term employment effects of 
surviving cancer 
2011 DiD 
 
Osborne, N. H.; Nicholas, L. H.; 
Ryan, A. M.; Thumma, J. R.; 
Dimick, J. B. 
Association of hospital participation in a 
quality reporting program with surgical 
outcomes and expenditures for 
medicare beneficiaries 
2015 DiD 
 
Reid, R. O.; Ashwood, J. S.; 
Friedberg, M. W.; Weber, E. S.; 
Setodji, C. M.; Mehrotra, A. 
Retail clinic visits and receipt of primary 
care 
2013 DiD 
 
Sadhu, A. R.; Ang, A. C.; Ingram-
Drake, L. A.; Martinez, D. S.; 
Hsueh, W. A.; Ettner, S. L. 
Economic benefits of intensive insulin 
therapy in critically Ill patients: The 
targeted insulin therapy to improve 
hospital outcomes (TRIUMPH) project 
2008 DiD 
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Sarkar, U.; Lyles, C. R.; Parker, M. 
M.; Allen, J.; Nguyen, R.; Moffet, 
H. H.; Schillinger, D.; Karter, A. J. 
Use of the refill function through an 
online patient portal is associated with 
improved adherence to statins in an 
integrated health system 
2014 DiD 
 
Watt, C.; Abuya, T.; Warren, C. E.; 
Obare, F.; Kanya, L.; Bellows, B. 
Can reproductive health voucher 
programs improve quality of postnatal 
care? A quasi-experimental evaluation 
of Kenya ' s Safe Motherhood voucher 
scheme 
2015 DiD 
 
De Preux, L. B. Anticipatory ex ante moral hazard and 
the effect of medicare on prevention 
2011 DiD; DiDiD 
 
Rajaram, R.; Chung, J. W.; Jones, 
A. T.; Cohen, M. E.; Dahlke, A. R.; 
Ko, C. Y.; Tarpley, J. L.; Lewis, F. 
R.; Hoyt, D. B.; Bilimoria, K. Y. 
Association of the 2011 ACGME 
resident duty hour reform with general 
surgery patient outcomes and with 
resident examination performance 
2014 DiD; DiDiD 
 
Domino, M. E.; Norton, E. C.; 
Morrissey, J. P.; Thakur, N. 
Cost shifting to jails after a change to 
managed mental health care 
2004 DiD; Fixed effects 
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Hodgkin, D.; Parks Thomas, C.; 
Simoni-Wastila, L.; Ritter, G. A.; 
Lee, S. 
The effect of a three-tier formulary on 
antidepressant utilization and 
expenditures 
2008 Fixed effects 
 
Li, J.; Hurley, J.; DeCicca, P.; 
Buckley, G. 
Physician response to pay-for-
performance: evidence from a natural 
experiment 
2014 DiD pooled OLS; DiD 
(Fixed effects); DiD + 
differential trends 
 
Yoon, J.; Bernell, S. L. The role of adverse physical health 
events on the utilization of mental health 
services 
2013 DiD & Fixed Effects 
 
Fortney, J. C.; Steffick, D. E.; 
Burgess Jr, J. F.; Maciejewski, M. 
L.; Petersen, L. A. 
Are primary care services a substitute or 
complement for specialty and inpatient 
services? 
2005 IVA applied to DiD Geographic 
Hay, J.; Jhaveri, M.; Tangirala, M.; 
Kaliner, M. 
Cost and resource utilization 
comparisons of second-generation 
antihistamines vs. montelukast for 
allergic rhinitis treatment 
2009 IVA applied to Fixed 
effects 
Historical 
Chung, S.; Domino, M. E.; 
Stearns, S. C. 
The effect of retirement on weight 2009 Fixed Effects; IVA 
applied to Fixed effects 
Lagged 
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Wagner, T. H.; Jimison, H. B. Computerized health information and the 
demand for medical care 
2003 IVA applied to Fixed 
effects 
Other 
Kawatkar, A. A.; Hay, J. W.; Stohl, 
W.; Nichol, M. B. 
Incremental expenditure of biologic 
disease modifying antirheumatic 
treatment using instrumental variables in 
panel data 
2013 Dynamic panel model 
(IV-GMM) 
Lagged 
Piernas, C.; Ng, S. W.; Mendez, M. 
A.; Gordon-Larsen, P.; Popkin, B. 
M. 
A dynamic panel model of the 
associations of sweetened beverage 
purchases with dietary quality and food-
purchasing patterns 
2015 Dynamic panel model 
(IV-GMM) 
Lagged 
Lei, X.; Lin, W. The new cooperative medical scheme in 
rural China: Does more coverage mean 
more service and better health? 
2009 Fixed effects; IVA; DiD Geographic 
Lin, M. J.; Liu, J. T. Do lower birth weight babies have lower 
grades? Twin fixed effect and 
instrumental variable method evidence 
from Taiwan 
2009 Fixed effects; IVA Geographic 
Schmittdiel, J. A.; Karter, A. J.; 
Dyer, W.; Parker, M.; Uratsu, C.; 
Chan, J.; Duru, O. K. 
The comparative effectiveness of mail 
order pharmacy use vs. local pharmacy 
use on LDL-C control in new statin users 
2011 DiD; IVA Other 
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Basu, A. Estimating Decision-Relevant 
Comparative Effects Using Instrumental 
Variables 
2011 IVA Geographic 
Beck, C. A.; Penrod, J.; Gyorkos, 
T. W.; Shapiro, S.; Pilote, L. 
Does Aggressive Care Following Acute 
Myocardial Infarction Reduce Mortality? 
Analysis with Instrumental Variables to 
Compare Effectiveness in Canadian and 
United States Patient Populations 
2003 IVA Geographic 
Chen, L. F.; Chen, H. P.; Huang, 
Y. S.; Huang, K. Y.; Chou, P.; Lee, 
C. C. 
Pneumococcal Pneumonia and the Risk 
of Stroke: A Population-Based Follow-
Up Study 
2012 IVA Geographic 
Edwards, S. T.; Prentice, J. C.; 
Simon, S. R.; Pizer, S. D. 
Home-Based Primary Care and the risk 
of ambulatory care-sensitive condition 
hospitalization among older veterans 
with diabetes mellitus 
2014 IVA Geographic 
Frances, C. D.; Shlipak, M. G.; 
Noguchi, H.; Heidenreich, P. A.; 
McClellan, M. 
Does physician specialty affect the 
survival of elderly patients with 
myocardial infarction? 
2000 IVA Geographic 
Goldman, D. P.; Bao, Y. Effective HIV treatment and the 
employment of HIV+ adults 
2004 IVA Geographic 
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Gowrisankaran, G.; Town, R. J. Estimating the quality of care in 
hospitals using instrumental variables 
1999 IVA Geographic 
Hirth, R. A.; Grabowski, D. C.; 
Feng, Z.; Rahman, M.; Mor, V. 
Effect of nursing home ownership on 
hospitalization of long-stay residents: An 
instrumental variables approach 
2014 IVA Geographic 
Kahn, J. M.; Werner, R. M.; David, 
G.; Ten Have, T. R.; Benson, N. 
M.; Asch, D. A. 
Effectiveness of long-term acute care 
hospitalization in elderly patients with 
chronic critical illness 
2013 IVA Geographic 
Linden, A.; Adams, J. L. Evaluating disease management 
programme effectiveness: An 
introduction to instrumental variables 
2006 IVA Geographic 
Norton, E. C.; Lindrooth, R. C.; 
Ennett, S. T. 
Controlling for the endogeneity of peer 
substance use on adolescent alcohol 
and tobacco use 
1998 IVA Geographic 
Pilote, L.; Beck, C. A.; Eisenberg, 
M. J.; Humphries, K.; Joseph, L.; 
Penrod, J. R.; Tu, J. V. 
Comparing invasive and noninvasive 
management strategies for acute 
myocardial infarction using 
administrative databases 
2008 IVA Geographic 
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Pracht, E. E.; Tepas, Iii J. J.; 
Celso, B. G.; Langland-Orban, B.; 
Flint, L. 
Survival advantage associated with 
treatment of injury at designated trauma 
centers: A bivariate probit model with 
instrumental variables 
2007 IVA Geographic 
Slade, E. P.; McCarthy, J. F.; 
Valenstein, M.; Visnic, S.; Dixon, L. 
B. 
Cost savings from assertive community 
treatment services in an era of declining 
psychiatric inpatient use 
2013 IVA Geographic 
Tsai, A. C.; Votruba, M.; Bridges, 
J. F. P.; Cebul, R. D. 
Overcoming bias in estimating the 
volume-outcome relationship 
2006 IVA Geographic 
Wehby, G. L.; Ullrich, F.; Xie, Y. Very low birth weight hospital volume 
and mortality: An instrumental variables 
approach 
2012 IVA Geographic 
Hadley, J.; Polsky, D.; Mandelblatt, 
J. S.; Mitchell, J. M.; Weeks, J. C.; 
Wang, Q.; Hwang, Y. T. 
An exploratory instrumental variable 
analysis of the outcomes of localized 
breast cancer treatments in a medicare 
population 
2003 IVA Geographic + 
Historical + 
Time 
O'Malley, A. J.; Frank, R. G.; 
Normand, S. L. T. 
Estimating cost-offsets of new 
medications: Use of new antipsychotics 
and mental health costs for 
schizophrenia 
2011 IVA Geographic + 
Time 
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Abrahamowicz, M.; Beauchamp, 
M. E.; Ionescu-Ittu, R.; Delaney, J. 
A. C.; Pilote, L. 
Reducing the variance of the prescribing 
preference-based instrumental variable 
estimates of the treatment effect 
2011 IVA Historical 
An, J.; Nichol, M. B.  Multiple medication adherence and its 
effect on clinical outcomes among 
patients with comorbid type 2 diabetes 
and hypertension 
2013 IVA Historical 
Bekelman, J. E.; Mitra, N.; 
Handorf, E. A.; Uzzo, R. G.; Hahn, 
S. A.; Polsky, D.; Armstrong, K. 
Effectiveness of androgen-deprivation 
therapy and radiotherapy for older men 
with locally advanced prostate cancer 
2015 IVA Historical 
Bhowmik, D.; Aparasu, R. R.; 
Rajan, S. S.; Sherer, J. T.; Ochoa-
Perez, M.; Chen, H. 
Risk of manic switch associated with 
antidepressant therapy in pediatric 
bipolar depression 
2014 IVA Historical 
Brooks, J. M.; Tang, Y.; Chapman, 
C. G.; Cook, E. A.; Chrischilles, E. 
A. 
What is the effect of area size when 
using local area practice style as an 
instrument? 
2013 IVA Historical 
Chuang, C. M.; Chou, Y. J.; Yen, 
M. S.; Chao, K. C.; Twu, N. F.; Wu, 
H. H.; Wen, K. C.; Chen, Y. J.; 
Wang, P. H.; Lai, C. R.; Chou, P. 
The role of secondary cytoreductive 
surgery in patients with recurrent 
epithelial ovarian, tubal, and peritoneal 
cancers: A comparative effectiveness 
analysis 
2012 IVA Historical 
   
 
 259 
De Ridder, A.; De Graeve, D. Can we account for selection bias? A 
comparison between bare metal and 
drug-eluting stents 
2011 IVA Historical 
Fang, G.; Brooks, J. M.; 
Chrischilles, E. A. 
Comparison of instrumental variable 
analysis using a new instrument with risk 
adjustment methods to reduce 
confounding by indication 
2012 IVA Historical 
Figueroa, R.; Harman, J.; Engberg, 
J. 
Use of Claims Data to Examine the 
Impact of Length of Inpatient Psychiatric 
Stay on Readmission Rate 
2004 IVA Historical 
Huesch, M. D. External adjustment sensitivity analysis 
for unmeasured confounding: An 
application to coronary stent outcomes, 
Pennsylvania 2004-2008 
2013 IVA Historical 
Huybrechts, K. F.; Brookhart, M. 
A.; Rothman, K. J.; Silliman, R. A.; 
Gerhard, T.; Crystal, S.; 
Schneeweiss, S. 
Comparison of different approaches to 
confounding adjustment in a study on 
the association of antipsychotic 
medication with mortality in older nursing 
home patients 
2011 IVA Historical 
   
 
 260 
Ionescu-Ittu, R. Treatment effect estimates varied 
depending on the definition of the 
provider prescribing preference-based 
instrumental variables 
2012 IVA Historical 
Kivimaki, M.; Vahtera, J.; Kawachi, 
I.; Ferrie, J. E.; Oksanen, T.; 
Joensuu, M.; Pentti, J.; Salo, P.; 
Elovainio, M.; Virtanen, M. 
Psychosocial work environment as a risk 
factor for absence with a psychiatric 
diagnosis: An instrumental-variables 
analysis 
2010 IVA Historical 
Kramer, A.; Jager, K. J.; Fogarty, 
D. G.; Ravani, P.; Finne, P.; Perez-
Panades, J.; Prutz, K. G.; Arias, 
M.; Heaf, J. G.; Wanner, C.; Stel, 
V. S. 
Association between pre-transplant 
dialysis modality and patient and graft 
survival after kidney transplantation 
2012 IVA Historical 
Kuo, Y. F.; Montie, J. E.; 
Shahinian, V. B. 
Reducing bias in the assessment of 
treatment effectiveness: Androgen 
deprivation therapy for prostate cancer 
2012 IVA Historical 
Lakdawalla, D. N.; Mascarenhas, 
M.; Jena, A. B.; Vanderpuye-Orgle, 
J.; Lavallee, C.; Linthicum, M. T.; 
Snider, J. T. 
Impact of oral nutrition supplements on 
hospital outcomes in pediatric patients 
2014 IVA Historical 
   
 
 261 
MacKenzie, T. A.; Tosteson, T. D.; 
Morden, N. E.; Stukel, T. A.; 
O'Malley, A. J. 
Using instrumental variables to estimate 
a Cox's proportional hazards regression 
subject to additive confounding 
2014 IVA Historical 
Margolis, D. J.; Gupta, J.; Hoffstad, 
O.; Papdopoulos, M.; Glick, H. A.; 
Thom, S. R.; Mitra, N. 
Lack of effectiveness of hyperbaric 
oxygen therapy for the treatment of 
diabetic foot ulcer and the prevention of 
amputation a cohort study 
2013 IVA Historical 
Parmar, A. D.; Sheffield, K. M.; Han, Y.; 
Vargas, G. M.; Guturu, P.; Kuo, Y. F.; 
Goodwin, J. S.; Riall, T. S. 
Evaluating comparative effectiveness 
with observational data: Endoscopic 
ultrasound and survival in pancreatic 
cancer 
2013 IVA Historical 
Pisoni, R. L.; Arrington, C. J.; 
Albert, J. M.; Ethier, J.; Kimata, N.; 
Krishnan, M.; Rayner, H. C.; Saito, 
A.; Sands, J. J.; Saran, R.; 
Gillespie, B.; Wolfe, R. A.; Port, F. 
K. 
Facility Hemodialysis Vascular Access 
Use and Mortality in Countries 
Participating in DOPPS: An Instrumental 
Variable Analysis 
2009 IVA Historical 
Prentice, J. C.; Conlin, P. R.; 
Gellad, W. F.; Edelman, D.; Lee, T. 
A.; Pizer, S. D. 
Capitalizing on prescribing pattern 
variation to compare medications for 
type 2 diabetes 
2014 IVA Historical 
   
 
 262 
Rassen, J. A.; Brookhart, M. A.; 
Glynn, R. J.; Mittleman, M. A.; 
Schneeweiss, S. 
Instrumental variables II: instrumental 
variable application-in 25 variations, the 
physician prescribing preference 
generally was strong and reduced 
covariate imbalance 
2009 IVA Historical 
Rosenthal, M. B.; Li, Z.; 
Robertson, A. D.; Milstein, A. 
Impact of financial incentives for 
prenatal care on birth outcomes and 
spending 
2009 IVA Historical 
Sheffield, K. M.; Riall, T. S.; Han, 
Y.; Kuo, Y. F.; Townsend, C. M., 
Jr.; Goodwin, J. S. 
Association between cholecystectomy 
with vs without intraoperative 
cholangiography and risk of common 
duct injury 
2013 IVA Historical 
Steingrub, J. S.; Lagu, T.; 
Rothberg, M. B.; Nathanson, B. H.; 
Raghunathan, K.; Lindenauer, P. 
K. 
Treatment with neuromuscular blocking 
agents and the risk of in-hospital 
mortality among mechanically ventilated 
patients with severe sepsis 
2014 IVA Historical 
Stukel, Thérèse A; Fisher, Elliott S; 
Wennberg, David E; Alter, David 
A; Gottlieb, Daniel J; Vermeulen, 
Marian J 
Analysis of observational studies in the 
presence of treatment selection bias: 
effects of invasive cardiac management 
on AMI survival using propensity score 
and instrumental variable methods. 
2007 IVA Historical 
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Tagami, T.; Matsui, H.; Horiguchi, 
H.; Fushimi, K.; Yasunaga, H. 
Antithrombin and mortality in severe 
pneumonia patients with sepsis-
associated disseminated intravascular 
coagulation: An observational 
nationwide study 
2014 IVA Historical 
VanDyke, R. D.; McPhail, G. L.; 
Huang, B.; Fenchel, M. C.; Amin, 
R. S.; Carle, A. C.; Chini, B. A.; 
Seid, M. 
Inhaled tobramycin effectively reduces 
FEV1 decline in cystic fibrosis an 
instrumental variables analysis 
2013 IVA Historical 
Wong, K.; Campitelli, M. A.; Stukel, 
T. A.; Kwong, J. C. 
Estimating influenza vaccine 
effectiveness in community-dwelling 
elderly patients using the instrumental 
variable analysis method 
2012 IVA Historical 
Chen, H.; Mehta, S.; Aparasu, R.; 
Patel, A.; Ochoa-Perez, M. 
Comparative effectiveness of 
monotherapy with mood stabilizers 
versus second generation (atypical) 
antipsychotics for the treatment of 
bipolar disorder in children and 
adolescents 
2014 IVA Historical + 
Time 
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Newman, T. B.; Vittinghoff, E.; 
McCulloch, C. E. 
Efficacy of phototherapy for newborns 
with hyperbilirubinemia: a cautionary 
example of an instrumental variable 
analysis 
2012 IVA Historical + 
Time 
Ahern, T. P.; Pedersen, L.; 
Svaerke, C.; Rothman, K. J.; 
Sorensen, H. T.; Lash, T. L. 
The association between vitamin K 
antagonist therapy and site-specific 
cancer incidence estimated by using 
heart valve replacement as an 
instrumental variable 
2011 IVA Lagged 
Cai, B.; Hennessy, S.; Flory, J. H.; 
Sha, D.;Ten Have, T. R.; Small, D. 
S. 
Simulation study of instrumental variable 
approaches with an application to a 
study of the antidiabetic effect of 
bezafibrate 
2012 IVA Lagged 
O'Malley, A. J. Instrumental variable specifications and 
assumptions for longitudinal analysis of 
mental health cost offsets 
2012 IVA Lagged 
Cawley, J.; Meyerhoefer, C. The medical care costs of obesity: An 
instrumental variables approach 
2012 IVA Other 
   
 
 265 
Groenwold, R. H.; Hak, E.; 
Klungel, O. H.; Hoes, A. W. 
Instrumental variables in influenza 
vaccination studies: mission 
impossible?! 
2010 IVA Other 
Kim, D.; Leigh, J. P. Estimating the effects of wages on 
obesity 
2010 IVA Other 
Pirracchio, R.; Sprung, C.; Payen, 
D.; Chevret, S. 
Benefits of ICU admission in critically ill 
patients: whether instrumental variable 
methods or propensity scores should be 
used 
2011 IVA Other 
Selden, T. M.; Hudson, J. L. Access to care and utilization among 
children: Estimating the effects of public 
and private coverage 
2006 IVA Other 
Slade, E. P.; Wissow, L. S.; Davis, 
M.; Abrams, M. T.; Dixon, L. B. 
Medicaid lapses and low-income young 
adults' receipt of outpatient mental 
health care after an inpatient stay 
2014 IVA Other 
Hay, J. W.; Lawler, E.; Yucel, K.; 
Guo, A.; Balzer, T.; Gaziano, J. M.; 
Scranton, R. E. 
Cost impact of diagnostic imaging for 
lower extremity peripheral vascular 
occlusive disease 
2009 IVA PScore 
(historical 
EHRs) 
   
 
 266 
Guo, J.; Konetzka, R. T.; Manning, 
W. G. 
The causal effects of home care use on 
institutional long-term care utilization 
and expenditures 
2015 IVA Randomisation 
Federspiel, J. J.; Stearns, S. C.; 
Sheridan, B. C.; Kuritzky, J. J.; 
D'Arcy, L. P.; Crespin, D. J.; 
Carey, T. S.; Rossi, J. S. 
Evaluating the effectiveness of a rapidly 
adopted cardiovascular technology with 
administrative data: The case of drug-
eluting stents for acute coronary 
syndromes 
2012 IVA Time 
Goyal, N.; Zubizarreta, J. R.; 
Small, D. S.; Lorch, S. A. 
Length of stay and readmission among 
late preterm infants: An instrumental 
variable approach 
2013 IVA Time 
Hollingsworth, J. M.; Norton, E. C.; 
Kaufman, S. R.; Smith, R. M.; Wolf 
Jr, J. S.; Hollenbeck, B. K. 
Medical expulsive therapy versus early 
endoscopic stone removal for acute 
renal colic: An instrumental variable 
analysis 
2013 IVA Time 
Johnston, K. M.; Gustafson, P.; 
Levy, A. R.; Grootendorst, P. 
Use of instrumental variables in the 
analysis of generalized linear models in 
the presence of unmeasured 
confounding with applications to 
epidemiological research 
2008 IVA Time 
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O'Donnell, H. C.; Colman, G.; 
Trachtman, R. A.; Velazco, N.; 
Racine, A. D. 
Impact of newborn follow-up visit timing 
on subsequent ED visits and hospital 
readmissions: AN instrumental variable 
analysis 
2014 IVA Time 
Zeliadt, S. B.; Loggers, E. T.; 
Slatore, C. G.; Au, D. H.; Hebert, 
P. L.; Klein, G. J.; Kessler, L. G.; 
Backhus, L. M. 
Preoperative PET and the reduction of 
unnecessary surgery among newly 
diagnosed lung cancer patients in a 
community setting 
2014 IVA Time 
Brunner, E. J.; Kivimaki, M.; Witte, 
D. R.; Lawlor, D. A.; Davey Smith, 
G.; Cooper, J. A.; Miller, M.; Lowe, 
G. D.; Rumley, A.; Casas, J. P.; 
Shah, T.; Humphries, S. E.; 
Hingorani, A. D.; Marmot, M. G.; 
Timpson, N. J.; Kumari, M. 
Inflammation, insulin resistance, and 
diabetes--Mendelian randomization 
using CRP haplotypes points upstream 
2008 IVA (Mendelian) Mendelian 
Burgess, S.; Thompson, S. G. Avoiding bias from weak instruments in 
mendelian randomization studies 
2011 IVA (Mendelian) Mendelian 
   
 
 268 
Haring, R.; Teumer, A.; Volker, U.; 
Dorr, M.; Nauck, M.; Biffar, R.; 
Volzke, H.; Baumeister, S. E.; 
Wallaschofski, H. 
Mendelian randomization suggests non-
causal associations of testosterone with 
cardiometabolic risk factors and 
mortality 
2013 IVA (Mendelian) Mendelian 
Jokela, M.; Elovainio, M.; 
Keltikangas-Jarvinen, L.; Batty, G. 
D.; Hintsanen, M.; Seppala, I.; 
Kahonen, M.; Viikari, J. S.; 
Raitakari, O. T.; Lehtimaki, T.; 
Kivimaki, M. 
Body mass index and depressive 
symptoms: Instrumental-variables 
regression with genetic risk score 
2012 IVA (Mendelian) Mendelian 
Kivimaki, M.; Magnussen, C. G.; 
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Appendix C – ISAC protocol 
Below is the final accepted version of protocol submitted to ISAC for approval. 
Highlighted text in blue indicates changes that have been made at the request 
of the initial ISAC review. Yellow highlights indicates text that was added since 
the previous version. 
ISAC APPLICATION FORM 
PROTOCOLS FOR RESEARCH USING THE CLINICAL PRACTICE RESEARCH DATALINK (CPRD) 
 
ISAC use only: 
Protocol Number 
Date submitted 
 
............................. 
............................. 
IMPORTANT 
If you have any queries, please contact ISAC Secretariat: 
ISAC@cprd.com 
 
1. Study Title  
Influenza and Pneumococcal Vaccination Effectiveness and an Investigation into Association with 
Cardiovascular Outcomes in the Elderly 
2. Principal Investigator (full name, job title, organisation & e-mail address for correspondence regarding this 
protocol) 
David Melzer 
Professor of Epidemiology and Public Health 
Epidemiology and Public Health Group 
University of Exeter 
Medical School 
Email: D.Melzer@exeter.ac.uk 
 
3. Affiliation (full address) 
University of Exeter 
Medical School 
Barrack Road, Exeter, EX2 5DW  
United Kingdom 
4. Protocol’s Author (if different from the principal investigator) 
PI plus Alessandro Ble, Adam Streeter and William Henley 
5. List of all investigators/collaborators (please list the names, affiliations and e-mail addresses* of all collaborators, 
other than the principal investigator) 
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Alessandro Ble 
Research Fellow in Epidemiology and Public Health 
Epidemiology and Public Health Group 
University of Exeter 
Medical School 
Email: A.Ble@exeter.ac.uk 
 
Kirsty Bowman  
PhD student in Epidemiology and Public Health 
Epidemiology and Public Health Group 
University of Exeter 
Medical School 
Email: khb202@exeter.ac.uk 
 
William Henley 
Professor of Medical Statistics 
Health Statistics Group 
University of Exeter 
Medical School 
Email: W.E.Henley@exeter.ac.uk 
 
Jane Masoli  
NIHR Academic Clinical Fellow & Specialist Registrar in Geriatric Medicine, 
Epidemiology and Public Health Group & Healthcare for Older People, RD&E Hospital, Exeter  
University of Exeter 
Medical School 
Email: J.Masoli@exeter.ac.uk 
 
Ruben Mujica Mota,  
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Senior Lecturer in Economics 
University of Exeter 
Medical School 
Email: E.Mujica-Mota@exeter.ac.uk 
 
Suzanne Richards,  
Senior Lecturer in Primary Care,  
Primary Care Research Group 
University of Exeter 
Medical School 
Email: S.H.Richards@exeter.ac.uk 
 
Adam Streeter 
PhD student in Medical Statistics 
Health Statistics Group 
University of Exeter 
Medical School 
Email: A.J.Streeter@exeter.ac.uk 
 
Jose M. Valderas,  
Professor of Health Services and Policy Research & Academic General Practitioner  
Primary Care Research Group 
University of Exeter 
Medical School 
Email: J.M.Valderas@exeter.ac.uk  
 
Lauren Rogers 
Research fellow in Medical Statistics 
Health Statistics Group 
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University of Exeter 
Medical School 
L.R.Rodgers@exeter.ac.uk 
 
   
 
*Please note that your ISAC application form and protocol must be copied to all e-mail addresses listed above at the time of 
submission of your application to the ISAC mailbox. Failure to do so will result in delays in the processing of your application. 
 
6. Type of Institution (please tick one box below) 
 
Academia  Research Service Provider  Pharmaceutical Industry  
NHS   Government Departments  Others    
 
7. Financial Sponsor of study 
 
Pharmaceutical Industry (please specify)         Academia(please specify)        
Government / NHS (please specify)    NIHR      None    
Other (please specify)           
 
8. Data source  (please tick one box below)      
 
Sponsor has on-line access   Purchase of ad hoc dataset   
Commissioned study    
Other      (please specify)  amended use of 14-135R database 
 
9. Has this protocol been peer reviewed by another Committee? 
 
Yes*    No   Note: sub-study within NIHR School for Public Health Ageing Well 
research programme – programme proposal peer reviewed and approved  
 
* Please state in your protocol the name of the reviewing Committee(s) and provide an outline of the review process 
and outcome. 
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10. Type of Study (please tick all the relevant boxes which apply) 
 
Adverse Drug Reaction/Drug Safety  Drug Use   Disease Epidemiology  
Drug Effectiveness   Pharmacoeconomic          Other    
 
11. This study is intended for: 
 
Publication in peer reviewed journals   Presentation at scientific conference   
Presentation at company/institutional meetings  Other           
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12. Does this protocol also seek access to data held under the CPRD Data Linkage Scheme? 
 
Yes    No   
 
 
13. If you are seeking access to data held under the CPRD Data Linkage Scheme*, please select the 
source(s) of linked data being requested. 
 
 Hospital Episode Statistics                Cancer Registry Data**               
 MINAP                                              ONS Mortality Data    
 Index of Multiple Deprivation/ Townsend Score  
 Mother Baby Link                  Other: (please specify)        
 
* As part of the ISAC review of linkages, the protocol may be shared - in confidence - with a 
representative of the requested linked data set(s) and summary details may be shared - in confidence - 
with the Confidentiality Advisory Group of the Health Research Authority.   
 
**Please note that applicants seeking access to cancer registry data must provide consent for 
publication of their study title and study institution on the UK Cancer Registry website. Please contact 
the CPRD Research Team on +44 (20) 3080 6383 or email kc@cprd.com to discuss this requirement 
further. 
 
 
14. If you are seeking access to data held under the CPRD Data Linkage Scheme, have you already 
discussed your request with a member of the Research team?  
 
Yes    No*   
 
*Please contact the CPRD Research Team on +44 (20) 3080 6383 or email kc@cprd.com to discuss 
your requirements before submitting your application. 
 
Please list below the name of the person/s at the CPRD with whom you have discussed your request. 
 Kendal Chidwick  
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15. If you are seeking access to data held under the CPRD Data Linkage Scheme, please provide the 
following information: 
 
The number of linked datasets requested: 4 
 
A synopsis of the purpose(s) for which the linkages are required:  
We request the CPRD standard data (for the linked subsample), plus HES data to cover 
hospital event outcomes. We also request ONS mortality data as these seem to improve 
ascertainment of death over GP recorded date of death data, at least in the oldest old 
(from our previous work). Permission for MINAP data is also requested, if possible, as the 
study is focussed on CVD outcomes 
 
Is linkage to a local dataset with <1 million patients being requested?  
 
Yes*  No  
 
* If yes, please provide further details: 
            
            
 
16. If you have requested linked data sets, please indicate whether the Principal Investigator or any of 
the collaborators listed in response to question 5 above, have access to any of the linked datasets 
in a patient identifiable form, or associated with a patient index.  
 
Yes*    No   
 
* If yes, please provide further details: 
           
           
 
17. Does this protocol involve requesting any additional information from GPs?  
 
Yes*   No   
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 * Please indicate what will be required:  
Completion of questionnaires by the GP    Yes      No   
Provision of anonymised records (e.g.  hospital discharge summaries)  Yes      No   
Other (please describe)       
 
 Any questionnaire for completion by GPs or other health care professional must be approved by ISAC 
before circulation for completion.   
18. Does this protocol describe a purely observational study using CPRD data (this may include the 
review of anonymised free text)? 
 
Yes*   No**   
 
 * Yes: If you will be using data obtained from the CPRD Group, this study does not require separate 
ethics approval from an NHS Research Ethics Committee. 
** No: You may need to seek separate ethics approval from an NHS Research Ethics Committee for this 
study. The ISAC will provide advice on whether this may be needed. 
 
19. Does this study involve linking to patient identifiable data from other sources? 
 
Yes    No   
 
20. Does this study require contact with patients in order for them to complete a questionnaire? 
 
Yes    No   
 
N.B. Any questionnaire for completion by patients must be approved by ISAC before circulation for 
completion.   
21. Does this study require contact with patients in order to collect a sample? 
 
Yes*   No   
 
* Please state what will be collected         
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22. Experience/expertise available  
 
Please complete the following questions to indicate the experience/expertise available within the team of researchers 
actively involved in the proposed research, including  analysis of data and interpretation of results 
 Previous GPRD/CPRD Studies  Publications using GPRD/CPRD data 
 
None      
1-3       
> 3       
          Yes                              No 
Is statistical expertise available within the research team?      
                           If yes, please outline level of experience    
 
Co-I William Henley is Professor of Medical Statistics with extensive experience in methods, including accounting for 
missing values. Co-I Adam Streeter is a PhD student in Medical Statistics. PI David Melzer has got more than 15 years 
of experience in analysing data from large studies on ageing and from genomic array datasets. 
 
Is experience of handling large data sets (>1 million records)  
available within the research team?           
                           If yes, please outline level of experience    
 
PI David Melzer and Co-I William Hanley have 2-year experience in analysing a 50,000 patient extract of the CPRD 
data. CI Alessandro Ble and CI Adam Streeter have a 1-year experience in working with the CPRD database. DM has 
got more than 15-years’ experience in analysing very large genomic array datasets, including UK Biobank. 
 
 
Is UK primary care experience available within the research team?       
                           If yes, please outline level of experience    
 
Suzanne Richards is Senior Lecturer in Primary Care and Dr Jose Valderas is academic general practitioner and 
Professor of Health Services and Policy Research at the University of Exeter. They will provide extensive inputs on 
primary care issues.     
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23.  References relating to your study 
 
Please list up to 3 references (most relevant) relating to your proposed study. 
Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the 
elderly. Cochrane database Syst Rev. 2010;(2):CD004876. doi:10.1002/14651858.CD004876.pub3.      
 
Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane 
database Syst Rev. 2013;1:CD000422. doi:10.1002/14651858.CD000422.pub3. 
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PROTOCOL CONTENT CHECKLIST 
In order to help ensure that protocols submitted for review contain adequate information for protocol 
evaluation, ISAC have produced instructions on the content of protocols for research using CPRD data. 
These instructions are available on the CPRD website (www.cprd.com/ISAC). All protocols using CPRD data 
which are submitted for review by ISAC must contain information on the areas detailed in the instructions.  
IF you do not feel that a specific area required by ISAC is relevant for your protocol, you will need to justify 
this decision to ISAC.  
 
Applicants must complete the checklist below to confirm that the protocol being submitted includes all the 
areas required by ISAC, or to provide justification where a required area is not considered to be relevant for 
a specific protocol.  Protocols will not be circulated to ISAC for review until the checklist has been completed 
by the applicant.  
 
Please note, your protocol will be returned to you if you do not complete this checklist, or if 
you answer ‘no’ and fail to include justification for the omission of any required area. 
 
 Included in 
protocol? 
 
Required area Yes No If no, reason for 
omission 
Lay Summary (max.200 words)         
Background         
Objective, specific aims and rationale         
Study Type 
Descriptive 
Hypothesis Generating 
Hypothesis Testing 
 
 
 
 
  
 
 
 
 
Hypothesis testing 
Hypothesis testing 
Study Design         
Sample size/power calculation  
(Please provide justification of  
sample size in the protocol) 
        
Study population  
(including estimate of expected number of  
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relevant patients in the CPRD)  
Selection of comparison group(s) or controls         
Exposures, outcomes and covariates 
Exposures are clearly described  
Outcomes are clearly described 
 
 
 
 
 
 
      
      
Use of linked data  
(if applicable) 
        
Data/ Statistical Analysis Plan 
There is plan for addressing confounding  
There is a plan for addressing missing data 
 
 
 
 
 
 
      
please see  
Patient/ user group involvement †         
Limitations of the study design, data sources  
and analytic methods 
        
Plans for disseminating and communicating study 
results 
        
 
† It is expected that many studies will benefit from the involvement of patient or user groups 
in their planning and refinement, and/or in the interpretation of the results and plans for 
further work. This is particularly, but not exclusively true of studies with interests in the 
impact on quality of life.   Please indicate whether or not you intend to engage patients in any 
of the ways mentioned above. 
 
Voluntary registration of ISAC approved studies:  
Epidemiological studies are increasingly being included in registries of research around the world, including 
those primarily set up for clinical trials. To increase awareness amongst researchers of ongoing research, 
ISAC encourages voluntary registration of epidemiological research conducted using MHRA databases. This 
will not replace information on ISAC approved protocols that may be published in its summary minutes or 
annual report. It is for the applicant to determine the most appropriate registry for their study. Please 
inform the ISAC secretariat that you have registered a protocol and provide the location. 
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Lay summary 
Adults aged over 65y are presently targeted in the UK for vaccination against influenza and 
pneumococcal infection. Yet recent studies have suggested a possible additional protective 
effect against major cardiovascular events. Evidence from randomized clinical trials to 
support the policy of vaccination and the effect on cardiovascular outcomes is sparse due to 
the ethical and practical difficulties of recruiting a representative sample of elderly subjects, 
many of who have multiple co-morbidities. Observational data can offer an information-rich 
addition to trial evidence. However analysis of such data is subject to confounding bias, with 
studies into vaccine effectiveness variously failing to control for the effects of unmeasured 
confounding. Therefore evaluation of vaccine effectiveness needs to be robust against the 
effects of unmeasured confounders. Accordingly, the analysis in this study will be validated 
against other analytical methods and the results compared with estimates synthesised from 
existing evidence and current epidemiological data. Pneumococcal pneumonia is a common 
complication of influenza, and both present as respiratory disease, so the effects of both 
vaccines should be considered together.  This project is part of the NIHR School for Public 
Health Research ‘Ageing Well’ research programme and extends work on risk factors and 
prevention of cardiovascular disease in different clinically relevant groups of older patients. 
 
Objectives, Specific Aims and Rationale 
The objective of this project is to estimate the effects of vaccination against Influenza and 
Pneumococcal infection in the elderly (age 65 and over), on:  
a) rates of lower respiratory infection, measured through hospital diagnoses and primary 
care prescribing  
b) major cardiovascular events, to reappraise previous claims of major protective effects.  
 
To provide valid results we will employ and compare two statistical methods, which aim to 
deal with bias and confounding, namely propensity scoring and the prior event rate ratio 
(PERR). In addition to producing estimates of effect, we aim also to understand the nature 
and source of bias present in this observational study context.  
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The elderly population is diverse, and we therefore plan to estimate vaccination effects in 
younger and older groups separately in men and women and in those with different 
burdens of co-morbidity    
 
Background 
The overall objective of the NIHR National School for Public Health Research ‘ageing well’ 
research programme is to help improve the evidence base for prevention and health 
promotion in later life. This CPRD application is focused on General Practitioner (GP) 
delivered influenza and pneumococcal vaccination, which is claimed to have a role in 
cardiovascular prevention in older people.  
Vaccination against influenza viruses and the streptococcus pneumoniae (pneumococcus) 
bacterium is currently recommended in adults aged over 65y and is intended to tackle age-
related incidents of lower respiratory tract infection, of which the most acute form is 
pneumonia. Estimated to be the fifth leading cause of mortality in adults aged over 65y with 
prevalence highest in the very old 344,345, pneumonia is increasingly a cause for 
hospitalisation in the elderly 346. Conversely deaths from influenza are difficult to discern 
without laboratory confirmation, but while morality rates due to influenza per se are 
estimated to be low compared to those from pneumonia 345, the US Centers for Disease 
Control and Prevention recommend vaccination against influenza to reduce the risk of 
complications, such as pneumonia, in the at-risk populations. In the USA, it has been 
estimated that influenza and its complications are responsible on average for 186 000 
excess hospitalisations347 and 132.5 deaths per 100 000 person-years348. 
Reliable estimates of the benefits of vaccination are important for establishing informed 
policies regarding resource allocation and identifying the need for new vaccines and 
prevention strategies. However, there is currently a lack of robust evidence for effectiveness 
of influenza and pneumococcal vaccines in older populations: 
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a) A meta-analysis of studies evaluating the effectiveness of vaccination against 
pneumococcal infection in adults 280 found immunisation to be effective against culture-
confirmed invasive pneumococcal disease, but provided inconclusive results for the 
respiratory disease of pneumonia, by far the most common presentation of infection. The 
effect of routine vaccination to prevent all-cause pneumonia and mortality among the 
elderly, therefore, remains unresolved. 
b) Observational studies evaluating the effectiveness of the influenza vaccine have so far 
largely proved to be unsatisfactory, failing to adequately control for indication bias 349, while 
in the only major randomised controlled trial in the elderly using laboratory-confirmed 
outcomes, those above 70y of age were under-represented 350.   
c) In addition to the intended effect of vaccination, a recent meta-analysis of RCT evidence 
on influenza vaccination312 (n=6735 patients, mean age 67 years) concluded that vaccination 
was associated with a risk reduction of about 35% from major adverse cardiovascular 
events, but recommended further investigation on a larger scale. Furthermore, there is 
some evidence suggesting that pneumococcal vaccination may also be associated with a 
reduced risk of myocardial infarction351 although this has been less consistently found than 
for influenza vaccination352,353.  
Older patients included in clinical trials often tend to be selected according to criteria that 
are more narrowly representative of the general population. In this project we aim to 
estimate ‘real world’ effects of pneumococcal and influenza vaccination in the whole elderly 
population. However, the older population is very diverse, with for example disease-free 67 
year olds having little in common with 85 year olds on medication for three or more major 
conditions. We therefore seek to estimate vaccination effects in defined major sub-groups 
of the older population, based on age, gender and co-morbidity.  
 
Study type 
The study will principally be a hypothesis test of the effectiveness of the pneumococcal and 
influenza vaccines against the respiratory diseases caused by those pathogens targeted for 
immunisation and major cardiovascular outcomes. Based on experience and evidence from 
previous studies, confounding bias presents a major challenge in the analysis of 
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observational data. Therefore the analysis plan includes the comparison of the effects of 
measured confounding against adjustment made for residual confounding. 
 
Study design 
 
This study is designed as a parallel matched cohorts study.  This study involves statistical 
analysis of existing data from GP and linked hospital records for patients aged 65 and over.  
We plan to apply two statistical methods analyses to the data in order to address potential 
confounding, comparing patients who received each vaccination with similar patients who 
did not. We will apply propensity scoring, which seeks to match patients on measures that 
predict the outcomes of interest. We will also use the PERR approach (see statistics section), 
which aims to use the rates of the outcome of interest (e.g. rates for lower respiratory 
infections) before vaccination to correct for prior differences between the case group who 
got vaccinations and a control group who didn’t.  
 
Data/Statistical analysis 
The purpose of this study is to evaluate the true effect of vaccination against influenza and 
pneumococcal infection, and to verify recently reported secondary effects on cardiovascular 
disease. As the data are observational, the best method will be sought to adjust for any 
confounding bias, that is likely to be unmeasured and otherwise retained in the residual of 
any analysis. In doing so, we aim to understand the nature of this bias, and compare the 
contribution from measured and unmeasured sources. This will require comparing the 
different approaches to the analysis, as described below. 
The data will be modelled as survival times from the vaccination date (or equivalent date for 
the controls) to the outcome of interest. Vaccine effectiveness will initially be estimated 
using Cox’s regression – the fundamental model to which adjustment for confounding bias 
will be applied. 
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Propensity scoring 
An important step in the analysis will be to assess the contribution of known confounders 
where they are provided in the data. Vaccination and the outcomes will individually be 
tested for association with covariates and factors identified as potential confounders 
through multivariate modelling. Significant variables will be modelled in a best-fit model of 
vaccination status. This will be used to generate predictions, or propensity scores11. The 
literature on how to apply the propensity score methodology is extensive 212,294,354,355 and 
shall not be repeated here, but the treatment-prediction model generating the scores needs 
to be specified correctly in order to adjust for confounding. Proper adjustment for 
confounding bias is of course contingent on correct specification of all variables associated 
with both treatment and outcome. The treatment effect with adjustment for known 
confounders through the propensity score can then be estimated using Cox’s regression. 
Here we are interested in the marginal effect, rather than any conditional effects, so bias 
due to non-collapsibility of the non-linear regression model will be avoided. 
 
The prior event rate ratio  
Since routinely collected data such as that supplied by CPRD is unlikely to have collected 
information on all confounders relating to any particular study, further methods are 
required to adjust for confounding bias, which would otherwise remain in the residual of 
analysis. 
The Prior Event Rate Ratio (PERR) method does not require identification of individual 
confounders and can be applied to the hazard ratio of vaccine effectiveness from the Cox’s 
regression. This quasi-experimental analytic method requires knowledge of event rates in 
the vaccinated and control patients during a vaccination-free period prior to the period 
under study. The assumption is made that the ratio of outcome events in the vaccinated and 
control groups during the prior period will reflect the combined effect of all identified and 
unidentified confounders related to that outcome. Having estimated the hazard ratio of 
treatment between the two groups in both prior and study periods through Cox’s 
regression, the hazard ratio from the treatment-free prior period is used to adjust the 
hazard ratio of treatment in the study period. Applying PERR to time-to-event data from the 
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Clinical Practice Research Datalink in order to estimate effectiveness of treatment for 
hypertension yielded convincing results that control for confounding bias can be achieved188 
study by Yu et al 246 provided further support for the validity of the method, suggesting that 
the method is robust to deviations from key assumptions. 
The alternative formulation of the PERR method will also be applied. The PERR-ALT method 
differs slightly in that the prior period data is used to adjust the study period within each 
treatment group, before hazard ratio for the treatment is derived. The pairwise adjustment 
of PERR-ALT within each treatment arm could be viewed as analogous to that of the self-
controlled case series method. While the authors of PERR suggest that PERR-ALT is robust to 
interactions between unmeasured confounders and time intervals in the presence of 
relatively large treatment effects, the PERR method itself is computationally more stable 
when the events are rare. The purpose of applying both PERR and PERR-ALT will be to arrive 
at the best unbiased estimate, and in doing so, demonstrate the level of bias that may be 
inherent from the effects of hidden covariates in the PERR treatment of the nonlinear Cox 
model 225. 
The hazard ratio in the treatment-free prior period will be used to gauge the level of 
unmeasured confounding and the results from the PERR-adjusted and PERR-ALT models 
compared to those achieved through propensity score adjusted models (recommended by 
Yu et al) and basic models adjusted for gender and age. The interaction of both vaccine 
statuses will be tested for all outcomes. 
Results from the analysis of cardiovascular outcomes will be reported for clinically 
important sub-groups defined by age-band, gender and beyond a certain level of existing co-
morbidities (i.e: in top 30% of count) : see study population patient subgroups.  
Stata v13 and R will be used in the analysis.  
Missing data would likely comprise longitudinal measurement such as blood pressure or 
weight. Such data would be best imputed deploying the two-fold fully conditional 
specification (FCS) algorithm 356, available in Stata as the twofold, with attention paid to the 
specification in the imputed models of survival time, the outcome of subsequent 
substantive models fitted to the imputed data 357. An assumption of missing-at-random will 
be required for the covariates. The data will be explored to investigate the plausibility of 
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being missing-at-random. For key inferences, sensitivity analysis performed to test 
departures from this assumption. The results from imputed data will be compared to those 
from complete-case analysis to assess the level of bias corrected through imputation and 
whether the magnitude and direction of bias is consistent with prior expectations. 
 
Sensitivity analysis 
It can be argued that first and subsequent myocardial infarctions can differ with respect to 
underlying mechanism and associated treatments.   
We therefore plan the following sensitivity analyses:  
1. We will add terms relating to first or subsequent MI and revascularisation (receipt and 
procedure, from HES data) as a confounder in the propensity score models and the PERR 
proportional hazards models 
2. We will conduct a subgroup analyses excluding those with second and subsequent  MIs 
3. if possible in the full dataset, we will examine those with at least one prior MI  before the 
period of interst, and then model the effect of flu vaccination on subsequent MI incidence  
 
Sample size 
Vaccination effectiveness will be estimated from Cox regression models. Based on estimates 
from the 2012 edition of the Coronary Heart Disease Statistics, from the British Heart 
Foundation, women aged over 84y, a clinically interesting subgroup, experienced of 139 
incidences of acute myocardial infarction (a primary outcome for ischemic heart disease) 
per 100 000 person-years.  As the meta-analysis into studies of influenza vaccination on 
cardiovascular disease found the effect could reduce the risk by about 35%, the power to 
detect a hazard ratio of 0.65 is sought at a power of 0.8 and significance level of 5%. Using 
the Schoenfeld approximation, this would require a sample size of 121 710 patients. If the 
power to detect a hazard ratio of, say, 0.70 were sought, this would increase to 177 550 
patients. 
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The sample size required for the preliminary investigation of intended effect of the 
vaccinations on respiratory conditions is rather less demanding. An estimate of incidence for 
community-acquired pneumonia among adults aged over 65y put the rate at 7.99 per 1000 
person-years from CPRD data. Therefore the probability of survival times ending in such an 
outcome over a three-year study period of the pneumococcal vaccine would be 
approximately 0.024. Results from a meta analysis of studies into the pneumococcal vaccine 
suggested that the risk of pneumococcal pneumonia could be reduced by approximately 
16%. Therefore to detect a hazard ratio of 0.85 at a power of 0.8 and significance level of 5% 
would require 49 530 eligible patients.  
The Melzer group is arranging an institutional CPRD annual academic licence supported by 
the NIHR School for Public Health Research Ageing Well programme funding.  This will 
provide online access to the full  CPRD-Gold database of patients aged 65 and over, with 
linked HES and mortalty data, estimated at 1.6 million patients aged 65 and over. This will 
provide the most robust estimates possible, and given the above minimum sample size 
requirements the full database should afford more than an acceptable level of power.  
Sample size calculations were performed in Stata v.13. 
Data linkage 
While suspected pneumonia cases may be treated with antibiotics prescribed within 
primary care, hospitalisation is a common consequence of pneumonia in the elderly. For this 
reason access to Hospital Episode Statistics (HES) is integral to the study of vaccines against 
respiratory diseases. Analysis will be conducted using antibiotic outcomes in all available 
patients in the cohort. Additionally we will analyse hospitalisations with a pneumonia 
diagnosis, combining these with the primary care antibiotic outcomes into a composite 
outcome among the HES-linked patients only.  
Secondarily we will examine admissions with a cardiovascular disease code.  
Given the advancing age of the cohort, linkage to ONS-sourced death dates is required to 
ensure a reliable record of death. 
Study population 
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The policy of routine immunisation against influenza and pneumococcus was originally 
extended to adults aged over 65y in 2000 and 2003, respectively. Immunisation against 
influenza is recommended every year, primarily due to the evolution of the influenza 
viruses, while that against pneumococcus is officially regarded as conferring lifetime 
immunity. Monitoring by the Health Protection Agency/ Public Health England shows that 
coverage for pneumococcal vaccination has risen from a baseline of below 30% before 2003 
to the current level of 69.1% in England, while that for influenza has witnessed an increase 
from 46% in 1999 to current levels between 71% and 75%. 
We would therefore use an extracted dataset of adults who have reached the age of 65y 
since the year 1997. The timing is especially critical for analysis of the pneumococcal 
vaccine, whose effect is accepted as lifelong. Given the post-millennial increase in vaccine 
coverage, data from the period preceding the policy change is needed to deliver estimates 
from a vaccine-free period for a sufficient number of yet-to-be-vaccinated elderly 
individuals.  Analysis of this treatment-free period prior to intervention is necessary to 
evaluate the level of confounding bias between two treatment groups (see figure 1 in 
Appendix B). Integral to the PERR method, explained in the Data/Statistical Methods 
section, the treatment estimate from this prior period is used to account for unmeasured 
confounding. Adults aged at least 65y at the start of the study would subsequently be 
recruited from the extracted data to the cohort for the study period of interest. Further 
inclusion criteria for each cohort are that the subjects should be continually registered at 
their GP practice for the duration of the study and prior periods.  
In making a quasi-experimental comparison with a prior period, the principal method for 
our analysis is only applicable to recurrent events in that these should be possible in both 
the study and prior periods. Death, particularly from the diseases subjected to vaccination, 
is of interest and shall be investigated with regard to how much imbalance might be created 
between the analyses of the prior and study periods. Since individuals need to have survived 
into the study period, sampling from the extracted data should of course exclude deaths in 
the prior period. 
Another consequence of the lifelong effect of the pneumococcal vaccination is that over 
time the increasing coverage since 2003 effectively reduces the pool of non-vaccinees from 
which to recruit controls. Using the pilot data, we calculated that a study period of three 
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years would optimise the size of the recruited sample without reducing the ratio of controls 
to vaccinees to below unity. The responses in the three-year treatment-free prior period, 
preceding the study period would control for bias, subject to the assumptions required for 
the PERR method, outlined in the Statistical Analysis section. To study the effectiveness of 
the influenza vaccine, the study and prior period will be restricted to one year, covering 
each influenza season. 
The sample size calculations dictate that a cohort size of at least 50 000 adults aged over 
65y would be required for the necessary preliminary investigation into vaccine effectiveness 
against intended respiratory outcomes. However to answer the principle research question 
looking at effectiveness against cardiovascular events, we would foresee a full extraction to 
the maximum permissible size of 300K would be justified to allow annual estimates of 
specific sub-groups to be reported with sufficient power. 
 
Patient subgroups:  
 
Sub-group analysis will be restricted to a pre-specified hypothesis. Age and gender are 
commonly considered to be essential variables for sub-group analysis. Consistent with the 
School for Public Health Ageing Well programme, a fundamental comparison of two age 
groups per gender will carried out through a simple sub-group analysis of two age bands (65 
to 84y and 85+y) for each gender, the null hypothesis being that the response is the same in 
the “oldest old” as it is for less-elderly patients in either gender. 
 
Another major aim of the programme is to determine the risk from the level of pre-existing 
co-morbidities at the time of exposure. We plan to compute a simple count of diseases and 
syndromes and analyse as a sub-group those patients in the top 30% of the count in each 
gender. The results will be compared with those of all patients in the study within each 
respective gender group. At the time of writing the conditions and syndromes to be counted 
are those based on our previous work on diagnostic trends in the oldest old (Melzer et al, 
Age and Ageing 2014), which are:  
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Hypertension, atrial fibrillation, CVD, heart failure, stroke, cancer, chronic kidney disease 
(stages 3-5) asthma, COD, Dementia, Depression, major mental conditions, epilepsy, 
diabetes, hypothyroidism, anaemia, osteoarthritis and osteoporosis. Five geriatric 
syndromes were identified from Read codes for dizziness (including vertigo and syncope), 
incontinence (urinary and faecal), skin ulcers (including bed sores), falls and fractures. 
It should be stressed that consistent with Bland (1995) that only a count of these conditions 
will be used as comorbidity index, rather than individual sub-groups and so are not subject 
to the type 1 errors of multiple testing. 
NHS England has supported the development of a similar measure of frailty to be used in 
electronic clinical records (http://www.hsj.co.uk/resource-centre/supplements/primary-
care-supplement-an-index-of-frailty/5065467.article#.U-OFqvldV8E), based on 
approximately 3000 Read codes, in the TPP system. Publication of the code list and 
validation studies is expected shortly (Dr A P Clegg, Clinical Senior Lecturer & Honorary 
Consultant Geriatrician | Academic Unit of Elderly Care and Rehabilitation | Bradford 
Institute for Health Research, private communication). We also plan to apply this approach 
in a sensitivity analysis, if the validation is convincing. 
 
Selection of controls 
Observation time in the treated group will begin with the date of exposure so that immortal 
time bias, though commonly associated with cohort studies, will not be an issue for this 
study. Furthermore the vaccination date will lag by the period required to establish a full 
immune response following vaccination. Consideration will also be given to the lag between 
the date, by which symptoms are presented, and the probable time of infection. 
The start of the study period, or index date, will depend on the vaccination under study. For 
influenza vaccine, this will be from the 1st September of each year, to coincide with the start 
of the season, during which vaccination typically occurs. For the pneumococcal vaccine, 
there is one single study period beginning on 1st September 2002 for a duration that 
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encompasses the increase in vaccination coverage arising from the implementation of the 
immunisation policy. 
Patients that remain unexposed to the vaccine throughout the study period will be matched 
as controls by age, gender and GP practice to the vaccinees from the same period. 
Observation times in the controls will start from the vaccination dates of the treated 
patients, with whom they are matched, rather than begin at the start date of the study 
period. Mapping treatment dates through matched individuals will avoid further bias if the 
outcome exhibits strong periodicity, for example with seasons, within the follow-up period. 
Both controls and vaccinees shall have a treatment-free period, necessary for the quasi-
experimental adjustment for confounding bias. The duration should be equal to the period 
over which the patients were recruited for the study and conclude with the start of the 
study period. In the prior period, each patient’s observation period starts at the date 
relative to the start date of the prior period mapped from the study period relative to the 
index date. 
Exposures, outcomes and covariates 
Exposure 
Vaccination status is recorded on the date of vaccination (eventdate) and coded (medcode) 
in the Immunisation file (see Appendix). 
Outcomes 
The outcomes of interest for the effect on major cardiovascular events will be incident 
cardiovascular disease, comprising incident stroke, myocardial infarction, coronary artery 
bypass graft and percutaneous transluminal coronary angioplasty, recorded in Hospital HES 
data. Coding approaches to classifying these are set out in the Appendix and are based on 
QoF business rules.  
Acute lower respiratory disease is the most common presentation of infection by either 
pneumococcus bacteria or the influenza viruses. In the absence of routine laboratory tests 
for both conditions, investigators must rely on correct diagnosis and the subsequent 
accurate recording in the clinical database. Antibiotic prescriptions are commonly 
prescribed to treat patients presenting with LRTIs and recommended by clinical guidelines 
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for the more acute form, pneumococcal pneumonia. Both diseases are common 
complications of infection by the influenza viruses. Where pneumococcal pneumonia is 
strongly suspected, then cases are frequently hospitalised290. Accordingly, hospitalisations 
for pneumonia have previously been used as an outcome, but the effect on prescribing rates 
for antibiotics in primary care should also be taken into account. Therefore besides 
independent evaluations of both outcomes, a composite comprising both outcomes will be 
analysed. A composite endpoint will be the first occurrence, since the start of the survival 
time, of either an antibiotic prescription for a respiratory infection in general practice, or a 
pneumonia related hospitalisation in HES, whichever occurs first. 
We will include antibiotics identified as appropriate in the British Thoracic Society guidelines 
on community acquired respiratory infections. We will identify product codes found in the 
CPRD Therapy file corresponding to the formulations given in the British National Formulary. 
The identified cases of antibiotic prescriptions will be further qualified by symptoms for LRTI 
as described by the corresponding codes (medcodes) from the Clinical file. Two clinicians will 
independently identify these. A third clinician will arbitrate any discordance between the 
two.  
Hospitalisation as recorded in the HES files, for HES-linked patients only, will be qualified by 
the primary reason for episodes as denoted by the ICD10 code (see Annex for codes). 
Covariates 
Matching for the purpose of mapping observation start times to controls will be based on 
variables, age, gender and GP practice as recorded in the patient files. 
Covariates and factors identified a priori as potential confounders may be included as 
adjustments to the analysis following the procedure for selection, detailed in the 
Data/Statistical Analysis section below. Besides basic demographic variables of age, gender 
and socio-economic status, confounders will be identified from the 15 diseases listed under 
the Quality Outcomes Framework of 2010. Read codes for each disorder have already been 
obtained through interrogation of the CPRD and HES data using version 18 of the QOF 
Business Rules, along with a summary of existing useable codes for each disorder (Salisbury 
2013). Consensus within the Age UK Project team at the University of Exeter Medical School 
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decided which QOF disease areas were included and which were not pertinent to a definite 
diagnosis. The final disease categories were: coronary heart disease, heart failure, stroke 
and transient ischaemic attack, hypertension, diabetes, chronic obstructive pulmonary 
disorder (COPD), epilepsy, hypothyroidism, cancer, mental health (includes schizophrenia, 
bipolar affective disorder and other psychoses), asthma, dementia, depression, chronic 
kidney disease (CKD), and atrial fibrillation. Smoking history will also be elicited from the 
records and treated as a potential confounder.  
Informed by the work from the “Estimating Cardiovascular Risk in the Elderly” study within 
the same project team, further confounders will be considered for analysis of cardiovascular 
events. These will include treatments for existing cardiovascular risk factors: cholesterol-
lowering drugs, anti-hypertensive drugs, anti-diabetic drugs, anti-platelets, oral anti-
coagulants, beta blockers, calcium antagonists, diuretics, angiotensin-converting enzyme 
inhibitors, angiotensin II antagonists, nitrates. 
Where data permits body mass index, alcohol consumption and total cholesterol / 
hypercholesterolemia diagnosis including low-density and high-density lipids will also be 
considered. 
For the cardiovascular disease models, we will summarise several of the above covariates by 
computing and adjusting for a cardiovascular risk score following the approach set out by 
van Staa et al (PLoS One. 2014 Oct 1;9(10):e106455.). We intend to use the QRISK2 
approach, but if costs for the necessary commercial software make it impractical we will use 
the Framingham model.    
We will also account for first vs subsequent MI, and for surgical intervention (percutaneous 
vs CABG vs none) in models and in the sensitivity analyses.  
Direct measures of comorbidity or frailty will also be potentially included, from our recent 
work on diagnostic trends in the oldest old (Accepted Age and Ageing 2014), which 
modestly extends a previous multi-morbidity measure by Salisbury et al to be a little more 
representative of later life co-morbidity. These are based on a count of common diseases 
and conditions as well as “geriatric syndromes” such as falls and fractures, dizziness, 
incontinence and skin ulcers. The “Estimating Cardiovascular Risk in the Elderly” study will 
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also aim to elicit information about family history of cardiovascular disease, although limited 
recording of this is acknowledged. 
Patient or user group involvement 
This project is part of the NIHR School for Public health Research programme on ‘Ageing 
Well’. In this framework, advancement of the work, partial and final results will be regularly 
shared and discussed in the context of advisory boards/meetings involving general 
practitioners, leaders from the academics, policy makers, and representatives from relevant 
patient and aging-related lobbying associations.  
We anticipate widespread interest in the results, as there have been many papers and 
editorials in the journals pointing out the difficulties of prevention and treatment in various 
older groups in the absence of evidence of effectiveness.  
We plan to publish in the public health, geriatrics and primary care journals and present at 
related conferences.  
    
Limitations of the study design, data sources, and analytic methods 
A fundamental limitation is that the original source of data is a database that was not 
originally created for research purposes. This is important, as characteristics that might 
allow post-hoc adjustment for non-randomised data are likely to have been unmeasured in 
routinely collected data. Here effects that are confounded with the intervention under 
study and the outcome are likely to give rise to biased estimates. However the purpose of 
this study is to deploy methods that can adjust for confounding, regardless of whether it has 
been measured. This includes all types of confounding, such as indication bias where, say, a 
history of CV disease has prompted vaccination. The method will not mitigate against that 
bias which, sometimes misleadingly described as confounding bias, has been imparted by 
the analytical method itself e.g: non-collapsibility when estimating conditional effects in 
non-linear models.  
A second limitation is in the absence of widespread serological testing, the available 
outcomes to identify pneumococcal and influenza infections may be insensitive to other 
pathological causes, although we believe antibiotic prescriptions and, in the case of 
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pneumococcal pneumonia, hospitalisations, both qualified by symptom descriptions, offer 
the next best alternative.  
Another important limitation is that PERR is only applicable to recurrent outcomes (such as 
angina or myocardial infarction) and only in secondary prevention settings. A consequence 
of this stipulation is that patients must be alive until the study period and death may impart 
further bias if used an outcome in the study period, or may be informative if used to censor 
survival times.  Other quasi-experimental study designs, including instrumental variable 
estimation or marginal structural models, that are useful in primary prevention are 
sometimes difficult to be implemented in certain circumstances, such as in the analysis of 
survival times. In spite of the Yu’s evidence of robustness to time and confounder 
interaction, an intrinsic assumption of the method is that the confounding effect is stable 
across the periods, for which it is adjusted. It should also be acknowledged from Yu’s paper 
that current insight into the method suggests. 
 
Plans for disseminating and communicating study results 
We plan to publish the results of the effectiveness analyses for the influenza and 
pneumococcal vaccines against their primary respiratory outcomes as well as the issue of 
their effectiveness against major cardiovascular outcomes.  In addition, we plan to publish 
academic articles on the development and extension of the quasi-experimental analytical 
methods used to address confounding bias.  We believe the results will be informative for 
shaping policy on vaccination in older patients, and that the methodological work will help 
validate and make available new tools to assist researchers in strengthening causal 
inferences from electronic medical record data. 
 
Other information: 
The University of Exeter based part of the NIHR National School for Public Health Research 
programme is led by Prof Melzer, who has extensive experience of analysing observational 
data on older populations, including large databases. Professor William Henley will oversee 
the statistics: he currently leads an MRC methodology project grant on the Prior Event Rate 
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Ratio approach. Adam Streeter is an experienced statistician, who will be leading the analyses 
of the vaccination data, and will also be writing this up for a PhD.  
Dr Alessandro Ble is a qualified geriatrician with extensive (>40 papers) experience in 
epidemiology of ageing. He has a Masters degree in medicines evaluation. Dr Jane Masoli is 
an academic clinical fellow in Geriatrics and will be leading work on the anti-hypertensives. 
Kirsty Bowman (MPH, PhD student) will be undertaking the modelling of risk factors in older 
people.  Dr Mujica-Mota is a health economist with an interest in older populations, and has 
experience of analysing the GP Patient Survey with over 1m records.   
Primary Care senior input will be from Professor Valderas (who has extensive related research 
experience especially on co-morbidity, plus clinical sessions in general practice) and Senior 
lecturer Dr Sue Richards.  
Our existing CPRD analysis over the last two years has provided coding approaches to the risk 
factors, common diseases and geriatric syndromes of interest, with a paper on diagnostic 
trends in the oldest old accepted by the journal “Age and Ageing”. We have also gained 
experience on the coding of common prescriptions in older people. We have an 8 Terabyte 
server capable of supporting our planned analyses and extensive experience of large dataset 
analysis.  
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ISAC protocol - Appendix A 
Pneumococcal vaccination coding in Clinical file 
medcode: 11363, 30411, 36826 
immstype: 13, 18, 28 
status: 1 
Pneumococcal vaccination coding in Therapy file 
prodcode: 821832, 42612, 42991 
Influenza vaccination coding in Clinical file 
medcode: 6 9039 10821 12104 12336 18330 18684 21123
 32942 
35655 44555 94301 95092 97941 98047 98183 98184 98217
 98234 
98302 98303 98306 98449 
immstype: 4 
status: 1 
Influenza vaccination coding in Therapy file 
prodcode: 398 639 834 922 1329 2139 2552 2601 9710 
10030 11824 13595 16585 18612 27407 30156 30198 32391
 38421 
40760 40876 
Coding of selected commonly used antibiotics for respiratory infections ( list 
to be extended following British Thoracic society guidelines)  
Amoxicillin product codes from Therapy file: 
9 48 62 133 427 503 585 847 870 
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1637 1722 1812 2153 2281 3669 3742 4154 7737
 9243 
11613 11634 12378 14371 14386 14396 14407 15148 17711
 18786 
21799 21827 21829 21844 21845 21963 22015 22016 22017
 22415 
22438 23238 23740 23967 24150 24200 24203 25484 26157
 26262  
27714 27725 28870 28872 28875 28882 29337 29463 29697
 29858  
30498 30528 30743 30745 31014 31286 31423 31535 31661
 31801  
32622 32640 32872 33109 33110 33112 33165 33222 33343
 33570  
33689 33690 33692 33696 33699 33706 34001 34042 34232
 34384  
34435 34638 34679 34714 34760 34775 34852 34855 34857
 34885  
34912 35570 36054 37755 38684 40238 40243 41090 41818
 41835 
 
Doxycycline product codes from Therapy file: 
264 268 970 1046 2202  2884 3152 6396 8724 9267 
10454 12987 14904 15071 21038 21828 21860 21878 23405
 23432 
23819 24126 24149 26392 26747 30739 32066 32419 33671
 34175 
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34300 34423 34594 34765 40391 41560 41605 46807 
 
ICD-10 codes describing pneumonia in HES data: 
Description Code 
Sepsis due to Streptococcus pneumoniae A40.3 
Streptococcus pneumoniae as the cause of diseases classified 
to other chapters 
B95.3 
Pneumococcal meningitis G00.1 
Pneumonia due to Streptococcus pneumoniae J13 
Pneumonia, organism unspecified J18 
 
Coding of covariates: we plan to use the same coding approaches as in our approved 
project 14_135R entitled " Estimating Cardiovascular risk in the Elderly." Below are the 
Read codes for coronary heart disease, for assessing the presence of disease in GP 
records. This will be used for patient selection but outcomes will be based on hospital 
HES records only and will include major CVD events.  
Coronary heart disease (MI)  
MEDCODE READCODE CONDITION 
240 G3...00 Ischaemic heart disease 
241 G30..00 Acute myocardial infarction 
1204 G30..14 Heart attack 
1344 G340.12 Coronary artery disease 
1655 G340.11 Triple vessel disease of the heart 
1676 G3z..00 Ischaemic heart disease NOS 
1677 G30..15 MI - acute myocardial infarction 
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1678 G308.00 Inferior myocardial infarction NOS 
1792 G3...13 IHD - Ischaemic heart disease 
2491 G30..12 Coronary thrombosis 
3704 G307.00 Acute subendocardial infarction 
3999 G340000 Single coronary vessel disease 
4017 G32..00 Old myocardial infarction 
5254 G340100 Double coronary vessel disease 
5387 G301.00 Other specified anterior myocardial infarction 
5413 G340.00 Coronary atherosclerosis 
7320 G343.00 Ischaemic cardiomyopathy 
8935 G302.00 Acute inferolateral infarction 
9276 G31y000 Acute coronary insufficiency 
9413 G31y.00 Other acute and subacute ischaemic heart disease 
9507 G307000 Acute non-Q wave infarction 
9555 G33z500 Post infarct angina 
10562 G307100 
Acute non-ST segment elevation myocardial 
infarction 
11983 G311500 Acute coronary syndrome 
12139 G300.00 Acute anterolateral infarction 
12229 G30X000 Acute ST segment elevation myocardial infarction 
13566 G30..11 Attack - heart 
13571 G30..16 Thrombosis - coronary 
14658 G30z.00 Acute myocardial infarction NOS 
14897 G301z00 Anterior myocardial infarction NOS 
14898 G305.00 Lateral myocardial infarction NOS 
15661 G310.11 Dressler's syndrome 
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15754 G34z.00 Other chronic ischaemic heart disease NOS 
16408 G32..11 Healed myocardial infarction 
17464 G32..12 Personal history of myocardial infarction 
17689 G30..17 Silent myocardial infarction 
17872 G301100 Acute anteroseptal infarction 
18842 G35..00 Subsequent myocardial infarction 
18889 G34z000 Asymptomatic coronary heart disease 
21844 G31y300 Transient myocardial ischaemia 
22383 G3y..00 Other specified ischaemic heart disease 
23078 G34y100 Chronic myocardial ischaemia 
23579 G310.00 Postmyocardial infarction syndrome 
23708 G361.00 
Atrial septal defect/curr comp folow acut myocardal 
infarct 
23892 G304.00 Posterior myocardial infarction NOS 
24126 G360.00 
Haemopericardium/current comp folow acut 
myocard infarct 
24540 G34y000 Chronic coronary insufficiency 
24783 G3...11 Arteriosclerotic heart disease 
25842 G33z.00 Angina pectoris NOS 
26863 G33z600 New onset angina 
27951 G31..00 Other acute and subacute ischaemic heart disease 
27977 G31yz00 
Other acute and subacute ischaemic heart disease 
NOS 
28138 G34..00 Other chronic ischaemic heart disease 
28554 G33zz00 Angina pectoris NOS 
28736 G30y000 Acute atrial infarction 
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29421 G344.00 Silent myocardial ischaemia 
29553 G366.00 
Thrombosis atrium,auric append&vent/curr comp foll 
acute MI 
29643 G303.00 Acute inferoposterior infarction 
29758 G30X.00 
Acute transmural myocardial infarction of unspecif 
site 
29902 G330z00 Angina decubitus NOS 
30330 G309.00 Acute Q-wave infarct 
30421 G30..13 Cardiac rupture following myocardial infarction (MI) 
32272 G38..00 Postoperative myocardial infarction 
32450 G33z400 Ischaemic chest pain 
32854 G30B.00 Acute posterolateral myocardial infarction 
34328 G311300 Refractory angina 
34633 G34y.00 Other specified chronic ischaemic heart disease 
34803 G30y.00 Other acute myocardial infarction 
35713 G34yz00 Other specified chronic ischaemic heart disease NOS 
36423 G36..00 
Certain current complication follow acute myocardial 
infarct 
36523 G311.00 Preinfarction syndrome 
36609 G342.00 Atherosclerotic cardiovascular disease 
37657 G362.00 
Ventric septal defect/curr comp fol acut myocardal 
infarctn 
38609 G351.00 Subsequent myocardial infarction of inferior wall 
39449 G312.00 
Coronary thrombosis not resulting in myocardial 
infarction 
39546 Gyu3000 [X]Other forms of angina pectoris 
39655 G311.12 Impending infarction 
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39693 G31y200 Subendocardial ischaemia 
40429 G301000 Acute anteroapical infarction 
41221 G30y200 Acute septal infarction 
41835 G384.00 Postoperative subendocardial myocardial infarction 
45809 G350.00 Subsequent myocardial infarction of anterior wall 
46017 G30yz00 Other acute myocardial infarction NOS 
46112 G380.00 
Postoperative transmural myocardial infarction 
anterior wall 
46166 G35X.00 Subsequent myocardial infarction of unspecified site 
46276 G381.00 
Postoperative transmural myocardial infarction 
inferior wall 
47637 Gyu3300 [X]Other forms of chronic ischaemic heart disease 
52517 Gyu3.00 [X]Ischaemic heart diseases 
54251 G311z00 Preinfarction syndrome NOS 
54535 G33z100 Stenocardia 
55137 G311011 MI - myocardial infarction aborted 
59189 G363.00 
Ruptur cardiac wall w'out haemopericard/cur comp 
fol ac MI 
59940 G364.00 
Ruptur chordae tendinae/curr comp fol acute 
myocard infarct 
61072 G311000 Myocardial infarction aborted 
62626 G30y100 Acute papillary muscle infarction 
63467 G306.00 True posterior myocardial infarction 
66388 G33z000 Status anginosus 
68357 G31y100 Microinfarction of heart 
68401 Gyu3200 [X]Other forms of acute ischaemic heart disease 
68748 G38z.00 Postoperative myocardial infarction, unspecified 
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69474 G365.00 
Rupture papillary muscle/curr comp fol acute 
myocard infarct 
72562 G353.00 Subsequent myocardial infarction of other sites 
96838 Gyu3400 
[X]Acute transmural myocardial infarction of unspecif 
site 
99991 Gyu3600 
[X]Subsequent myocardial infarction of unspecified 
site 
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ISAC protocol - Appendix B 
 
 
Figure 1: Timeline of prior and study observation periods for the PERR method 
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group 
Pre-exposure period 
No exposure 
Prior event
Study event
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Appendix D – CPRD and HES codes 
PPV codes (immstype) in immunisation file: 
13, 28 
[both codes conditioned on status = 1, i.e: vaccine “given”] 
 
PPV codes (prodcode) in therapy file: 
821, 832, 42612, 42991 
 
Influenza vaccine codes in immunisation file: 
6, 9039, 10821, 12104, 12336, 18330, 18684, 21123, 32942, 35655, 44555, 94301, 
95092, 97941, 98047, 98183, 98184, 98217, 98234, 98302, 98303, 98306, 98449 
 
Influenza vaccine codes in therapy file: 
398, 639, 834, 922, 1329, 2139, 2552, 2601, 9710, 10030, 11824, 13595, 16585, 
18612, 27407, 30156, 30198, 32391, 38421, 40760, 40876 
 
ICD10 codes for hospitalisation for suspected pneumococcal pneumonia in 
HES data: 
J13, J15.8, J15.9, J16.8, J17, J18 
ICD10 codes for myocardial infarction admissions to hospital in HES data: 
I20.0, I21.0 - I21.4, I21.9, I22.0, I22.1, I22.8, I22.9, I21 
Amoxicillin codes in therapy file: 
9, 48, 62, 133, 427, 503, 585, 847, 870,  1637, 1722, 1812, 2153, 2281, 3669, 3742, 
4154, 7737, 9243,  11613, 11634, 12378, 14371, 14386, 14396, 14407, 15148, 
17711, 18786,  21799, 21827, 21829, 21844, 21845, 21963, 22015, 22016, 22017, 
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22415,  22438, 23238, 23740, 23967, 24150, 24200, 24203, 25484, 26157, 26262,  
27714, 27725, 28870, 28872, 28875, 28882, 29337, 29463, 29697, 29858,  30498, 
30528, 30743, 30745, 31014, 31286, 31423, 31535, 31661, 31801,  32622, 32640, 
32872, 33109, 33110, 33112, 33165, 33222, 33343, 33570,  33689, 33690, 33692, 
33696, 33699, 33706, 34001, 34042, 34232, 34384,  34435, 34638, 34679, 34714, 
34760, 34775, 34852, 34855, 34857, 34885,  34912, 35570, 36054, 37755, 38684, 
40238, 40243, 41090, 41818, 41835 
 
Doxycycline codes in therapy file: 
264, 268, 970, 1046, 2202, 2884, 3152, 6396, 8724, 9267, 10454, 12987, 14904, 
15071, 21038, 21828, 21860, 21878, 23405, 23432, 23819, 24126, 24149, 26392, 
26747, 30739, 32066, 32419, 33671, 34175, 34300, 34423, 34594, 34765, 40391, 
41560, 41605, 46807 
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Product codes in therapy file for antiviral drugs: 
BNF code CPRD 
prodcode 
strength 
Amantadine 
hydrochloride 
5339 100mg 
Amantadine 
hydrochloride 
6035 50mg/5ml 
Zanamivir 6610 5mg 
Oseltamivir phosphate 10129 75mg 
Oseltamivir phosphate 10131 75mg 
Oseltamivir phosphate 10137 12mg/1ml 
Oseltamivir phosphate 18863 60mg/5ml 
Zanamivir 21169 5mg 
Amantadine 
hydrochloride 
21745 50mg/5ml 
Amantadine 
hydrochloride 
25890 100mg 
Oseltamivir phosphate 38523 30mg 
Oseltamivir phosphate 38955 30mg 
Oseltamivir Phosphate 39252 45mg 
Oseltamivir phosphate 39894 45mg 
Oseltamivir phosphate 40710 15mg/1ml 
Oseltamivir phosphate 42326 15mg/1ml 
Oseltamivir phosphate 52526 15mg/1ml 
Oseltamivir phosphate 53759 6mg/1ml 
Oseltamivir phosphate 54814 30mg/5ml 
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Medcodes from clinical file for symptom descriptions used to qualify antibiotic 
codes: 
Medcode Description 
293 Respiratory tract infection 
4899 Recurrent chest infection 
68 Chest infection 
2581 Chest infection NOS 
3358 Lower resp tract infection 
5534 Pneumococcal infection 
7074 Respiratory infection NOS 
8025 Acute respiratory infections 
14804 Sputum appears infected 
16287 Chest infection - unspecified bronchopneumonia 
17359 Chest infection - unspecified bronchitis 
19400 Chest infection - pnemonia due to unspecified organism 
21061 Chronic obstruct pulmonary dis with acute lower resp infectn 
21113 Acute respiratory infection NOS 
22795 Chest infection - other bacterial pneumonia 
23640 Other specified acute respiratory infections 
3382 Streptococcal infection 
572 Pneumonia due to unspecified organism 
886 Bronchopneumonia due to unspecified organism 
1849 Lobar (pneumococcal) pneumonia 
3683 Basal pneumonia due to unspecified organism 
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9639 Lobar pneumonia due to unspecified organism 
10086 Pneumonia and influenza 
11849 Other specified pneumonia or influenza 
12423 Pneumonia due to streptococcus 
13573 Influenza with bronchopneumonia 
22009 Streptococ pneumon/cause/disease classified/oth chapters 
23095 Bacterial pneumonia NOS 
25694 Pneumonia due to other specified organisms 
23333 Hypostatic pneumonia 
24356 Hypostatic bronchopneumonia 
1934 Laryngotracheobronchitis 
1019 Acute bronchiolitis 
17185 Acute bronchiolitis with bronchospasm 
17917 Acute bronchiolitis NOS 
29669 Acute bronchitis and bronchiolitis 
41137 Acute bronchitis or bronchiolitis NOS 
2195 Bronchiectasis 
20364 Recurrent bronchiectasis 
1234 Productive cough NOS 
7708 Productive cough-yellow sputum 
7773 Productive cough -green sputum 
18907 Cough with fever 
8760 [D]Positive culture findings in sputum 
15430 [D]Sputum abnormal - colour 
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16026 Sputum examination: abnormal 
24181 Sputum: mucopurulent 
30754 Yellow sputum 
36880 Green sputum 
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Appendix E – Diagnostic plots for Cox models in influenza 
study 
As a visual inspection of the extent to which the Cox models of MIs fitted to 
vaccination status, adjusting for age and gender, may have deviated from the 
proportional hazards assumption, the negative logarithm of the hazard function (also 
expressed as -ln(-ln(Survival probability)) in the plots) was plotted against the natural 
logarithm of analysis time in Stata – so-called log-log plots. The nature of 
transformation meant the most data points lay to the right end of the x-axis 
corresponding to the majority of survival times, which were greater than about 50 
days (ln(50)  4). Apart from the sparse points in the plots corresponding to the 
shorter survival times, the bulk of the data seemed to produce reasonably parallel 
lines for the vaccine recipients and controls. There was some concern about the 
study period of the 2009 and 1998 cohorts, and the prior period of the 1997 cohorts. 
The lines of their log-log plots were the least parallel of all the plots, and thus, 
appeared to potentially indicate deviation from the proportional hazards assumption. 
However, the estimates for these particular periods did not appear incongruous or 
remarkable, and so the condition of proportional hazards was assumed to be broadly 
satisfied. 
 
Figure 42: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 1997 cohort adjusted for age and gender 
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Figure 43: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 1998 cohort adjusted for age and gender 
 
Figure 44: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 1999 cohort adjusted for age and gender 
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Figure 45: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 2000 cohort adjusted for age and gender 
 
Figure 46: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 2001 cohort adjusted for age and gender 
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Figure 47: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 2002 cohort adjusted for age and gender 
 
Figure 48: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 2003 cohort adjusted for age and gender 
  
323 
 
 
Figure 49: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 2004 cohort adjusted for age and gender 
 
Figure 50: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 2005 cohort adjusted for age and gender 
  
324 
 
 
Figure 51: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 2006 cohort adjusted for age and gender 
 
Figure 52: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 2007 cohort adjusted for age and gender 
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Figure 53: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 2009 cohort adjusted for age and gender 
 
Figure 54: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 2009 cohort adjusted for age and gender 
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Figure 55: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 2010 cohort adjusted for age and gender 
 
Figure 56: log-log plot for the prior and study period Cox model of MIs on vaccination 
status in the 2011 cohort adjusted for age and gender 
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Appendix F – codes for statins in CPRD data 
Atorvastatin 
28 75 745 2955 3411 5775 7374 17683 47065 47090 
47630 47721 48518 49558 49751 5023 50272 50788 50790 
50963 51134 51200 51359 51622 51876 52097 52168 52211 
52397 52398 52459 52460 52821 53594 53772 53887 53890 
54535 55032 55034 55444 55727 56182 56248 56564 56841 
57117 57348 57834 57836 58041 58110 58394 58418 58742 
58834 58868 59272 59331 59357 59446 59776 59859 60511 
60607 60989 61149 
Rosuvastatin 
713 6213 7347 7554 9897 9930 15252 17688 53460 
57763 57999 59447 59452 60160 
Fluvastatin 
379 2137 5985 8380 9153 11627 53770 59278 
Simvastatin 
25 42 51 802 818 2718 5148 6168 
9920 13041 22579 31930 32909 33082 34312 34316  
34353 34366 34376 34381 34476 34481 34502 34535 34545 
34560 34746 34814 34879 34891 34907 34955 34969 37434 
39060 39652 39675 39870 40340 40601 41657 44528 44650 
44878 45219 45235 45245 45346 46878 46956 47774 47948 
48018 48051 48058 48078 48431 48867 49061 49062 49587 
50483 50564 50670 50703 50754 50882 51085 51166 51233 
51483 51715 52098 52257 52625 52676 52812 52953 52962 
53087 53340 53415 53676 53822 53908 53966 54240 54266 
54493 54655 54819 54947 54976 54985 55452 56481 56494 
57568 58315 58755 61155 61321 61360 61665 
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Pravastatin 
490 730 1219 1221 1223 3690  
32921 34820 36377 40382 43218 47988 48097 50925 51676 
51890 52755 54435 54607 55912 56146 56607 56735 56893 
56916 57108 57137 57296 57397 59508 60251 61134 
Simvastatin + ezetimibe 
7552 10172 10183 10206 11815 14219 16186 17059 21020  
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